<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005063.pub2" GROUP_ID="ADDICTN" ID="230304022414584471" MERGED_FROM="" MODIFIED="2010-02-15 16:04:12 +0100" MODIFIED_BY="Laura Amato" NOTES="&lt;p&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 15:59:46 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="28" REVMAN_SUB_VERSION="5.0.23" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.3">
<COVER_SHEET MODIFIED="2010-02-15 15:59:01 +0100" MODIFIED_BY="Laura Amato">
<TITLE>Benzodiazepines for alcohol withdrawal</TITLE>
<CONTACT>
<PERSON ID="11445" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Laura</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Amato</LAST_NAME>
<SUFFIX/>
<POSITION>Coordinator</POSITION>
<EMAIL_1>amato@asplazio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>ASL RM/E</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+390683060479</PHONE_1>
<PHONE_2/>
<FAX_1>+390683060463</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-02-15 15:59:01 +0100" MODIFIED_BY="Laura Amato">
<PERSON ID="11445" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Laura</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Amato</LAST_NAME>
<SUFFIX/>
<POSITION>Coordinator</POSITION>
<EMAIL_1>amato@asplazio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>ASL RM/E</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+390683060479</PHONE_1>
<PHONE_2/>
<FAX_1>+390683060463</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6297" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Silvia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Minozzi</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>minozzi.silvia@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>ASL RM/E</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11551" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Simona</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Vecchi</LAST_NAME>
<SUFFIX/>
<POSITION>Research worker</POSITION>
<EMAIL_1>vecchi@asplazio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>ASL RM/E</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>39 0683060421</PHONE_1>
<PHONE_2/>
<FAX_1>39 0683060374</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6213" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Davoli</LAST_NAME>
<SUFFIX/>
<POSITION>Coordinating Editor</POSITION>
<EMAIL_1>davoli@asplazio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>ASL RM/E</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00199</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 06 83060 483</PHONE_1>
<PHONE_2/>
<FAX_1>+39 06 83060463</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2009-12-14 10:22:43 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 19/05/05&lt;/p&gt;" NOTES_MODIFIED="2009-12-14 10:22:43 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="19" MONTH="5" YEAR="2005"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="12" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="12" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2010-01-08 09:13:09 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-01-08 09:13:09 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="1" YEAR="2010"/>
<DESCRIPTION>
<P>substantially update; authors changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-01-07 09:12:19 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="1" YEAR="2010"/>
<DESCRIPTION>
<P>new studies</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-01-07 09:12:51 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-01-07 09:12:51 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="3" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="19" MONTH="5" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-01-07 10:23:34 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-01-07 09:54:19 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-01-07 09:54:19 +0100" MODIFIED_BY="[Empty name]">
<NAME>Department of Epidemiology, ASL RM/E Rome</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-01-07 10:23:34 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-01-07 10:23:34 +0100" MODIFIED_BY="[Empty name]">
<NAME>AIFA (Italian Pharmaceutical Agency)</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION>
<P>Public regulatory agency founded t<I>o </I>contribute to the development of a world class regulatory system for medicinal products based on a Network of agencies operating to best practice standards</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-02-15 15:59:46 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-01-07 14:51:34 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-11-27 11:21:29 +0100" MODIFIED_BY="[Empty name]">Benzodiazepines for alcohol withdrawal</TITLE>
<SUMMARY_BODY MODIFIED="2010-01-07 14:51:34 +0100" MODIFIED_BY="[Empty name]">
<P>Benzodiazepines are more effective than placebo against alcohol withdrawal seizures while they have variable profile against other commonly used treatments</P>
<P>This Cochrane review summarizes evidence from sixty-four randomised controlled trials evaluating the effectiveness and safety of benzodiazepines in the treatment of alcohol withdrawal symptoms. The available data show that benzodiazepines are effective against alcohol withdrawal seizures when compared to placebo and a potentially protective benefit for many outcomes when compared with other drugs. Data on safety outcomes are sparse and fragmented. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-01-07 15:16:59 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-01-07 15:12:14 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol abuse and dependence represents a serious health problem worldwide with social, interpersonal and legal interpolations. Benzodiazepines have been widely used for the treatment of alcohol withdrawal symptoms. Moreover it is unknown whether different benzodiazepines and different regimens of administration may have the same merits.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the effectiveness and safety of benzodiazepines in the treatment of alcohol withdrawal.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-01-07 15:16:59 +0100" MODIFIED_BY="[Empty name]">
<P>Cochrane Drugs and Alcohol Group' Register of Trials (December 2009), PubMed,  EMBASE,  CINAHL (January 1966 to December 2009), EconLIT (1969 to December 2009). Parallel searches on web sites of health technology assessment and related agencies, and their databases.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-01-07 15:08:11 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials examining effectiveness, safety and risk-benefit of benzodiazepines in comparison with placebo or other pharmacological treatment and between themselves. All patients were included regardless of age, gender, nationality, and outpatient or inpatient therapy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-11-27 11:19:57 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently screened and extracted data from studies.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-01-07 15:11:37 +0100" MODIFIED_BY="[Empty name]">
<P>Sixty four studies, 4309 participants, met the inclusion criteria.</P>
<P>- Comparing benzodiazepines versus placebo, benzodiazepines performed better for seizures, 3 studies, 324 participants, RR 0.16 (0.04 to 0.69), no statistically significant difference for the other outcomes considered.</P>
<P>- Comparing benzodiazepines versus other drugs, there is a trend in favour of benzodiazepines for seizure and delirium control, severe life threatening side effect, dropouts, dropouts due to side effects and patient's global assessment score.  A trend in favour of control group was observed for CIWA-Ar scores at 48 hours and at the end of treatment. The results reach statistical significance only in one study, with 61 participants, results on Hamilton anxiety rating scale favour control MD -1.60 (-2.59 to -0.61)</P>
<P>- Comparing different benzodiazepines among themselves,results never reached statistical significance but chlordiazepoxide performed better</P>
<P>- Comparing benzodiazepine plus other drug versus other drug, results never reached statistical significance.</P>
<P>- In the comparison of fixed-schedule versus symptom-triggered regimens, results from a single study, with 159 participants, favour  symptom-triggered regimens MD -1.10 [-3.27, 1.07] for CIWA-Ar scores at the end of treatment. Differences in isolated trials should be interpreted very cautiously.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-11-27 11:20:56 +0100" MODIFIED_BY="[Empty name]">
<P>Benzodiazepines showed a protective benefit against alcohol withdrawal symptoms, in particular seizures, when compared to placebo and a potentially protective benefit for many outcomes when compared with other drugs. Nevertheless, no definite conclusions about the effectiveness and safety of benzodiazepines was possible, because of the heterogeneity of the trials both in interventions and the assessment of outcomes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-02-15 15:59:46 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-02-15 15:59:46 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2009-11-27 11:26:22 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol abuse and dependence represents a most serious health problem worldwide with major social, interpersonal and legal interpolations. Dependence on alcohol is associated with both physiological symptoms such as tolerance and withdrawal, and behavioural symptoms such as impaired control over drinking (<LINK REF="REF-Hasin-1990" TYPE="REFERENCE">Hasin 1990</LINK>). Alcohol withdrawal syndrome is a cluster of symptoms that occurs in alcohol-dependent people after cessation or reduction in alcohol use that has been heavy or prolonged. The clinical presentation varies from mild to serious and the onset of symptoms typically occurs a few hours after the last alcohol intake. The most common manifestations are tremor, restlessness, insomnia, nightmares, paroxysmal sweats, tachycardia, fever, nausea, vomiting, seizures, hallucinations (auditory, visual, tactile), increased agitation, tremulousness and delirium. These symptoms involve a wide range of neurotransmitter circuits that are implicated in alcohol tolerance and reflect a homeostatic readjustment of the central nervous system (<LINK REF="REF-De-Witte-2003" TYPE="REFERENCE">De Witte 2003</LINK>; <LINK REF="REF-Koob-1997" TYPE="REFERENCE">Koob 1997</LINK>; <LINK REF="REF-Nutt-1999" TYPE="REFERENCE">Nutt 1999</LINK>; <LINK REF="REF-Slawecki-1999" TYPE="REFERENCE">Slawecki 1999</LINK>). Long-term alcohol consumption affects brain receptors that undergo adaptive changes in an attempt to maintain normal function. Some of the key changes involve reduced brain gamma-aminobutyric acid (GABA) levels and GABA- receptor sensitivity (<LINK REF="REF-Dodd-2000" TYPE="REFERENCE">Dodd 2000</LINK>; <LINK REF="REF-Gilman-1996" TYPE="REFERENCE">Gilman 1996</LINK>; <LINK REF="REF-Kohl-1998" TYPE="REFERENCE">Kohl 1998</LINK>; <LINK REF="REF-Petty-1993" TYPE="REFERENCE">Petty 1993</LINK>) and activation of glutamate systems (<LINK REF="REF-Tsai-1995" TYPE="REFERENCE">Tsai 1995</LINK>), which lead to nervous system hyperactivity in the absence of alcohol. The advances in knowledge of neurobiology and neurochemistry have prompted the use of drugs in the treatment of alcohol dependence and withdrawal that act through these GABA pathways.</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-12-14 10:23:33 +0100" MODIFIED_BY="[Empty name]">
<P>Benzodiazepines in particular have been widely used for the treatment of alcohol withdrawal symptoms. A meta-analysis of studies concerning pharmacological therapies of alcohol withdrawal (<LINK REF="REF-Mayo_x002d_Smith-1997" TYPE="REFERENCE">Mayo-Smith 1997</LINK>) has suggested that benzodiazepines are effective in reducing withdrawal severity, incidence of delirium and seizures with a greater margin of safety and lower abuse potential when compared to other therapies.<BR/>A more recent systematic review (<LINK REF="REF-Holbrook-1999" TYPE="REFERENCE">Holbrook 1999</LINK>) of randomised controlled trials (RCTs) comparing benzodiazepines to placebo or other therapy reached similar conclusions. However a large amount of evidence of benzodiazepine use has been published during the last years and it is important that an up-to-date systematic review is performed. Moreover not all patients may need pharmacological treatment and it is unknown whether different benzodiazepines and different regimens of administration (e.g. fixed versus symptom-triggered schedule) may have the same merits.</P>
</INTERVENTION>
<THEORY MODIFIED="2009-11-27 11:23:19 +0100" MODIFIED_BY="[Empty name]">
<P>Benzodiazepines have been shown to be one of the most effective class of drugs in the management of alcohol withdrawal syndrome. The rationale of the use of benzodiazepine is to modulate CNS hyperactivity, interacting with GABA receptors, due to the alcohol withdrawal.</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-02-15 15:59:46 +0100" MODIFIED_BY="[Empty name]">
<P>The purpose of this systematic review was to examine the evidence on the effectiveness and safety of benzodiazepines in the management of alcohol withdrawal. Results of a previous version of a Cochrane Systematic review (<LINK REF="REF-Ntais-2005" TYPE="REFERENCE">Ntais 2005</LINK>) on benzodiazepines efficacy and safety are not conclusive. New trials have been published and the review needs update.</P>
<P>Area of uncertainty: no conclusive evidence of comparative effectiveness between benzodiazepine and other medications.</P>
<P>This review has a parallel one on anticonvulsants for alcohol withdrawal (<LINK REF="REF-Minozzi-2010" TYPE="REFERENCE">Minozzi 2010</LINK>) and together they are part of a series of reviews and protocols on the efficacy of pharmacological treatment (Acamprosate GHB, nitrous oxide, magnesium) for alcohol withdrawal (<LINK REF="REF-Gillman-2007" TYPE="REFERENCE">Gillman 2007</LINK>; <LINK REF="REF-Leone-2010" TYPE="REFERENCE">Leone 2010</LINK>; <LINK REF="REF-Fox-2003" TYPE="REFERENCE">Fox 2003</LINK>; <LINK REF="REF-Tejani-2010" TYPE="REFERENCE">Tejani 2010</LINK>)</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-11-27 11:31:33 +0100" MODIFIED_BY="[Empty name]">
<P>The objectives of this systematic review are:</P>
<OL>
<LI>To evaluate the effectiveness of benzodiazepines in the treatment of alcohol withdrawal.</LI>
<LI>To evaluate the safety (potential arms) of benzodiazepines in the treatment of the alcohol withdrawal symptoms (AWS).</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2010-01-15 11:00:53 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-01-15 11:00:53 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-12-23 08:36:42 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized Controlled Trials (RCT) and Controlled Clinical Trials (CCT) evaluating the efficacy, safety and overall risk-benefit of benzodiazepines for the treatment of alcohol withdrawal. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-01-15 11:00:53 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients diagnosed in accordance with appropriate standardized criteria (e.g., criteria of Diagnostic and Statistical Manual of Mental Disorders (<LINK REF="REF-DSM_x002d_IV_x002d_R" TYPE="REFERENCE">DSM-IV-R</LINK>) or ICD) who experienced alcohol withdrawal symptoms regardless of the severity of the withdrawal manifestations.  All patients were included regardless of age, gender, nationality, and outpatient or inpatient therapy. The history of previous treatments was considered, but it was not an eligibility criterion.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-11-27 11:38:11 +0100" MODIFIED_BY="[Empty name]">
<P>-<I>
<B> Experimental intervention</B>
</I>
</P>
<UL>
<LI>Benzodiazepines alone or in combination with other drugs</LI>
</UL>
<P>
<I>
<B>- Control Intervention</B>
</I>
</P>
<UL>
<LI>Placebo; Other pharmacological interventions</LI>
</UL>
<P>
<I>
<B>- Types of comparisons</B>
</I>
</P>
<OL>
<LI>benzodiazepines versus placebo;</LI>
<LI>benzodiazepines versus other drug</LI>
<LI>different benzodiazepines between themselves;</LI>
<LI>benzodiazepines combined with other drug versus other drug.</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-12-14 10:24:35 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-12-14 10:24:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy outcomes</B>
</P>
<OL>
<LI>Alcohol withdrawal seizures as number of subjects experiencing seizures</LI>
<LI>Alcohol withdrawal delirium as number of subjects experiencing delirium</LI>
<LI>Alcohol withdrawal symptoms as measured by prespecified scales(as the CIWA-Ar score)</LI>
<LI>Global improvement of overall alcohol withdrawal syndrome as measured in pre-specified scales ( as number of patients with global improvement, global doctors assessment of efficacy, Patients assessment of efficacy)</LI>
<LI>Craving as measured by prespecified scales</LI>
</OL>
<P>
<B>Safety outcomes </B>
</P>
<OL>
<LI>Adverse events as number of subjects experiencing at least one adverse event</LI>
<LI>Severe, life-threatening adverse events as measured by number of subjects experiencing severe, life threatening adverse events</LI>
</OL>
<P>
<B>Acceptability outcomes</B>
</P>
<OL>
<LI>Dropout</LI>
<LI>Dropout due to adverse events</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-12-07 08:35:33 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Additional medication needed</LI>
<LI>Length of stay in intensive therapy</LI>
<LI>Mortality</LI>
<LI>Quality of life</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-12-14 11:13:26 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-12-14 11:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>Relevant trials were obtained from the following sources:</P>
<OL>
<LI>Cochrane Drugs and Alcohol Group' Register of Trials (December 2009)</LI>
<LI>PubMed (January 1966&#8211; December 2009)<B> </B>
</LI>
<LI>EMBASE (January 1988&#8211; December 2009)</LI>
<LI>CINAHL (January 1982&#8211; December 2009)</LI>
<LI>EconLIT (1969 to December 2009)</LI>
</OL>
<P>We compiled detailed search strategies for each database searched, for detail see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-11-27 11:50:57 +0100" MODIFIED_BY="[Empty name]">
<P>We also searched:</P>
<OL>
<LI>the reference lists of all relevant papers to identify further studies.</LI>
<LI>conference proceedings likely to contain trials relevant to the review.</LI>
</OL>
<P>We contacted investigators seeking information about unpublished or incomplete trials.All searches included non-English language literature and studies with English abstracts were assessed for inclusion. When considered likely to meet inclusion criteria, studies were translated.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-01-07 11:00:23 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-11-27 11:53:22 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently screened the titles and abstracts of all publications, obtained through the search strategy. All potentially eligible studies were obtained as full articles and two authors independently assessed these for inclusion. In doubtful or controversial cases, all identified discrepancies were discussed and reached consensus on all items.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-11-27 11:53:29 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted data from published sources, where differences in data extracted occurred this was resolved through discussion. Where required additional information was obtained through collaboration with the original authors.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-12-14 10:37:58 +0100" MODIFIED_BY="[Empty name]">
<P>The risk of bias assessment  for RCTs and CCTs in this review was performed using four out of the six criteria recommended by the Cochrane Handbbok (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). The recommended approach for assessing risk of bias in studies included in Cochrane Review is a two-part tool, addressing four specific domains (namely sequence generation, allocation concealment, blinding, incomplete outcome data). The first part of the tool involves describing what was reported to have happened in the study. The second part of the tool involves assigning a judgement relating to the risk of bias for that entry. This is achieved by answering a pre-specified question about the adequacy of the study in relation to the entry, such that a judgement of "Yes" indicates low risk of bias, "No" indicates high risk of bias, and "Unclear" indicates unclear or unknown risk of bias. To make these judgments we will use the criteria indicated by the handbook adapted to  the addiction field. See <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> for details.</P>
<P>The domains of sequence generation and  allocation concealment (avoidance of selection bias) will be addressed in the tool by a single entry for each study.</P>
<P>Blinding of participants, personnel and outcome assessor (avoidance of performance bias and detection bias) was considered separately for objective outcomes (e.g. drop out, drop out due to adverse events, seizures, delirium, adverse events) and subjective outcomes (e.g. duration and severity of signs and symptoms of withdrawal, craving, psychiatric symptoms; improvements assessed by doctors and patients). </P>
<P>Incomplete outcome data (avoidance of attrition bias) was considered for all outcomes except for the drop out from the treatment, which is very often the primary outcome measure in trials on addiction.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-12-14 10:36:30 +0100" MODIFIED_BY="[Empty name]">
<P>Dichotomous outcomes were analysed calculating the Relative risk (RR) for each trial with the uncertainty in each result being expressed by their confidence intervals. Continuous outcomes were analysed calculating the MD or the SMD with 95%CI. In case of missing standard deviation of the differences from baseline to the end of treatment, the standard deviation were imputed using the standard deviation of the mean at the end of treatment for each group. </P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-12-14 10:36:31 +0100" MODIFIED_BY="[Empty name]">
<P>Statistically significant heterogeneity among primary outcome studies will be assessed with Chi-squared (Q) test and I-squared (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). A significant Q ( P&lt;.05) and I-squared of at least 50% will be considered as statistical heterogeneity </P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-12-14 10:38:16 +0100" MODIFIED_BY="[Empty name]">
<P>Funnel plot (plot of the effect estimate from each study against the sample size or effect standard error) was not used to assess the potential for bias related to the size of the trials, because all the included studies had small sample size and not statistically significant results.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-12-14 10:38:34 +0100" MODIFIED_BY="[Empty name]">
<P>The outcomes from the individual trials have been combined through meta-analysis where possible (comparability of intervention and outcomes between trials) using a fixed effect model unless there was significant heterogeneity, in which case a random effect model have been used.</P>
<P>If all arms in a multi-arm trial are to be included in the meta-analysis and one treatment arm is to be included in more than one of the treatment comparisons, then we divided the number of events and the number of participants in that arm by the number of treatment comparisons made. This method avoid the multiple use of participants in the pooled estimate of treatment effect while retaining information from each arm of the trial. It compromise the precision of the pooled estimate slightly.</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-01-07 11:00:23 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effect of methodological quality on the results, we first performed a graphical inspection of any effect sorting the results on the forest plots according to risk of bias for sequence generation, allocation concealment, blinding (subjective outcomes) ; if we found a difference in the results between studies at low, unclear, high risk of bias, we performed a sensitivity analysis excluding studies at high risk of bias.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-01-15 11:04:08 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-01-15 11:04:08 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2010-01-07 14:52:42 +0100" MODIFIED_BY="[Empty name]">
<P>We identified 695 reports from all electronic databases searched excluding duplicate, 603 were excluded on basis of title and abstract; 1 article is awaiting classification because we cannot find the full text, 91 articles were retrieved in full text for more detailed evaluation, 27 of which were excluded, 64 satisfied all the criteria to be included in the review. See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> to see a flow chart showing identification of studies.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-01-15 11:04:08 +0100" MODIFIED_BY="[Empty name]">
<P>64 studies met the inclusion criteria, with a total of 4309 participants. For a description of the characteristics of the included studies, See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> Table</P>
<P>
<I>
<B>Country of origin of the included studies</B>
</I>
</P>
<P>26 studies were conducted in Europe, 32 in North America, 3 in Asia, 2 in South Africa and 1 in Australia</P>
<P>
<I>
<B>Number of studies per type of comparison</B>
</I>
</P>
<OL>
<LI>
<U>Benzodiazepines versus placebo</U> (No. = 11 studies) (<LINK REF="STD-Adinoff-1994" TYPE="STUDY">Adinoff 1994</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Kaim-1969" TYPE="STUDY">Kaim 1969</LINK>; <LINK REF="STD-Kaim-1972" TYPE="STUDY">Kaim 1972</LINK>; <LINK REF="STD-Krupitsky-2007" TYPE="STUDY">Krupitsky 2007</LINK>; <LINK REF="STD-Martin-1975" TYPE="STUDY">Martin 1975</LINK>; <LINK REF="STD-McLendon-1980" TYPE="STUDY">McLendon 1980</LINK>; <LINK REF="STD-Mielke-1976" TYPE="STUDY">Mielke 1976</LINK>; <LINK REF="STD-Naranjo-1983" TYPE="STUDY">Naranjo 1983</LINK>; <LINK REF="STD-Sellers-1977" TYPE="STUDY">Sellers 1977</LINK>; <LINK REF="STD-Sellers-1983" TYPE="STUDY">Sellers 1983</LINK>)</LI>
<LI>
<U>Benzodiazepines versus other drug</U> (No. = 42 studies) (<LINK REF="STD-Addolorato-1999" TYPE="STUDY">Addolorato 1999</LINK>; <LINK REF="STD-Addolorato-2006" TYPE="STUDY">Addolorato 2006</LINK>; <LINK REF="STD-Adinoff-1994" TYPE="STUDY">Adinoff 1994</LINK>; <LINK REF="STD-Bailly-1992" TYPE="STUDY">Bailly 1992</LINK>; <LINK REF="STD-Baumgartner-1987" TYPE="STUDY">Baumgartner 1987</LINK>; <LINK REF="STD-Baumgartner-1991" TYPE="STUDY">Baumgartner 1991</LINK>; <LINK REF="STD-Borg-1986" TYPE="STUDY">Borg 1986</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Choi-2005" TYPE="STUDY">Choi 2005</LINK>; <LINK REF="STD-Dion-1968" TYPE="STUDY">Dion 1968</LINK>; <LINK REF="STD-Favre-2005" TYPE="STUDY">Favre 2005</LINK>; <LINK REF="STD-Funderburk-1978" TYPE="STUDY">Funderburk 1978</LINK>; <LINK REF="STD-Gillman-2004" TYPE="STUDY">Gillman 2004</LINK>; <LINK REF="STD-Gillmer-1973" TYPE="STUDY">Gillmer 1973</LINK>; <LINK REF="STD-Golbert-1967" TYPE="STUDY">Golbert 1967</LINK>; <LINK REF="STD-Kaim-1969" TYPE="STUDY">Kaim 1969</LINK>; <LINK REF="STD-Kaim-1972" TYPE="STUDY">Kaim 1972</LINK>; <LINK REF="STD-Kalyoncu-1996" TYPE="STUDY">Kalyoncu 1996</LINK>; <LINK REF="STD-Kramp-1978" TYPE="STUDY">Kramp 1978</LINK>; <LINK REF="STD-Krupitsky-2007" TYPE="STUDY">Krupitsky 2007</LINK>; <LINK REF="STD-Lapierre-1983" TYPE="STUDY">Lapierre 1983</LINK>; <LINK REF="STD-Lenzenhuber-1999" TYPE="STUDY">Lenzenhuber 1999</LINK>; <LINK REF="STD-Lepola-1984" TYPE="STUDY">Lepola 1984</LINK>; <LINK REF="STD-Longo-2002" TYPE="STUDY">Longo 2002</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Malcolm-1989" TYPE="STUDY">Malcolm 1989</LINK>; <LINK REF="STD-Malcolm-2002" TYPE="STUDY">Malcolm 2002</LINK>; <LINK REF="STD-Malcolm-2007" TYPE="STUDY">Malcolm 2007</LINK>; <LINK REF="STD-McGrath-1975" TYPE="STUDY">McGrath 1975</LINK>; <LINK REF="STD-Nava-2007" TYPE="STUDY">Nava 2007</LINK>; <LINK REF="STD-Overall-1973" TYPE="STUDY">Overall 1973</LINK>; <LINK REF="STD-Palestine-1976" TYPE="STUDY">Palestine 1976</LINK>; <LINK REF="STD-Pena_x002d_Ramos-1977" TYPE="STUDY">Pena-Ramos 1977</LINK>; <LINK REF="STD-Pena_x002d_Ramos-1979" TYPE="STUDY">Pena-Ramos 1979</LINK>; <LINK REF="STD-Radouco_x002d_Thomas-1989" TYPE="STUDY">Radouco-Thomas 1989</LINK>; <LINK REF="STD-Runion-1978" TYPE="STUDY">Runion 1978</LINK>; <LINK REF="STD-Sellers-1977" TYPE="STUDY">Sellers 1977</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>; <LINK REF="STD-Worner-1994" TYPE="STUDY">Worner 1994</LINK> ).</LI>
<LI>Different benzodiazepines between themselves (No.= 18 studies) (<LINK REF="STD-Adinoff-1994" TYPE="STUDY">Adinoff 1994</LINK>; <LINK REF="STD-Anton-1997" TYPE="STUDY">Anton 1997</LINK>; <LINK REF="STD-Brown-1972" TYPE="STUDY">Brown 1972</LINK>;  <LINK REF="STD-Day-2004" TYPE="STUDY">Day 2004</LINK>; <LINK REF="STD-Jauhar-2000" TYPE="STUDY">Jauhar 2000</LINK>; <LINK REF="STD-Kolin-1981" TYPE="STUDY">Kolin 1981</LINK>;<LINK REF="STD-Kumar-2009" TYPE="STUDY">Kumar 2009</LINK>; <LINK REF="STD-Martin-1975" TYPE="STUDY">Martin 1975</LINK>; <LINK REF="STD-McLendon-1980" TYPE="STUDY">McLendon 1980</LINK>; <LINK REF="STD-Mendels-1985" TYPE="STUDY">Mendels 1985</LINK>; <LINK REF="STD-Mielke-1976" TYPE="STUDY">Mielke 1976</LINK>; <LINK REF="STD-Miller-1984" TYPE="STUDY">Miller 1984</LINK>; <LINK REF="STD-Mukherjee-1983" TYPE="STUDY">Mukherjee 1983</LINK>; <LINK REF="STD-O_x0027_Brien-1983" TYPE="STUDY">O'Brien 1983</LINK>; <LINK REF="STD-Ritson-1986" TYPE="STUDY">Ritson 1986</LINK>; <LINK REF="STD-Saletu-1983" TYPE="STUDY">Saletu 1983</LINK>; <LINK REF="STD-Solomon-1983" TYPE="STUDY">Solomon 1983</LINK>; <LINK REF="STD-Wilson-1985" TYPE="STUDY">Wilson 1985</LINK>)</LI>
<LI>Benzodiazepines alone versus benzodiazepines combined with other drug (No. = 3 studies) (<LINK REF="STD-Dion-1968" TYPE="STUDY">Dion 1968</LINK>; <LINK REF="STD-Sellers-1977" TYPE="STUDY">Sellers 1977</LINK>; <LINK REF="STD-Spies-1996" TYPE="STUDY">Spies 1996</LINK>)</LI>
</OL>
<P>For a more detailed information about the comparisons considered in the studies, see Addictional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>; <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>
</P>
<P>The benzodiazepines considered in the 64 studies included were:Abecamil, Alprazolam, Chlordiazepoxide, Clobazam, Clorazepate, Diazepam, Flunitrazepam, Halazepam, Lometazepam, Lopirazepam, Lorazepam, Oxazepam, Prazepam</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-01-07 11:44:00 +0100" MODIFIED_BY="[Empty name]">
<P>27 studies did not meet the criteria for inclusion in this review. The grounds for exclusion were: type of intervention not in the inclusion criteria: 6 studies; study design not in the inclusion criteria: 12 studies; type of outcomes measures not in the inclusion criteria: 1 study; Type of comparison not in the inclusion criteria : 4 studies;  duplicate publication: 3 studies, outcome measures presented in a way not suitable for meta-analysis: 1 study. See <LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK> Table</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-01-07 12:05:56 +0100" MODIFIED_BY="[Empty name]">
<P>All the studies were randomised controlled trials.</P>
<ALLOCATION MODIFIED="2010-01-07 12:00:25 +0100" MODIFIED_BY="[Empty name]">
<P>The sequence generation was adequate in 16 studies, unclear in 43 and  inadequate in 5 studies ; the allocation concealment was adequate in 13 studies, unclear in 47 and  inadequate in 4 studies;</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-01-07 12:00:44 +0100" MODIFIED_BY="[Empty name]">
<P>Blinding for subjective outcomes was adequate in 43 studies, it was unclear in 14 and inadequate in 7;</P>
<P>Blinding for objective outcomes was adequate in 52 studies and unclear in 12 studies</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-01-07 12:05:56 +0100" MODIFIED_BY="[Empty name]">
<P>Incomplete outcome data were addressed in 48 studies, it was unclear in 13 studies and were not addressed in 3 studies</P>
<P>See <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK> Table and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for a more detailed description of risk of bias across the studies.</P>
<P>With a graphical inspection of the forest plots sorting studies according to the risk of bias, we didn't find any systematic difference in the results between studies at high risk of bias and studies at low or unclear risk of bias. For that sensitivity analysis excluding studies at high risk of bias was not performed.</P>
</EXCLUSIONS>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-01-15 11:04:08 +0100" MODIFIED_BY="[Empty name]">
<P>We only performed meta-analysis for the studies that had directly comparable interventions and used exactly the same rating scales for continuous outcome measures or had the same binary outcomes. The rest of the data retrieved from the studies (single comparison data) were not synthesized quantitatively. The following results refer to the cases where quantitative synthesis was performed.</P>
<P>The Results are split into four sections referring to the four main comparisons:</P>
<OL>
<LI>Benzodiazepine versus Placebo,</LI>
<LI>Benzodiazepine versus Other Drug,</LI>
<LI>Benzodiazepine 1 versus Benzodiazepine 2</LI>
<LI>Benzodiazepine alone versus Benzodiazepine + Other drug</LI>
<LI>Benzodiazepines (fixed schedules) versus Benzodiazepines (symptom-triggered)</LI>
</OL>
<P>The outcomes are categorized as primary efficacy outcomes and secondary efficacy outcomes, according to the protocol. We dived them according to efficacy, safety and acceptability. For a summary of results of some important outcomes see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> and <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>
</P>
<P>
<B>Comparison 1 Benzodiazepines versus placebo:</B>
</P>
<P>
<B>Efficacy </B>
</P>
<P>
<I>
<B>1.1 Alcohol withdrawal seizures</B>
</I>
</P>
<P>3 studies (<LINK REF="STD-Kaim-1969" TYPE="STUDY">Kaim 1969</LINK>; <LINK REF="STD-Naranjo-1983" TYPE="STUDY">Naranjo 1983</LINK>; <LINK REF="STD-Sellers-1983" TYPE="STUDY">Sellers 1983</LINK>), 324 participants, RR 0.16 (0.04 to 0.69), the result is in favour of benzodiazepines; see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> or <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>
</P>
<P>
<B>Safety </B>
</P>
<P>
<I>
<B>1.2 Adverse events as number of participants with at least one adverse event </B>
</I>
</P>
<P>2 studies (<LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Krupitsky-2007" TYPE="STUDY">Krupitsky 2007</LINK>), 71 participants, RR 3.28 (0.31 to 34.52), the result is not statistically significant; see <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> or <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>
</P>
<P>
<B>Acceptability </B>
</P>
<P>
<I>
<B>1.3 Dropout</B>
</I>
</P>
<P>3 studies (<LINK REF="STD-Adinoff-1994" TYPE="STUDY">Adinoff 1994</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Kaim-1969" TYPE="STUDY">Kaim 1969</LINK>), 312 participants, RR 0.68 (0.38 to 1.24), the result is not statistically significant; see <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> or <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>
</P>
<P>
<I>
<B>1.4 Dropout due to adverse events</B>
</I>
</P>
<P>2 studies (<LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-McLendon-1980" TYPE="STUDY">McLendon 1980</LINK>), 86 participants, RR 0.36 (0.02 to 8.03), the result is not statistically significant; see <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>
</P>
<P>
<B>Comparison 2 Benzodiazepines versus Other Drugs:</B>
</P>
<P>
<B>Efficacy </B>
</P>
<P>
<I>
<B>2.1 Alcohol withdrawal seizures</B>
</I>
</P>
<P>
<I>
<U>2.1.1</U>
</I>
<U> <I>Any Benzodiazepine versus any Other</I>
</U>, 12 studies (<LINK REF="STD-Bailly-1992" TYPE="STUDY">Bailly 1992</LINK>; <LINK REF="STD-Baumgartner-1991" TYPE="STUDY">Baumgartner 1991</LINK>; <LINK REF="STD-Borg-1986" TYPE="STUDY">Borg 1986</LINK>; <LINK REF="STD-Favre-2005" TYPE="STUDY">Favre 2005</LINK>; <LINK REF="STD-Kaim-1969" TYPE="STUDY">Kaim 1969</LINK>; <LINK REF="STD-Kaim-1972" TYPE="STUDY">Kaim 1972</LINK>; <LINK REF="STD-Kramp-1978" TYPE="STUDY">Kramp 1978</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Radouco_x002d_Thomas-1989" TYPE="STUDY">Radouco-Thomas 1989</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>; <LINK REF="STD-Worner-1994" TYPE="STUDY">Worner 1994</LINK>), 1228 participants, RR 0.52 (0.21 to 1.31), the result is not statistically significant, see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> or <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>
</P>
<P>
<I>
<U>2.1.2</U>
</I>
<U> <I>Any Benzodiazepine versus Anticonvulsants</I>
</U>, 7 studies (<LINK REF="STD-Borg-1986" TYPE="STUDY">Borg 1986</LINK>; <LINK REF="STD-Kaim-1972" TYPE="STUDY">Kaim 1972</LINK>; <LINK REF="STD-Kramp-1978" TYPE="STUDY">Kramp 1978</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Radouco_x002d_Thomas-1989" TYPE="STUDY">Radouco-Thomas 1989</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 523 participants, RR 1.70 (0.39 to 7.37), the result is not statistically significant, see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> or <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>
</P>
<P>
<I>
<B>2.2 Alcohol withdrawal delirium </B>
</I>
</P>
<P>
<I>
<U>2.2.1</U>
</I>
<U> <I>Any Benzodiazepine versus any Other,</I>
</U> 8 studies (<LINK REF="STD-Dion-1968" TYPE="STUDY">Dion 1968</LINK>; <LINK REF="STD-Favre-2005" TYPE="STUDY">Favre 2005</LINK>; <LINK REF="STD-Golbert-1967" TYPE="STUDY">Golbert 1967</LINK>; <LINK REF="STD-Kaim-1969" TYPE="STUDY">Kaim 1969</LINK>; <LINK REF="STD-Kalyoncu-1996" TYPE="STUDY">Kalyoncu 1996</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-McGrath-1975" TYPE="STUDY">McGrath 1975</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>), 893 participants, RR 0.65 [0.21, 1.98], the result is not statistically significant, see <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> or <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>
</P>
<P>
<I>
<U>2.2.2</U>
</I>
<U> <I>Any Benzodiazepine versus Anticonvulsants,</I>
</U> 5 studies (<LINK REF="STD-Golbert-1967" TYPE="STUDY">Golbert 1967</LINK>; <LINK REF="STD-Kalyoncu-1996" TYPE="STUDY">Kalyoncu 1996</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-McGrath-1975" TYPE="STUDY">McGrath 1975</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>), 342 participants, RR 1.90 [0.43, 8.38), the result is not statistically significant, see <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> or <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>
</P>
<P>
<I>
<B>2.3 CIWA-Ar score at 48 hours</B>
</I>
</P>
<P>
<I>
<U>2.3.1</U>
</I>
<U> <I>Any Benzodiazepine versus any Other</I>
</U>
<I>
<B>, </B>
</I>5 studies (<LINK REF="STD-Addolorato-1999" TYPE="STUDY">Addolorato 1999</LINK>; <LINK REF="STD-Baumgartner-1987" TYPE="STUDY">Baumgartner 1987</LINK>; <LINK REF="STD-Malcolm-1989" TYPE="STUDY">Malcolm 1989</LINK>; <LINK REF="STD-Malcolm-2002" TYPE="STUDY">Malcolm 2002</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>), 355 participants, MD -1.03 (-2.21 to 0.15), the result is not statistically significant, see <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>
</P>
<P>
<I>
<U>2.3.2</U>
</I>
<U> <I>Any Benzodiazepine versus Anticonvulsants</I>
</U>
<I>
<B>,</B>
</I> 3 studies ( <LINK REF="STD-Malcolm-1989" TYPE="STUDY">Malcolm 1989</LINK>; <LINK REF="STD-Malcolm-2002" TYPE="STUDY">Malcolm 2002</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>), 260 participants, MD -0.73 (-2.88 to 1.42), the result is not statistically significant, see <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>
</P>
<P>
<I>
<B>2.4 CIWA-Ar score at the end of treatment</B>
</I>
</P>
<P>
<I>
<U>2.4.1 Any Benzodiazepine versus any Other</U>
<B>, </B>
</I>6 studies (<LINK REF="STD-Addolorato-1999" TYPE="STUDY">Addolorato 1999</LINK>; <LINK REF="STD-Baumgartner-1987" TYPE="STUDY">Baumgartner 1987</LINK>; <LINK REF="STD-Favre-2005" TYPE="STUDY">Favre 2005</LINK>; <LINK REF="STD-Malcolm-1989" TYPE="STUDY">Malcolm 1989</LINK>; <LINK REF="STD-Malcolm-2002" TYPE="STUDY">Malcolm 2002</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>), 435 participants, MD -0.17 (-1.29 to 0.95), the result is not statistically significant, see <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>
</P>
<P>
<I>
<U>2.4.2</U>
</I>
<U> <I>Any Benzodiazepine versus Anticonvulsants,</I>
</U> 3 studies ( <LINK REF="STD-Malcolm-1989" TYPE="STUDY">Malcolm 1989</LINK>; <LINK REF="STD-Malcolm-2002" TYPE="STUDY">Malcolm 2002</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>), 260 participants, MD -1.04 (-3.45 to 1.38), the result is not statistically significant, see <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>
</P>
<P>
<I>
<B>2.5 HARS score at 48 hours</B>
</I>
</P>
<P>1 study (<LINK REF="STD-Baumgartner-1991" TYPE="STUDY">Baumgartner 1991</LINK>), 43 participants, MD -1.60 (-2.59 to -0.61), the result is in favour of other drugs, see <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>
</P>
<P>
<I>
<B>2.6 HARS score at the end of treatment</B>
</I>
</P>
<P>2 studies (<LINK REF="STD-Baumgartner-1987" TYPE="STUDY">Baumgartner 1987</LINK>; <LINK REF="STD-Baumgartner-1991" TYPE="STUDY">Baumgartner 1991</LINK>), 90 participants, MD -2.05 (-4.37 to 0.27), the result is not statistically significant, see <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>
</P>
<P>
<I>
<B>2.7 Zung Anxiety scale</B>
</I>
</P>
<P>1 study (<LINK REF="STD-Malcolm-2002" TYPE="STUDY">Malcolm 2002</LINK>), 136 participants, MD 0.80 (-24.18 to 22.58), the result is not statistically significant, see <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>
</P>
<P>
<I>
<B>2.8 Global Improvement as number of participants with global improvement</B>
</I>
</P>
<P>
<I>
<U>2.8.1</U>
</I>
<U> <I>Any Benzodiazepine versus any Other,</I>
</U> 11 studies (<LINK REF="STD-Ansoms-1991" TYPE="STUDY">Ansoms 1991</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Gillman-2004" TYPE="STUDY">Gillman 2004</LINK>; <LINK REF="STD-Gillmer-1973" TYPE="STUDY">Gillmer 1973</LINK>; <LINK REF="STD-Golbert-1967" TYPE="STUDY">Golbert 1967</LINK>; <LINK REF="STD-Kramp-1978" TYPE="STUDY">Kramp 1978</LINK>; <LINK REF="STD-Lepola-1984" TYPE="STUDY">Lepola 1984</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Palestine-1976" TYPE="STUDY">Palestine 1976</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 619 participants, RR 1.01 (0.90 to 1.12), the result is not statistically significant, see <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>
</P>
<P>
<I>
<U>2.8.2</U>
</I>
<U> <I>Any Benzodiazepine versus Anticonvulsants,</I>
</U> 6 studies (<LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Golbert-1967" TYPE="STUDY">Golbert 1967</LINK>; <LINK REF="STD-Kramp-1978" TYPE="STUDY">Kramp 1978</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 338 participants, RR 1.00 (0.87 to 1.16), the result is not statistically significant, see <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>
</P>
<P>
<I>
<B>2.9 Global doctor&#8217;s assessment of efficacy</B>
</I>
</P>
<P>
<I>
<U>2.9.1</U>
</I>
<U> <I>Any Benzodiazepine versus any Other,</I>
</U> 3 studies (<LINK REF="STD-Ansoms-1991" TYPE="STUDY">Ansoms 1991</LINK>; <LINK REF="STD-Kramp-1978" TYPE="STUDY">Kramp 1978</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 233 participants RR 1.04 (0.97 to 1.11), the result is not statistically significant, see <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>
</P>
<P>
<I>
<U>2.9.2</U>
</I>
<U> <I>Any Benzodiazepine versus Anticonvulsants,</I>
</U> 2 studies (<LINK REF="STD-Kramp-1978" TYPE="STUDY">Kramp 1978</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 181 participants, RR 1.03 (0.93 to 1.14), the result is not statistically significant, see <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>
</P>
<P>
<I>
<B>2.10 Global patient&#8217;s assessment of efficacy</B>
</I>
</P>
<P>2 studies (<LINK REF="STD-Lepola-1984" TYPE="STUDY">Lepola 1984</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 140 participants, RR 1.04 (0.97 to 1.12), the result is not statistically significant, see <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>
</P>
<P>
<B>Safety </B>
</P>
<P>
<I>
<B>2.11 Adverse events as number of participants with at least one adverse event </B>
</I>
</P>
<P>
<I>
<U>2.11.1</U>
</I>
<U> <I>Any Benzodiazepine versus any Other,</I>
</U> 18 studies (<LINK REF="STD-Addolorato-1999" TYPE="STUDY">Addolorato 1999</LINK>; <LINK REF="STD-Addolorato-2006" TYPE="STUDY">Addolorato 2006</LINK>; <LINK REF="STD-Ansoms-1991" TYPE="STUDY">Ansoms 1991</LINK>; <LINK REF="STD-Bailly-1992" TYPE="STUDY">Bailly 1992</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Favre-2005" TYPE="STUDY">Favre 2005</LINK>; <LINK REF="STD-Gillmer-1973" TYPE="STUDY">Gillmer 1973</LINK>; <LINK REF="STD-Krupitsky-2007" TYPE="STUDY">Krupitsky 2007</LINK>; <LINK REF="STD-Lapierre-1983" TYPE="STUDY">Lapierre 1983</LINK>; <LINK REF="STD-Lepola-1984" TYPE="STUDY">Lepola 1984</LINK>; <LINK REF="STD-Longo-2002" TYPE="STUDY">Longo 2002</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Nava-2007" TYPE="STUDY">Nava 2007</LINK>; <LINK REF="STD-Palestine-1976" TYPE="STUDY">Palestine 1976</LINK>; <LINK REF="STD-Radouco_x002d_Thomas-1989" TYPE="STUDY">Radouco-Thomas 1989</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 919 participants, RR 1.31 (0.99 to 1.72), the result is not statistically significant, see <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK> or <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>
</P>
<P>
<I>
<U>2.11.2</U>
</I>
<U> <I>Any Benzodiazepine versus Anticonvulsants,</I>
</U> 9 studies (<LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Krupitsky-2007" TYPE="STUDY">Krupitsky 2007</LINK>; <LINK REF="STD-Lapierre-1983" TYPE="STUDY">Lapierre 1983</LINK>; <LINK REF="STD-Longo-2002" TYPE="STUDY">Longo 2002</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Radouco_x002d_Thomas-1989" TYPE="STUDY">Radouco-Thomas 1989</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 471 participants, RR 1.50 (0.83 to 2.70), the result is not statistically significant, see <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK> or <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>
</P>
<P>
<I>
<B>2.12 Severe, life-treating adverse events </B>
</I>
</P>
<P>
<I>
<U>2.12.1</U>
</I>
<U> <I>Any Benzodiazepine versus any Other,</I>
</U> 7 studies (<LINK REF="STD-Addolorato-1999" TYPE="STUDY">Addolorato 1999</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Lapierre-1983" TYPE="STUDY">Lapierre 1983</LINK>; <LINK REF="STD-Nava-2007" TYPE="STUDY">Nava 2007</LINK>; <LINK REF="STD-Radouco_x002d_Thomas-1989" TYPE="STUDY">Radouco-Thomas 1989</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 340 participants, RR 1.95 (0.25 to 15.28), the result is not statistically significant, see <LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK> or <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>
</P>
<P>
<I>
<U>2.12.2 Any Benzodiazepine versus Anticonvulsants,</U>
</I>  5 studies (<LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Lapierre-1983" TYPE="STUDY">Lapierre 1983</LINK>; <LINK REF="STD-Radouco_x002d_Thomas-1989" TYPE="STUDY">Radouco-Thomas 1989</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>, 230 participants, RR 1.45 (0.19 to 11.24), the result is not statistically significant, see <LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK> or <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>
</P>
<P>
<I>
<B>2.13 Mortality</B>
</I>
</P>
<P>32 studies (<LINK REF="STD-Addolorato-1999" TYPE="STUDY">Addolorato 1999</LINK>; <LINK REF="STD-Adinoff-1994" TYPE="STUDY">Adinoff 1994</LINK>; <LINK REF="STD-Ansoms-1991" TYPE="STUDY">Ansoms 1991</LINK>; <LINK REF="STD-Bailly-1992" TYPE="STUDY">Bailly 1992</LINK>; <LINK REF="STD-Baumgartner-1987" TYPE="STUDY">Baumgartner 1987</LINK>; <LINK REF="STD-Baumgartner-1991" TYPE="STUDY">Baumgartner 1991</LINK>; <LINK REF="STD-Borg-1986" TYPE="STUDY">Borg 1986</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Dion-1968" TYPE="STUDY">Dion 1968</LINK>; <LINK REF="STD-Gillman-2004" TYPE="STUDY">Gillman 2004</LINK>; <LINK REF="STD-Gillmer-1973" TYPE="STUDY">Gillmer 1973</LINK>; <LINK REF="STD-Golbert-1967" TYPE="STUDY">Golbert 1967</LINK>; <LINK REF="STD-Kaim-1969" TYPE="STUDY">Kaim 1969</LINK>; <LINK REF="STD-Kaim-1972" TYPE="STUDY">Kaim 1972</LINK>; <LINK REF="STD-Kalyoncu-1996" TYPE="STUDY">Kalyoncu 1996</LINK>; <LINK REF="STD-Kramp-1978" TYPE="STUDY">Kramp 1978</LINK>; <LINK REF="STD-Lapierre-1983" TYPE="STUDY">Lapierre 1983</LINK>; <LINK REF="STD-Lenzenhuber-1999" TYPE="STUDY">Lenzenhuber 1999</LINK>; <LINK REF="STD-Lepola-1984" TYPE="STUDY">Lepola 1984</LINK>; <LINK REF="STD-Longo-2002" TYPE="STUDY">Longo 2002</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Malcolm-2002" TYPE="STUDY">Malcolm 2002</LINK>; <LINK REF="STD-Malcolm-2002" TYPE="STUDY">Malcolm 2002</LINK>; <LINK REF="STD-Palestine-1976" TYPE="STUDY">Palestine 1976</LINK>; <LINK REF="STD-Pena_x002d_Ramos-1977" TYPE="STUDY">Pena-Ramos 1977</LINK>; <LINK REF="STD-Radouco_x002d_Thomas-1989" TYPE="STUDY">Radouco-Thomas 1989</LINK>; <LINK REF="STD-Runion-1978" TYPE="STUDY">Runion 1978</LINK>; <LINK REF="STD-Sellers-1977" TYPE="STUDY">Sellers 1977</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>; <LINK REF="STD-Worner-1994" TYPE="STUDY">Worner 1994</LINK>), 2088 participants, only 4/21 studies reported deaths, see <LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>
</P>
<P>
<B>Acceptability </B>
</P>
<P>
<I>
<B>2.14 Dropout</B>
</I>
</P>
<P>
<I>
<U>2.14.1</U>
</I>
<U> <I>Any Benzodiazepine versus any Other,</I>
</U> 22 studies (<LINK REF="STD-Addolorato-1999" TYPE="STUDY">Addolorato 1999</LINK>; <LINK REF="STD-Addolorato-2006" TYPE="STUDY">Addolorato 2006</LINK>; <LINK REF="STD-Adinoff-1994" TYPE="STUDY">Adinoff 1994</LINK>; <LINK REF="STD-Bailly-1992" TYPE="STUDY">Bailly 1992</LINK>; <LINK REF="STD-Baumgartner-1987" TYPE="STUDY">Baumgartner 1987</LINK>; <LINK REF="STD-Baumgartner-1991" TYPE="STUDY">Baumgartner 1991</LINK>; <LINK REF="STD-Borg-1986" TYPE="STUDY">Borg 1986</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Favre-2005" TYPE="STUDY">Favre 2005</LINK>; <LINK REF="STD-Gillmer-1973" TYPE="STUDY">Gillmer 1973</LINK>; <LINK REF="STD-Kaim-1969" TYPE="STUDY">Kaim 1969</LINK>; <LINK REF="STD-Kaim-1972" TYPE="STUDY">Kaim 1972</LINK>; <LINK REF="STD-Kalyoncu-1996" TYPE="STUDY">Kalyoncu 1996</LINK>; <LINK REF="STD-Kramp-1978" TYPE="STUDY">Kramp 1978</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-McGrath-1975" TYPE="STUDY">McGrath 1975</LINK>; <LINK REF="STD-Nava-2007" TYPE="STUDY">Nava 2007</LINK>; <LINK REF="STD-Radouco_x002d_Thomas-1989" TYPE="STUDY">Radouco-Thomas 1989</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>; <LINK REF="STD-Worner-1994" TYPE="STUDY">Worner 1994</LINK>), 1848 participants, RR 0.93 (0.70, 1.24), the result is not statistically significant, see <LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK> or <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>
</P>
<P>
<I>
<U>2.14.2</U>
</I>
<U> <I>Any Benzodiazepine versus Anticonvulsants</I>
</U>
<I>
<B>,</B>
</I> 11 studies (<LINK REF="STD-Borg-1986" TYPE="STUDY">Borg 1986</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Kaim-1972" TYPE="STUDY">Kaim 1972</LINK>; <LINK REF="STD-Kalyoncu-1996" TYPE="STUDY">Kalyoncu 1996</LINK>; <LINK REF="STD-Kramp-1978" TYPE="STUDY">Kramp 1978</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>;<LINK REF="STD-McGrath-1975" TYPE="STUDY">McGrath 1975</LINK>; <LINK REF="STD-Radouco_x002d_Thomas-1989" TYPE="STUDY">Radouco-Thomas 1989</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 839 participants,RR 1.11 (0.75, 1.63), the result is not statistically significant, see <LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK> or <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>
</P>
<P>
<I>
<B>2.15 Dropout due to adverse events</B>
</I>
</P>
<P>
<I>
<U>2.15.1</U>
</I>
<U> <I>Any Benzodiazepine versus any Other,</I>
</U> 8 studies (<LINK REF="STD-Addolorato-1999" TYPE="STUDY">Addolorato 1999</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Kaim-1972" TYPE="STUDY">Kaim 1972</LINK>; <LINK REF="STD-Lapierre-1983" TYPE="STUDY">Lapierre 1983</LINK>; <LINK REF="STD-Palestine-1976" TYPE="STUDY">Palestine 1976</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 533 participants, RR 0.82 (0.23 to 2.88), the result is not statistically significant, see <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>
</P>
<P>
<I>
<U>2.15.2</U>
</I>
<U> <I>Any Benzodiazepine versus Anticonvulsants,</I>
</U> 6 studies (<LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Kaim-1972" TYPE="STUDY">Kaim 1972</LINK>; <LINK REF="STD-Lapierre-1983" TYPE="STUDY">Lapierre 1983</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>, 370 participants, RR 0.54 (0.14 to 2.16), the result is not statistically significant, see <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>
</P>
<P>
<B>Comparison 3 Different Benzodiazepines among themselves</B>
</P>
<P>
<B>Efficacy </B>
</P>
<P>
<I>
<B>3.1 Alcohol withdrawal seizures</B>
</I>
</P>
<P>
<I>
<U>3.1.1 Chlordiazepoxide versus Alprazolam </U>,</I> 1 study (<LINK REF="STD-Wilson-1985" TYPE="STUDY">Wilson 1985</LINK>), 100 participants, RR 0.44 (0.15 to 1.35)</P>
<P>
<I>
<U>3.1.2 Chlordiazepoxide versus Diazepam,</U>
</I>  1 study, 24 participants, RR 0.33 (0.01 to 7.45)</P>
<P>
<I>
<U>3.1.3 Chlordiazepoxide versus Lorazepam</U>
</I>
<U>,</U>  1 study (<LINK REF="STD-Solomon-1983" TYPE="STUDY">Solomon 1983</LINK>), 50 participants, RR 0.20 (0.01 to 3.97)</P>
<P>
<I>
<U>3.1.2 Lorazepam versus Diazepam</U>,</I> 1 study (<LINK REF="STD-Ritson-1986" TYPE="STUDY">Ritson 1986</LINK>), 40 participants, RR 3.00 (0.13 to 69.52)</P>
<P>None found statistically significant differences, but chlordiazepoxide performed better, see <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> or <LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>
</P>
<P>
<I>
<B>3.2 Alcohol withdrawal delirium</B>
</I>
</P>
<P>
<I>
<U>3.2.1 Alprazolam versus Chlordiazepoxide,</U>
</I> 1 study (<LINK REF="STD-Wilson-1985" TYPE="STUDY">Wilson 1985</LINK>), 100 participants, RR 1.00 (0.21 to 4.72)</P>
<P>
<I>
<U>3.2.2 Diazepam versus Abecamil,</U>
</I> 1 study (<LINK REF="STD-Anton-1997" TYPE="STUDY">Anton 1997</LINK>), 48 participants, RR 0.33 (0.01 to 7.80)</P>
<P>
<I>
<U>3.2.3 Diazepam versus Lorazepam ,</U>
</I> 1 study (<LINK REF="STD-Miller-1984" TYPE="STUDY">Miller 1984</LINK>), 55 participants, RR 0.19 (0.01 to 3.85)</P>
<P>
<I>
<U>3.2.4 Lorazepam versus Chlordiazepoxide</U>
</I>, 1 study (<LINK REF="STD-Kumar-2009" TYPE="STUDY">Kumar 2009</LINK>)100 participants, RR 0.33 (0.01, 7.99)</P>
<P>None found statistically significant differences, but diazepam performed better, see <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> or <LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>
</P>
<P>
<I>
<B>3.3 CIWA-Ar score at 48 hours</B>
</I>
</P>
<P>
<I>
<U>3.3.1 Diazepam versus Abecamil,</U>
</I> 1 study (<LINK REF="STD-Anton-1997" TYPE="STUDY">Anton 1997</LINK>), 48 participants, MD 1.80 (-1.85 to 5.45)</P>
<P>
<I>
<U>3.2.2 Diazepam versus Chlordiazepoxide,</U>
</I> 1 study (<LINK REF="STD-Jauhar-2000" TYPE="STUDY">Jauhar 2000</LINK>), 20 participants, MD -4.50 (-11.44 to 2.44)</P>
<P>
<I>3.3.3 <U>Lorazepam versus Chlordiazepoxide</U>
</I>, 1 study (<LINK REF="STD-Kumar-2009" TYPE="STUDY">Kumar 2009</LINK>) 100 participants MD 0.00 (-0.60, 0.60)</P>
<P>None found statistically significant differences, see <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>
</P>
<P>
<I>
<B>3.4 CIWA-Ar score at the end of treatment </B>
</I>
</P>
<P>
<I>
<U>3.4.1 Diazepam versus Abecamil,</U>
</I> 1 study (<LINK REF="STD-Anton-1997" TYPE="STUDY">Anton 1997</LINK>), 48 participants, MD 2.50 (-1.14 to 6.14)</P>
<P>
<I>
<U>3.4.2 Diazepam versus Chlordiazepoxide,</U>
</I> 1 study (<LINK REF="STD-Jauhar-2000" TYPE="STUDY">Jauhar 2000</LINK>), 20 participants, MD -3.30 (-10.79 to 4.19)</P>
<P>
<U>3.4.3 <I>Lorazepam versus Chlordiazepoxide</I>
</U>, 1 study (<LINK REF="STD-Kumar-2009" TYPE="STUDY">Kumar 2009</LINK>) 100 participants MD 0.00 (-0.51, 0.51)</P>
<P>None found statistically significant differences, see <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>
</P>
<P>
<I>
<B>3.5 HARS score at 48 hours</B>
</I>
</P>
<P>
<I>
<U>3.5.1 Clobazam versus Diazepam,</U>
</I> 1 study (<LINK REF="STD-Martin-1975" TYPE="STUDY">Martin 1975</LINK>), 30 participants, MD -0.40 (-1.92 to 1.12)</P>
<P>
<I>
<U>3.5.2 Clobazam versus Chlordiazepoxide,</U>
</I> (<LINK REF="STD-Mukherjee-1983" TYPE="STUDY">Mukherjee 1983</LINK>),1 study, 40 participants, MD -0.70 (-5.95 to 4.55)</P>
<P>
<I>
<U>3.5.3 Lopirazepam versus Prazepam,</U>
</I> 1 study (<LINK REF="STD-Saletu-1983" TYPE="STUDY">Saletu 1983</LINK>), 42 participants, MD 0.00 (-1.21 to 1.21)</P>
<P>None found statistically significant differences, see <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>
</P>
<P>
<I>
<B>3.6 HARS score at the end of treatment</B>
</I>
</P>
<P>
<I>
<U>3.6.1 Alprazolam versus Diazepam,</U>
</I> 1 study (<LINK REF="STD-Kolin-1981" TYPE="STUDY">Kolin 1981</LINK>), 44 participants, MD 0.80 (-0.38 to 1.98), the result is not statistically significant</P>
<P>
<I>
<U>3.6.3 Alprazolam versus Chlordiazepoxide,</U>
</I> 1 study (<LINK REF="STD-McLendon-1980" TYPE="STUDY">McLendon 1980</LINK>), 43 participants, MD -2.90 (-4.10 to -1.70), the result is in favour of Chlordiazepoxide</P>
<P>
<I>
<U>3.6.2 Clobazam versus Diazepam,</U>
</I> 1 study, (<LINK REF="STD-Martin-1975" TYPE="STUDY">Martin 1975</LINK>), 30 participants,  MD -0.30 (-1.82 to 1.22), the result is not statistically significant</P>
<P>
<I>
<U>3.6.4 Clobazam versus Chlordiazepoxide,</U>
</I> 1 study (<LINK REF="STD-Mukherjee-1983" TYPE="STUDY">Mukherjee 1983</LINK>), 40 participants, MD -3.50 (-8.65 to 1.65), the result is not statistically significant</P>
<P>
<I>
<U>3.6.5 Lopirazepam versus Prazepam,</U>
</I> 1 study (<LINK REF="STD-Saletu-1983" TYPE="STUDY">Saletu 1983</LINK>), 42 participants, MD 1.60 (0.39 to 2.81), the result is in favour of Lopirazepam</P>
<P>see <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>
</P>
<P>
<I>
<B>3.7 Global doctor&#8217;s assessment of efficacy</B>
</I>
</P>
<P>
<I>
<U>3.7.1 Alprazolam versus Diazepam,</U>
</I>  1 study (<LINK REF="STD-Kolin-1981" TYPE="STUDY">Kolin 1981</LINK>), 44 participants, RR 1.00 (0.87 to 1.13)</P>
<P>
<I>
<U>3.7.2 Alprazolam versus Chlordiazepoxide,</U>
</I> 1 study (<LINK REF="STD-Wilson-1985" TYPE="STUDY">Wilson 1985</LINK>), 100 participants, RR 0.93 (0.81 to 1.07)</P>
<P>
<I>
<U>3.7.3 Diazepam versus Abecamil,</U>
</I> 1 study (<LINK REF="STD-Anton-1997" TYPE="STUDY">Anton 1997</LINK>), 48 participants, RR 1.00 (0.84 to 1.19)</P>
<P>None found statistically significant differences, but chlordiazepoxide performed better, see <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>
</P>
<P>
<I>
<B>3.8 Global patient&#8217;s assessment of efficacy</B>
</I>
</P>
<P>
<U>3.8.1 <I>Alprazolam versus Diazepam<B>,</B>
</I>
</U>
<I>
<B> </B>
</I>1 study, (<LINK REF="STD-Kolin-1981" TYPE="STUDY">Kolin 1981</LINK>), 44 participants, RR 1.04 (0.92 to 1.18), the result is not statistically significant, see <LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>
</P>
<P>
<B>Safety </B>
</P>
<P>
<I>
<B>3.9 Adverse events as number of participants with at least one adverse event</B>
</I>
</P>
<P>
<I>
<U>3.9.1 Chlordiazepoxide versus Clobazam,</U>
</I> 1 study (<LINK REF="STD-Mukherjee-1983" TYPE="STUDY">Mukherjee 1983</LINK>), 40 participants, RR 0.80 (0.25 to 2.55),  </P>
<P>
<I>
<U>3.9.2 Chlordiazepoxide versus Diazepam,</U>
</I> 2 studies (<LINK REF="STD-Brown-1972" TYPE="STUDY">Brown 1972</LINK>; <LINK REF="STD-Jauhar-2000" TYPE="STUDY">Jauhar 2000</LINK>), 34 participants, RR 3.00 (0.14 to 63.15),</P>
<P>
<I>
<U>3.9.3 Chlordiazepoxide versus Halazepam,</U>
</I> 1 study (<LINK REF="STD-Mendels-1985" TYPE="STUDY">Mendels 1985</LINK>), 80 participants, RR 0.53 (0.05 to 5.57),  </P>
<P>
<I>
<U>3.9.4 Lorazepam versus Diazepam,</U>
</I> 2 studies (<LINK REF="STD-Miller-1984" TYPE="STUDY">Miller 1984</LINK>; <LINK REF="STD-O_x0027_Brien-1983" TYPE="STUDY">O'Brien 1983</LINK>), 96 participants, RR 2.56 (0.35 to 18.62),</P>
<P>
<I>
<U>3.9.5 </U>
</I> <I>
<U>Lorazepam versus Chlordiazepoxide</U>
</I>, 1 study (<LINK REF="STD-Kumar-2009" TYPE="STUDY">Kumar 2009</LINK>) 100 participants RR2.00 0.19, 21.36)</P>
<P>None found statistically significant differences, see <LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK> or <LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK>
</P>
<P>
<I>
<B>3.10 Severe, life-treating adverse events </B>
</I>
</P>
<P>
<I>
<U>3.10.1 Chlordiazepoxide versus Alprazolam,</U>
</I> 1 study (<LINK REF="STD-Wilson-1985" TYPE="STUDY">Wilson 1985</LINK>), 100 participants, only one severe, RR 3.00 (0.131 to 71.92), the result is not statistically significant</P>
<P>
<I>
<U>3.10.2 Chlordiazepoxide versus Clobazam,</U>
</I> 1 study (<LINK REF="STD-Mukherjee-1983" TYPE="STUDY">Mukherjee 1983</LINK>), 40 participants, no events in both groups</P>
<P>
<I>
<U>3.10.3 Chlordiazepoxide versus Diazepam,</U>
</I> 1 study (<LINK REF="STD-Jauhar-2000" TYPE="STUDY">Jauhar 2000</LINK>), 20 participants, no events in both groups</P>
<P>
<I>
<U>3.10.4 Chlordiazepoxide versus Halazepam,</U>
</I> 1 study (<LINK REF="STD-Mendels-1985" TYPE="STUDY">Mendels 1985</LINK>), 80 participants, no events in both groups</P>
<P>
<I>
<U>3.10.5 Diazepam versus Abecamil,</U>
</I> 1 study (<LINK REF="STD-Anton-1997" TYPE="STUDY">Anton 1997</LINK>), 48 participants, RR 0.33 (0.04 to 2.98), the result is not statistically significant</P>
<P>
<I>
<U>3.10.6 Diazepam versus Alprazolam,</U>
</I> 1 study (<LINK REF="STD-Kolin-1981" TYPE="STUDY">Kolin 1981</LINK>), 44 participants, no events in both groups</P>
<P>see <LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>
</P>
<P>
<B>Acceptability</B>
</P>
<P>
<B>3.11 Dropout</B>
</P>
<P>
<I>
<U>3.11.1 Alprazolam versus Diazepam</U>
</I>, 2 studies (<LINK REF="STD-Adinoff-1994" TYPE="STUDY">Adinoff 1994</LINK>; <LINK REF="STD-Kolin-1981" TYPE="STUDY">Kolin 1981</LINK>), 60 participants, RR 0.25 (0.01 to 5.03)</P>
<P>
<I>
<U>3.11.2 Chlordiazepoxide versus Diazepam</U>
<B>,</B>
</I>
<B> </B>2 studies (<LINK REF="STD-Brown-1972" TYPE="STUDY">Brown 1972</LINK>; <LINK REF="STD-Day-2004" TYPE="STUDY">Day 2004</LINK>), 41 participants, RR 6.00 (0.37 to 98.65)</P>
<P>
<I>
<U>3.11.3 Chlordiazepoxide versus Halazepam,</U>
</I> 1 study (<LINK REF="STD-Mendels-1985" TYPE="STUDY">Mendels 1985</LINK>), 92 participants, RR 2.75 (0.80 to 9.51)</P>
<P>
<I>
<U>3.11.4 Chlordiazepoxide versus Clobazam,</U>
</I> 1 study (<LINK REF="STD-Mukherjee-1983" TYPE="STUDY">Mukherjee 1983</LINK>), 54 participants, RR 0.81 (0.32 to 2.01)</P>
<P>
<I>
<U>3.11.5 Chlordiazepoxide versus Lorazepam,</U>
</I> 2 study (<LINK REF="STD-Kumar-2009" TYPE="STUDY">Kumar 2009</LINK>; <LINK REF="STD-Solomon-1983" TYPE="STUDY">Solomon 1983</LINK>), 158 participants, RR 0.75 (0.24, 2.37)</P>
<P>
<I>
<U>3.11.6 Lorazepam versus Diazepam,</U>
</I> 3 studies (<LINK REF="STD-Miller-1984" TYPE="STUDY">Miller 1984</LINK>; <LINK REF="STD-O_x0027_Brien-1983" TYPE="STUDY">O'Brien 1983</LINK>; <LINK REF="STD-Ritson-1986" TYPE="STUDY">Ritson 1986</LINK>), 156 participants, RR 1.20 (0.54 to 2.65)</P>
<P>None found statistically significant differences, see <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK> or <LINK REF="FIG-15" TYPE="FIGURE">Figure 15</LINK>
</P>
<P>
<I>
<B>3.12 Dropout due to adverse events</B>
</I>
</P>
<P>
<I>
<U>3.12.1 Chlordiazepoxide versus Alprazolam, </U>
</I>2 studies (<LINK REF="STD-McLendon-1980" TYPE="STUDY">McLendon 1980</LINK>; <LINK REF="STD-Wilson-1985" TYPE="STUDY">Wilson 1985</LINK>), 143 participants, RR 1.00 (0.21 to 4.72)</P>
<P>
<I>
<U>3.12.2 Chlordiazepoxide versus Clobazam,</U>
</I> 1 study (<LINK REF="STD-Mukherjee-1983" TYPE="STUDY">Mukherjee 1983</LINK>), 40 participants,no events in both groups</P>
<P>
<I>
<U>3.12.3 Chlordiazepoxide versus Diazepam,</U>
</I> 2 studies (<LINK REF="STD-Brown-1972" TYPE="STUDY">Brown 1972</LINK>; <LINK REF="STD-Jauhar-2000" TYPE="STUDY">Jauhar 2000</LINK>), 34 participants, RR 3.00 (0.14 to 63.15)</P>
<P>
<I>
<U>3.12.4 Chlordiazepoxide versus Halazepam,</U>
</I> 1 study (<LINK REF="STD-Mendels-1985" TYPE="STUDY">Mendels 1985</LINK>), 80 participants, no events in both groups</P>
<P>
<I>
<U>3.12.5 Chlordiazepoxide versus Lorazepam,</U>
</I> 1 study, 50 participants, no events in both groups</P>
<P>
<I>
<U>3.12.6 Diazepam versus Abecamil,</U>
</I> 1 study (<LINK REF="STD-Anton-1997" TYPE="STUDY">Anton 1997</LINK>), 48 participants, RR 0.14 (0.01 to 2.62)</P>
<P>
<I>
<U>3.12.7 Diazepam versus Alprazolam, </U>
</I>1 study (<LINK REF="STD-Kolin-1981" TYPE="STUDY">Kolin 1981</LINK>), 44 participants, RR 2.75 (0.12 to 64. 04)</P>
<P>
<I>
<U>3.12.8 Diazepam versus Lorazepam ,</U>
</I> 2 studies (<LINK REF="STD-Miller-1984" TYPE="STUDY">Miller 1984</LINK>; <LINK REF="STD-O_x0027_Brien-1983" TYPE="STUDY">O'Brien 1983</LINK>), 96 participants, RR 0.60 (0.08 to 4.69)</P>
<P>None found statistically significant differences, see <LINK REF="CMP-003.12" TYPE="ANALYSIS">Analysis 3.12</LINK>
<BR/>
</P>
<P>
<B>Benzodiazepine+Other Drug versus Other Drug<BR/>
</B>Three trials including a total of 207 participants, compared benzodiazepine with the combination of a benzodiazepine with another drug : <LINK REF="STD-Dion-1968" TYPE="STUDY">Dion 1968</LINK> (Chlordiazepoxide  + Magnesium sulphate); <LINK REF="STD-Sellers-1977" TYPE="STUDY">Sellers 1977</LINK>; (Chlordiazepoxide  + Propanol) and <LINK REF="STD-Spies-1996" TYPE="STUDY">Spies 1996</LINK> (Flunitrazepam + Clonidine). Very limited data were available, thus making quantitative synthesis not very informative, for more details see <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>.</P>
<P>
<B>Benzodiazepine (fixed schedule) versus Benzodiazepine (symptom-triggered)<BR/>
</B>Three trials (<LINK REF="STD-Daeppen-2002" TYPE="STUDY">Daeppen 2002</LINK>; <LINK REF="STD-Saitz-1994" TYPE="STUDY">Saitz 1994</LINK>; <LINK REF="STD-Spies-2003" TYPE="STUDY">Spies 2003</LINK>), including a total of 262 randomised participants, compared fixed versus symptom-triggered schedules of a benzodiazepine (chlordiazepoxide, oxazepam, flunitrazepam) for various outcomes. There was a small significant benefit of symptom-triggered regimens regarding CIWA-Ar score (change from baseline) at 48 hrs /MD -5.70, CI -11.02 to -0.38). Data on all other outcomes were very all not statistically significant. For more details see <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>; <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>; <LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>; <LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-12-14 10:40:20 +0100" MODIFIED_BY="[Empty name]">
<P>Overall, the small sample size of published RCTs and lack of detailed information on various outcomes illustrate a need for larger, well-designed studies in this field. These studies should be limited to more important efficacy variables and consistency on rating continuous outcomes with the same scales should also be achieved among researchers. </P>
<SUMMARY_OF_RESULTS MODIFIED="2009-12-06 00:23:58 +0100" MODIFIED_BY="[Empty name]">
<P>This systematic review includes data from 57 RCTs with over 4,000 patients with alcohol withdrawal syndrome. Despite the considerable number of RCTs, the large variety of outcomes and rating scales limited considerably the ability to perform a quantitative synthesis of all available data.</P>
<P>Benzodiazepines clearly offered a significant benefit against alcohol withdrawal seizures compared to placebo. This might suggest that their current status as first-line treatment for alcohol withdrawal syndrome is justified. Nevertheless, the available evidence did not suggest that benzodiazepines are clearly superior to other drugs with the exception of a possible superiority in seizure control when compared against non-anticonvulsants. Broadly defined success rates were very similar with benzodiazepines versus other drugs and the 95% confidence intervals even exclude any clinically meaningful differences in this regard. This was true for both short-acting and long-acting benzodiazepines.</P>
<P>Differences between regimens in isolated small trials using more particular outcome measures should be interpreted very cautiously given the large number of outcomes in this field and the small sample size of the studies conducted therein. Nevertheless, even the limited data on such outcomes are not suggestive of any clear superiority of benzodiazepines. Benzodiazepines were less effective, if anything, compared to other drugs in reducing the severity of alcohol withdrawal symptoms, as indicated by change from baseline in doctor's global assessment score at the end of treatment and Hamilton Anxiety Rating Scale score at both 48 hours and the end of treatment in a few small trials. When compared to anticonvulsants, benzodiazepines tended to offer a non-significant benefit for change from baseline in the patient's global assessment score at the end of treatment, but also a non-significant increased risk for alcohol withdrawal seizures.</P>
<P>Data on the comparisons of different benzodiazepines among themselves, benzodiazepine combined with other drug versus other drug, and fixed-schedule versus symptom-triggered regimens of benzodiazepines were very limited, thus making quantitative synthesis for various outcomes either not applicable or not very informative. Based on indirect comparisons, there is no strong evidence at the moment that particular benzodiazepines are more effective than others.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-12-06 00:26:39 +0100" MODIFIED_BY="[Empty name]">
<P>Information on side-effects was not consistently reported in the trial reports. More detailed data on adverse effects would be important to record in these trials, since discontinuation due to side-effects may affect the success of treatment. Moreover, data on side effects should be compared cautiously, as they were derived from patients with potentially different co-morbidity. Patients with severe medical conditions, such as hepatic, heart or lung disease, were often excluded from these trials. However, these patients may be more susceptible to various adverse effects of benzodiazepines. The extremely small mortality rate in all these studies is reassuring, but data on other harms-related outcomes are sparse and fragmented. This important deficiency of the benzodiazepine literature needs to be highlighted for improving future clinical research efforts in this field.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-12-06 00:24:59 +0100" MODIFIED_BY="[Empty name]">
<P>The overall results need to be interpreted with caution, as bias cannot be excluded. Most trials were of very small sample size. Although randomisation was an inclusion criterion indicating some methodological quality for these studies, the method of randomisation was not usually described in sufficient detail in the published reports. Moreover, allocation concealment was usually unclear and information on follow-up was often missing. Furthermore, it was difficult to interpret comparisons of specific settings of treatment (inpatient or outpatient), because a large number of the analysed studies did not present sufficient background information so as to allow a clear understanding of the treatment setting. We could not also examine dose-response effects since patients were not treated with even similar doses of various benzodiazepines across RCTs. Small trials are difficult to interpret in isolation, especially in the face of potential selective reporting of outcomes.</P>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Benzodiazepines are effective against alcohol withdrawal symptoms, in particular seizures, when compared to placebo. It is not possible to draw very precise conclusions about the relative effectiveness and safety of benzodiazepines against other drugs in alcohol withdrawal, because of the large heterogeneity of the trials both in interventions and assessment of outcomes. Nevertheless, the available data do not show differences between benzodiazepines and other drugs in broadly defined success rates. Data on potential harms are sparse and fragmented. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Although a significant number of trends has emerged, most of these were small and the data for most outcomes did not reach statistical significance, indicating the need for larger, well-designed studies in this field. These studies should be limited to few, important efficacy variables such as severity of the alcohol withdrawal syndrome, incidence of seizures and delirium tremens, side effects and mortality. Consistency on rating continuous outcomes in the same scales should also be achieved in order to obtain comparable information from all relevant studies. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-01-08 09:16:26 +0100" MODIFIED_BY="[Empty name]">
<P>We thank the author of the first version of the review that did an excellent work that was very helpful for this update and Zuzana Mitrova for providing helpful assistance during all the process</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-01-07 12:31:07 +0100" MODIFIED_BY="[Empty name]">
<P>Vecchi performed the literature searches; Mitrova organised papers collection; Minozzi and Vecchi reviewed the papers, abstracted data from the papers for meta-analysis. Amato wrote abstract, introduction, discussion and conclusions sections. Minozzi wrote methods and assessed methodological quality of included studies and results sections. Davoli supervised to all the process and all authors provided comments to the final version</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-02-15 15:59:46 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-01-15 11:04:08 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-01-15 11:04:08 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Addolorato-1999" MODIFIED="2008-03-25 10:00:27 +0100" MODIFIED_BY="[Empty name]" NAME="Addolorato 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-03-25 10:00:27 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0145-6008&lt;/p&gt;" NOTES_MODIFIED="2008-03-25 10:00:27 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Addolorato G, Balducci G, Capristo E, Attilia ML, Taggi F, Gasbarrini G et al</AU>
<TI>Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomised comparative study versus benzodiazepine</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>1999</YR>
<VL>23</VL>
<NO>10</NO>
<PG>1596-604</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Addolorato-2006" MODIFIED="2010-01-15 11:04:08 +0100" MODIFIED_BY="[Empty name]" NAME="Addolorato 2006" YEAR="2005">
<REFERENCE MODIFIED="2010-01-15 11:03:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, et al</AU>
<TI>Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam</TI>
<SO>America Journal of Medicine</SO>
<YR>2006</YR>
<VL>119</VL>
<NO>3</NO>
<PG>276.e13-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Adinoff-1994" NAME="Adinoff 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;0145-6008&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adinoff B</AU>
<TI>Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: preliminary findings</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>4</NO>
<PG>873-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ansoms-1991" MODIFIED="2010-01-07 12:49:19 +0100" MODIFIED_BY="[Empty name]" NAME="Ansoms 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-01-07 12:49:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ansoms S, Lebon O, Pelc I, Cabri C, Poels R</AU>
<TI>Zopiclone or Lormetazepam in the treatment of insomnia and the effect on behavior and mood in patients during the post alcoholism withdrawal period</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1991</YR>
<VL>49</VL>
<NO>1</NO>
<PG>54-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anton-1997" MODIFIED="2010-01-07 12:49:48 +0100" MODIFIED_BY="[Empty name]" NAME="Anton 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-01-07 12:49:48 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0033-3158&lt;/p&gt;" NOTES_MODIFIED="2010-01-07 12:49:48 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anton RF, Kranzler HR, McEvoy JP, Moak DH, Bianca R</AU>
<TI>A double-blind comparison of Abecamil and diazepam in the treatment of uncomplicated alcohol withdrawal</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>1997</YR>
<VL>131</VL>
<NO>2</NO>
<PG>123-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bailly-1992" NAME="Bailly 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;0753-3322&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bailly D, Servant D, Blandin N, Beuscart R, Parquet PJ</AU>
<TI>Effects of beta-blocking drugs in alcohol withdrawal: a double-blind comparative study with propranolol and diazepam</TI>
<SO>Biomedicine and Pharmacotherapy</SO>
<YR>1992</YR>
<VL>46</VL>
<NO>9</NO>
<PG>419-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baumgartner-1987" NAME="Baumgartner 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;0003-9926&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baumgartner GR, Rowen RC</AU>
<TI>Clonidine vs chlordiazepoxide in the management of acute alcohol withdrawal syndrome</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1987</YR>
<VL>147</VL>
<NO>7</NO>
<PG>1223-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baumgartner-1991" MODIFIED="2008-03-25 10:01:07 +0100" MODIFIED_BY="[Empty name]" NAME="Baumgartner 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-03-25 10:01:07 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0038-4348&lt;/p&gt;" NOTES_MODIFIED="2008-03-25 10:01:07 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baumgartner GR, Rowen RC</AU>
<TI>Transdermal clonidine versus chlordiazepoxide in alcohol withdrawal: a randomised, controlled clinical trial</TI>
<SO>South African Medical Journal</SO>
<YR>1991</YR>
<VL>84</VL>
<NO>3</NO>
<PG>312-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borg-1986" NAME="Borg 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;0033-3158&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borg S, Kvande H, Valverius P</AU>
<TI>Clinical conditions and central dopamine metabolism in alcoholics during acute withdrawal under treatment with different pharmacological agents</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>1986</YR>
<VL>88</VL>
<NO>1</NO>
<PG>12-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1972" NAME="Brown 1972" YEAR="1972">
<REFERENCE NOTES="&lt;p&gt;0036-9330&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown JH, Moggey DE, Shane FH</AU>
<TI>Delirium tremens: a comparison of intravenous treatment with diazepam and chlordiazepoxide</TI>
<SO>Scottish Medical Journal</SO>
<YR>1972</YR>
<VL>17</VL>
<NO>1</NO>
<PG>9-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burroughs-1985a" MODIFIED="2010-01-07 12:50:03 +0100" MODIFIED_BY="[Empty name]" NAME="Burroughs 1985a" YEAR="1985">
<REFERENCE MODIFIED="2010-01-07 12:50:03 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0735-0414&lt;/p&gt;" NOTES_MODIFIED="2010-01-07 12:50:03 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burroughs AK, Morgan MY, Sherlock S</AU>
<TI>Double-blind controlled trial of bromocriptine, chlordiazepoxide and Chlormethiazole for alcohol withdrawal symptoms</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>1985</YR>
<VL>20</VL>
<NO>3</NO>
<PG>263-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burroughs-1985b" MODIFIED="2010-01-07 12:50:22 +0100" MODIFIED_BY="[Empty name]" NAME="Burroughs 1985b" YEAR="1985">
<REFERENCE MODIFIED="2010-01-07 12:50:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bourroughs AK, Morgan MY, Sherlock S</AU>
<TI>Double-blind controlled trial of bromocriptine, chlordiazepoxide and Chlormethiazole for alcohol withdrawal symptoms</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>1985</YR>
<VL>20</VL>
<NO>3</NO>
<PG>263-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Choi-2005" MODIFIED="2009-11-27 12:44:02 +0100" MODIFIED_BY="[Empty name]" NAME="Choi 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-27 12:44:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Choi EA, Ki SW, Kim SE, Kim JW, Park JK</AU>
<TI>The Efficacy and Safety of Topiramate in the Treatment of Alcohol Withdrawal</TI>
<SO>Journal of Korean Neuropsychiatry Association</SO>
<YR>2005</YR>
<VL>44</VL>
<NO>3</NO>
<PG>328-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daeppen-2002" MODIFIED="2008-03-25 10:01:18 +0100" MODIFIED_BY="[Empty name]" NAME="Daeppen 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-03-25 10:01:18 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0003-9926&lt;/p&gt;" NOTES_MODIFIED="2008-03-25 10:01:18 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daeppen JB, Gache P, Landry U, Sekera E, Schweizer V, Gloor S et al</AU>
<TI>Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomised treatment trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2002</YR>
<VL>162</VL>
<NO>10</NO>
<PG>1117-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Day-2004" MODIFIED="2009-11-27 12:45:27 +0100" MODIFIED_BY="[Empty name]" NAME="Day 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-27 12:45:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Day E.J., Patel J, Georgiou G</AU>
<TI>Evaluation of a symptom-triggered front-loading detoxification technique for alcohol dependence: A pilot study</TI>
<SO>Psychiatric Bulletin </SO>
<YR>2004</YR>
<VL>28</VL>
<NO>11</NO>
<PG>407-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dion-1968" NAME="Dion 1968" YEAR="1968">
<REFERENCE NOTES="&lt;p&gt;0023-9046&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dion C, Simard N, Carle R, Roberge ML</AU>
<TI>Comparative study of chlordiazepoxide and hypertonic MgSO4 in the alcohol withdrawal syndrome</TI>
<SO>Laval Medical</SO>
<YR>1968</YR>
<VL>39</VL>
<NO>3</NO>
<PG>222-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Favre-2005" MODIFIED="2009-11-27 12:48:46 +0100" MODIFIED_BY="[Empty name]" NAME="Favre 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-27 12:48:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Favre JD, Allain H, Aubin HJ, Frija-Orvoen E, Gillet C, Lejoyeux M, et al</AU>
<TI>Double-blind study of cyamemazine and diazepam in the alcohol withdrawal syndrome</TI>
<SO>Human Psychopharmacology</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>7</NO>
<PG>511-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Funderburk-1978" NAME="Funderburk 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Funderburk FR, Allen RP, Wagman AM</AU>
<TI>Residual effects of ethanol and chlordiazepoxide treatments for alcohol withdrawal</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1978</YR>
<VL>166</VL>
<NO>3</NO>
<PG>195-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gillman-2004" NAME="Gillman 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;0306-4603&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gillman MA, Lichtigfeld FJ</AU>
<TI>Enlarged double-blind randomised trial of benzodiazepines against psychotropic analgesic nitrous oxide for alcohol withdrawal</TI>
<SO>Addictive Behaviors</SO>
<YR>2004</YR>
<VL>29</VL>
<NO>6</NO>
<PG>1183-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gillmer-1973" NAME="Gillmer 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;0256-9574&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gillmer RE</AU>
<TI>Benzoctamine and oxazepam in the management of alcohol withdrawal states. Comparison by double-blind trial</TI>
<SO>South African Medical Journal</SO>
<YR>1973</YR>
<VL>47</VL>
<NO>47</NO>
<PG>2267-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Golbert-1967" NAME="Golbert 1967" YEAR="1967">
<REFERENCE NOTES="&lt;p&gt;0098-7484&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Golbert TM, Sanz CJ, Rose HD, Leitschuh TH</AU>
<TI>Comparative evaluation of treatments of alcohol withdrawal syndromes</TI>
<SO>The Journal of the American Medical Association</SO>
<YR>1967</YR>
<VL>201</VL>
<NO>2</NO>
<PG>99-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jauhar-2000" NAME="Jauhar 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;0735-0414&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jauhar P, Anderson J</AU>
<TI>Is daily single dosage of diazepam as effective as chlordiazepoxide in divided doses in alcohol withdrawal: a pilot study</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>2</NO>
<PG>212-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaim-1969" NAME="Kaim 1969" YEAR="1969">
<REFERENCE NOTES="&lt;p&gt;0002-953x&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaim SC, Klett CJ, Rothfeld B</AU>
<TI>Treatment of the acute alcohol withdrawal state: a comparison of four drugs</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1969</YR>
<VL>125</VL>
<NO>12</NO>
<PG>1640-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaim-1972" NAME="Kaim 1972" YEAR="1972">
<REFERENCE NOTES="&lt;p&gt;0033-5649&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaim SC, Klett CJ</AU>
<TI>Treatment of delirium tremens. A comparative evaluation of four drugs</TI>
<SO>Quarterly Journal of Studies on Alcohol</SO>
<YR>1972</YR>
<VL>33</VL>
<NO>4</NO>
<PG>1065-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalyoncu-1996" NAME="Kalyoncu 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalyoncu OA, Beyazyurek M, Kuru L, Solukcu R, Yazman U</AU>
<TI>Double-blind comparative trial with carbamazepine vs diazepam treatment of alcohol withdrawal</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1996</YR>
<VL>6 Suppl 3</VL>
<PG>1-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kolin-1981" NAME="Kolin 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;0160-6689&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kolin IS, Linet OI</AU>
<TI>Double-blind comparison of alprazolam and diazepam for subchronic withdrawal from alcohol</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1981</YR>
<VL>42</VL>
<NO>4</NO>
<PG>169-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kramp-1978" NAME="Kramp 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;0001-690x&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kramp P, Rafaelsen OJ</AU>
<TI>Delirium tremens: a double-blind comparison of diazepam and barbital treatment</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1978</YR>
<VL>58</VL>
<NO>2</NO>
<PG>174-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krupitsky-2007" MODIFIED="2009-11-27 12:51:40 +0100" MODIFIED_BY="[Empty name]" NAME="Krupitsky 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-27 12:51:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, et al</AU>
<TI>Antiglutamatergic strategies for ethanol detoxification: comparison with placebo  and diazepam</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>2007</YR>
<VL>31</VL>
<NO>4</NO>
<PG>604-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumar-2009" MODIFIED="2009-12-29 14:00:57 +0100" MODIFIED_BY="[Empty name]" NAME="Kumar 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-12-29 14:00:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumar CN, Andrade C, Murthy P</AU>
<TI>A Randomized, Double-Blind Comparison of Lorazepamand Chlordiazepoxide in Patients With Uncomplicated Alcohol Withdrawal</TI>
<SO>J. Stud. AlcoholDrugs</SO>
<YR>2009</YR>
<VL>70</VL>
<PG>467-474</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapierre-1983" MODIFIED="2010-01-07 12:57:20 +0100" MODIFIED_BY="[Empty name]" NAME="Lapierre 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-01-07 12:57:20 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0302-282x&lt;/p&gt;" NOTES_MODIFIED="2010-01-07 12:57:20 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lapierre YD, Bulmer DR, Oyewumi LK, Mauguin ML, Knott VJ</AU>
<TI>Comparison of Chlormethiazole (Heminevrin) and chlordiazepoxide (Librium) in the treatment of acute alcohol withdrawal</TI>
<SO>Neuropsychobiology</SO>
<YR>1983</YR>
<VL>10</VL>
<NO>2-3</NO>
<PG>127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lenzenhuber-1999" NAME="Lenzenhuber 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;0003-2417&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lenzenhuber E, Muller C, Rommelspacher H, Spies C</AU>
<TI>Gamma-hydroxybutyrate for treatment of alcohol withdrawal syndrome in intensive care patients. A comparison between with two symptom-oriented therapeutic concepts</TI>
<SO>Anaesthesist</SO>
<YR>1999</YR>
<VL>48</VL>
<NO>2</NO>
<PG>89-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lepola-1984" NAME="Lepola 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;0251-1649&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lepola U, Kokko S, Nuutila J, Gordin A</AU>
<TI>Tiapride and chlordiazepoxide in acute alcohol withdrawal. A controlled clinical trial</TI>
<SO>International Journal of Clinical Pharmacology Research</SO>
<YR>1984</YR>
<VL>4</VL>
<NO>5</NO>
<PG>321-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Longo-2002" NAME="Longo 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;1055-0887&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Longo LP, Campbell T, Hubatch S</AU>
<TI>Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention</TI>
<SO>Journal of Addictive Diseases</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>2</NO>
<PG>55-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lucht-2003" MODIFIED="2010-01-07 12:58:14 +0100" MODIFIED_BY="[Empty name]" NAME="Lucht 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-07 12:58:14 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0735-0414&lt;/p&gt;" NOTES_MODIFIED="2010-01-07 12:58:14 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lucht M, Kuehn KU, Armbruster J, Abraham G, Gaensicke M, Barnow S et al</AU>
<TI>Alcohol withdrawal treatment in intoxicated vs non-intoxicated patients: a controlled open-label study with Tiapride/carbamazepine, Chlormethiazole and diazepam</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>2</NO>
<PG>168-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malcolm-1989" NAME="Malcolm 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;0002-953x&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malcolm R, Ballenger JC, Sturgis ET, Anton R</AU>
<TI>Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>146</VL>
<NO>5</NO>
<PG>617-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malcolm-2002" MODIFIED="2009-11-30 12:00:07 +0100" MODIFIED_BY="[Empty name]" NAME="Malcolm 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-03-25 10:01:51 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0884-8734&lt;/p&gt;" NOTES_MODIFIED="2008-03-25 10:01:51 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC</AU>
<TI>The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomised trial</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>5</NO>
<PG>349-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malcolm-2007" MODIFIED="2009-11-27 12:53:10 +0100" MODIFIED_BY="[Empty name]" NAME="Malcolm 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-27 12:53:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malcolm R, Myrick LH, Veatch LM, Boyle E, Randall PK</AU>
<TI>Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomised,  double blind, controlled comparison of lorazepam vs gabapentin</TI>
<SO>Journal of Clinical Sleep Medicine</SO>
<YR>2007</YR>
<VL>3</VL>
<NO>1</NO>
<PG>24-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-1975" MODIFIED="2010-01-07 12:58:43 +0100" MODIFIED_BY="[Empty name]" NAME="Martin 1975" YEAR="1975">
<REFERENCE MODIFIED="2010-01-07 12:58:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin JC</AU>
<TI>Controlled study on a new tranquillizing (clobazam) for chronic alcoholics with withdrawal syndrome</TI>
<TO>Essai controle d' un nouveau tranquillisant (le clobazam) chez des alcooliques chroniques en phase de sevrage</TO>
<SO>Journal de Pharmacologie Clinique</SO>
<YR>1975</YR>
<VL>II</VL>
<PG>21-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGrath-1975" MODIFIED="2010-01-07 12:59:00 +0100" MODIFIED_BY="[Empty name]" NAME="McGrath 1975" YEAR="1975">
<REFERENCE MODIFIED="2010-01-07 12:59:00 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0007-0890&lt;/p&gt;" NOTES_MODIFIED="2010-01-07 12:59:00 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGrath SD</AU>
<TI>A controlled trial of Chlormethiazole and chlordiazepoxide in the treatment of the acute withdrawal phase of alcoholism</TI>
<SO>British Journal of Addiction to Alcohol and Other Drugs</SO>
<YR>1975</YR>
<VL>70 Suppl 1</VL>
<PG>81-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McLendon-1980" NAME="McLendon 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McLendon DM, Fabre LF</AU>
<TI>A double-blind comparison of the efficacy of alprazolam, chlordiazepoxide hydrochloride and placebo in the chronic withdrawal period from alcohol</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1980</YR>
<VL>28</VL>
<NO>3 II</NO>
<PG>447-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendels-1985" NAME="Mendels 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;0160-6689&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mendels J, Wasserman TW, Michals TJ, Fine EW</AU>
<TI>Halazepam in the management of acute alcohol withdrawal syndrome</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1985</YR>
<VL>46</VL>
<NO>5</NO>
<PG>172-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mielke-1976" NAME="Mielke 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;0011-393x&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mielke DH, Gallant DM, McFarlain RA</AU>
<TI>Clorazepate dipotassium (Tranxene): a controlled evaluation in alcoholic patients after withdrawal</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1976</YR>
<VL>19</VL>
<NO>5</NO>
<PG>506-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1984" NAME="Miller 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;0149-2918&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller WC, Jr., McCurdy L</AU>
<TI>A double-blind comparison of the efficacy and safety of lorazepam and diazepam in the treatment of the acute alcohol withdrawal syndrome</TI>
<SO>Clinical Therapeutics</SO>
<YR>1984</YR>
<VL>6</VL>
<NO>3</NO>
<PG>364-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mukherjee-1983" NAME="Mukherjee 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;0300-0605&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mukherjee PK</AU>
<TI>A comparison of the efficacy and tolerability of clobazam and chlordiazepoxide in the treatment of acute withdrawal from alcohol in patients with primary alcoholism</TI>
<SO>Journal of International Medical Research</SO>
<YR>1983</YR>
<VL>11</VL>
<NO>4</NO>
<PG>205-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naranjo-1983" NAME="Naranjo 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;0009-9236&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naranjo CA, Sellers EM, Chater K, Iversen P, Roach C, Sykora K</AU>
<TI>Nonpharmacologic intervention in acute alcohol withdrawal</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>1983</YR>
<VL>34</VL>
<NO>2</NO>
<PG>214-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nava-2007" MODIFIED="2009-11-27 12:54:43 +0100" MODIFIED_BY="[Empty name]" NAME="Nava 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-27 12:54:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nava F, Premi S, Manzato E, Campagnola W, Lucchini A, Gessa GL</AU>
<TI>Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam</TI>
<SO>The American Journal of Drug and Alcohol Abuse</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>3</NO>
<PG>379-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Brien-1983" NAME="O'Brien 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien JE, Meyer RE, Thoms DC</AU>
<TI>Double-blind comparison of lorazepam and diazepam in the treatment of the acute alcohol abstinence syndrome</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1983</YR>
<VL>34</VL>
<NO>5</NO>
<PG>825-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Overall-1973" NAME="Overall 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;0003-990x&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Brown D, Williams JD, Neill LT</AU>
<TI>Drug treatment of anxiety and depression in detoxified alcoholic patients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1973</YR>
<VL>29</VL>
<NO>2</NO>
<PG>218-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palestine-1976" NAME="Palestine 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;0011-393x&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palestine ML, Alatorre E</AU>
<TI>Control of acute alcoholic withdrawal symptoms: a comparative study of haloperidol and chlordiazepoxide</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1976</YR>
<VL>20</VL>
<NO>3</NO>
<PG>289-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pena_x002d_Ramos-1977" NAME="Pena-Ramos 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;0012-3714&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pena-Ramos A</AU>
<TI>Thioridazine HCl Vs. chlordiazepoxide HCl in controlling symptoms attributable to alcohol withdrawal</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1977</YR>
<VL>38</VL>
<NO>3</NO>
<PG>143-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pena_x002d_Ramos-1979" NAME="Pena-Ramos 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;0160-6689&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pena-Ramos A, Hornberger R</AU>
<TI>MMPI and drug treatment in alcohol withdrawal</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1979</YR>
<VL>40</VL>
<NO>8</NO>
<PG>361-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Radouco_x002d_Thomas-1989" MODIFIED="2010-01-07 12:59:32 +0100" MODIFIED_BY="[Empty name]" NAME="Radouco-Thomas 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-01-07 12:59:32 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0278-5846&lt;/p&gt;" NOTES_MODIFIED="2010-01-07 12:59:32 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Radouco-Thomas S, Garcin F, Guay D, Marquis PA, Chabot F, Huot J et al</AU>
<TI>Double blind study on the efficacy and safety of Tetrabamate and chlordiazepoxide in the treatment of the acute alcohol withdrawal syndrome</TI>
<SO>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>1-2</NO>
<PG>55-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritson-1986" NAME="Ritson 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;0376-8716&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritson B, Chick J</AU>
<TI>Comparison of two benzodiazepines in the treatment of alcohol withdrawal: effects on symptoms and cognitive recovery</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>1986</YR>
<VL>18</VL>
<NO>4</NO>
<PG>329-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Runion-1978" NAME="Runion 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;0083-8969&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Runion HI, Fowler FN</AU>
<TI>A double blind study of chlordiazepoxide and hydroxyzine HC1 therapy in acute alcohol withdrawal utilizing chronic electromyography for tremor assessment</TI>
<SO>Proceedings of the Western Pharmacology Society</SO>
<YR>1978</YR>
<VL>21</VL>
<PG>303-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saitz-1994" MODIFIED="2008-03-25 10:02:25 +0100" MODIFIED_BY="[Empty name]" NAME="Saitz 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-03-25 10:02:25 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0098-7484&lt;/p&gt;" NOTES_MODIFIED="2008-03-25 10:02:25 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saitz R, Mayo-Smith MF, Roberts MS, Redmond HA, Bernard DR, Calkins DR</AU>
<TI>Individualized treatment for alcohol withdrawal. A randomised double-blind controlled trial</TI>
<SO>The Journal of the American Medical Association</SO>
<YR>1994</YR>
<VL>272</VL>
<NO>7</NO>
<PG>519-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saletu-1983" MODIFIED="2008-03-25 10:02:39 +0100" MODIFIED_BY="[Empty name]" NAME="Saletu 1983" YEAR="1983">
<REFERENCE MODIFIED="2008-03-25 10:02:39 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0302-282x&lt;/p&gt;" NOTES_MODIFIED="2008-03-25 10:02:39 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saletu M, Saletu B, Grunberger J, Mader R, Karobath M</AU>
<TI>Clinical symptomatology and computer analysed EEG before, during and after anxiolytic therapy of alcohol withdrawal patients</TI>
<SO>Neuropsychobiology</SO>
<YR>1983</YR>
<VL>9</VL>
<NO>2-3</NO>
<PG>119-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sellers-1977" NAME="Sellers 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;0096-882x&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sellers EM, Zilm DH, Degani NC</AU>
<TI>Comparative efficacy of propranolol and chlordiazepoxide in alcohol withdrawal</TI>
<SO>Journal of Studies on Alcohol</SO>
<YR>1977</YR>
<VL>38</VL>
<NO>11</NO>
<PG>2096-108</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sellers-1983" NAME="Sellers 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;0009-9236&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sellers EM, Naranjo CA, Harrison M, Devenyi P, Roach C, Sykora K</AU>
<TI>Diazepam loading: simplified treatment of alcohol withdrawal</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>1983</YR>
<VL>34</VL>
<NO>6</NO>
<PG>822-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solomon-1983" NAME="Solomon 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;0149-2918&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Solomon J, Rouck LA, Koepke HH</AU>
<TI>Double-blind comparison of lorazepam and chlordiazepoxide in the treatment of the acute alcohol abstinence syndrome</TI>
<SO>Clinical Therapeutics</SO>
<YR>1983</YR>
<VL>6</VL>
<NO>1</NO>
<PG>52-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spies-1996" MODIFIED="2008-03-25 10:02:54 +0100" MODIFIED_BY="[Empty name]" NAME="Spies 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-03-25 10:02:54 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0090-3493&lt;/p&gt;" NOTES_MODIFIED="2008-03-25 10:02:54 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spies CD, Dubisz N, Neumann T, Blum S, Muller C, Rommelspacher H et al</AU>
<TI>Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomised trial</TI>
<SO>Critical Care Medicine</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>3</NO>
<PG>414-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spies-2003" NAME="Spies 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;0342-4642&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spies CD, Otter HE, Huske B, Sinha P, Neumann T, Rettig J et al</AU>
<TI>Alcohol withdrawal severity is decreased by symptom-orientated adjusted bolus therapy in the ICU</TI>
<SO>Intensive Care Medicine</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>12</NO>
<PG>2230-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stuppaeck-1992" NAME="Stuppaeck 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;0735-0414&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stuppaeck CH, Pycha R, Miller C, Whitworth AB, Oberbauer H, Fleischhacker WW</AU>
<TI>Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>1992</YR>
<VL>27</VL>
<NO>2</NO>
<PG>153-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tubridy-1988" MODIFIED="2010-01-07 12:59:46 +0100" MODIFIED_BY="[Empty name]" NAME="Tubridy 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-01-07 12:59:46 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0952-0481&lt;/p&gt;" NOTES_MODIFIED="2010-01-07 12:59:46 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tubridy P</AU>
<TI>Alprazolam versus Chlormethiazole in acute alcohol withdrawal</TI>
<SO>British Journal of Addiction</SO>
<YR>1988</YR>
<VL>83</VL>
<NO>5</NO>
<PG>581-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1985" NAME="Wilson 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;0145-6008&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson A, Vulcano BA</AU>
<TI>Double-blind trial of alprazolam and chlordiazepoxide in the management of the acute ethanol withdrawal syndrome</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>1985</YR>
<VL>9</VL>
<NO>1</NO>
<PG>23-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Worner-1994" NAME="Worner 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;0095-2990&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Worner TM</AU>
<TI>Propranolol versus diazepam in the management of the alcohol withdrawal syndrome: double-blind controlled trial</TI>
<SO>American Journal of Drug and Alcohol Abuse</SO>
<YR>1994</YR>
<VL>20</VL>
<NO>1</NO>
<PG>115-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-01-07 13:00:28 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Baumgartner-1988" NAME="Baumgartner 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;0038-4348&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baumgartner GR</AU>
<TI>Clonidine versus chlordiazepoxide in acute alcohol withdrawal: a preliminary report</TI>
<SO>Southern Medical Journal</SO>
<YR>1988</YR>
<VL>81</VL>
<NO>1</NO>
<PG>56-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benuzzi-1967" NAME="Benuzzi 1967" YEAR="1967">
<REFERENCE NOTES="&lt;p&gt;0036-7672&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benuzzi P, Muller C</AU>
<TI>[3 methods of treating delirium tremens. Comparative study]</TI>
<SO>Schweizerische Medizinische Wochenschrift. Journal Suisse de Medecine</SO>
<YR>1967</YR>
<VL>97</VL>
<NO>39</NO>
<PG>1283-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bowman-1966" NAME="Bowman 1966" YEAR="1966">
<REFERENCE NOTES="&lt;p&gt;0012-3714&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowman EH, Thimann J</AU>
<TI>Treatment of alcoholism in the subacute stage. (A study of three active agents)</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1966</YR>
<VL>27</VL>
<NO>5</NO>
<PG>342-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dobrydnjov-2004" MODIFIED="2009-11-27 12:59:59 +0100" MODIFIED_BY="[Empty name]" NAME="Dobrydnjov 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-27 12:59:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dobrydnjov I, Axelsson K, Berggren L, Samarütel J, Holmström B</AU>
<TI>Intrathecal and Oral Clonidine as Prophylaxis for Postoperative Alcohol Withdrawal Syndrome: A Randomized Double-Blinded Study</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2004</YR>
<VL>98</VL>
<NO>3</NO>
<PG>738-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallant-1969" NAME="Gallant 1969" YEAR="1969">
<REFERENCE NOTES="&lt;p&gt;0095-9863&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallant DM, Bishop MP, Guerrero-Figueroa R, Selby M, Phillips R</AU>
<TI>Doxepin versus diazepam: a controlled evaluation in 100 chronic alcoholic patients</TI>
<SO>Journal of Clinical Pharmacology and New Drugs</SO>
<YR>1969</YR>
<VL>9</VL>
<NO>1</NO>
<PG>57-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerra-1991" NAME="Gerra 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerra G, Caccavari R, Volpi R, Maninetti L, Delsignore R, Coiro V</AU>
<TI>Effectiveness of flumazenil in the treatment of ethanol withdrawal</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1991</YR>
<VL>50</VL>
<NO>1</NO>
<PG>62-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gillman-2002" NAME="Gillman 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;0740-5472&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gillman MA, Lichtigfeld FJ</AU>
<TI>Randomized double-blind trial of psychotropic analgesic nitrous oxide compared with diazepam for alcohol withdrawal state</TI>
<SO>Journal of Substance Abuse Treatment</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>3</NO>
<PG>129-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gillman-2008" MODIFIED="2010-01-07 12:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Gillman 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-01-07 12:59:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gillman MA</AU>
<TI>Psychotropic analgesic nitrous oxide for alcohol withdrawal</TI>
<SO>Am J Health-Syst Pharm</SO>
<YR>2008</YR>
<VL>65</VL>
<PG>2205</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huber-1990" MODIFIED="2008-03-25 10:03:09 +0100" MODIFIED_BY="[Empty name]" NAME="Huber 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-03-25 10:03:09 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0173-0541&lt;/p&gt;" NOTES_MODIFIED="2008-03-25 10:03:09 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huber FT, Bartels H, Siewert JR</AU>
<TI>[Treatment of postoperative alcohol withdrawal syndrome after oesophageal resection]</TI>
<SO>Langenbecks Archiv Fur Chirurgie. Supplement II, Verhandlungen der Deutschen Gesellschaft Fur Chirurgie</SO>
<YR>1990</YR>
<VL>Suppl II</VL>
<PG>1141-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klett-1971" NAME="Klett 1971" YEAR="1971">
<REFERENCE NOTES="&lt;p&gt;0003-990x&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klett CJ, Hollister LE, Caffey EM, Jr., Kaim SC</AU>
<TI>Evaluating changes in symptoms during acute alcohol withdrawal</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1971</YR>
<VL>24</VL>
<NO>2</NO>
<PG>174-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lazarova-2003" MODIFIED="2010-01-07 13:00:08 +0100" MODIFIED_BY="[Empty name]" NAME="Lazarova 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-07 13:00:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lazarova V, Jakovcevska-Kujundziska M, Filovska V</AU>
<TI>Diazepam in combination with Piracetam in the treatment of alcohol withdrawal syndrome</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13 Suppl 4</VL>
<PG>S413</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malcolm-2000" NAME="Malcolm 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;0741-8329&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malcolm R, Roberts JS, Wang W, Myrick H, Anton RF</AU>
<TI>Multiple previous detoxifications are associated with less responsive treatment and heavier drinking during an index outpatient detoxification</TI>
<SO>Alcohol</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>3</NO>
<PG>159-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malmgren-1967" MODIFIED="2010-01-07 13:00:28 +0100" MODIFIED_BY="[Empty name]" NAME="Malmgren 1967" YEAR="1967">
<REFERENCE MODIFIED="2010-01-07 13:00:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0001-6284&lt;/p&gt;" NOTES_MODIFIED="2010-01-07 13:00:28 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malmgren G</AU>
<TI>Comparative investigation of the effects of Dixyrazine, placebo and chlordiazepoxide on alcoholics during hospital care</TI>
<SO>Acta Neurologica et Psychiatrica Belga</SO>
<YR>1967</YR>
<VL>67 Suppl</VL>
<PG>65-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mery-1979" NAME="Mery 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;0306-5251&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mery C, Martin JC</AU>
<TI>Clinical study of clobazam in alcohol detoxification [proceedings]</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1979</YR>
<VL>7 Suppl 1</VL>
<PG>133S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller-1969" NAME="Muller 1969" YEAR="1969">
<REFERENCE NOTES="&lt;p&gt;0038-4348&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muller DJ</AU>
<TI>A comparison of three approaches to alcohol-withdrawal states</TI>
<SO>Southern Medical Journal</SO>
<YR>1969</YR>
<VL>62</VL>
<NO>4</NO>
<PG>495-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myrick-2000" NAME="Myrick 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;0095-2990&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myrick H, Brady KT, Malcolm R</AU>
<TI>Divalproex in the treatment of alcohol withdrawal</TI>
<SO>American Journal of Drug and Alcohol Abuse</SO>
<YR>2000</YR>
<VL>26</VL>
<NO>1</NO>
<PG>155-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myrick-2009" MODIFIED="2009-12-23 09:05:49 +0100" MODIFIED_BY="[Empty name]" NAME="Myrick 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-12-23 09:05:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC et al.</AU>
<TI>A Double-Blind Trial of Gabapentin Versus Lorazepam inthe Treatment of Alcohol Withdrawal</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2009</YR>
<VL>33</VL>
<NO>9</NO>
<PG>1582-1588</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ponce-2005" MODIFIED="2009-11-27 13:01:24 +0100" MODIFIED_BY="[Empty name]" NAME="Ponce 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-27 13:01:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponce G, Rodriguez-Jimenez R, Ortiz H, Rubio G, Jimenez-Arriero MA, Palomo T</AU>
<TI>Oxcarbazepine in the prevention of epileptic syndromes in alcohol detoxification</TI>
<SO>Revista de neurologia</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>10</NO>
<PG>577-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poulos-2004" MODIFIED="2009-11-27 13:03:10 +0100" MODIFIED_BY="[Empty name]" NAME="Poulos 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-27 13:03:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poulos CX, Zack M</AU>
<TI>Low-dose diazepam primes motivation for alcohol and alcohol-related semantic networks in problem drinkers</TI>
<SO>Behavioural Pharmacology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>7</NO>
<PG>503-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rothstein-1973" NAME="Rothstein 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rothstein E</AU>
<TI>Prevention of alcohol withdrawal seizures: the roles of diphenylhydantoin and chlordiazepoxide</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1973</YR>
<VL>130</VL>
<NO>12</NO>
<PG>1381-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sampliner-1974" NAME="Sampliner 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;0098-7484&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sampliner R, Iber FL</AU>
<TI>Diphenylhydantoin control of alcohol withdrawal seizures. Results of a controlled study</TI>
<SO>The Journal of the American Medical Association</SO>
<YR>1974</YR>
<VL>230</VL>
<NO>10</NO>
<PG>1430-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sereny-1965" NAME="Sereny 1965" YEAR="1965">
<REFERENCE NOTES="&lt;p&gt;0007-1447&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sereny G, Kalant H</AU>
<TI>Comparative Clinical Evaluation of Chlordiazepoxide and Promazine in Treatment of Alcohol-Withdrawal Syndrome</TI>
<SO>British Medical Journal</SO>
<YR>1965</YR>
<VL>5427</VL>
<PG>92-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaffer-1968" NAME="Shaffer 1968" YEAR="1968">
<REFERENCE NOTES="&lt;p&gt;0095-9863&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaffer JW, Yeganeh ML, Foxwell NH, Kurland AA</AU>
<TI>A comparison of the effects of prazepam, chlordiazepoxide, and placebo in the short-term treatment of convalescing alcoholics</TI>
<SO>Journal of Clinical Pharmacology and New Drugs</SO>
<YR>1968</YR>
<VL>8</VL>
<NO>6</NO>
<PG>392-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silpakit-1999" NAME="Silpakit 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silpakit C, Silpakit O, Kumyam S</AU>
<TI>Treatment of alcohol withdrawal: a fixed schedule regimen versus symptom-triggered regimen</TI>
<SO>International Medical Journal</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>4</NO>
<PG>287-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-1975" MODIFIED="2009-12-03 17:20:04 +0100" MODIFIED_BY="[Empty name]" NAME="Thompson 1975" YEAR="1975">
<REFERENCE MODIFIED="2009-12-03 17:20:04 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0003-4819&lt;/p&gt;" NOTES_MODIFIED="2009-12-03 17:20:04 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson WL, Johnson AD, Maddrey WL</AU>
<TI>Diazepam and paraldehyde for treatment of severe delirium tremens. A controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1975</YR>
<VL>82</VL>
<NO>2</NO>
<PG>175-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waver-2007" MODIFIED="2009-11-27 13:04:13 +0100" MODIFIED_BY="[Empty name]" NAME="Waver 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-27 13:04:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weaver MF, Hoffman HJ, Johnson RE, Mauck K</AU>
<TI>Alcohol withdrawal pharmacotherapy for inpatients with medical comorbidity</TI>
<SO>Journal of Addictive Diseases.</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>2</NO>
<PG>17-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinberg-2008" MODIFIED="2009-11-27 13:06:32 +0100" MODIFIED_BY="[Empty name]" NAME="Weinberg 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-11-27 13:06:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinberg JA, Magnotti LJ, Fischer PE, Edwards NM, Schroeppel T, Fabian TC, et al</AU>
<TI>Comparison of intravenous ethanol versus diazepam for alcohol withdrawal prophylaxis in the trauma ICU: results of a randomised trial</TI>
<SO>Journal of Trauma</SO>
<YR>2008</YR>
<VL>64</VL>
<NO>1</NO>
<PG>99-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-01-07 10:53:12 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Trevisan-2008" MODIFIED="2010-01-07 10:53:12 +0100" MODIFIED_BY="[Empty name]" NAME="Trevisan 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-01-07 10:53:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trevisan L.A, Ralevski E, Keegan K, Oville A, Vuppalapati D, Gonzalez G, et al</AU>
<TI>Alcohol detoxification and relapse prevention using valproic acid versus gabapentin in alcohol-dependent patients</TI>
<SO>Addictive Disorders and their Treatment</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>3</NO>
<PG>119-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-02-15 15:59:46 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-02-15 15:59:46 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-De-Witte-2003" NAME="De Witte 2003" TYPE="JOURNAL_ARTICLE">
<AU>De Witte P, Pinto E, Ansseau M, Verbanck P</AU>
<TI>Alcohol and withdrawal: from animal research to clinical issues</TI>
<SO>Neuroscience and Biobehavioral Reviews</SO>
<YR>2003</YR>
<VL>27</VL>
<NO>3</NO>
<PG>189-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dodd-2000" NAME="Dodd 2000" TYPE="JOURNAL_ARTICLE">
<AU>Dodd PR, Beckmann AM, Davidson MS, Wilce PA</AU>
<TI>Glutamate-mediated transmission, alcohol, and alcoholism</TI>
<SO>Neurochemistry International</SO>
<YR>2000</YR>
<VL>37</VL>
<NO>5-6</NO>
<PG>509-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DSM_x002d_IV_x002d_R" MODIFIED="2009-11-27 11:35:12 +0100" MODIFIED_BY="[Empty name]" NAME="DSM-IV-R" TYPE="BOOK">
<AU>American Psychiatric Association  (Pub.)</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders., Fourth Edidtion-revised</SO>
<YR>1995</YR>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fox-2003" MODIFIED="2010-02-15 15:59:46 +0100" MODIFIED_BY="[Empty name]" NAME="Fox 2003" TYPE="COCHRANE_PROTOCOL">
<AU>Fox C, Cook C, Loughlin P, Mangal R</AU>
<TI>Acamprosate for alcohol dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-01-15 10:54:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-15 10:54:33 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004332"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gillman-2007" MODIFIED="2010-01-15 10:51:43 +0100" MODIFIED_BY="[Empty name]" NAME="Gillman 2007" TYPE="COCHRANE_REVIEW">
<AU>Gillman MA, Lichtigfeld F, Young T</AU>
<TI>Psychotropic analgesic nitrous oxide for alcoholic withdrawal states</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-01-15 10:51:37 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-15 10:51:37 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005190.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gilman-1996" MODIFIED="2008-03-25 10:03:29 +0100" MODIFIED_BY="[Empty name]" NAME="Gilman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St Laurent RT</AU>
<TI>Benzodiazepine receptor binding in the cerebellum in multiple system atrophy and olivopontocerebellar atrophy studied with positron emission tomography</TI>
<SO>Advances in Neurology</SO>
<YR>1996</YR>
<VL>69</VL>
<PG>456-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hasin-1990" NAME="Hasin 1990" TYPE="JOURNAL_ARTICLE">
<AU>Hasin DS, Grant B, Endicott J</AU>
<TI>The natural history of alcohol abuse: implications for definitions of alcohol use disorders</TI>
<SO>The American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<NO>11</NO>
<PG>1537-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-01-07 15:14:35 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors).</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]</TI>
<SO>The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holbrook-1999" MODIFIED="2008-03-25 10:03:21 +0100" MODIFIED_BY="[Empty name]" NAME="Holbrook 1999" TYPE="JOURNAL_ARTICLE">
<AU>Holbrook AM, Growther R, Lotter A, Cheng C, King D</AU>
<TI>Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal</TI>
<SO>CMAJ: Canadian Medical Association Journal</SO>
<YR>1999</YR>
<VL>282</VL>
<NO>11</NO>
<PG>1054-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kohl-1998" NAME="Kohl 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kohl RR, Katner JS, Chernet E, McBride WJ</AU>
<TI>Ethanol and negative feedback regulation of mesolimbic dopamine release in rats</TI>
<SO>Psychopharmacology</SO>
<YR>1998</YR>
<VL>139</VL>
<NO>1-2</NO>
<PG>79-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koob-1997" NAME="Koob 1997" TYPE="JOURNAL_ARTICLE">
<AU>Koob GF, Nestler EJ</AU>
<TI>The neurobiology of drug addiction</TI>
<SO>The Journal of Neuropsychiatry and Clinical Neurosciences</SO>
<YR>1997</YR>
<VL>9</VL>
<NO>3</NO>
<PG>482-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leone-2010" MODIFIED="2010-01-15 10:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Leone 2010" TYPE="COCHRANE_REVIEW">
<AU>Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F</AU>
<TI>Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-01-15 10:49:15 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-15 10:49:15 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006266"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mayo_x002d_Smith-1997" NAME="Mayo-Smith 1997" TYPE="JOURNAL_ARTICLE">
<AU>Mayo-Smith MF</AU>
<TI>Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guidelines</TI>
<SO>The Journal of the American Medical Association</SO>
<YR>1997</YR>
<VL>278</VL>
<NO>2</NO>
<PG>144-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Minozzi-2010" MODIFIED="2009-12-14 13:29:40 +0100" MODIFIED_BY="[Empty name]" NAME="Minozzi 2010" TYPE="COCHRANE_REVIEW">
<AU>Minozzi S, Amato L, Vecchi S, Davoli M.</AU>
<TI>Anticonvulsants for alcohol withdrawal</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-12-14 13:29:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-12-14 13:29:34 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005064"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ntais-2005" MODIFIED="2009-11-27 11:30:14 +0100" MODIFIED_BY="[Empty name]" NAME="Ntais 2005" TYPE="COCHRANE_REVIEW">
<AU>Ntais C, Pakos E, Kyzas P, Ioannidis JPA</AU>
<TI>Benzodiazepines for alcohol withdrawal</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-11-27 11:30:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-27 11:30:02 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005063"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nutt-1999" NAME="Nutt 1999" TYPE="JOURNAL_ARTICLE">
<AU>Nutt D</AU>
<TI>Alcohol and brain. Pharmacological insights for psychiatrists</TI>
<SO>The British Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>175</VL>
<PG>114-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petty-1993" NAME="Petty 1993" TYPE="JOURNAL_ARTICLE">
<AU>Petty F, Fulton M, Moeller FG, Kramer G, Wilson L, Fraser K et al</AU>
<TI>Plasma gamma-aminobutyric acid (GABA) is low in alcoholics</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1993</YR>
<VL>29</VL>
<NO>2</NO>
<PG>277-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Slawecki-1999" NAME="Slawecki 1999" TYPE="JOURNAL_ARTICLE">
<AU>Slawecki CJ, Somes C, Ehlers CL</AU>
<TI>Effects of chronic ethanol exposure on neurophysiological responses to corticotropin-releasing factor and neuropeptide Y</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>1999</YR>
<VL>34</VL>
<NO>3</NO>
<PG>289-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tejani-2010" MODIFIED="2010-02-15 12:11:59 +0100" MODIFIED_BY="[Empty name]" NAME="Tejani 2010" TYPE="COCHRANE_PROTOCOL">
<AU>Tejani AM, Chan AHill Wah, Kuo IF, Li J</AU>
<TI>Magnesium for alcohol withdrawal.</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-02-15 12:11:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-02-15 12:11:59 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008358 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tsai-1995" NAME="Tsai 1995" TYPE="JOURNAL_ARTICLE">
<AU>Tsai G, Gastfriend DR, Coyle JT</AU>
<TI>The glutamatergic basis of human alcoholism</TI>
<SO>The American Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>152</VL>
<NO>3</NO>
<PG>332-40</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-02-15 12:14:49 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-02-15 12:14:49 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-12-01 12:42:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Addolorato-1999">
<CHAR_METHODS MODIFIED="2009-11-30 14:45:48 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 14:44:13 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 60; Gender: 85% male; age range: 19-63 years<BR/>
<B>Inclusion criteria:</B> Alcoholics (DSM-IV criteria for alcohol abuse and/or dependence), daily alcohol consumption over 80g of ethanol during the last 24h; CIWA-Ar score &gt; 10 (moderate or severe alcohol withdrawal syndrome). <B>Exclusion criteria: </B>delirium tremens; alcoholic hallucinosis; severe psychiatric disease; epilepsy; severe cardiac failure; diabetes mellitus; severe liver impairment; hepatic encephalopathy; kidney failure; neoplastic disease; polydrug abusers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:42:33 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (22) oral diazepam, <B>Group B</B> (26) oral GHB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:16:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> changes in CIWA-Ar scores; STAI; Zung self-rating depression scale; <B>Safety:</B> adverse events, severe life-treating adverse events, mortality; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-30 17:50:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Addolorato-2006">
<CHAR_METHODS MODIFIED="2009-11-30 14:47:54 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 14:45:11 +0100" MODIFIED_BY="[Empty name]">
<P>No: 37. Gender: 86% male; mean age: 42</P>
<P>
<B>Inclusion criteria</B>: met DSM-IV criteria for  alcohol dependence; daily alcohol consumption of more than 80g alcohol/day during the previous 24 hours. <B>Exclusion criteria:</B> current presence of delirium tremens or hallucinosis; severe psychiatric disease; epilepsy; severe cardiac failure; diabetes mellitus; severe liver impairment; liver encephalopathy; kidney failure; neoplastic disease; lack of cooperating relatives; abuse or dependence on other drugs except nicotine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-30 14:48:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> ( 19) diazepam,  total dose of 0.5-0.75mg/kg divided in 6 daily administration; <B>Group B </B>(18) baclofen; 30 mg/day  fractionated in 3 daily administration</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-30 17:50:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>Withdrawal symptoms (CIWA-Ar scale); <B>Safety:</B> adverse events; <B>Acceptability:</B> dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-30 14:45:01 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-02 09:40:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adinoff-1994">
<CHAR_METHODS MODIFIED="2009-11-30 14:49:25 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 14:49:53 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 25; Gender: 100% male.</P>
<P>
<B>Inclusion criteria:</B> alcoholics (DSM-III-R criteria), who have been drinking at least six standard drinks daily for at least 2 weeks before admission and have ingested alcohol within 24h prior admission. <B>Exclusion criteria: </B>concurrent use of other psychoactive substances (except marijuana) within the previous 14 days or history or within the previous 30 days; past or present diagnosis of schizophrenia or bipolar affective disorder; history of seizures or medical conditions (such as liver disease); present use of medication (psychotropics, calcium channel blockers, b-blockers, hypoglycemics, anticonvulsants, sympathetico mimetics)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-02 09:40:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(6) diazepam, <B>Group B</B> (6) placebo,<B>Group C</B> (7) clonidine, <B>Group D</B> (6) alprazolam,</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:02:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>Treatment requirements in order to obtain CIWA-Ar score less than 5; change in CIWA-Ar score 1h after the first medication dose; mean change in CIWA-Ar score/dose of medication administrated; changes in blood pressure and heart rate 1h after the first dose of medication; <B>Safety:</B> mortality; <B>Acceptability:</B> dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:44:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ansoms-1991">
<CHAR_METHODS MODIFIED="2009-11-30 14:50:57 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 14:51:46 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 54; Gender: 67% male; age: 20-55</P>
<P>
<B>Inclusion criteria:</B> insomniac participants in post alcoholism withdrawal period of at least ten days and patients that it was expected to need a hypnotic every day because of their alcohol withdrawal. <B>Exclusion criteria: </B>treatment with psychotropic drugs for the first time during the study period; change of the existing psychotropic drug medication; use of tranquillizers of benzodiazepine type; use of high doses of hypnotics or other drug abuse prior the study period; myasthenia gravis; any disease accompanied with pain; living in an unstable fluctuating condition with mental or physical stress; severe liver or kidney disturbance; shift workers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:44:08 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(25) lometazepam 1mg/day for 5 days, <B>Group B</B> (27) zopiclone, 7.5mg/day for 5 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:03:08 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>global improvement,<B> </B>Hypnotic efficacy (Spiegel sleep questionnaire); behavior and mood at awakening (Norris Mood Rating Scale); doctor's assessment of efficacy; <B>Safety:</B> adverse events, mortality;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-07 12:31:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anton-1997">
<CHAR_METHODS MODIFIED="2009-11-30 14:53:20 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 14:53:47 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 49; Gender: 100% male</P>
<P>
<B>Inclusion criteria:</B> met DSM-III-R criteria for uncomplicated alcohol withdrawal; no history of seizures; blood alcohol levels less than or equal to 100 mg% at study entry; alcohol withdrawal of mild-to-moderate severity, as indicated by a CIWA-Ar score; good cognitive function. <B>Exclusion criteria: </B>incidental use of prescribed benzodiazepines or other sedative-hypnotic drugs in the 5 days prior to the study; a past psychotic or bipolar affective disorder; current anxiety disorder or organic mental disorder; recent use of therapeutic psychotropic medications; other substance abuse disorder in the month prior to the study; liver enzyme elevations more than 2.5 times normal; increased medical risk during alcohol withdrawal due to serious medical conditions (e.g. IDDM, uncontrolled hypertension, renal disease)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 12:31:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(24) diazepam, total daily dosage over 5 days: 25 mg, 20 mg, 15 mg, 10 mg, and 5 mg. <B>Group B </B>(25) Abecamil; total daily dosage over 5 days: 20 mg, 17.5 mg, 12.5 mg, 7.5mg, and 2.5 mg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:17:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>delirium, change in CIWA-Ar score; global improvement, doctor's assessment of efficacy; <B>Safety:</B> adverse events, severe life-treating adverse events, mortality; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:45:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bailly-1992">
<CHAR_METHODS MODIFIED="2009-11-30 14:56:21 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-01 12:45:17 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 28 Gender: 100% male</P>
<P>
<B>Inclusion criteria:</B> met  DSM-III-R criteria for alcohol dependence; exhibited moderate uncomplicated alcohol withdrawal the day following admission. <B>Exclusion criteria: </B>score &lt; 8 in the Gross Rating Scale for Alcohol Withdrawal; alcohol withdrawal delirium and other mental disorders specific medical problems, especially intolerance to propranolol or diazepam treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:45:28 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (14) diazepam; 30 mg for 15 days, <B>Group B</B> (14) propranolol; 75 mg for 15 days. All patients received vitamins and hydrated as appropriate. Additional diazepam treatment was administered when necessary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:03:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>seizures,<B> </B>Changes in GRSAW; evaluation of anxiety with HARS and CAS; sedation assessment; changes in pulse rate, blood pressure, breathing frequency; <B>Safety:</B> adverse events, mortality; <B>Acceptability:</B> dropouts; <B>Other:</B> duration and total dose of extra administered diazepam.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:45:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baumgartner-1987">
<CHAR_METHODS MODIFIED="2009-11-30 14:58:01 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 14:58:09 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 61Gender: 100% male; age range: 18-65 years</P>
<P>
<B>Inclusion criteria:</B> met DSM-III criteria for alcohol dependence; histories consistent with daily drinking of large volumes of alcoholic beverages for the month prior to admission <B>Exclusion criteria: </B>history, physical examination, or laboratory evidence suggestive of severe medical or psychiatric illness; history of use of prescription or illicit drugs; and history of seizures</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:45:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (21) chlordiazepoxide oral, <B>Group B </B>(26) clonidine oral.<BR/>All participants could receive up to 650 mg of acetaminophen for headache if needed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:03:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>changes in CIWA-Ar scores, HARS, CCSE; SRS; vital signs; <B>Safety:</B> mortality; <B>Acceptability:</B> dropouts;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:45:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baumgartner-1991">
<CHAR_METHODS MODIFIED="2009-11-30 15:00:17 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 15:00:03 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 50</P>
<P>
<B>Inclusion criteria: </B>meet DSM-III-R criteria for alcohol dependence; drinking more than 160g of ethanol per day for more than 10 days before the study and an average of more than 80g of ethanol per day for more than 2 years; an AWAS score 15 or higher; a CCSE score of at least 15; and be able to sign informed consent. <B>Exclusion criteria:</B> participation in any drug protocol within the preceding 16 months; use of any concurrent prescription, non prescription or illicit drug; use of illicit drugs for 3 or more days during the 60 days before admission; severe medical or psychiatric illness; history of a hypersensitivity response to either clonidine or chlordiazepoxide</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:45:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (20) chlordiazepoxide, <B>Group B </B>(23) transdermal clonidine. All participants could receive up to 650mg of acetaminophen for headache if needed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:04:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>seizures, Withdrawal severity with AWAS; HARS, CCSE; evaluation of sleep quality and vital signs; <B>Safety:</B> mortality; <B>Acceptability:</B> dropouts;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-07 12:32:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Borg-1986">
<CHAR_METHODS MODIFIED="2009-11-30 15:03:18 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 15:03:42 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 45; Gender: 100% male; age range: 29-73 years</P>
<P>
<B>Inclusion criteria</B>: WHO criteria for alcohol dependence. <B>Exclusion criteria:</B> history of liver cirrhosis or psychotic disorders</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 12:32:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (15) oxazepam; initial dose=120 mg/day reduced in steps of 10 mg/day during the week, <B>Group B </B>(15) amobarbital; initial dose=800 mg/day reduced in steps of 100 mg/day during the week. <B>Group C</B> (15) Melperone; 200 mg/day throughout the week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:04:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>seizures,<B> </B>CPRS scores ;  homovanillic acid levels in cerebrospinal fluid; <B>Safety:</B> mortality; <B>Acceptability:</B> dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-02 10:09:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brown-1972">
<CHAR_METHODS MODIFIED="2009-11-30 15:18:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 15:24:02 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 18</P>
<P>
<B>Inclusion criteria </B>: history of alcoholism; recent heavy drinking ending not more than 72h previously; disorientation for time and impaired retention of information on simple testing; visual and/or auditory hallucinations; restlessness and/or aggressiveness; and coarse irregular tremor. <B>Exclusion criteria:</B> pre-existing functional or organic psychosis; addiction to other drugs; other significant physical illness; previous treatment for the presence attack; administration of phenothiazines within the past 48h; pregnancy; age &gt; 55 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-02 10:09:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (7) chlordiazepoxide injection, <B>Group B </B>(7) diazepam injection, .</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:34:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>Changes in blood pressure, heart rate; blood alcohol levels; symptoms check list; <B>Safety:</B> adverse events; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-07 12:33:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burroughs-1985a">
<CHAR_METHODS MODIFIED="2009-11-30 15:27:42 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-05 13:01:55 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 44</P>
<P>
<B>Inclusion criteria:</B> history of alcohol drinking in excess of 80 g/day for five or more years; history of previous alcohol withdrawal.Patient with minimal withdrawal syndrome </P>
<P>
<B>Exclusion criteria: </B>participants who had taken psychotropic drugs within 48h of hospital administration</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 12:33:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (10) chlordiazepoxide, <B>Group B</B> (11) placebo, <B>Group C </B>(12) Chlormethiazole, <B>Group D </B>(11) bromocriptine<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:17:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>global improvement, Changes in Gross scale and Borg scale; <B>Safety:</B> adverse events, severe life-treating adverse events, mortality; <B>Acceptability:</B> dropouts dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-30 18:00:45 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-07 12:33:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burroughs-1985b">
<CHAR_METHODS MODIFIED="2009-11-30 15:31:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-05 13:02:03 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 27</P>
<P>
<B>Inclusion criteria:</B> history of alcohol drinking in excess of 80 g/day for five or more years; history of previous alcohol withdrawal.Patients with intense withdrawal syndrome</P>
<P> <B>Exclusion criteria: </B>participants who had taken psychotropic drugs within 48h of hospital administration</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 12:33:47 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (10) chlordiazepoxide, <B>Group B</B> (8) Chlormethiazole, <B>Group C </B>(9) bromocriptine<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:17:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>global improvement, Changes in Gross scale and Borg scale; <B>Safety:</B> adverse events, severe life-treating adverse events, mortality; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-07 12:33:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Choi-2005">
<CHAR_METHODS MODIFIED="2009-11-30 15:32:40 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 15:32:55 +0100" MODIFIED_BY="[Empty name]">
<P>No: 52. . Gender: male:93%; mean age: 46</P>
<P>
<B>Inclusion criteria: </B>meet DSM-IV criteria for alcohol dependence</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 12:33:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (27) lorazepam 4mg divided by 4 doses on day 1, tapering to 2mg divided by 2 doses. <B>Group B </B>(25) Topiramate fixed, single dose, 50mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-30 18:02:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>Withdrawal symptoms (CIWA-Ar scale)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 11:45:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daeppen-2002">
<CHAR_METHODS MODIFIED="2009-11-30 15:34:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 15:34:36 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 117, Gender: 77% male</P>
<P>
<B>Inclusion criteria: </B>meet DSM-IV criteria for alcohol dependence. <B>Exclusion criteria</B>:  last alcoholic beverage intake more than 72 hours prior to admission; daily use of medication for treatment of alcohol withdrawal for the 30 days prior to admission; major cognitive, psychiatric, or medical comorbidity; opiate or stimulant dependence; no fluency in French</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-30 15:35:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(56) oxazepam in response to signs of alcohol withdrawal (symptom-triggered) plus placebo every 6 hours (4 doses of 30 mg/6 hours, then 8 doses of 15 mg/6 hours). <B>Group B</B> (61) oxazepam every 6 hours (fixed-schedule); 4 doses of 30 mg/6 hours, then 8 doses of 15 mg/6 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:45:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>seizures<B>, </B>delirium,<B> </B>changes in<B> </B>CIWA-Ar scores; <B>Safety:</B> mortality; <B>Other: </B>comfort level (well-being schedule and health-related quality of life)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-30 15:34:46 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:04:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Day-2004">
<CHAR_METHODS MODIFIED="2009-11-30 15:35:35 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 15:35:57 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 23 Gender: 61% male; mean age: 45</P>
<P>
<B>Inclusion criteria:</B> patients meeting ICD-10 criteria for alcohol dependence; requiring inpatient detoxification; one of the following criteria: history of seizures related to alcohol withdrawal, history of delirium tremens, more than three previous unsuccessful attempts at home detoxification in the past, physical or psychiatric comorbidity, making community detoxification unsafe, lack of social support for a community detoxification <B>Exclusion criteria: </B>dependents on substances other than alcohol; severe liver impairment; other major physical illness; unable or unwilling to give informed consent.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:04:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (11) diazepam 20 or 10 mg according to CIWA-Ar score. <B>Group B</B> (12) chlordiazepoxide 30mg of every 6 hours on the first day then tapered to 0.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:21:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>seizures;<B> Acceptability:</B> dropouts; <B>Other: </B>Amount of medication used; duration of the detoxification period; patient satisfaction;view of the nursing staff</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:04:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dion-1968">
<CHAR_METHODS MODIFIED="2009-11-30 15:36:50 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 15:42:05 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 45, Gender: 100% male</P>
<P>
<B>Inclusion criteria:</B> gamma alcoholics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:04:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (15) chlordiazepoxide; 50 mg, <B>Group B </B>(15) MgSO4; 2000 mg, <B>Group C</B> (15) chlordiazepoxide 25 mg + MgSO4 1000 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:04:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>delirium, Patients' improvement; <B>Safety:</B> mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Article in French</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-07 12:34:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Favre-2005">
<CHAR_METHODS MODIFIED="2009-11-30 15:41:05 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-07 12:34:26 +0100" MODIFIED_BY="[Empty name]">
<P>No.= 89 Gender: 86 % male; mean age: 43.</P>
<P>
<B>Inclusion criteria:</B> patients hospitalised to achieve alcohol withdrawal; alcohol-dependence syndrome (DSM IV criteria); alcohol withdrawal symptoms score between 10 and 30 at the CIWA_Ar scale. <B>Exclusion criteria: </B>psychiatric or neurological disorders; dependence on illicit substances; respiratory insufficiency; cancer; HIV infection; immuno-depression syndrome; serious hepatic, renal, cardiac or metabolic pathologies; pregnancy; women taking contraceptives; any established contra-indication for cyamemazine and diazepam; regular treatment during the preceding 2 weeks  with meprobamate, antidepressants, neuroleptics, opioid agonists, anticonvulsant agents, levodopa; treatment during the week preceding the inclusion with hypnotic or sedative agents, antipsychotics, central  antihypertensive agents, guanethidine and guanethidine-like drugs, sulpiride, or drugs used to treat alcohol withdrawal; participation in any clinical trial during the preceding month or any previous inclusion in an alcohol withdrawal trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:49:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (44) diazepam 10 mg, <B>Group B</B> (45) cyamemazine 50mg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:15:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>seizures,delirium, changes in CIWA-Ar scores, change in the anxiety intensity; global clinical impression; global improvement (CGI scale); <B>Safety:</B> adverse events, extrapyramidal symptom;blood pressure; oxygen saturation; <B>Acceptability:</B> dropouts;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:05:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Funderburk-1978">
<CHAR_METHODS MODIFIED="2009-11-30 15:44:36 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 15:44:58 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 18, Gender: 100% male; age range: 22-45 years (mean = 45)</P>
<P>
<B>Inclusion criteria: </B>Alcoholics admitted to the sleep research ward at Baltimore City Hospitals. All subjects were volunteers who were screened for medical and neurological problems and who had been drinking at the time of admission.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:05:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>chlordiazepoxide; 50-200 mg daily during a 2- to 4-day treatment period, <B>Group B</B> ethanol; 8 doses daily of 60 ml every 2 hours for 2 to 5 days, reduced to 30 ml on the final treatment day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-30 18:07:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>Sleep characteristics; BCL; MAC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:06:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gillman-2004">
<CHAR_METHODS MODIFIED="2009-11-30 15:46:01 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 18:07:19 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 51</P>
<P>
<B>Inclusion criteria: </B>meet DSM-IV criteria for alcohol withdrawal. <B>Exclusion criteria:</B> other medical or psychiatric condition; other substances of abuse; alcoholic delirium and pre delirium;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:06:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (28) diazepam 5 mg, <B>Group B </B>(23) psychotropic analgesic nitrous oxide </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:05:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> alcohol withdrawal seizures, global improvement, modified Gross scale (similar to CIWA-Ar); <B>Safety:</B> mortality<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:08:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gillmer-1973">
<CHAR_METHODS MODIFIED="2009-11-30 15:47:18 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 15:47:22 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 35 Gender: 74% male</P>
<P>
<B>Exclusion criteria: </B>endogenous depression, severe hepatitis or renal disease<BR/>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:08:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (19) oxazepam, <B>Group B</B> (15) benzoctamine.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:05:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>global improvement, Changes in doctor's global assessment in a 5-point scale; changes in patient's assessment in a thermometer scale; <B>Safety:</B> adverse events, mortality; <B>Acceptability:</B> dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:09:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Golbert-1967">
<CHAR_METHODS MODIFIED="2009-11-30 15:48:16 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-01 09:01:22 +0100" MODIFIED_BY="[Empty name]">
<P>N=49, Gender: 100% male; age range: 31-71 years</P>
<P>
<B>Inclusion criteria: </B>patients admitted to the Veterans Administration Hospital, and in whom alcohol withdrawal syndromes subsequently developed. 47 were classified as in the "tremulous state" and 2 patients were classified as in "acute hallucinosis"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:09:44 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (12) chlordiazepoxide, <B>Group B </B>(13) promazine. <B>Group C</B> (12) paraldehyde and chloral hydrate. <B>Group D</B> (12) alcohol.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 12:09:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>delirium, global improvement; <B>Safety:</B> mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 11:34:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jauhar-2000">
<CHAR_METHODS MODIFIED="2009-11-30 15:50:41 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 15:51:33 +0100" MODIFIED_BY="[Empty name]">
<P>N = 20</P>
<P>
<B>Inclusion criteria</B>: in-patients with severe alcohol-dependence syndrome. <B>Exclusion criteria:</B> severe physical illness or psychiatric co-morbidity</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-30 15:51:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(9) chlordiazepoxide 4 times a day over 8 days; starting daily dose of 80 mg. <B>Group B</B> (11) diazepam once and placebo 3 times a day over 8 days; starting daily dose of 40 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:34:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> changes in CIWA-Ar scores, pulse; temperature; blood pressure; <B>Safety:</B> adverse events, severe life-treating adverse events; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-30 18:11:27 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:11:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaim-1969">
<CHAR_METHODS MODIFIED="2009-11-30 15:52:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 15:52:58 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 537</P>
<P>
<B>Inclusion criteria: </B>newly admitted male who had been drinking for a period of at least two weeks preceding hospitalisation, and patients admitted for relatively minor medical or surgical conditions and developed AWS during the early part of hospitalisation; all with at least four of the following symptoms: gastrointestinal distress sweatiness or flushing or both; insomnia; tremulousness; irritability; apprehension; clouded sensorium; confusion <B>Exclusion criteria:</B> age over 55; frank schizophrenia or obvious chronic brain syndrome; complications requiring primarily medical or surgical attention; delirium tremens at the time of hospitalisation; known epilepsy or diabetes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:11:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (103) chlordiazepoxide. <B>Group B</B> (130) placebo, <B>Group C</B> (103) chlorpromazine. <B>Group D </B>(98) hydroxyzine. <B>Group D</B> (103) thiamine<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:05:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> seizures; delirium, Nurse Rating Scale; Lorr's Mood; symptoms checklist; global rating; <B>Safety:</B> mortality; <B>Acceptability:</B> dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:50:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaim-1972">
<CHAR_METHODS MODIFIED="2009-11-30 15:55:47 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 15:56:20 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 202, Gender: 100% male</P>
<P>
<B>Inclusion criteria</B>: patients with a clearly established history of alcoholism and manifested all three of the cardinal symptoms of delirium tremens - disorientation, tremor, and hallucinations - during the episode that led to their hospitalisation. <B>Exclusion criteria</B>: frank schizophrenic reaction; obvious chronic brain syndrome; serious medical or surgical conditions; diabetes mellitus; or a diagnosis of epilepsy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:50:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (46) chlordiazepoxide, <B>Group B</B> (14) placebo, <B>Group C</B> (55) paraldehyde, <B>Group D</B> (41) pentobarbital, <B>Group E</B> (46) perphenazine,<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:18:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> seizures; Nurse Rating Scale; Physicians Symptom Recor d;symptoms checklist; global rating; <B>Safety:</B> mortality; <B>Acceptability:</B> dropouts, dropouts due to adverse events; <B>Other:</B> Treatment Booklet</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:13:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalyoncu-1996">
<CHAR_METHODS MODIFIED="2009-11-30 15:57:18 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 15:57:33 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 83, Gender: 100% male; age range: 18-65 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:13:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (34) diazepam; max. 80 mg/day for 7 days, <B>Group B </B>(33) carbamazepine; max. 800mg/day for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:05:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> delirium, MMSE; CIWA score; SCL-90-R; Beck depression inventory; global pathology assessment; <B>Safety:</B> mortality; <B>Acceptability:</B> dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Meeting Abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:15:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kolin-1981">
<CHAR_METHODS MODIFIED="2009-11-30 15:58:26 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 15:58:51 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 49, Gender: 57% male; age range: 18-70 years</P>
<P>
<B>Inclusion criteria: </B>chronic alcoholics on the 5th day after their last drink with moderate to severe anxiety. <B>Exclusion criteria:</B> acute withdrawal reaction; history of delirium tremens; additional psychiatric disease; uncontrolled organic disease; pregnancy; use of contraceptive pills; sensitivity to benzodiazepines; drug addiction; treatment with another psychotropic medication, strong analgesics, or another investigational drug</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:15:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (23) oral diazepam, <B>Group B</B> (21) oral alprazolam.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:35:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> changes in HARS scores; doctor's assessment of efficacy; patient's assessment of efficacy; HSCL; target symptoms record; <B>Safety:</B> adverse events, severe life-treating adverse events; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 11:06:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kramp-1978">
<CHAR_METHODS MODIFIED="2009-11-30 15:59:44 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:00:12 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 91, Gender: 89% male; age range: 21-62 years</P>
<P>
<B>Inclusion criteria: </B>delirium tremens; history of alcohol abuse; actual condition was related to alcohol abuse; severity of the symptoms permitted admission and treatment according to the general routine of the department; intense gross tremor of the extremities and intense perspiration; duration of the symptoms should be at least some hours. <B>Exclusion criteria:</B> intake of psychoactive drugs during the last 24 hours before treatment; alcohol in the blood at the time of treatment; acute event in chronic alcoholic hallucinosis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-30 16:00:38 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(44) diazepam 20 mg i.m. plus placebo p.os. <B>Group B</B> (47) barbital 500 mg p.os plus placebo i.m.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:06:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>seizures, global improvement, doctor's assessment of efficacy; <B>Safety:</B> mortality; <B>Acceptability:</B> dropouts; <B>Other:</B> Physical status; mental condition<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-07 12:35:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krupitsky-2007">
<CHAR_METHODS MODIFIED="2009-11-30 16:01:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:01:28 +0100" MODIFIED_BY="[Empty name]">
<P>No.= 127 Gender: 100 % male; mean age: 43.</P>
<P>
<B>Inclusion criteria:</B> meet DSM-IV criteria for alcohol dependence; history of most recent alcohol consumption between 8 and 48 hours before study entry; clinically significant alcohol withdrawal symptoms on the basis of the CIWA-Ar. <B>Exclusion criteria </B>: use of  psychoactive or anticonvulsant medications other than those prescribed in the study; opiate dependence; need of urgent treatment for other symptoms; to be at high risk for untoward side effects from study medications</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 12:35:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (25) diazepam 10 mg every 8 hours for a total daily dose of 30 mg/d. <B>Group B </B>(25) placebo, <B>Group C</B> (26) Topiramate 25mg every 6 hours for a total of 100 mg/d, <B>Group D </B>(26) memantine 10 mg every 8 hours for a total of 30 mg/d, <B>Group E </B>(25) lamotrigine 25 mg every 6 hours for a total daily dose of 100 mg/d.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 10:30:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> Withdrawal symptom (CIVA-Ar observer and self rated); Dysphoric mood (MADRS scale); <B>Safety</B>: adverse events; <B>Acceptability:</B> dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-29 14:16:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kumar-2009">
<CHAR_METHODS MODIFIED="2009-12-29 14:02:52 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-29 14:06:42 +0100" MODIFIED_BY="[Empty name]">
<P>No: 100, Gender: 100% male; age ranges: 18-55 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-29 14:10:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B>: lorazepam (n = 50) ; <B>Group B</B>: chlordiazepoxide (n = 50)</P>
<P>
<B>Inclusion criteria</B>: Patients admitted to hospital for detoxification form alcohol, free of medical conditions that required immediate attention or that could decompensate during the course of the study.</P>
<P>
<B>Exclusion criteria</B>: patients dependent on any substance other than nicotine; had used a drug known to lower the seizure threshold during the past 14 days; had already received medication that could influence the clinical picture of alcohol withdrawal or the outcome assessments; had clinically signifi cant psychiatric comorbidity (e.g., major depression or psychosis); had contraindications for the use of either of the study medications; or had already experienced a complication related to alcohol withdrawal at the time of screening.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-29 14:16:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: CIWA-Ar score , delirium, seizures, <B>Safety</B>:adverse events; <B>Acceptability</B>: drop out</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-07 12:36:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lapierre-1983">
<CHAR_METHODS MODIFIED="2009-11-30 16:02:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:02:53 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 40, Gender: 83% male; age range: 24-60 years</P>
<P>
<B>Inclusion criteria: </B>patients admitted to hospital for moderate to acute symptoms of alcohol withdrawal; history of alcohol abuse of at least 5 years; current episode of heavy drinking of at least 10 days duration. <B>Exclusion criteria:</B> history or positive urine drug screen for other substances' addiction; acute infections; head or major bony injures; medical conditions involving the cardiovascular; endocrine; pulmonary; and nervous system; gross and severe physical deterioration secondary to excessive alcohol intake resulting in severe renal, hepatic, nutritional, hematological and electrolytic disturbances; and schizophrenic illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 12:36:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (20) chlordiazepoxide, <B>Group B </B>(20) Chlormethiazole.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:18:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> Changes in AWS; TSA; SSA; <B>Safety:</B> adverse events, severe life-treating adverse events, mortality; <B>Acceptability:</B> dropouts, dropouts due to adverse events; <B>Other</B>: psychophysiological assessment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:18:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lenzenhuber-1999">
<CHAR_METHODS MODIFIED="2009-11-30 16:03:48 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>No. = 42</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:18:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (21) flunitrazepam, <B>Group B </B>(21) gamma-hydroxybutyrate (GHB).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:06:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> CIWA-Ar score; <B>Safety:</B> mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Article in German</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-07 12:36:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lepola-1984">
<CHAR_METHODS MODIFIED="2009-11-30 16:04:31 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:04:59 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 60, Gender: 88% male; age range: 20-60 years</P>
<P>
<B>Inclusion criteria: </B>patients admitted to Harjamaki Mental Hospitalbecause of abuse of alcohol and acute alcohol withdrawal symptoms, who signed informed consent. <B>Exclusion criteria:</B> treatment with the study medication for at least 3 days<BR/>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 12:36:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (26) chlordiazepoxide, <B>Group B</B> (24) Tiapride.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:06:36 +0100" MODIFIED_BY="[Empty name]">
<P>Efficacy: global improvement, patient's assessment of efficacy, changes in heart rate, blood pressure, symptomatology; patients' assessment of efficacy; changes in laboratory values; <B>Safety:</B> adverse events, mortality;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-07 12:36:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Longo-2002">
<CHAR_METHODS MODIFIED="2009-11-30 16:06:04 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:06:32 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 16, Gender: 50% male; age: 18-65</P>
<P>
<B>Inclusion criteria:</B> DSM-IV criteria for alcohol dependence; desire to quit drinking; acceptable health; reliable and compliant; CIWA-Ar score &gt; 8 and &lt; 20 on entry. <B>Exclusion criteria: </B>history of seizures or delirium tremens; significant medical co-morbidity; abuse or dependence on drugs other than alcohol, cannabis, nicotine or caffeine; DSM-IV diagnosis of an Axis I psychiatric disorder for which pharmacotherapy was required; pregnancy or lack of birth control; treatment within the month prior to screening and during the six week period with medications which might influence drinking outcomes; no fixed domicile or collateral informant</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 12:36:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(7) chlordiazepoxide <B>Group B</B> (5) Depakote 5-day detoxification. <B>Group C</B> (5) Depakote plus 6-week maintenance</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-07 12:36:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> changes in CIWA-Ar scores, ADS; TLFB, drinking diary; treatment utilization; CGI; ASI; VCS; OCDS; VSS; SIP; Laboratory values; <B>Safety:</B> adverse events, mortality;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-07 12:36:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lucht-2003">
<CHAR_METHODS MODIFIED="2009-11-30 16:08:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:08:33 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 127, Gender: 93% male; mean age = 43.1 years</P>
<P>
<B>Inclusion criteria</B>: patients with alcohol dependence (ICD-10) admitted for alcohol detoxification therapy; alcohol withdrawal syndrome; age &gt; or = 18 years; direct admission. <B>Exclusion criteria:</B> delirium on admission; contraindications or severe side effects against the study medications; other drug/substance dependence; pregnancy and lactation; psychosis; severe physical diseases; more than 5 single doses of study medications 2 weeks prior to study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 12:36:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (34) diazepam (max. 80 mg/day) for 9 days, <B>Group B</B> (31) Chlormethiazole (max. 3840 mg/day) for 9 days, <B>Group C </B>(28) carbamazepine (max. 1200 mg/day) for 9 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:06:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B>
<I> </I>seizure; delirium; CIWA-Ar score; global improvement, VAS; SCL-90-R; <B>Safety:</B> adverse events, mortality; <B>Acceptability:</B> dropouts<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:20:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malcolm-1989">
<CHAR_METHODS MODIFIED="2009-11-30 16:09:45 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:10:12 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 66, Gender: 100% male; age range: 18-65 years</P>
<P>
<B>Inclusion criteria: </B>met DSM-III criteria for alcohol dependency, MMSE &gt;25; CIWA = or &gt; 20. <B>Exclusion criteria:</B> history of daily use of CNS active drugs, including prescription, nonprescription, and illicit agents; 5 or more days of illicit drug abuse (other than alcohol) in the 30 days before admission; allergic or adverse reactions to oxazepam or carbamazepine; manic-depressive illness, schizophrenia, or dementia; history of hepatic encephalopathy, jaundice, ascites, diabetes, renal disease, neurologic disease (excluding peripheral neuropathy), or leukopenia; liver function transaminase levels (SGOT, LDH, SGPT) 2.5 times higher than normal; total WBC &lt;4000/mm3; platelet count &lt;100,000/mm3; participating in any drug</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:20:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (34) oxazepam 120 mg/day for 7 days, <B>Group B </B>(32) carbamazepine 800 mg/day for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 10:40:57 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> changes in CIWA-Ar scores, physiological measures; neurological measures; self-report measures; standard psychological testing ( SCL-90-R, [Beck depression inventory, State-Trait anxiety inventory, Wechsler Memory scale)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 11:07:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malcolm-2002">
<CHAR_METHODS MODIFIED="2009-11-30 16:11:23 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:11:54 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 136, Gender: 75% male</P>
<P>
<B>Inclusion criteria: </B>met DSM-IV criteria for alcohol dependence and alcohol withdrawal; blood alcohol level = or &lt;0.1 g/dl; residence within 50 miles of the study site; MMSE = or &gt;26; admission score on CIWA-Ar = or &gt;10. <B>Exclusion criteria:</B> all substance abuse syndromes other than alcohol, nicotine or cannabis; major Axis I psychiatric disorder; use of medication in the preceding 30 days that could alter the withdrawal process; history of head injury or other neurologic illness including idiopathic epilepsy; medical instability; electroencephalogram abnormalities; grossly abnormal laboratory values<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-30 16:12:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (75) lorazepam 6-8 mg on day 1 tapering to 2 mg on day 5. <B>Group B</B> (61) carbamazepine 600-800 mg on day 1 tapering to 200 mg on day 5</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:07:03 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> changes in CIWA-Ar scores; ADS; daily drinking log; Zung Anxiety scale; Beck depression inventory; ability to return to work; sleep quality measures; <B>Safety:</B> mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:21:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malcolm-2007">
<CHAR_METHODS MODIFIED="2009-11-30 16:12:41 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-01 09:12:57 +0100" MODIFIED_BY="[Empty name]">
<P>No.= 101 Gender: 75 % male; mean age: 41.</P>
<P>
<B>Inclusion criteria:</B> meet DSM-IV1 criteria for alcohol dependence and for current alcohol withdrawal syndrome;  medically stable and not likely to require hospitalisation for medical complications within 10 days of entry into the study;  score of 10 or higher (CIWA-Ar); negative urine drug screens for benzodiazepines, other sedative-hypnotics, opiates, and amphetamine. <B>Exclusion criteria: </B>history of taking medications known to ameliorate or intensify the AWS ; diagnosis of any other substance-dependence syndrome other than alcohol , except cannabis and cocaine; history of idiopathic epilepsy, schizophrenia, bipolar disorder, or dementia; liver function tests 4 times higher than the upper range of normal; history of hepatic encephalopathy, jaundice, ascites, insulin-dependent diabetes mellitus, or renal insufficiency .</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:21:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (21) lorazepam 2 mg 3 times a day for the first 3 days and 2 mg twice daily on the last day of treat­ment, <B>Group B</B> (20) Gabapentin, mid-range dose 300 mg 3 times a day for 3 days and 300 mg twice daily for the last day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 09:13:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>Insomnia measured by CIWA-AR scale; Quality of sleep measured by Beck Depression Inventory (BDI); Sleepiness measured by the Eporth Sleepiness Scale; </P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-02 10:42:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martin-1975">
<CHAR_METHODS MODIFIED="2009-11-30 16:15:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:15:25 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 40; Gender: 70% male; age range: 26-63 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-02 10:42:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (10) diazepam, <B>Group B</B> (10) placebo, <B>Group C </B>(10) clobazam (15 mg). <B>Group D</B> (10) clobazam (30mg).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:23:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> changes in HARS scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Article in French</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-07 12:37:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McGrath-1975">
<CHAR_METHODS MODIFIED="2009-12-29 09:29:53 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-07 12:37:33 +0100" MODIFIED_BY="[Empty name]">
<P>No: 100, Gender: not reported, age range: not reported</P>
<P>
<B>Inclusion criteria</B>: patients with acute withdrawals phase of alcoholism. No further detailes given</P>
<P>
<B>Exclusion criteria</B>: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 11:40:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group A</B>: chlordiazepoxide (50);<B> Groupd B</B>: Chlormethiazole (50)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-29 11:29:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> delirium</P>
<P>
<B>Acceptaibility</B>: drop out</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-23 08:35:56 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-02 10:43:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McLendon-1980">
<CHAR_METHODS MODIFIED="2009-11-30 16:16:10 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:16:35 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 65; Gender: 100% male; age range: 18-63 years</P>
<P>
<B>Inclusion criteria:</B> age 18-70 years; admission before the fifth day after the last drink, with moderate to severe anxiety which would normally be treated with oral minor tranquillizers, and without taking any pharmacological treatment during the last five days;voluntarily and informed consent should be signed by all of the participants <B>Exclusion criteria: </B>acute withdrawal reaction; not suffering primarily from uncomplicated alcohol withdrawal accompanied by anxiety;  psychopathic; sociopathic; or primarily depressed patients; uncontrolled liver, kidney, cardiovascular, or pulmonary disease; sensitivity to benzodiazepines; requirement of other psychotropic medication, analgesics, or hypnotics; lack of at least 7th grade education; experience of delirium tremens during withdrawal; possibility of drinking alcohol during the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-02 10:43:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (21) chlordiazepoxide, <B>Group B</B> (22) placebo, <B>Group C</B> (22) alprazolam</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:25:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> changes in HARS scores; doctor's global assessment; target symptoms record; SRS; patient's global assessment; <B>Acceptability:</B> dropouts, dropouts due to side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 11:38:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mendels-1985">
<CHAR_METHODS MODIFIED="2009-11-30 16:17:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:18:09 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 92Gender: 96% male; age range: 21-60 years</P>
<P>
<B>Inclusion criteria:</B> alcoholics with blood alcohol level of 0.15% or less; not currently intoxicated; not suffering from grand mal seizures. <B>Exclusion criteria: </B>evidence on urine screening of recent use of amphetamines, barbiturates, benzodiazepines, ethchlorvynol, glutethimide, methylphenidate, or opiates; unstable or serious medical condition, history of psychosis, organic brain syndrome, seizure disorder, current hepatic or pancreatic disease; pregnant and nursing women; allergy or sensitivity to benzodiazepines; use of psychotropic drugs on a regular basis the 2 weeks prior admission</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-30 16:18:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (39) chlordiazepoxide. <B>Group B </B>(41) halazepam</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:38:07 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>Changes in TSA scale; doctor's global improvement scale; <B>Safety:</B> adverse events, severe life-treating adverse events; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-02 10:54:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mielke-1976">
<CHAR_METHODS MODIFIED="2009-11-30 16:18:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:19:26 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 97</P>
<P>
<B>Inclusion criteria: </B>met  DSM III criteria for alcohol addiction; 20 through 56 years of age;  lack of child-bearing potential; signed informed consent; physical examinations within normal limits; results of laboratory tests within normal limits; no concomitant psychotropic agents during the study; no psychotropic agents for a minimum of five days prior to initial baseline psychological evaluation; Zung Self-Rating Scale score of 36 or higher; no alcohol for a minimum of seven days prior to entry the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-02 10:54:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> diazepam, <B>Group B</B> placebo, <B>Group C</B> clorazepate<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 09:16:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> Changes in : Zung interviewer anxiety scale, NIMH Self-Rating Symptom Scale, Zung Self-Rating Scale; doctor's global ratings; <B>Other:</B> compliance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-07 12:38:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-1984">
<CHAR_METHODS MODIFIED="2009-11-30 16:20:54 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-07 12:38:21 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 55Gender: 98% male; age range: 21-65 years</P>
<P>
<B>Inclusion criteria:</B> alcoholics residents of an alcoholic rehabilitation centre; diagnosis of acute alcohol withdrawal syndrome requiring drug therapy; free of grand-mal seizures during the current alcohol withdrawal episode; initial TSA score of at least 40. <B>Exclusion criteria</B>: pregnancy; blood alcohol level greater than 0.2% as determined by serum osmolarity; inability to take oral medicine; signs or symptoms of severe pathophysiological changes associated with alcoholism; clinically other significant medical disorders; history of seizures either related or unrelated to alcohol use; history of psychosis or chronic organic brain syndrome, unrelated to alcohol use; Wernickes's encephalopathy or other severe nutritionally related medical complications; history of abuse of any of the following drugs: amphetamines, barbiturates, benzodiazepines, ethchlorvynol, glutethimide, marijuana, methyl-Phenidate, opiates; positive findings or urinary drug screen for any drug; concurrent medications other than antibiotics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:23:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (28) oral diazepam, <B>Group B</B> (27) oral lorazepam.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:38:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> delirium, Changes in TSA score; doctor's global assessment; changes in vital signs and laboratory measures; <B>Safety:</B> adverse events; <B>Acceptability:</B> dropout, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:24:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mukherjee-1983">
<CHAR_METHODS MODIFIED="2009-11-30 16:22:22 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:22:54 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 40; Age range: 18-65 years</P>
<P>
<B>Inclusion criteria: </B>no concomitant drug abuse; no concurrent psychotropic therapy; no hepatic or renal disease; no symptoms of florid alcohol psychosis (i.e. delirium tremens); no intake of psychotropic agents for a period of one week before the start of the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:24:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (20) chlordiazepoxide, <B>Group B</B> (20) clobazam.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:38:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> changes in HARS scores; LSAA; LAR; LSEQ; <B>Safety:</B> adverse events, severe life-treating adverse events; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 09:19:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naranjo-1983">
<CHAR_METHODS MODIFIED="2009-11-30 16:23:43 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:24:06 +0100" MODIFIED_BY="[Empty name]">
<P>N = 41Gender: 85% male</P>
<P>
<B>Inclusion criteria:</B> Ambulatory patients without medical complications</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-30 16:24:38 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(n=21) lorazepam 3 doses of 2 mg/2 hours plus supportive care. <B>Group B</B> (n=20) placebo 3 doses/2 hours plus supportive care</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 09:19:23 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: seizures, CIWA score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-30 16:24:06 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 11:01:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nava-2007">
<CHAR_METHODS MODIFIED="2009-11-30 16:25:16 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:25:07 +0100" MODIFIED_BY="[Empty name]">
<P>No.= 42 Gender: 75 % male; mean age: 41.</P>
<P>
<B>Inclusion criteria:</B> meet DSM-IV TR diagnosis for alcohol dependence; age 18 years or older; severe alcohol withdrawal syndrome (CIWA-Ar score ?20). <B>Exclusion criteria: </B>pregnancy; axis I psychiatric or other drug dependence disorders; HIV antibodies; serious physical illness; previous pharmacological treatment for drug abuse</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-30 16:25:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> ( 21) diazepam 5 mg/kg/day of bodyweight fractionated in four daily doses. <B>Group B </B>(21) GHB 50 mg/kg/day of bodyweight fractionated in four daily doses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:01:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> Severity of alcohol withdrawal syndrome (CIWA-Ar); Plasma cortisol level; <B>Safety:</B> adverse events, severe life-treating adverse events; <B>Acceptability:</B> dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-07 12:38:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Brien-1983">
<CHAR_METHODS MODIFIED="2009-11-30 16:26:15 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-07 12:38:45 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 52Gender: 79% male; age range: 21-65 years</P>
<P>
<B>Inclusion criteria</B>: diagnosis of acute alcohol withdrawal syndrome requiring drug therapy; freedom from grand-mal seizures during the current alcohol withdrawal episode; having an initial TSA score of at least 40. <B>Exclusion criteria</B>: pregnancy; blood alcohol level greater than 0.2%; inability to take oral medicine; signs or symptoms of severe pathophysiological changes associated with alcoholism; clinically significant medical disorders; history of seizures (excluding childhood febrile seizures) either related or unrelated to alcohol use; history of psychosis or chronic organic brain syndrome, unrelated to alcohol use; Wernickes's encephalopathy or other severe nutritionally related medical complications; history of abuse of any of the following drugs: amphetamines, barbiturates, benzodiazepines, ethchlorvynol, glutethimide, marijuana, methyl-Phenidate, opiates; positive findings or urinary drug screen for any concurrent medications other than antibiotics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:25:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (26) oral diazepam, <B>Group B </B>(26) oral lorazepam. One extra dose of either medication was allowed on study day 1 at the discretion of the investigator</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:38:28 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Changes in TSA score; doctor's global assessment; changes in vital signs and laboratory measures; <B>Safety:</B> adverse events; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:26:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Overall-1973">
<CHAR_METHODS MODIFIED="2009-11-30 16:27:49 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:28:18 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 147</P>
<P>
<B>Inclusion criteria: </B>alcoholics newly admitted to the Alcohol Treatment Unit at the Rusk State Hospital; patients detoxified and withdrawn from alcohol for a period of 10 to 14 days prior to being placed on study medication</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:26:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> chlordiazepoxide, <B>Group B</B> mesoridazine<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 09:21:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> Changes in doctor and patient scales of MMPI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:26:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Palestine-1976">
<CHAR_METHODS MODIFIED="2009-11-30 16:29:18 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:29:43 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 49; Gender: 84% male; age range: 27-66 years</P>
<P>
<B>Inclusion criteria:</B> chronic alcoholics of various stages of acute alcohol withdrawal who were admitted to the emergency room of MetropolitanState Hospital, Norwalk. <B>Exclusion criteria: </B>pregnancy; severe central nervous system depression; traumatic brain injury; psychotropic medication within the previous 12 hours</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:26:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (25) chlordiazepoxide, <B>Group B </B>(24) haloperidol.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:18:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> seizures, global improvement, evaluation of the target symptoms; changes in BPRS; doctor's global assessment; <B>Safety:</B> adverse events, mortality; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:27:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pena_x002d_Ramos-1977">
<CHAR_METHODS MODIFIED="2009-11-30 16:30:48 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:31:18 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 70; Age range: 21-65 years</P>
<P>
<B>Inclusion criteria:</B> alcoholics with mild to moderate alcohol withdrawal syndrome. <B>Exclusion criteria: </B>central nervous system complications due to other causes; cardiovascular disease, glaucoma, history of psychiatric disorder, sensitivity to phenothiazines or chlordiazepoxide, treatment with tranquillizing or antidepressant drug for at least 14 days, or anxiolytic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:27:47 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> oral chlordiazepoxide, <B>Group B</B> oral thioridazine.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>Changes in Hamilton Psychiatric Rating Scale for depression; in Zung Self-Rating Scale for depression; and in LSRS; </P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:28:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pena_x002d_Ramos-1979">
<CHAR_METHODS MODIFIED="2009-11-30 16:32:10 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-01 09:23:25 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 34; Gender: 82% male, age range: 27-58 years</P>
<P>
<B>Inclusion criteria:</B> alcoholics with mild to moderate alcohol withdrawal syndrome, including overt anxiety and depression. <B>Exclusion criteria: </B>central nervous system complications due to other causes; cardiovascular disease, glaucoma, history of psychiatric disorder, sensitivity to phenothiazines or chlordiazepoxide, treatment with tranquillizing or antidepressant drug for at least 14 days, or anxiolytic or sedative agent for 3 days before admission</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:28:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (17) oral chlordiazepoxide, <B>Group B</B> (17) oral thioridazine.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:07:44 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> Changes in MMPI; <B>Safety:</B> mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Same participants as Pena-Ramos A. Dis Nerv Syst 1977; 38: 144-7 but each report targets on different outcomes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-02 11:03:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Radouco_x002d_Thomas-1989">
<CHAR_METHODS MODIFIED="2009-11-30 16:35:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:35:58 +0100" MODIFIED_BY="[Empty name]">
<P>No.= 67; Gender: 100% male; age range: 32-60 years</P>
<P>
<B>Inclusion criteria:</B> patients admitted to the detoxification unit of Quebec Hospital; met the DSM-III criteria for alcohol dependence; presented acute alcohol withdrawal syndrome requiring drug therapy. <B>Exclusion criteria: </B>history, medical examination or laboratory evidence suggesting severe neurologic, psychiatric, hepatic or cardiovascular illness and the use of prescription or illicit drugs (polydrug addiction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-02 11:03:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (30) oral chlordiazepoxide, <B>Group B</B> (30) oral phenobarbital. Additional medication doses were given according to the clinician judgment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:07:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> seizures, CIWA-Ar score, REG; vital signs and sleep evaluation; DSST, PPT; HSCL-35, Zung Self Rating Anxiety Scale, Zerssen bipolar mood test-Z; changes in blood alcohol levels; <B>Safety:</B> adverse events, severe life-treating adverse events, mortality; <B>Acceptability:</B> dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:29:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ritson-1986">
<CHAR_METHODS MODIFIED="2009-11-30 16:37:36 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:38:04 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 40; Gender: 70% male</P>
<P>
<B>Inclusion criteria</B>: alcohol-dependent participants requiring withdrawal medication. <B>Exclusion criteria: </B>current active hepatocellular pathology; grossly disordered hepatic or renal function; sensitive to benzodiazepines; psychotic or suffered from epilepsy; history of withdrawal fits, or psychosis or drug abuse or recent sedative usage</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:29:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (20) oral diazepam, <B>Group B</B> (20) oral lorazepam.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:20:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> seizures, Physical and mental state; Bexley Maudsley Automated Psychological Screening; Bexley Maudsley Category Sorting; psychomotor accuracy; visual analogue scale for self perceived anxiety and depression; nurse's evaluation; Mill Hill vocabulary scale; <B>Acceptability:</B> dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:52:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Runion-1978">
<CHAR_METHODS MODIFIED="2009-11-30 16:38:57 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:39:21 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 50</P>
<P>
<B>Inclusion criteria: </B>alcoholics with a diagnosis of alcohol withdrawal syndrome, presenting 4 out of the 8 signs and symptoms seen in acute alcohol withdrawal and signed informed consent</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:52:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (20) chlordiazepoxide, <B>Group B</B> (21) hydroxizine </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:08:03 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> Changes in electromyograph; <B>Safety:</B> mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 11:47:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saitz-1994">
<CHAR_METHODS MODIFIED="2009-11-30 16:40:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-01 09:26:21 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 101; Gender: 99% male</P>
<P>
<B>Inclusion criteria</B>: meet DSM-III-R criteria for alcohol abuse or dependence. <B>Exclusion criteria: </B>concurrent acute medical or psychiatric illness requiring acute care hospitalisation; history of seizures; inability to take oral medication; current use of or withdrawal from medication that might alter the clinical course of withdrawal; inability or unwillingness to consent to participation in the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-30 16:40:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(50) chlordiazepoxide every 6 hours for 12 doses (fixed-schedule); 4 doses of 50 mg followed by 8 doses of 25 mg. <B>Group B</B> (51) chlordiazepoxide (25-100 mg) in response to signs and symptoms of alcohol withdrawal (symptom-triggered) plus placebo every 6 hours for 12 doses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:47:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> delirium, Duration of treatment; total amount of chlordiazepoxide administered; number and amount of as-needed benzodiazepine doses given in response to increased CIWA-Ar score; leaving the hospital against medical advice; development of hallucinations, seizures, or delirium tremens; level of alertness; degree of general discomfort and craving for alcohol; <B>Safety:</B> mortality; <B>Acceptability:</B> dropouts; <B>Other:</B> rates of rehabilitation, readmission, compliance with follow-up</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-15 12:14:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saletu-1983">
<CHAR_METHODS MODIFIED="2009-11-30 16:41:41 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:42:00 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 42; Gender: 100% male</P>
<P>
<B>Inclusion criteria: </B>hospitalised patients with diagnosis of alcohol dependency (ICD 303), in whom an anxiolytic drug therapy was indicated due to the expected withdrawal and anxiety syndrome; signed informed consent and had to be a minimum of 10 days off any psychoactive medication and at least 24h off alcohol</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-15 12:14:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(21) Lopirazepam for 3 weeks. <B>Group B</B> (21) prazepam for 3 weeks<BR/>In the 4th week, both the intervention groups were divided in 3 subgroups: one subgroup in each main group continued active medication (no. = 7x2), one received placebo (no. = 7x2) and one did not receive any drug (no. = 7x2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:24:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>Changes in alcohol blood levels; CGI rating scale; changes in HARS scores; Zung Self Rating Scale for Anxiety; von Zerssen scale for self-rating of mood; assessment of somatic findings, changes in pulse, weight, pressure; psychometric investigations; changes in electroencephalogram</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:31:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sellers-1977">
<CHAR_METHODS MODIFIED="2009-11-30 16:42:52 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:43:36 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 30; Gender: 100% male; age range: 21-56 year</P>
<P>
<B>Inclusion criteria:</B> male alcoholics who had been drinking more than 160g of ethanol per day for more than 7 days prior to the study, and have been drinking on average more than 80g of ethanol for the past 2 years. <B>Exclusion criteria: </B>concurrent medical disease requiring active treatment; levels of serum albumin, serum glutamic oxaloacetic transaminase, alkaline phosphatase, or bilirubin exceeding the maximum normal levels by more than 10%; liver cirrhosis; cardiac disease; thyroid disease; and asthma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:31:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (6) chlordiazepoxide, <B>Group B</B> (6) placebo, <B>Group C</B> (6) propranolol high dose, <B>Group D</B> (6) propranolol low dose. <B>Group E</B> (6) combined therapy of propranolol and chlordiazepoxide</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:08:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>Changes in hand tremor, hart rate and blood pressure; presence and severity of 34 common alcohol withdrawal symptoms; degree of cardiac b-blockade with isoprenaline test; changes in total plasma catecholamine concentrations and 24h urinary norepinephrine and epinephrine level; <B>Safety:</B> mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-30 16:44:54 +0100" MODIFIED_BY="[Empty name]">
<P> </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 09:29:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sellers-1983">
<CHAR_METHODS MODIFIED="2009-11-30 16:45:56 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:46:01 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 50; Gender: 86% male</P>
<P>
<B>Exclusion criteria</B>: surgery within 48 hours under a general anaesthetic; head injury; drug overdose; history of benzodiazepine allergy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-30 16:46:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(25) diazepam 20 mg p.os plus supportive care. <B>Group B</B> (25) placebo plus supportive care<BR/>All patients with a history of withdrawal seizures also received phenytoin 300 mg/day p.os for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 09:29:28 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>seizures,<B> </B>CIWA score; <B>Other:</B> duration and number of doses of medication treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:53:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Solomon-1983">
<CHAR_METHODS MODIFIED="2009-11-30 16:46:46 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-01 12:53:45 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 50; Gender: 100% male; age range: 21-65 years</P>
<P>
<B>Inclusion criteria</B>: alcoholics residents of an alcoholic rehabilitation centre and met diagnosis of acute alcohol withdrawal syndrome requiring drug therapy; free of grand-mal seizures during the current alcohol withdrawal episode; initial TSA score of at least 40. <B>Exclusion criteria: </B>blood alcohol level greater than 0.2%; inability to take oral medicine; signs or symptoms of severe pathophysiological changes associated with alcoholism; clinically significant medical disorders, other than those directly related to alcoholism; history of seizures (excluding childhood febrile seizures) either related or unrelated to alcohol use; history of psychosis or chronic organic brain syndrome, unrelated to alcohol use; Wernickes's encephalopathy or other severe nutritionally related medical complications; history of abuse of any of the following drugs: amphetamines, barbiturates, benzodiazepines, ethchlorvynol, glutethimide, marijuana, methyl-phrenicae, opiates; positive findings or urinary drug screen for any drug; concurrent medications other than antibiotics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:32:08 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (25) oral chlordiazepoxide, <B>Group B</B> (25) oral lorazepam;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:38:59 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> seizures, Changes in TSA score; doctor's global assessment; changes in vital signs and laboratory measures; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:33:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spies-1996">
<CHAR_METHODS MODIFIED="2009-11-30 16:48:26 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:50:14 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 159; Gender: 94% male; age range: 18-83 years</P>
<P>
<B>Inclusion criteria:</B> multiple-injured alcohol-dependent patients who met the DSM-III-R criteria for alcohol dependence. <B>Exclusion criteria: </B>age &lt; 18 years; chronic obstructive lung disease and poor pulmonary function or pneumonia; bradycardia (heart rate &lt; 45/min); systolic blood pressure &lt; 95 mmHg; second- or third-degree atrioventricular node block; history of current use or abuse of benzodiazepines, barbiturates, clonidine, or beta-adrenergic receptor blockers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:33:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (55) flunitrazepam/haloperidol, <B>Group B</B> (54) flunitrazepam/clonidine. <B>Group C</B> (50) clomethiazole/haloperidol.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:42:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> changes in CIWA-Ar scores, Duration of controlled or assisted mechanical ventilation; <B>Safety:</B> mortality; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 11:46:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spies-2003">
<CHAR_METHODS MODIFIED="2009-11-30 16:51:49 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:52:21 +0100" MODIFIED_BY="[Empty name]">
<P>No.= 44; Gender: 82% male; age range: 33-68 years</P>
<P>
<B>Inclusion criteria</B>: met DSM-IV criteria for alcohol abuse (not dependence); alcohol consumption &gt; 60 g/day; CIWA-Ar &gt;20. <B>Exclusion criteria: </B>age &lt;18 years; pregnancy; intubation and ventilation at the onset of alcohol withdrawal syndrome; continuous sedation at the onset of alcohol withdrawal syndrome; concurrent acute medical, acute angina, metabolic or endocrinological disorders; head injury, intoxications or psychiatric illness; history of seizures of any case; corticosteroid use or chemotherapy; current use or withdrawal from clonidine, b-blockers, or haloperidol and withdrawal from or known misuse of opiates, benzodiazepines, or barbiturates; patients diagnosed as alcohol-dependent (DSM-IV criteria) before the onset of AWS; patients with treatment failure (persisting CIWA-Ar &gt;20) for longer than 8 hours despite administration of rescue medication</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-30 16:52:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (21) flunitrazepam, clonidine, haloperidol i.v. (infusion-titrated group). <B>Group B</B> (23) flunitrazepam, clonidine, haloperidol i.v. (bolus-titrated group)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:46:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>change in<B> </B>CIWA-Ar scores; medication requirements; duration of intensive care unit treatment; infection; sepsis; bleeding; cardiac complications; drug-related complications; <B>Safety:</B> mortality; <B>Acceptability:</B> dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:34:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stuppaeck-1992">
<CHAR_METHODS MODIFIED="2009-11-30 16:53:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:53:53 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 60; Gender: 82% male</P>
<P>
<B>Inclusion criteria:</B> DSM-III criteria for alcohol dependence; CIWA-Ar score &gt; 20 on admission; be able to sign informed consent. <B>Exclusion criteria: </B>age &lt;18 or &gt;65 years; severe somatic illness; polysubstance dependence; pre-treatment with psychotropic drugs; full-blown alcohol delirium</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:34:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (29) oxazepam, <B>Group B </B>(29) carbamazepine.<BR/>Additional B-polyvitamin compound was given orally.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:18:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> seizures, delirium, changes in CIWA-Ar scores; self-rating adjective checklist; CGI scale; <B>Safety:</B> adverse events, mortality; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-07 12:40:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tubridy-1988">
<CHAR_METHODS MODIFIED="2009-11-30 16:57:57 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-07 12:40:36 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 102; Age range: 21-65 years</P>
<P>
<B>Inclusion criteria:</B> alcohol dependent participants admitted to St John of God Hospital, Dublin. <B>Exclusion criteria: </B>patients sensitive to benzodiazepines or Chlormethiazole; dependent on or abused substances other than alcohol; psychotic or suffered from another mental disorder; serious physical illness; pregnant or lactating; taking other psychotropic drugs; history of withdrawal seizures</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 12:40:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (51) alprazolam. <B>Group B</B> (49) Chlormethiazole<BR/>All patients received daily intravenous injections of vitamin B complex and ascorbic acid on days 1-5</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:18:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> seizures, global improvement, doctor's assessment of efficacy, patient's assessment of efficacy, Patient's general physical condition; presence of symptoms of alcohol withdrawal throughout the trial; HARS; doctor's and patient's global ratings of well-being; changes in blood tests measures; <B>Safety:</B> adverse events, severe life-treating adverse events, mortality; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 12:35:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wilson-1985">
<CHAR_METHODS MODIFIED="2009-11-30 17:00:20 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 17:00:59 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 101; Age range: 18-65 years</P>
<P>
<B>Inclusion criteria</B>: alcoholics entering the Chemical Withdrawal Unit for detoxification, giving informed consent for participation to this program. <B>Exclusion criteria: </B>pregnancy; history of epilepsy; sensitivity to benzodiazepines; biopsy proven cirrhosis; refractory ascites; portal hypertension; hepatic encephalopathy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-01 12:35:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (50) chlordiazepoxide, <B>Group B</B> (50) alprazolam.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:37:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> seizures, delirium, Alcohol withdrawal signs; incidence of delirium tremens; overall severity of withdrawal; BDI on discharge; disposition on discharge; doctor's assessment of efficacy; <B>Safety:</B> adverse events, severe life-treating adverse events; <B>Acceptability:</B> dropouts, dropouts due to adverse events; <B>Other:</B> requirements of additional intravenous medication for treatment failures</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-01 11:08:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Worner-1994">
<CHAR_METHODS MODIFIED="2009-11-30 17:10:22 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 17:11:03 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 37; Gender: 100% male; age range: 24-68 years</P>
<P>
<B>Inclusion criteria:</B> veterans requesting admission for alcohol detoxification. <B>Exclusion criteria: </B>current polydrug use; medical contraindications to the use of propranolol; inability to tolerate oral medication</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-30 17:11:33 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (18) diazepam 10-15 mg p.os. <B>Group B</B> (19) propranolol 20-30 mg p.os</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-01 11:08:44 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>seizures, CIWA score; <B>Safety:</B> adverse events, mortality; <B>Acceptability:</B> dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ADS: Alcohol Dependence Scale; ASI: Addiction Severity Index; AWAS: Alcohol Withdrawal Assessment Score; AWS: alcohol withdrawal symptoms; BCL: Behavior CheckList; BDI: Beck Depression Inventory; BPRS: Brief Psychiatric Rating Scale; CAS: Covi Anxiety Scale; CCSE: Cognitive Capacity Screening Exam; CGI: Clinical Global Impression; CIWA-Ar: Rivised Clinical Institude Withdrawal Assessment for Alcohol; CPRS: Comprehensive Psychopathological Rating Scale; DOTES: Dosage Record and Treatment Emergent Symptom Scale; DSM III: Diagnostic and Statistical Manual for Mental Disorders, third edition; DSM IV: Diagnostic and Statistical Manual for Mental Disorders, fourth edition; DSST: Digit Symbol Substitution Test; GRSAW: Gross Rating Scale for Alcohol Withdrawal; HARS: Hamilton Anxiety Rating Scale; HSCL: Hopkins Symptoms Check List; ICD-10: International Classification of Diseases; IDDM: Insulin-Dependent Diabetes Mellitus. LAR: Linear Analogue Rating Scale; LDH: Lactate Dehydrogenase LSAA: Leeds Specific Assessment of Anxiety Scale; LSEQ: Leeds Sleep Evaluation Questionnaire; MAC: Mood Adjective Checklist; MADRS: Montgomery Åsberg Depression Rating Scale MMPI: Minnesota Multiphasic Personality Inventory; MMSE: Mini-Mental State Examination; NIMH: National Institute of Mental Health OCDS: Obsessive Compulsive Drinking Scale; PPT: Purdue Pegboard Test; REG: Rada-Extensive Grid; SCL-90-R: Symptom Checklist 90 revised, SDS Zung: Self Rating Depression Scale di Zung; SGOT: Serum Glutamate Oxaloacetate Transaminase; SGPT: Serum Glutamic Pyruvic Transaminase; SIP: Short Index of Problems; SRS: Self-Rating Symptom Scale; SSA: Selected Severity Assessment; STAI: State Anxiety Inventory; TLFB: Time Line Follow Back; TSA: Total Severity Assessment; VCS: Visual Craving Scale; VSS: Visual Success Scale; WBC: White Blood Cell WHO: World Health Organization</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-01-07 10:49:18 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:11:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baumgartner-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:11:03 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:11:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benuzzi-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:11:21 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:11:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bowman-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:11:37 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:11:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dobrydnjov-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:11:53 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:11:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gallant-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:11:58 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:12:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerra-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:12:20 +0100" MODIFIED_BY="[Empty name]">
<P>Type of comparison not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:12:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gillman-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:12:38 +0100" MODIFIED_BY="[Empty name]">
<P>Duplicate publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-23 08:51:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gillman-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-23 08:51:05 +0100" MODIFIED_BY="[Empty name]">
<P>Letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:12:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huber-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:12:54 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:13:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klett-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:13:04 +0100" MODIFIED_BY="[Empty name]">
<P>Duplicate publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:13:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lazarova-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:13:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malcolm-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:13:35 +0100" MODIFIED_BY="[Empty name]">
<P>Duplicate publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:13:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malmgren-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:13:54 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:13:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mery-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:13:59 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:14:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muller-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:14:03 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:14:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Myrick-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:14:23 +0100" MODIFIED_BY="[Empty name]">
<P>Type of comparison not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-23 09:06:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Myrick-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-23 09:06:41 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes measures presented in a way not suitable for meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:14:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ponce-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:14:33 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:15:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poulos-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:15:26 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:15:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rothstein-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:15:47 +0100" MODIFIED_BY="[Empty name]">
<P>Type of comparison not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:15:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sampliner-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:15:51 +0100" MODIFIED_BY="[Empty name]">
<P>Type of comparison not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:16:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sereny-1965">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:16:06 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:17:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shaffer-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:17:23 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:17:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Silpakit-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:17:37 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:20:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thompson-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:20:46 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:17:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Waver-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:17:55 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-03 17:18:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weinberg-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-03 17:18:08 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-01-07 12:47:48 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2010-01-07 12:47:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trevisan-2008">
<CHAR_METHODS MODIFIED="2010-01-07 12:41:00 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-07 12:46:17 +0100" MODIFIED_BY="[Empty name]">
<P>57 male veterans</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 12:47:26 +0100" MODIFIED_BY="[Empty name]">
<P>valproic acid or gabapentin or placebo for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-07 12:47:48 +0100" MODIFIED_BY="[Empty name]">
<P>alcohol withdrawal symptoms in the first 5 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-07 12:41:30 +0100" MODIFIED_BY="[Empty name]">
<P>We are trying to find the full text of the article</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-02-15 12:14:26 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-02-15 12:14:05 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 12:47:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Addolorato-1999">
<DESCRIPTION>
<P>"All the patiens were randomly divided into two group of treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 12:31:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Addolorato-2006">
<DESCRIPTION>
<P>"all subjects were randomly divided into 2 groups by a 1:1 randomisation procedure"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 12:50:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adinoff-1994">
<DESCRIPTION>
<P>"Subjects were randomly assigned to 1 of the 4 treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:39:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ansoms-1991">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 12:32:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-1997">
<DESCRIPTION>
<P>"Patients were randomly assigned to receive either Abecamil or diazepam in double blind fashion"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:03:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bailly-1992">
<DESCRIPTION>
<P>"patients were randomly allocated to one of the two group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:40:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baumgartner-1987">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:40:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baumgartner-1991">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 12:32:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borg-1986">
<DESCRIPTION>
<P>"the patients were randomly assigned to treatment with either amobarbital, oxazepam or Melperone"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:41:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1972">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 08:59:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985a">
<DESCRIPTION>
<P>"the patients in each group were randomised to treatment using a pre-fixed code devised by the hospital pharmacy from a random number table, with a blocked design to ensure roughly equal numbers in the different treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 08:59:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985b">
<DESCRIPTION>
<P>"the patients in each group were randomised to treatment using a pre-fixed code devised by the hospital pharmacy from a random number table, with a blocked design to ensure roughly equal numbers in the different treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 12:34:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Choi-2005">
<DESCRIPTION>
<P>"Fifty-two patients after providing written informed consent are randomised to either lorazepam (N=27) or Topiramate (N=25) groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-15 12:14:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daeppen-2002">
<DESCRIPTION>
<P>"A pharmacist not involved in other aspects of the trial randomly assigned eligible patients in cluster of 10 subjects to one of the two group. The allocation was generated using a program running on Excel. During the trial each patient was allocated an identification number. A safety sealed envelope labelled with the patient's identification number contained the code of randomisation of each individual.".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:20:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Day-2004">
<DESCRIPTION>
<P>method of sequence generation not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:41:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dion-1968">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 12:34:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Favre-2005">
<DESCRIPTION>
<P>"The attribution of a randomised treatment number was decided prior to the first dose administration. The randomisation was balanced between the two treatment arms (1:1), each containing four patients (block size)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 18:07:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Funderburk-1978">
<DESCRIPTION>
<P>"Patient were randomly assigned to one of two treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 18:07:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gillman-2004">
<DESCRIPTION>
<P>"Patients were randomised into two groups using a random number table"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:22:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gillmer-1973">
<DESCRIPTION>
<P>"Patients were allocated blindly to one or the other treatment in accordance with a predetermined random list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:22:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Golbert-1967">
<DESCRIPTION>
<P>"Random selection was achieved by assigning each patients medication by rotation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:23:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jauhar-2000">
<DESCRIPTION>
<P>"Patients were randomly allocated, by pharmacy, to one of two regimens"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 15:55:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaim-1969">
<DESCRIPTION>
<P>"Patients were assigned by random code to one of five treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:24:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaim-1972">
<DESCRIPTION>
<P>"The random assignment of patients to treatments was controlled by a study code number;; patients were assigned consecutive numbers. Prepackaged box of study medication corresponding to the patient's code number."</P>
<P>COMMENT: it is not clear how the code numbers were generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:02:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalyoncu-1996">
<DESCRIPTION>
<P>"patients were randomly assigned to either carbamazepine or diazepam"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:25:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kolin-1981">
<DESCRIPTION>
<P>"The design of the study was double blind with random allocation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 18:17:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kramp-1978">
<DESCRIPTION>
<P>"The patients were allocated double blind to treatment"</P>
<P>COMMENT: it was not state if the study was randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:26:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krupitsky-2007">
<DESCRIPTION>
<P>Block randomisation was used with block sizes of 15, 20, and 25 randomly varied</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 12:36:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-2009">
<DESCRIPTION>
<P>"A computer-generated randomisation chart was used to assign patients into groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:54:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lapierre-1983">
<DESCRIPTION>
<P>"Treatment were randomly administered sequentially as the patients were included in the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:41:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lenzenhuber-1999">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:07:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lepola-1984">
<DESCRIPTION>
<P>"The patients were randomised to one of the two groups by mean of randomisation tables"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:08:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Longo-2002">
<DESCRIPTION>
<P>"Patients were sequentially randomised into one of three group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:57:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lucht-2003">
<DESCRIPTION>
<P>"Assignment took place in blocks of 10 in order of admission ( first 10 patients into group A, next 10 patients into group B, etc)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 12:37:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-1989">
<DESCRIPTION>
<P>"Subjetcs were blindly assigned to a group who received carbamazepine or to a group who received oxazepam"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:12:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2002">
<DESCRIPTION>
<P>"Subjects randomisation was based on on a computer generated schedule administered by a research pharmacist not involved in data collection"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 16:14:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2007">
<DESCRIPTION>
<P>Subjects were randomised using a stratified permuted block method in which individuals with particular characteristics were assigned to medication groups with constraint that the assignment was balanced within successive blocks of subjects. We used a relatively small block size of q=4in order to promote a high degree of balance. Stratifications were based on the intersection of previous alcohol treatment history (0-1 or more than 1 past treated withdrawals) and sex (male or female).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:42:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martin-1975">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-29 12:08:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGrath-1975">
<DESCRIPTION>
<P>"One hundred consecutive admissions to a specialized unit for the treatment of alcoholism in a psychiatric hospital were allotted code numbers and in accordance with a list of randomised numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:14:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McLendon-1980">
<DESCRIPTION>
<P>"patients were treated in a double blind manner and evaluated weekly for three weeks"</P>
<P>COMMENT: it was not stated if the study was randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:15:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mendels-1985">
<DESCRIPTION>
<P>"Patients were assigned on a random list basis to one of two treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:17:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mielke-1976">
<DESCRIPTION>
<P>"Subjects were assigned sequentially to one of the three treatment groups according to a pre-assigned randomised schedule"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:42:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1984">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:16:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mukherjee-1983">
<DESCRIPTION>
<P>"Patients were randomly allocated to one of the two group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:19:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Naranjo-1983">
<DESCRIPTION>
<P>"The patient were randomly allocated to receive either supportive care with sublingual lorazepam or supportive care with sublingual placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:18:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nava-2007">
<DESCRIPTION>
<P>"The randomisation assignment was generated via computer software"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:42:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Brien-1983">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:18:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Overall-1973">
<DESCRIPTION>
<P>"The subjects were assigned to one of three drug treatment groups in rotation according to the order of admission to the ward"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:21:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Palestine-1976">
<DESCRIPTION>
<P>"patients were randomly assigned to a treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:43:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pena_x002d_Ramos-1977">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:21:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pena_x002d_Ramos-1979">
<DESCRIPTION>
<P>"Each patient was assigned either to chlordiazepoxide or the thioridazine group on a random basis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 16:37:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Radouco_x002d_Thomas-1989">
<DESCRIPTION>
<P>"After enrolment, patients were assigned to receive the next in a sequentially numbered supply of medication. The sequence was previously determined by the hospital pharmacist from a table of random numbers with a blocked design to ensure a roughly equal numbers in the two treatment group and in the different season of the year"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:22:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ritson-1986">
<DESCRIPTION>
<P>"Number were allocated at random and the trial were therefore double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:26:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Runion-1978">
<DESCRIPTION>
<P>"A randomised allocation table supplied by the sponsor was used to assign patients to the appropriate treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:23:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saitz-1994">
<DESCRIPTION>
<P>"A pharmacist not involved in other aspects of the trial randomly assigned the 111 eligible patients in blocks of 10 to either symptom triggered therapy or standard fixed schedule therapy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:43:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saletu-1983">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 12:39:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sellers-1977">
<DESCRIPTION>
<P>"Six patients were randomly assigned to each of five treatments groups"</P>
<P>COMMENT: information about sequence generation not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 16:45:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sellers-1983">
<DESCRIPTION>
<P>randomisation method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:25:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Solomon-1983">
<DESCRIPTION>
<P>"The patients were assigned randomly to one of the two treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 16:51:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spies-1996">
<DESCRIPTION>
<P>"Patient was randomised to receive one of the three treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 16:53:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spies-2003">
<DESCRIPTION>
<P>study described as "prospective randomised (per envelope) controlled study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:28:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stuppaeck-1992">
<DESCRIPTION>
<P>"Patients were randomly allocated to a double blind study comparing CBZ abs oxazepam"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 16:59:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tubridy-1988">
<DESCRIPTION>
<P>"Patients were randomised to one or the two treatment group by consecutive assignment of patients identification numbers that had previously been distributed between the two treatments by a computer generated list of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:35:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilson-1985">
<DESCRIPTION>
<P>"When the physician decided that a given patient required sedation, that patient was assigned to receive the next in a sequentially numbered supply of medication, the sequence of which had previously been determined from a table of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 17:14:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Worner-1994">
<DESCRIPTION>
<P>"Subjects were randomised to one of the two drug regimens"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-02-15 12:14:07 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 12:48:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Addolorato-1999">
<DESCRIPTION>
<P>"All the patiens were randomly divided into two group of treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 12:31:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Addolorato-2006">
<DESCRIPTION>
<P>"all subjects were randomly divided into 2 groups by a 1:1 randomisation procedure"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 12:50:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adinoff-1994">
<DESCRIPTION>
<P>"Subjects were randomly assigned to 1 of the 4 treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:40:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ansoms-1991">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 12:32:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-1997">
<DESCRIPTION>
<P>"Patients were randomly assigned to receive either Abecamil or diazepam in double blind fashion"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:03:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bailly-1992">
<DESCRIPTION>
<P>"patients were randomly allocated to one of the two group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:40:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baumgartner-1987">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:40:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Baumgartner-1991">
<DESCRIPTION>
<P> Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 12:32:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borg-1986">
<DESCRIPTION>
<P>"the patients were randomly assigned to treatment with either amobarbital, oxazepam or Melperone"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:41:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brown-1972">
<DESCRIPTION>
<P> Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 08:59:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985a">
<DESCRIPTION>
<P>"the patients in each group were randomised to treatment using a pre-fixed code devised by the hospital pharmacy from a random number table, with a blocked design to ensure roughly equal numbers in the different treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 08:59:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985b">
<DESCRIPTION>
<P>"the patients in each group were randomised to treatment using a pre-fixed code devised by the hospital pharmacy from a random number table, with a blocked design to ensure roughly equal numbers in the different treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 12:34:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Choi-2005">
<DESCRIPTION>
<P>"Fifty-two patients after providing written informed consent are randomised to either lorazepam (N=27) or Topiramate (N=25) groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-15 12:14:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daeppen-2002">
<DESCRIPTION>
<P>"A pharmacist not involved in other aspects of the trial randomly assigned eligible patients in cluster of 10 subjects to one of the two group. The allocation was generated using a program running on ExcelDuring the trial each patient was allocated an identification number. A safety sealed envelope labelled with the patient's identification number contained the code of randomisation of each individual.. ".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:20:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Day-2004">
<DESCRIPTION>
<P>"The admitting doctor then telephoned a remote randomisation service and the patient was allocated to either symptom-triggered front-loading detoxification or usual treatment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:41:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dion-1968">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:01:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Favre-2005">
<DESCRIPTION>
<P>"The number of capsules necessary to treat a single patient was placed in<BR/>an appropriately numbered package matched with a sealed envelope containing the treatment code (such a code could only be opened by the physician when justified by a worsening of the patient&#8217;s clinical status)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 18:07:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Funderburk-1978">
<DESCRIPTION>
<P>"Patient were randomly assigned to one of two treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 18:07:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gillman-2004">
<DESCRIPTION>
<P>"Patients were randomised into two groups using a random number table"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:22:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gillmer-1973">
<DESCRIPTION>
<P>"Patients were allocated blindly to one or the other treatment in accordance with a predetermined random list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:22:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Golbert-1967">
<DESCRIPTION>
<P>"Random selection was achieved by assigning each patients medication by rotation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:23:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jauhar-2000">
<DESCRIPTION>
<P>"Patients were randomly allocated, by pharmacy, to one of two regimens"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 15:55:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaim-1969">
<DESCRIPTION>
<P>"Patients were assigned by random code to one of five treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:24:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaim-1972">
<DESCRIPTION>
<P>"The random assignment of patients to treatments was controlled by a study code number;; patients were assigned consecutive numbers. Prepackaged box of study medication corresponding to the patient's code number."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:02:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalyoncu-1996">
<DESCRIPTION>
<P>"patients were randomly assigned to either carbamazepine or diazepam"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:25:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kolin-1981">
<DESCRIPTION>
<P>"The design of the study was double blind with random allocation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 18:17:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kramp-1978">
<DESCRIPTION>
<P>"The patients were allocated double blind to treatment"</P>
<P>COMMENT: it was not state if the study was randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:26:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krupitsky-2007">
<DESCRIPTION>
<P>patients randomly chose from blocks of 15, 20, or 25 envelopes, each envelope containing 1 treatment<BR/>assignment. Assessors were unaware of block sizes and were not involved with any aspect of the randomization. Patient treatment assignment was kept under lock and key throughout the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 12:36:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumar-2009">
<DESCRIPTION>
<P>COMMENT: allocation concealment not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:54:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lapierre-1983">
<DESCRIPTION>
<P>"Treatment were randomly administered sequentially as the patients were included in the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:42:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lenzenhuber-1999">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:07:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lepola-1984">
<DESCRIPTION>
<P>"The patients were randomised to one of the two groups by mean of randomisation tables"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 12:51:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Longo-2002">
<DESCRIPTION>
<P>"Patients were randomised to receive a standard benzodiazepine detoxification or Depakote detox plus maintenance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 13:57:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lucht-2003">
<DESCRIPTION>
<P>"Assignment took place in blocks of 10 in order of admission ( first 10 patients into group A, next 10 patients into group B, etc)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 12:37:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-1989">
<DESCRIPTION>
<P>"Subjetcs were blindly assigned to a group who received carbamazepine or to a group who received oxazepam"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:12:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2002">
<DESCRIPTION>
<P>"Subjects randomisation was based on on a computer generated schedule administered by a research pharmacist not involved in data collection"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 16:14:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-2007">
<DESCRIPTION>
<P>not specified if providers including subjects were aware of the criteria used to allocate patients to groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:42:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martin-1975">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 12:37:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGrath-1975">
<DESCRIPTION>
<P>"The true nature of the medication was known only to the hospital pharmacist who packaged them for each patient according to number. It was agreed that the code could be broken only if a patient's condition deteriorated to the extent that knowledge of the medication he was receiving was essential."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:15:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McLendon-1980">
<DESCRIPTION>
<P>"patients were treated in a double blind manner and evaluated weekly for three weeks"</P>
<P>COMMENT: it was not stated if the study was randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:15:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mendels-1985">
<DESCRIPTION>
<P>"Patients were assigned on a random list basis to one of two treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:17:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mielke-1976">
<DESCRIPTION>
<P>"Subjects were assigned sequentially to one of the three treatment groups according to a pre-assigned randomised schedule"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:42:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1984">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:16:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mukherjee-1983">
<DESCRIPTION>
<P>"Patients were randomly allocated to one of the two group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:19:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Naranjo-1983">
<DESCRIPTION>
<P>"The patient were randomly allocated to receive either supportive care with sublingual lorazepam or supportive care with sublingual placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:18:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nava-2007">
<DESCRIPTION>
<P>no information about allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:42:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Brien-1983">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:18:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Overall-1973">
<DESCRIPTION>
<P>"The subjects were assigned to one of three drug treatment groups in rotation according to the order of admission to the ward"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:21:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Palestine-1976">
<DESCRIPTION>
<P>"patients were randomly assigned to a treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:43:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pena_x002d_Ramos-1977">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:21:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pena_x002d_Ramos-1979">
<DESCRIPTION>
<P>"Each patient was assigned either to chlordiazepoxide or the thioridazine group on a random basis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 16:37:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Radouco_x002d_Thomas-1989">
<DESCRIPTION>
<P>"After enrolment, patients were assigned to receive the next in a sequentially numbered supply of medication. The sequence was previously determined by the hospital pharmacist from a table of random numbers with a blocked design to ensure a roughly equal numbers in the two treatment group and in the different season of the year"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:22:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ritson-1986">
<DESCRIPTION>
<P>"Number were allocated at random and the trial were therefore double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:26:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Runion-1978">
<DESCRIPTION>
<P>"A randomised allocation table supplied by the sponsor was used to assign patients to the appropriate treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:23:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saitz-1994">
<DESCRIPTION>
<P>"A pharmacist not involved in other aspects of the trial randomly assigned the 111 eligible patients in blocks of 10 to either symptom triggered therapy or standard fixed schedule therapy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-23 08:43:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saletu-1983">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 12:39:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sellers-1977">
<DESCRIPTION>
<P>"Six patients were randomly assigned to each of five treatments groups"</P>
<P>COMMENT: information about allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 16:45:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sellers-1983">
<DESCRIPTION>
<P>randomizations method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:25:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Solomon-1983">
<DESCRIPTION>
<P>"The patients were assigned randomly to one of the two treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 16:51:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spies-1996">
<DESCRIPTION>
<P>"Patient was randomised to receive one of the three treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 16:53:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spies-2003">
<DESCRIPTION>
<P>study described as "prospective randomised (per envelope) controlled study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 14:28:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stuppaeck-1992">
<DESCRIPTION>
<P>"Patients were randomly allocated to a double blind study comparing CBZ abs oxazepam"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 16:59:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tubridy-1988">
<DESCRIPTION>
<P>"Patients were randomised to one or the two treatment group by consecutive assignment of patients identification numbers that had previously been distributed between the two treatments by a computer generated list of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 09:35:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1985">
<DESCRIPTION>
<P>"When the physician decided that a given patient required sedation, that patient was assigned to receive the next in a sequentially numbered supply of medication, the sequence of which had previously been determined from a table of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-30 17:14:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Worner-1994">
<DESCRIPTION>
<P>"Subjects were randomised to one of the two drug regimens"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-02-15 12:14:26 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 12:49:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Addolorato-1999">
<DESCRIPTION>
<P>"The whole study was performed on a single blind design; in particular investigators who performed CIWA-Ar and Zung test at the different time of treatment did not know which drug was being administered to the patients"COMMENT: we judged the study at low risk of bias because the outcome assessors were blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 20:36:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Addolorato-1999">
<DESCRIPTION>
<P>"The whole study was performed on a singke blind design; in particular investigators who performed CIWA-Ar and Zung test at the different time of treatment did not know which drug was being administered to the patients"</P>
<P>COMMENT: outcomes unlikely to be biased by lack of blinding of patients and personnel who administered the treatments</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-07 12:31:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Addolorato-2006">
<DESCRIPTION>
<P>"the whole study was performed on a single blind design: in particular investigators who performed the CIVWA-Ar at the different times of treatment were always the same and were unaware as to which drug was being administered to patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-07 12:31:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Addolorato-2006">
<DESCRIPTION>
<P>"the whole study was performed on a single blind design: in particular investigators who performed the CIVWA-Ar at the different times of treatment were always the same and were unaware as to which drug was being administered to patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 12:50:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adinoff-1994">
<DESCRIPTION>
<P>"Medications were in identical capsules and were administered in a double blind paradigm".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-07 12:31:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Adinoff-1994">
<DESCRIPTION>
<P>"Medications were in identical capsules and were administered in a double blind paradigm"</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-23 08:40:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ansoms-1991">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-23 08:40:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ansoms-1991">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 12:51:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-1997">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 20:45:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-1997">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 13:03:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bailly-1992">
<DESCRIPTION>
<P>"patients were studies for 15 days in a double blind treatment design".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 20:45:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bailly-1992">
<DESCRIPTION>
<P>"patients were studies for 15 days in a double blind treatment design".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-23 08:40:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baumgartner-1987">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-23 08:40:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baumgartner-1987">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-23 08:40:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baumgartner-1991">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-23 08:40:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baumgartner-1991">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-07 12:32:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borg-1986">
<DESCRIPTION>
<P>"patients were treated with amobarbital, oxazepam and Melperone in a double blind design".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-07 12:33:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borg-1986">
<DESCRIPTION>
<P>"patients were treated with amobarbital, oxazepam and Melperone in a double blind design".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-23 08:41:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1972">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-23 08:41:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1972">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-01 08:59:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985a">
<DESCRIPTION>
<P>"the patients in each group were randomised to treatment in double blind fashion using a pre-fixed code devised by the hospital pharmacy" "The drugs were masked in the same size capsule and were pre-packaged into daily dosage containers".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-07 12:33:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985a">
<DESCRIPTION>
<P>"the patients in each group were randomised to treatment in double blind fashion using a pre-fixed code devised by the hospital pharmacy" "The drugs were masked in the same size capsule and were pre-packaged into daily dosage containers".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-01 08:59:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985b">
<DESCRIPTION>
<P>"the patients in each group were randomised to treatment in double blind fashion using a pre-fixed code devised by the hospital pharmacy" "The drugs were masked in the same size capsule and were pre-packaged into daily dosage containers".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-07 12:33:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985b">
<DESCRIPTION>
<P>"the patients in each group were randomised to treatment in double blind fashion using a pre-fixed code devised by the hospital pharmacy" "The drugs were masked in the same size capsule and were pre-packaged into daily dosage containers".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 13:10:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Choi-2005">
<DESCRIPTION>
<P>no information about blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 20:49:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Choi-2005">
<DESCRIPTION>
<P>no information about blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-01 09:00:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daeppen-2002">
<DESCRIPTION>
<P>"Oxazepan and placebo were manufactured in capsules of identical appearance". "Physicians , nurses, research assistant and patients were blinded to treatment assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 20:50:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daeppen-2002">
<DESCRIPTION>
<P>"Oxazepan and placebo were manufactured in capsules of identical appearance". "Physicians , nurses, research assistant and patients were blinded to treatment assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 13:20:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Day-2004">
<DESCRIPTION>
<P>patients, providers and outcome assessor not blind to treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-07 12:34:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Day-2004">
<DESCRIPTION>
<P>patients, providers and outcome assessor not blind to treatment</P>
<P>COMMENT: objective outcomes unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-23 08:41:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dion-1968">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-23 08:41:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dion-1968">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 13:20:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Favre-2005">
<DESCRIPTION>
<P>"double blind study". "Cyamemazine (Tercian1) and diazepam (Valium1) were used in 50 mg and 10 mg capsules, respectively, of the same type and appearance to preserve the double-blind requirement for the trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 20:52:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Favre-2005">
<DESCRIPTION>
<P>"double blind study". "Cyamemazine (Tercian1) and diazepam (Valium1) were used in 50 mg and 10 mg capsules, respectively, of the same type and appearance to preserve the double-blind requirement for the trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-07 12:34:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Funderburk-1978">
<DESCRIPTION>
<P>blinding not mentioned.</P>
<P>COMMENT: we judged the study not blind because the way and the frequency of treatment administration were different among group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 20:52:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Funderburk-1978">
<DESCRIPTION>
<P>blinding not mentioned.</P>
<P>COMMENT: outcomes unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 18:08:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gillman-2004">
<DESCRIPTION>
<P>Study defined as Double blind. "Gases were titrated through two identical Quantiflex relative dental analgesia machines disguised to avoid identification of the gas line. Placebo tablets looked identical to active tablets" . "The identity of the gas and medication given was only revealed to the investigators after completion of the trial. All assessments were made by a trained nurse who was blinded to the code".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 20:53:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gillman-2004">
<DESCRIPTION>
<P>Study defined as Double blind. "Gases were titrated through two identical Quantiflex relative dental analgesia machines disguised to avoid identification of the gaslinePlacebo tablets looked identical to active tablets " . "The identity of the gas and medication given was only revealed to the investigators after completion of the trial. All assessments were made by a trained nurse who was blinded to the code".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 13:22:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gillmer-1973">
<DESCRIPTION>
<P>Study described as double blind. "The two comparatives medications were made up in identical capsules".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 20:54:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gillmer-1973">
<DESCRIPTION>
<P>Study described as double blind. "The two comparatives medications were made up in identical capsules".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 18:11:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Golbert-1967">
<DESCRIPTION>
<P>Blinding: Not mentioned.</P>
<P>COMMENT:We judged that the study was not blind because the route of administration of treatment was different (alcohol administered orally vs drug administered intramuscularly)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 20:54:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Golbert-1967">
<DESCRIPTION>
<P>Blinding: Not mentioned.</P>
<P>COMMENT: the outcomes are unlikely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 13:23:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jauhar-2000">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 20:54:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jauhar-2000">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 13:23:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaim-1969">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 20:55:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaim-1969">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-01 09:02:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaim-1972">
<DESCRIPTION>
<P>"The parenteral form of chlordiazepoxide is straw-coloured and required to be mixed with an intramuscular diluent; The IM form of prephenazine is a clear fluid supplied in 2cc. ampoules: IM sodium pentobarbital is colourless fluid, supplied in 5cc ampules.To maintain a partial double blind all IM medication was prepared with matching placebo and each patients was supplied with two injections of equivalent amount, one of which was placebo" "Oral medication other than paraldehyde were in capsule of identical appearance"</P>
<P>.Blinding of outcomes assessor: it was not stated if the outcome assessor was blind,</P>
<P>COMMENT: the authors described the study as partial double blind; we judged that physicians could easily understand the type of treatment given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-07 12:35:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaim-1972">
<DESCRIPTION>
<P>The parenteral form of chlordiazepoxide is straw-coloured and required to be mixed with an intramuscular diluent; The IM form of perphenazine is a clear fluid supplied in 2cc. ampoules: IM sodium pentobarbital is colourless fluid, supplied in 5cc ampules.To maintain a partial double blind all IM medication was prepared with matching placebo and each patients was supplied with two injections of equivalent amount, one of which was placebo" "Oral medication other than paraldehyde were in capsule of identical appearance".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind,</P>
<P>COMMENT: the outcomes are unlikely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 13:24:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalyoncu-1996">
<DESCRIPTION>
<P>blinding not mentioned</P>
<P>COMMENT: there are no sufficient information about treatments to judge if the study could be blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 20:57:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kalyoncu-1996">
<DESCRIPTION>
<P>linding not mentioned</P>
<P>COMMENT: outcomes unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 13:25:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kolin-1981">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 20:58:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kolin-1981">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 13:25:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kramp-1978">
<DESCRIPTION>
<P>"The patients were allocated double blind to treatment with either barbital (by oral route ) or diazepam (by intramuscular route). Patients received tablets as well as injections when medication was given(active tables plus placebo injection or active injection plus placebo tablet) ".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 20:58:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kramp-1978">
<DESCRIPTION>
<P>"The patients were allocated double blind to treatment with either barbital (by oral route ) or diazepam (by intramuscular route). Patients received tablets as well as injections when medication was given(active tables plus placebo injection or active injection plus placebo tablet) ".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 13:26:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krupitsky-2007">
<DESCRIPTION>
<P>placebo-controlled randomised single-blinded</P>
<P>Blinding of outcome assessor: "raters blind to the treatment assignment administered an alcohol withdrawal severity scale ". Patients blinded to treatment completed a self reported withdrawal symptoms checklist "Because study medications were not encapsulated, there was a potential for subjects to learn their group assignment by studying their medications if they were aware of distinctive markings associated with each study medication. We suspect that the blind was largely intact in this patient group based on informal clinical interactions with patients, although the integrity of the blind was not formally assessed. To promote the integrity of the blind, no medication could be identified by its administration schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-02-15 12:14:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krupitsky-2007">
<DESCRIPTION>
<P>placebo-controlled randomised single-blinded</P>
<P>Blinding of outcome assessor: "raters blind to the treatment assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-29 14:21:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-2009">
<DESCRIPTION>
<P>"Double-blind assessments were obtained at baseline and throughout the course of the study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-29 14:21:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-2009">
<DESCRIPTION>
<P>"Double-blind assessments were obtained at baseline and throughout the course of the study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-01 09:05:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lapierre-1983">
<DESCRIPTION>
<P>"Double blind was assured by the double dummy technique in which the patient received equal number of either of the two active drugs and the placebo of the other". Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-07 12:36:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lapierre-1983">
<DESCRIPTION>
<P>"Double blind was assured by the double dummy technique in which the patient received equal number of either of the two active drugs and the placebo of the other".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-23 08:42:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lenzenhuber-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-23 08:42:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lenzenhuber-1999">
<DESCRIPTION>
<P> unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-01 09:07:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lepola-1984">
<DESCRIPTION>
<P>"The study followed a double blind design".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-07 12:36:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lepola-1984">
<DESCRIPTION>
<P>"The study followed a double blind design".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-01 09:08:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Longo-2002">
<DESCRIPTION>
<P>"CIWA-Ar raters were unaware of subjects cohort group assignment"</P>
<P>COMMENT: we judged that the study was not blinded because the treatment differed in duration and way and frequency of drug administration.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:11:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Longo-2002">
<DESCRIPTION>
<P>COMMENT: the outcomes are unlikely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 13:57:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lucht-2003">
<DESCRIPTION>
<P>"patients, physicians and nurses were not blind to the study medication"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-07 12:37:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lucht-2003">
<DESCRIPTION>
<P>"patients, physicians and nurses were not blind to the study medication"</P>
<P>COMMENT: lack of blinding unlikely or influence outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 13:57:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-1989">
<DESCRIPTION>
<P>study described ad "double blind".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:12:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-1989">
<DESCRIPTION>
<P>study described ad "double blind".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 13:58:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2002">
<DESCRIPTION>
<P>Study describes as double blind".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:12:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2002">
<DESCRIPTION>
<P>Study describes as double blind".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 13:59:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2007">
<DESCRIPTION>
<P>"double blind study" "Medications prepared for the project were identical capsules prepared and distributed by the Alcohol Research Center Shared Scientific Core pharmacists under supervision by the University Research Pharmacy Office"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:15:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2007">
<DESCRIPTION>
<P>"double blind study" "Medications prepared for the project were identical capsules prepared and distributed by the Alcohol Research Center Shared Scientific Core pharmacists under supervision by the University Research Pharmacy Office"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-23 08:42:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martin-1975">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-23 08:42:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martin-1975">
<DESCRIPTION>
<P> unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-29 12:11:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGrath-1975">
<DESCRIPTION>
<P>"As the two preparations being tested were very different in presentation, one being a tablet and the other a capsule with Arachis oil, it was decided that both tablet and capsule would be given to each patient. Patients received either active capsules and placebo tablets, or vice versa."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-29 12:12:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGrath-1975">
<DESCRIPTION>
<P>"As the two preparations being tested were very different in presentation, one being a tablet and the other a capsule with Arachis oil, it was decided that both tablet and capsule would be given to each patient. Patients received either active capsules and placebo tablets, or vice versa."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:15:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McLendon-1980">
<DESCRIPTION>
<P>study describes as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:16:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McLendon-1980">
<DESCRIPTION>
<P>study describes as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:15:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mendels-1985">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:17:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mendels-1985">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:16:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mielke-1976">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:17:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mielke-1976">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-23 08:42:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1984">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:17:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1984">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:16:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mukherjee-1983">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:18:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mukherjee-1983">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:17:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Naranjo-1983">
<DESCRIPTION>
<P>study described as double blind. "The validity of double blind was tested by asking the nurses to indicate at the end of the treatment whether each patient had received sublingual lorazepam or placebo".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:18:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Naranjo-1983">
<DESCRIPTION>
<P>study described as double blind. "The validity of double blind was tested by asking the nurses to indicate at the end of the treatment whether each patient had received sublingual lorazepam or placebo".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:18:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nava-2007">
<DESCRIPTION>
<P>"open label study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:19:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nava-2007">
<DESCRIPTION>
<P>"open label study"</P>
<P>COMMNENT: objective outcome unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-23 08:42:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Brien-1983">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:19:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Brien-1983">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:18:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Overall-1973">
<DESCRIPTION>
<P>blinding not mentioned.</P>
<P>COMMENT: it was not possible to ascertain if the treatments had different way and frequency of administration because this information was not reported in the study. We judged that the study was not blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:20:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Overall-1973">
<DESCRIPTION>
<P>blinding not mentioned.</P>
<P>COMMENT: outcomes unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:21:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palestine-1976">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:20:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palestine-1976">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-23 08:43:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pena_x002d_Ramos-1977">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:20:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pena_x002d_Ramos-1977">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:21:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pena_x002d_Ramos-1979">
<DESCRIPTION>
<P>study described as double blind. "Thioridazine and chlordiazepoxide were separately encapsulated in pink and blue capsules of 25 mg each, meeting the standard requirement for double blind administration.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:21:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pena_x002d_Ramos-1979">
<DESCRIPTION>
<P>study described as double blind. "Thioridazine and chlordiazepoxide were separately encapsulated in pink and blue capsules of 25 mg each, meeting the standard requirement for double blind administration.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 16:37:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Radouco_x002d_Thomas-1989">
<DESCRIPTION>
<P>Double blind. "Double dummy administration procedure".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:21:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Radouco_x002d_Thomas-1989">
<DESCRIPTION>
<P>Double blind. "Double bummy administration procedure".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:22:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ritson-1986">
<DESCRIPTION>
<P>Study described as double blind. "Identical tablets containing either lorazepam or diazepam were supplied in numbered bottles".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:22:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ritson-1986">
<DESCRIPTION>
<P>Study described as double blind. "Identical tablets containing either lorazepam or diazepam were supplied in numbered bottles".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:23:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Runion-1978">
<DESCRIPTION>
<P>Study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:22:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Runion-1978">
<DESCRIPTION>
<P>Study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-01 09:27:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saitz-1994">
<DESCRIPTION>
<P>study described as double blind. "Physicians, nurses and patients were blinded to treatment assignment through the trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-07 12:38:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saitz-1994">
<DESCRIPTION>
<P>study described as double blind. "Physicians, nurses and patients were blinded to treatment assignment through the trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-23 08:43:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saletu-1983">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:23:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saletu-1983">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-07 12:39:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sellers-1977">
<DESCRIPTION>
<P>"The placebo group received placebo identical in appearance to the active drug, in both capsule and tablet; the chlordiazepoxide group received chlordiazepoxide in capsule and placebo in tablet; the high and low dose propranolol groups received a placebo capsule and propranolol tablet."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-07 12:39:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sellers-1977">
<DESCRIPTION>
<P>"The placebo group received placebo identical in appearance to the active drug, in both capsule and tablet; the chlordiazepoxide group received chlordiazepoxide in capsule and placebo in tablet; the high and low dose propranolol groups received a placebo capsule and propranolol tablet."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:25:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sellers-1983">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:23:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sellers-1983">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:25:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Solomon-1983">
<DESCRIPTION>
<P>study described as double blind. "The drugs were supplied in identical capsules"</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:24:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Solomon-1983">
<DESCRIPTION>
<P>study described as double blind. "The drugs were supplied in identical capsules"</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:27:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spies-1996">
<DESCRIPTION>
<P>Study reported as blinded. "The investigator who documented the alcoholism related history was unaware of the treatment and of the complication during the ICU stay"</P>
<P>COMMENT: it is not clear if the patients and outcome assessor were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:24:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spies-1996">
<DESCRIPTION>
<P>Study reported as blinded. "The investigator who documented the alcoholism related history was unaware of the treatment and of the complication during the ICU stay"</P>
<P>COMMENT: outcomes unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:27:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spies-2003">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:25:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spies-2003">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:28:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stuppaeck-1992">
<DESCRIPTION>
<P>Study defined as double blind. "Oxazepam and CBZ were administered in identical capsules".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:25:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stuppaeck-1992">
<DESCRIPTION>
<P>Study defined as double blind. "Oxazepam and CBZ were administered in identical capsules".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:29:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tubridy-1988">
<DESCRIPTION>
<P>blindness not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:25:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tubridy-1988">
<DESCRIPTION>
<P>blindness not mentioned</P>
<P>COMMENT: outcomes unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:29:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilson-1985">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:26:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilson-1985">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-30 14:29:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Worner-1994">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-22 21:26:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Worner-1994">
<DESCRIPTION>
<P>study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-01-07 12:40:25 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-01 11:17:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Addolorato-1999">
<DESCRIPTION>
<P>"26% of the patients in the diazepam group and 13.3% of patients in the GHB group dropped out from the study". Reason for drop out not given except the information that none dropped out for side effect</P>
<P>COMMENT: percentage dropped out different between group. Information about reason not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-22 20:41:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Addolorato-2006">
<DESCRIPTION>
<P>"all patients completed the study, with no drop out in either groups and no different in patients' compliance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 12:50:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Adinoff-1994">
<DESCRIPTION>
<P>no drop out from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-23 08:40:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ansoms-1991">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-07 12:32:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-1997">
<DESCRIPTION>
<P>28% of the patients in the Abecamil group and 21% of the patients in the diazepam group dropped out. Reason for drop out reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:03:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bailly-1992">
<DESCRIPTION>
<P>"1 drop out in the diazepam group due to non compliance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-23 08:40:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baumgartner-1987">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-23 08:40:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baumgartner-1991">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-07 12:33:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borg-1986">
<DESCRIPTION>
<P>"four patients were excluded before the study was finished from the Melperone group because of epileptic fits"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-23 08:41:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1972">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-14 10:20:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985a">
<DESCRIPTION>
<P>"three patients withdrawn from the study: Two in the minor withdrawal group from the placebo group. One in the major withdrawal group taking chlordiazepoxide". " Analysis of difference between groups was based on intent to treat regardless of subsequent withdrawal from the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:09:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985b">
<DESCRIPTION>
<P>"three patients withdrawn from the study: Two in the minor withdrawal group from the placebo group. One in the major withdrawal group taking chlordiazepoxide". " Analysis of difference between groups was based on intent to treat regardless of subsequent withdreawal from the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:10:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choi-2005">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-01 09:00:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daeppen-2002">
<DESCRIPTION>
<P>7 patients exit from the trial after randomisation. reason for drop out reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:20:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Day-2004">
<DESCRIPTION>
<P>"All 23 participants completed the full detoxification process, and no one left<BR/>the unit prematurely."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-23 08:41:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dion-1968">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-03 17:01:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Favre-2005">
<DESCRIPTION>
<P>"Eighty nine patients were randomised (45 in the cyamemazine group and 44 in the diazepam group). Two patients of the cyamemazine group were excluded from the intention to treat (ITT) population. One patient withdrew his protocol consent before<BR/>initiating treatment and the other had a major protocol deviation (hepatic failure). Thus, the intention to treat (ITT) population was reduced to 87 patients (43 and 44 in the cyamemazine and diazepam groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:21:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Funderburk-1978">
<DESCRIPTION>
<P>no information reported about the number of patients who terminated the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:21:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gillman-2004">
<DESCRIPTION>
<P>no drop out from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 18:11:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gillmer-1973">
<DESCRIPTION>
<P>one patient in the benzoctamine group dropped out. reason for drop out given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:22:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Golbert-1967">
<DESCRIPTION>
<P>no drop out from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:23:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jauhar-2000">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 15:55:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaim-1969">
<DESCRIPTION>
<P>106 out of 537 patients terminated early the study. Reason for early termination given. "The early terminators were fairly even distributed among the five group with the exception of the hydroxyzine group who lost only two patients . It is difficult to account for this difference because the patients left the study for a variety of reasons".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:24:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaim-1972">
<DESCRIPTION>
<P>"The random assignment of patients to treatments was controlled by a study code number;; patients were assigned consecutive numbers. Prepackaged box of study medication corresponding to the patient's code number."</P>
<P>COMMENT: it is not clear how the code numbers were generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:24:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kalyoncu-1996">
<DESCRIPTION>
<P>16 patients dropped out from studies. reason given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:25:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kolin-1981">
<DESCRIPTION>
<P>3 patients from the alprazolam group and two from the diazepam group withdrawn from the study. Reason for withdrawn given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 18:17:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kramp-1978">
<DESCRIPTION>
<P>"The patients were allocated double blind to treatment"</P>
<P>COMMENT: it was not state if the study was randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:26:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krupitsky-2007">
<DESCRIPTION>
<P>Block randomisation was used with block sizes of 15, 20, and 25 randomly varied</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-07 12:36:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-2009">
<DESCRIPTION>
<P>"An intent-to-treat analysis was conducted on randomised patients using the last-observation-carried-forward method<BR/>for patients who dropped out. Four lorazepam and five chlordiazepoxide patients did not complete the study because withdrew consent"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:55:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lapierre-1983">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-23 08:42:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lenzenhuber-1999">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:55:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lepola-1984">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:57:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Longo-2002">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:57:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lucht-2003">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:57:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-1989">
<DESCRIPTION>
<P>20 subjects dropped out from the study. Reason for drop out give, No difference in number of subjects dropped out between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 13:58:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2002">
<DESCRIPTION>
<P>"Retention rate did not differ between the groups". Reported flow chart of treatment retention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 16:14:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-2007">
<DESCRIPTION>
<P>reported the number of subjects excluded or who dropped out for treatment but not divided for group assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-23 08:42:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martin-1975">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-07 12:38:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGrath-1975">
<DESCRIPTION>
<P>14 patients dropped out from Chlordiazepoxide group and 7 from Chlormethiazole because feelings of tension and restlessness or to breaking of the code due to the development of delirium tremens</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 14:15:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McLendon-1980">
<DESCRIPTION>
<P>5 patients in the alprazolam group, 8 in the chlordiazepoxide and 8 in the placebo group dropped out from the study because were lost at follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 14:15:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mendels-1985">
<DESCRIPTION>
<P>3 patients from halazepam group and 9 from the chlordiazepoxide drop out form the study. Reason for drop out given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-01 09:18:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mielke-1976">
<DESCRIPTION>
<P>6 patients dropped out from the study. Reason for withdrawn not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-23 08:42:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1984">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-07 12:38:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mukherjee-1983">
<DESCRIPTION>
<P>2 patients in each group discharged themselves from the study during the first week. 4 patients in the chlordiazepoxide group had no response to treatment and were withdrawn. 4 patients in the clobazam and 2 in the chlordiazepoxide group were withdrawn having had a good response., with no further medication necessary</P>
<P>COMMENT: it is not clear why patients with no response to treatment and patients with good response were withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 14:18:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Naranjo-1983">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 14:18:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nava-2007">
<DESCRIPTION>
<P>no drop out from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-23 08:43:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Brien-1983">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 14:18:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Overall-1973">
<DESCRIPTION>
<P>19 patients withdrawn for the study. reason for withdrawn given.</P>
<P>COMMENT: not specified from which group the patients dropped out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 14:21:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palestine-1976">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-23 08:43:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pena_x002d_Ramos-1977">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 14:21:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pena_x002d_Ramos-1979">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 16:37:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Radouco_x002d_Thomas-1989">
<DESCRIPTION>
<P>7 patients drop out from the study. Reason for drop out given. No differences in the number of drop out between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-01 09:25:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ritson-1986">
<DESCRIPTION>
<P>"One patients from the lorazepam group was withdrawn because the symptoms were not controlled"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 14:23:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Runion-1978">
<DESCRIPTION>
<P>"The 9 patients which were removed from the study were done for some breach of the protocol". 4 patients withdrawn from the hydroxine group and 5 from the chlordiazepoxide group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-01 09:27:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saitz-1994">
<DESCRIPTION>
<P>10 patients withdrawn from the trial, 5 from each group. Reason for withdrawn not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-23 08:43:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saletu-1983">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-30 16:19:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sellers-1977">
<DESCRIPTION>
<P>no drop out from the the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 14:25:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sellers-1983">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 16:49:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Solomon-1983">
<DESCRIPTION>
<P>"Six patients in the lorazepam group and two in the chlordiazepoxide group discontinued the treatment, but none because of drug related adverse effects"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-07 12:39:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spies-1996">
<DESCRIPTION>
<P>6 patients from the flunitrazepam/clonidine group, 10 patients from the Chlormethiazole/haloperidol group, 5 patients in the flunitrazepam/haloperidol group were excluded from the studies for medical reasons described in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-07 12:40:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spies-2003">
<DESCRIPTION>
<P>1 patients withdrawn from the bolus titrated group and 3 withdrawn from the infusion titrated group. Reason for withdrawn reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 14:28:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stuppaeck-1992">
<DESCRIPTION>
<P>"4 patients from each group dropped out from treatment." Reason for drop out given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 14:29:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tubridy-1988">
<DESCRIPTION>
<P>"Data from two patients in each group were lost"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 14:29:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilson-1985">
<DESCRIPTION>
<P>3 patients from each group were removed from the study because they developed delirium tremens</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 14:29:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Worner-1994">
<DESCRIPTION>
<P>analysis done on the intention to treat basis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-01-07 14:47:22 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2010-01-07 14:47:22 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2010-01-07 14:47:08 +0100" MODIFIED_BY="Grade Profiler">Benzodiazepine versus Placebo for alcohol withdrawal</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TD COLSPAN="7">
<P>
<B>Benzodiazepine versus Placebo for alcohol withdrawal</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with alcohol withdrawal<BR/>
<B>Settings:</B> <BR/>
<B>Intervention:</B> Benzodiazepine versus Placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Benzodiazepine versus Placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Alcohol withdrawal seizures</B>
<BR/>objective</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.16 </B>
<BR/>(0.04 to 0.69)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>324<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>80 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>13 per 1000</B>
<BR/>(3 to 55)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>69 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>11 per 1000</B>
<BR/>(3 to 48)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 3.28 </B>
<BR/>(0.31 to 34.52)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>71<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>28 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>92 per 1000</B>
<BR/>(9 to 967)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>46 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>151 per 1000</B>
<BR/>(14 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Dropouts</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.68 </B>
<BR/>(0.38 to 1.24)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>312<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>162 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>110 per 1000</B>
<BR/>(62 to 201)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>167 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>114 per 1000</B>
<BR/>(63 to 207)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Allocation concealment unclear for 2/3 studies<BR/>
<SUP>2</SUP> only two studies, limited number of participants<BR/>
<SUP>3</SUP> Large confidence interval</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2010-01-07 14:47:22 +0100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2010-01-07 14:44:30 +0100" MODIFIED_BY="Grade Profiler">Benzodiazepine versus Other Drug for</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>Benzodiazepine versus Other Drug for </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with <BR/>
<B>Settings:</B> <BR/>
<B>Intervention:</B> Benzodiazepine versus Other Drug<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Benzodiazepine versus Other Drug</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Alcohol withdrawal seizures - Benzodiazepine vs. Other Drug</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.52 </B>
<BR/>(0.21 to 1.31)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1228<BR/>(12 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>47 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>24 per 1000</B>
<BR/>(10 to 62)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>18 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>9 per 1000</B>
<BR/>(4 to 24)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Alcohol withdrawal seizures - Benzodiazepine vs. Anticonvulsant</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.7 </B>
<BR/>(0.39 to 7.37)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>523<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>7 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>12 per 1000</B>
<BR/>(3 to 52)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse events - Benzodiazepine vs. Other Drug</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.31 </B>
<BR/>(0.99 to 1.72)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>919<BR/>(18 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>140 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>183 per 1000</B>
<BR/>(139 to 241)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>54 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>71 per 1000</B>
<BR/>(53 to 93)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse events - Benzodiazepine vs. Anticonvulsant</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.5 </B>
<BR/>(0.83 to 2.7)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>471<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>138 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>207 per 1000</B>
<BR/>(115 to 373)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>111 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>167 per 1000</B>
<BR/>(92 to 300)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Dropouts - Benzodiazepine vs. Other Drug</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.93 </B>
<BR/>(0.7 to 1.24)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1848<BR/>(22 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>117 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>109 per 1000</B>
<BR/>(82 to 145)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>77 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>72 per 1000</B>
<BR/>(54 to 95)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Dropouts - Benzodiazepine vs. Anticonvulsant</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.11 </B>
<BR/>(0.75 to 1.63)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>839<BR/>(11 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>98 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>109 per 1000</B>
<BR/>(74 to 160)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>102 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>113 per 1000</B>
<BR/>(76 to 166)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Allocation concealment adequate only for 3/12 studies<BR/>
<SUP>2</SUP> large confidence interval<BR/>
<SUP>3</SUP> Allcation concealment adequate in 6/18 studies<BR/>
<SUP>4</SUP> Allocation concealment adequate in 7/22 studies</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-01-07 11:42:06 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-12-02 13:26:36 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-12-02 11:45:37 +0100" MODIFIED_BY="[Empty name]">Comparisons Benzodiazepines versus Placebo</TITLE>
<TABLE COLS="3" ROWS="12">
<TR>
<TH>
<P>Author</P>
</TH>
<TH>
<P>Treatment (benzodiazepine)</P>
</TH>
<TH>
<P>Control</P>
</TH>
</TR>
<TR>
<TD>
<P>Adinoff 1994</P>
</TD>
<TD>
<P>Diazepam  </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Burroughs 1985a</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Kaim 1969</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Kaim 1972</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Krupitsky 2007</P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Martin 1975 </P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>McLendon 1980</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Mielke 1976</P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Naranjo 1983</P>
</TD>
<TD>
<P>Lorazepam </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Sellers 1977 </P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Sellers 1983</P>
</TD>
<TD>
<P>Diazepam  </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2010-01-07 11:42:06 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-12-02 12:22:45 +0100" MODIFIED_BY="[Empty name]">Comparisons Benzodiazepines versus Anticonvulsants</TITLE>
<TABLE COLS="3" ROWS="27">
<TR>
<TH>
<P>Author</P>
</TH>
<TH>
<P>Treatment (benzodiazepines)</P>
</TH>
<TH>
<P>Control (anticonvulsants)</P>
</TH>
</TR>
<TR>
<TD>
<P>Burroughs 1985a</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
</TR>
<TR>
<TD>
<P>Burroughs 1985b</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
</TR>
<TR>
<TD>
<P>Dion 1968</P>
</TD>
<TD>
<P>Chlordiazepoxide   </P>
</TD>
<TD>
<P>Magnesium sulphate </P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P/>
<P>Golbert 1967</P>
<P/>
</TD>
<TD ROWSPAN="2">
<P/>
<P>Chlordiazepoxide  </P>
<P>  </P>
</TD>
<TD>
<P>Promazine </P>
</TD>
</TR>
<TR>
<TD>
<P>Paraldehyde  + Chloral hydrate (sedative)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P/>
<P>Kaim 1972</P>
<P/>
</TD>
<TD ROWSPAN="2">
<P/>
<P>Chlordiazepoxide  </P>
<P> </P>
</TD>
<TD>
<P>Paraldehyde </P>
</TD>
</TR>
<TR>
<TD>
<P>Pentobarbital</P>
</TD>
</TR>
<TR>
<TD>
<P>Lapierre 1983</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
</TR>
<TR>
<TD>
<P>Longo 2002</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Sodium valproate </P>
</TD>
</TR>
<TR>
<TD>
<P>MC Grath 1975</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
</TR>
<TR>
<TD>
<P>Radouco-Thomas 1989</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Phenobarbital</P>
</TD>
</TR>
<TR>
<TD>
<P>Kalyoncu 1996</P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Carbamazepine</P>
</TD>
</TR>
<TR>
<TD>
<P>Kramp 1978</P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Barbital </P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Krupitsky 2007</P>
</TD>
<TD ROWSPAN="3">
<P>Diazepam</P>
</TD>
<TD>
<P>Topiramate </P>
</TD>
</TR>
<TR>
<TD>
<P> Memantine </P>
</TD>
</TR>
<TR>
<TD>
<P>Lamotrigine </P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P/>
<P>Lucht 2003</P>
<P/>
</TD>
<TD ROWSPAN="2">
<P/>
<P>Diazepam</P>
<P/>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
</TR>
<TR>
<TD>
<P>Carbamazepine</P>
</TD>
</TR>
<TR>
<TD>
<P>Thompson 1975</P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Paraldehyde </P>
</TD>
</TR>
<TR>
<TD>
<P>Malcom 2002</P>
</TD>
<TD>
<P>Lorazepam </P>
</TD>
<TD>
<P>Carbamazepine</P>
</TD>
</TR>
<TR>
<TD>
<P>Malcom 2007</P>
</TD>
<TD>
<P>Lorazepam </P>
</TD>
<TD>
<P>Gabapentin</P>
</TD>
</TR>
<TR>
<TD>
<P>Choi 2005</P>
</TD>
<TD>
<P>Lorazepam </P>
</TD>
<TD>
<P>Topiramate </P>
</TD>
</TR>
<TR>
<TD>
<P>Borg 1986</P>
</TD>
<TD>
<P>Oxazepam  </P>
</TD>
<TD>
<P>Amobarbital </P>
</TD>
</TR>
<TR>
<TD>
<P>Malcom 1989</P>
</TD>
<TD>
<P>Oxazepam  </P>
</TD>
<TD>
<P>Carbamazepine</P>
</TD>
</TR>
<TR>
<TD>
<P>Stuppaeck 1992</P>
</TD>
<TD>
<P>Oxazepam  </P>
</TD>
<TD>
<P>Carbamazepine</P>
</TD>
</TR>
<TR>
<TD>
<P>Tubridy 1988</P>
</TD>
<TD>
<P>Alprazolam </P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2009-12-02 13:15:04 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-12-02 12:42:09 +0100" MODIFIED_BY="[Empty name]">Comparison Benzodiazepines versus Antipsychotics</TITLE>
<TABLE COLS="3" ROWS="10">
<TR>
<TH>
<P>Author</P>
</TH>
<TH>
<P>Treatment (benzodiazepine)</P>
</TH>
<TH>
<P>Control (antipsychotic)</P>
</TH>
</TR>
<TR>
<TD>
<P>Kaim 1969</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Chlorpromazine </P>
</TD>
</TR>
<TR>
<TD>
<P>Kaim 1972</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Perhenazine </P>
</TD>
</TR>
<TR>
<TD>
<P>Lepola 1984</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Tiapride </P>
</TD>
</TR>
<TR>
<TD>
<P>Overall 1973</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Mesoridazine </P>
</TD>
</TR>
<TR>
<TD>
<P>Palestine 1976</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Haloperidol </P>
</TD>
</TR>
<TR>
<TD>
<P>Pena-Ramos 1977</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Thioridazine </P>
</TD>
</TR>
<TR>
<TD>
<P>Pena-Ramos 1979</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Thioridazine </P>
</TD>
</TR>
<TR>
<TD>
<P>Borg 1986</P>
</TD>
<TD>
<P>Oxazepam  </P>
</TD>
<TD>
<P>Melperone </P>
</TD>
</TR>
<TR>
<TD>
<P>Favre 2005</P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Cyametazine </P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2009-12-02 13:14:58 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2009-12-02 12:50:14 +0100" MODIFIED_BY="[Empty name]">Comparisons Benzodiazepines versus Miscellanea</TITLE>
<TABLE COLS="3" ROWS="21">
<TR>
<TH>
<P>Author</P>
</TH>
<TH>
<P>Treatment (benzodiazepine)</P>
</TH>
<TH>
<P>Control</P>
</TH>
</TR>
<TR>
<TD>
<P>Baumgartner 1987</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Clonidine (alpha adrenergic)</P>
</TD>
</TR>
<TR>
<TD>
<P>Baumgartner 1991 </P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Clonidine (alpha adrenergic)</P>
</TD>
</TR>
<TR>
<TD>
<P>Burroughs 1985a</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Bromocriptine (dopamine agonist) </P>
</TD>
</TR>
<TR>
<TD>
<P>Burroughs 1985b</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Bromocriptine (dopamine agonist) </P>
</TD>
</TR>
<TR>
<TD>
<P>Funderburk 1978</P>
</TD>
<TD>
<P> </P>
<P>Chlordiazepoxide   </P>
</TD>
<TD>
<P>Ethanol</P>
</TD>
</TR>
<TR>
<TD>
<P>Golbert 1967</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Alcohol</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P/>
<P>Kaim 1969</P>
<P/>
</TD>
<TD ROWSPAN="2">
<P/>
<P>Chlordiazepoxide  </P>
<P>  </P>
</TD>
<TD>
<P>Hydroxyzine (anxiolytic)</P>
</TD>
</TR>
<TR>
<TD>
<P>Thiamine  (vitamin B1)</P>
</TD>
</TR>
<TR>
<TD>
<P>Runion 1978</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Hydroxyzine (anxiolytic)</P>
</TD>
</TR>
<TR>
<TD>
<P>Sellers 1977 </P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Propranol (beta-blocking))</P>
</TD>
</TR>
<TR>
<TD>
<P>Addolorato 1999  </P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>GHB</P>
</TD>
</TR>
<TR>
<TD>
<P>Addolorato 2005 </P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Baclofen (muscle relaxant)</P>
</TD>
</TR>
<TR>
<TD>
<P>Bailly 1992</P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Propranol (beta-blocking))</P>
</TD>
</TR>
<TR>
<TD>
<P>Gillman 2004</P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Nitrous Oxide</P>
</TD>
</TR>
<TR>
<TD>
<P>Nava 2007</P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>GHB</P>
</TD>
</TR>
<TR>
<TD>
<P>Worner 1994</P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Propranol (beta-blocking))</P>
</TD>
</TR>
<TR>
<TD>
<P>Adinoff 1994</P>
</TD>
<TD>
<P>Diazepam  </P>
</TD>
<TD>
<P>Clonidine (alpha adrenergic)</P>
</TD>
</TR>
<TR>
<TD>
<P>Lenzenhuber 1999</P>
</TD>
<TD>
<P>Flunitrazepam </P>
</TD>
<TD>
<P>GHB</P>
</TD>
</TR>
<TR>
<TD>
<P>Ansoms 1991</P>
</TD>
<TD>
<P>Lometazepam </P>
</TD>
<TD>
<P>Zopiclone (anxiolytic)</P>
</TD>
</TR>
<TR>
<TD>
<P>Gillmer 1973</P>
</TD>
<TD>
<P>Oxazepam  </P>
</TD>
<TD>
<P>Benzoctamine (anxiolytic)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2010-01-07 11:17:39 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2009-12-02 13:03:47 +0100" MODIFIED_BY="[Empty name]">Comparisons of different Benzodiazepines</TITLE>
<TABLE COLS="3" ROWS="19">
<TR>
<TH>
<P>Author</P>
</TH>
<TH>
<P>Treatment (benzodiazepine 1)</P>
</TH>
<TH>
<P>Control (benzodiazepine 2</P>
</TH>
</TR>
<TR>
<TD>
<P>Brown 1972 </P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
</TR>
<TR>
<TD>
<P>Day 2004</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
</TR>
<TR>
<TD>
<P>Jauhar 2000</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
</TR>
<TR>
<TD>
<P>Kumar 2009</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Lorazepam</P>
</TD>
</TR>
<TR>
<TD>
<P>McLendon 1980</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Alprazolam </P>
</TD>
</TR>
<TR>
<TD>
<P>Mendels 1985</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Halazepam </P>
</TD>
</TR>
<TR>
<TD>
<P>Mukherjee 1983</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Clobazam </P>
</TD>
</TR>
<TR>
<TD>
<P>Solomon 1983</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Lorazepam </P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1985</P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Alprazolam </P>
</TD>
</TR>
<TR>
<TD>
<P>Anton 1997</P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Abecamil </P>
</TD>
</TR>
<TR>
<TD>
<P>Kolin 1981</P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Alprazolam </P>
</TD>
</TR>
<TR>
<TD>
<P>Martin 1975 </P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Clobazam </P>
</TD>
</TR>
<TR>
<TD>
<P>Mielke 1976</P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Clorazepate </P>
</TD>
</TR>
<TR>
<TD>
<P>Miller 1984</P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Lorazepam </P>
</TD>
</TR>
<TR>
<TD>
<P>O'Brien 1983</P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Lorazepam </P>
</TD>
</TR>
<TR>
<TD>
<P>Ritson 1986</P>
</TD>
<TD>
<P>Diazepam</P>
</TD>
<TD>
<P>Lorazepam </P>
</TD>
</TR>
<TR>
<TD>
<P>Adinoff 1994</P>
</TD>
<TD>
<P>Diazepam  </P>
</TD>
<TD>
<P>Alprazolam </P>
</TD>
</TR>
<TR>
<TD>
<P>Saletu 1983</P>
</TD>
<TD>
<P>Lopirazepam </P>
</TD>
<TD>
<P>Prazepam </P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2009-12-02 13:14:46 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2009-12-02 13:13:38 +0100" MODIFIED_BY="[Empty name]">Comparisons Benzodiazepines alone versus Benzodiazepine plus other drugs</TITLE>
<TABLE COLS="3" ROWS="4">
<TR>
<TH>
<P>Author</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Control</P>
</TH>
</TR>
<TR>
<TD>
<P>Dion 1968</P>
</TD>
<TD>
<P> </P>
<P>Chlordiazepoxide   </P>
</TD>
<TD>
<P>Chlordiazepoxide  + Magnesium sulphate (anticonvulsant)</P>
</TD>
</TR>
<TR>
<TD>
<P>Sellers 1977 </P>
</TD>
<TD>
<P>Chlordiazepoxide  </P>
</TD>
<TD>
<P>Chlordiazepoxide  + Propanol</P>
</TD>
</TR>
<TR>
<TD>
<P>Spies 1996</P>
</TD>
<TD>
<P>Flunitrazepam + haloperidol (antipsychotic)</P>
</TD>
<TD>
<P>Flunitrazepam + Clonidine (alpha adrenergic)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-01-05 12:44:58 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-01-05 10:03:33 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Benzodiazepine versus Placebo</NAME>
<DICH_OUTCOME CHI2="0.26538912733900366" CI_END="0.6892167175394768" CI_START="0.0361739209114712" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.157897659992594" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.16164419691308016" LOG_CI_START="-1.4416044152658263" LOG_EFFECT_SIZE="-0.8016243060894532" METHOD="MH" MODIFIED="2009-12-30 11:07:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8757325385626318" P_Q="0.0" P_Z="0.014088238317549536" Q="0.0" RANDOM="YES" SCALE="100000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="149" TOTAL_2="175" WEIGHT="100.0" Z="2.455005626798698">
<NAME>Alcohol withdrawal seizures</NAME>
<GROUP_LABEL_1>Benzodiazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0890686303798316" CI_START="0.018058097250576517" EFFECT_SIZE="0.14023732470334413" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="0.037055248769630546" LOG_CI_START="-1.7433280124449513" LOG_EFFECT_SIZE="-0.8531363818376603" MODIFIED="2009-12-04 11:19:53 +0100" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="1.0458059406767233" STUDY_ID="STD-Kaim-1972" TOTAL_1="103" TOTAL_2="130" VAR="1.0937100655547258" WEIGHT="51.685168762590344"/>
<DICH_DATA CI_END="7.382590940745529" CI_START="0.013713297978184326" EFFECT_SIZE="0.3181818181818182" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8682088054265786" LOG_CI_START="-1.8628580870424774" LOG_EFFECT_SIZE="-0.4973246408079494" MODIFIED="2009-12-03 11:00:14 +0100" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="1.6042422116354729" STUDY_ID="STD-Naranjo-1983" TOTAL_1="21" TOTAL_2="20" VAR="2.5735930735930737" WEIGHT="21.96485135725767"/>
<DICH_DATA CI_END="1.9610955310644043" CI_START="0.00629529710143439" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2924987500184138" LOG_CI_START="-2.2009837688970637" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2009-12-03 11:00:24 +0100" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="1.4646839745484845" STUDY_ID="STD-Sellers-1983" TOTAL_1="25" TOTAL_2="25" VAR="2.1452991452991457" WEIGHT="26.34997988015199"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4778698582624168" CI_END="34.52102958876168" CI_START="0.311575303116068" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2796189196303245" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="32.33504327805055" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.5380837400573586" LOG_CI_START="-0.5064369738026999" LOG_EFFECT_SIZE="0.5158233831273293" METHOD="MH" MODIFIED="2009-12-30 12:44:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.22410843187378182" P_Q="0.0" P_Z="0.3226728416922888" Q="0.0" RANDOM="YES" SCALE="1000000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.9351879708722892" TOTALS="YES" TOTAL_1="35" TOTAL_2="36" WEIGHT="99.99999999999999" Z="0.9889802010412608">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Benzodiazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.356053493226757" CI_START="0.07879628711463568" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1862796163245504" LOG_CI_START="-1.1034942460081005" LOG_EFFECT_SIZE="0.04139268515822507" MODIFIED="2009-12-03 11:29:09 +0100" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="1.3450245012976192" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="10" TOTAL_2="11" VAR="1.809090909090909" WEIGHT="52.556930203089564"/>
<DICH_DATA CI_END="188.94601143053802" CI_START="0.6403945713587241" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.276337728579093" LOG_CI_START="-0.19355235826264286" LOG_EFFECT_SIZE="1.041392685158225" MODIFIED="2009-12-03 11:29:25 +0100" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="1.4508256631639465" STUDY_ID="STD-Krupitsky-2007" TOTAL_1="25" TOTAL_2="25" VAR="2.104895104895105" WEIGHT="47.44306979691042"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6162002563961667" CI_END="1.2353160889376973" CI_START="0.37851950501553094" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6838064305945205" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.0917780977714673" LOG_CI_START="-0.4219117365011381" LOG_EFFECT_SIZE="-0.1650668193648354" METHOD="MH" MODIFIED="2010-01-05 10:03:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4324630035614524" P_Q="0.0" P_Z="0.20780927508965852" Q="0.0" RANDOM="YES" SCALE="100000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="139" TOTAL_2="173" WEIGHT="99.99999999999999" Z="1.2596123162755353">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Benzodiazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.061849678266867" CI_START="0.011719612874850554" EFFECT_SIZE="0.21818181818181817" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6087238469104387" LOG_CI_START="-1.9310867338036768" LOG_EFFECT_SIZE="-0.661181443446619" MODIFIED="2010-01-05 10:03:33 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="1.4918973073766089" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="10" TOTAL_2="11" VAR="2.2257575757575756" WEIGHT="4.090715594223972"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 11:32:04 +0100" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.0" STUDY_ID="STD-Adinoff-1994" TOTAL_1="12" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.3132838806300775" CI_START="0.3924896735631209" EFFECT_SIZE="0.717948717948718" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="0.1183586137248194" LOG_CI_START="-0.4061717650933794" LOG_EFFECT_SIZE="-0.14390657568427997" MODIFIED="2009-12-03 11:34:56 +0100" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.3081117409850604" STUDY_ID="STD-Kaim-1969" TOTAL_1="117" TOTAL_2="156" VAR="0.09493284493284493" WEIGHT="95.90928440577602"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.025911702882953" CI_START="0.01647556188677972" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.9044943775306834" LOG_CI_START="-1.7831597651912088" LOG_EFFECT_SIZE="-0.43933269383026263" METHOD="MH" MODIFIED="2009-12-03 11:42:17 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.5216759098125796" Q="0.0" RANDOM="YES" SCALE="100000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="53" TOTAL_2="33" WEIGHT="100.0" Z="0.6407641842385507">
<NAME>Dropout due to adverse events</NAME>
<GROUP_LABEL_1>Benzodiazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.025911702882953" CI_START="0.01647556188677972" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9044943775306834" LOG_CI_START="-1.7831597651912088" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2009-12-03 11:41:49 +0100" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="1.5787413475374117" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="10" TOTAL_2="11" VAR="2.492424242424242" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 11:41:58 +0100" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.0" STUDY_ID="STD-McLendon-1980" TOTAL_1="43" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-01-05 12:44:58 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Benzodiazepine versus Other Drug</NAME>
<DICH_OUTCOME CHI2="9.124334288418156" CI_END="1.5868079483583193" CI_START="0.33522754206518635" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7293433541602066" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.20052436719883138" LOG_CI_START="-0.4746603072388126" LOG_EFFECT_SIZE="-0.13706797001999063" METHOD="MH" MODIFIED="2009-12-30 12:49:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6922756235935089" P_Q="0.0" P_Z="0.4261615535632649" Q="0.0" RANDOM="YES" SCALE="100000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="686" TOTAL_2="1065" WEIGHT="200.0" Z="0.7957771994660647">
<NAME>Alcohol withdrawal seizures</NAME>
<GROUP_LABEL_1>Benzodiazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.743646288766199" CI_END="1.309942274865004" CI_START="0.20936949767423774" DF="8" EFFECT_SIZE="0.5237002540296636" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="37" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.11725215805274115" LOG_CI_START="-0.6790865889259031" LOG_EFFECT_SIZE="-0.280917215436581" MODIFIED="2009-12-03 10:14:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5645271193459788" P_Z="0.16672695757006986" STUDIES="12" TAU2="0.0" TOTAL_1="442" TOTAL_2="786" WEIGHT="99.99999999999999" Z="1.382797526760916">
<NAME>Benzodiazepine vs. Other Drug</NAME>
<DICH_DATA CI_END="8.14564106787806" CI_START="0.014253543881082626" EFFECT_SIZE="0.34074074074074073" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9109252692812447" LOG_CI_START="-1.8460771429081089" LOG_EFFECT_SIZE="-0.467575936813432" MODIFIED="2009-12-03 10:14:50 +0100" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.0" SE="1.619476864302069" STUDY_ID="STD-Favre-2005" TOTAL_1="44" TOTAL_2="45" VAR="2.6227053140096617" WEIGHT="8.342983846761506"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="115" O_E="0.0" SE="0.0" STUDY_ID="STD-Radouco_x002d_Thomas-1989" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.632411564410923" CI_START="0.14323389801599787" EFFECT_SIZE="1.5434782608695652" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="1.2209552229528713" LOG_CI_START="-0.843954188877869" LOG_EFFECT_SIZE="0.1885005170375012" ORDER="112" O_E="0.0" SE="1.2129380099758151" STUDY_ID="STD-Kaim-1972" TOTAL_1="46" TOTAL_2="142" VAR="1.4712186160440905" WEIGHT="14.872832515152473"/>
<DICH_DATA CI_END="0.7944093074034281" CI_START="0.015041836569168045" EFFECT_SIZE="0.10931319669183746" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="27" LOG_CI_END="-0.09995567623187165" LOG_CI_START="-1.82269913427894" LOG_EFFECT_SIZE="-0.9613274052554058" ORDER="111" O_E="0.0" SE="1.0119480349744985" STUDY_ID="STD-Kaim-1969" TOTAL_1="103" TOTAL_2="304" VAR="1.0240388254887487" WEIGHT="21.367537562997"/>
<DICH_DATA CI_END="70.73632649924672" CI_START="0.12723307026829894" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8496425021491933" LOG_CI_START="-0.8953999927098688" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="116" O_E="0.0" SE="1.61245154965971" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" VAR="2.6" WEIGHT="8.415841565230066"/>
<DICH_DATA CI_END="3.754457918288967" CI_START="0.012343864976933615" EFFECT_SIZE="0.2152777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.5745472409165846" LOG_CI_START="-1.9085488374385386" LOG_EFFECT_SIZE="-0.6670007982609769" ORDER="110" O_E="0.0" SE="1.4585829279496223" STUDY_ID="STD-Borg-1986" TOTAL_1="15" TOTAL_2="30" VAR="2.1274641577060933" WEIGHT="10.285103037031297"/>
<DICH_DATA CI_END="8.093763717196325" CI_START="0.015211069763955837" EFFECT_SIZE="0.3508771929824561" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9081505217981177" LOG_CI_START="-1.817840241815138" LOG_EFFECT_SIZE="-0.4548448600085102" ORDER="118" O_E="0.0" SE="1.6012604684183327" STUDY_ID="STD-Worner-1994" TOTAL_1="18" TOTAL_2="19" VAR="2.564035087719298" WEIGHT="8.533887923141265"/>
<DICH_DATA CI_END="16.561876486578946" CI_START="0.06889390810388205" EFFECT_SIZE="1.0681818181818181" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2191095414825224" LOG_CI_START="-1.1618191785834624" LOG_EFFECT_SIZE="0.02864518144953001" ORDER="113" O_E="0.0" SE="1.3985693159540025" STUDY_ID="STD-Kramp-1978" TOTAL_1="44" TOTAL_2="47" VAR="1.9559961315280465" WEIGHT="11.186723591577014"/>
<DICH_DATA CI_END="68.68448813501912" CI_START="0.12011940023381179" EFFECT_SIZE="2.872340425531915" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.836858666054806" LOG_CI_START="-0.9203868449362288" LOG_EFFECT_SIZE="0.4582359105592887" ORDER="117" O_E="0.0" SE="1.6196196617415348" STUDY_ID="STD-Tubridy-1988" TOTAL_1="46" TOTAL_2="44" VAR="2.6231678486997634" WEIGHT="8.341512755443429"/>
<DICH_DATA CI_END="8.060808530068371" CI_START="0.015823601309021704" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9063786053951904" LOG_CI_START="-1.8006946680796292" LOG_EFFECT_SIZE="-0.4471580313422192" ORDER="108" O_E="0.0" SE="1.5901482410679288" STUDY_ID="STD-Bailly-1992" TOTAL_1="13" TOTAL_2="14" VAR="2.528571428571428" WEIGHT="8.653577202665945"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="109" O_E="0.0" SE="0.0" STUDY_ID="STD-Baumgartner-1991" TOTAL_1="20" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="114" O_E="0.0" SE="0.0" STUDY_ID="STD-Lucht-2003" TOTAL_1="34" TOTAL_2="59" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.40471747871942954" CI_END="7.369987214030337" CI_START="0.39269737423689327" DF="3" EFFECT_SIZE="1.7012273884196638" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.8674667344152405" LOG_CI_START="-0.40594200262120517" LOG_EFFECT_SIZE="0.23076236589701765" MODIFIED="2009-12-03 10:15:50 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9392662731344206" P_Z="0.4774842264170247" STUDIES="7" TAU2="0.0" TOTAL_1="244" TOTAL_2="279" WEIGHT="100.0" Z="0.7103546771604473">
<NAME>Benzodiazepine vs. Anticonvulsant</NAME>
<DICH_DATA CI_END="18.591355255931727" CI_START="0.07689509997001787" EFFECT_SIZE="1.1956521739130435" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2693110497352822" LOG_CI_START="-1.1141013341099424" LOG_EFFECT_SIZE="0.07760485781266976" MODIFIED="2009-12-03 10:15:50 +0100" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="1.400028232352262" STUDY_ID="STD-Kaim-1972" TOTAL_1="46" TOTAL_2="55" VAR="1.9600790513833992" WEIGHT="28.545474565494693"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="123" O_E="0.0" SE="0.0" STUDY_ID="STD-Radouco_x002d_Thomas-1989" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="119" O_E="0.0" SE="0.0" STUDY_ID="STD-Borg-1986" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.561876486578946" CI_START="0.06889390810388205" EFFECT_SIZE="1.0681818181818181" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2191095414825224" LOG_CI_START="-1.1618191785834624" LOG_EFFECT_SIZE="0.02864518144953001" ORDER="121" O_E="0.0" SE="1.3985693159540025" STUDY_ID="STD-Kramp-1978" TOTAL_1="44" TOTAL_2="47" VAR="1.9559961315280465" WEIGHT="28.60506000280989"/>
<DICH_DATA CI_END="70.73632649924672" CI_START="0.12723307026829894" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8496425021491933" LOG_CI_START="-0.8953999927098688" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="124" O_E="0.0" SE="1.61245154965971" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" VAR="2.6" WEIGHT="21.51976411831684"/>
<DICH_DATA CI_END="68.68448813501912" CI_START="0.12011940023381179" EFFECT_SIZE="2.872340425531915" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.836858666054806" LOG_CI_START="-0.9203868449362288" LOG_EFFECT_SIZE="0.4582359105592887" ORDER="125" O_E="0.0" SE="1.6196196617415348" STUDY_ID="STD-Tubridy-1988" TOTAL_1="46" TOTAL_2="44" VAR="2.6231678486997634" WEIGHT="21.329701313378575"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="122" O_E="0.0" SE="0.0" STUDY_ID="STD-Lucht-2003" TOTAL_1="34" TOTAL_2="59" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.558103146599166" CI_END="2.3315192453779594" CI_START="0.3909739810936697" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9547582737855322" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="50" I2="44.336475624048475" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.3676390046616041" LOG_CI_START="-0.40785214348247895" LOG_EFFECT_SIZE="-0.02010656941043744" METHOD="MH" MODIFIED="2009-12-30 13:30:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.042781417030386626" P_Q="0.0" P_Z="0.9190471537830387" Q="0.0" RANDOM="YES" SCALE="10000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.9150812944837035" TOTALS="SUB" TOTAL_1="480" TOTAL_2="755" WEIGHT="199.99999999999997" Z="0.10163404699440944">
<NAME>Alcohol withdrawal delirium</NAME>
<GROUP_LABEL_1>Benzodiazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.48221114041005" CI_END="1.9773849628386153" CI_START="0.21154351699119486" DF="7" EFFECT_SIZE="0.6467634571343559" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="43" I2="51.66483949078924" ID="CMP-002.02.01" LOG_CI_END="0.2960912272101076" LOG_CI_START="-0.6746002796122541" LOG_EFFECT_SIZE="-0.1892545262010732" MODIFIED="2009-12-29 14:32:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04324012122446719" P_Z="0.44471022476378863" STUDIES="8" TAU2="1.1777828694669397" TOTAL_1="321" TOTAL_2="572" WEIGHT="99.99999999999999" Z="0.7642635227737226">
<NAME>Benzodiazepine vs. Other Drug</NAME>
<DICH_DATA CI_END="8.14564106787806" CI_START="0.014253543881082626" EFFECT_SIZE="0.34074074074074073" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9109252692812447" LOG_CI_START="-1.8460771429081089" LOG_EFFECT_SIZE="-0.467575936813432" MODIFIED="2009-12-03 10:29:28 +0100" MODIFIED_BY="[Empty name]" ORDER="329" O_E="0.0" SE="1.619476864302069" STUDY_ID="STD-Favre-2005" TOTAL_1="44" TOTAL_2="45" VAR="2.6227053140096617" WEIGHT="8.554571823063416"/>
<DICH_DATA CI_END="162.8894181229835" CI_START="0.49726987138504036" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2118928719078457" LOG_CI_START="-0.30340785302919543" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2009-12-29 14:32:20 +0100" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="1.4775000967674123" STUDY_ID="STD-McGrath-1975" TOTAL_1="50" TOTAL_2="50" VAR="2.1830065359477127" WEIGHT="9.673783509277381"/>
<DICH_DATA CI_END="0.9356576558045686" CI_START="0.0036981556138514435" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.028883024543217797" LOG_CI_START="-2.43201481821333" LOG_EFFECT_SIZE="-1.2304489213782739" ORDER="144" O_E="0.0" SE="1.411611511296054" STUDY_ID="STD-Dion-1968" TOTAL_1="15" TOTAL_2="15" VAR="1.9926470588235294" WEIGHT="10.254618415674933"/>
<DICH_DATA CI_END="1.4712601501273457" CI_START="0.026314839630945733" EFFECT_SIZE="0.19676375404530744" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="15" LOG_CI_END="0.16768947203099224" LOG_CI_START="-1.5797992723351917" LOG_EFFECT_SIZE="-0.7060549001520997" ORDER="146" O_E="0.0" SE="1.0264835386494897" STUDY_ID="STD-Kaim-1969" TOTAL_1="103" TOTAL_2="304" VAR="1.0536684551183784" WEIGHT="14.56968779468949"/>
<DICH_DATA CI_END="3.9002267358793152" CI_START="0.00967813958821039" EFFECT_SIZE="0.19428571428571428" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5910898550467423" LOG_CI_START="-2.014208118334821" LOG_EFFECT_SIZE="-0.7115591316440393" ORDER="147" O_E="0.0" SE="1.5303649259972893" STUDY_ID="STD-Kalyoncu-1996" TOTAL_1="34" TOTAL_2="33" VAR="2.342016806722689" WEIGHT="9.23676121348187"/>
<DICH_DATA CI_END="99.81638537428941" CI_START="0.25045988097300376" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9992018388177861" LOG_CI_START="-0.6012618301457486" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="149" O_E="0.0" SE="1.5275252316519468" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" VAR="2.3333333333333335" WEIGHT="9.259604994652406"/>
<DICH_DATA CI_END="3.725378952968956" CI_START="0.05051911685958585" EFFECT_SIZE="0.4338235294117647" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.5711704566312847" LOG_CI_START="-1.2965442500874316" LOG_EFFECT_SIZE="-0.3626868967280733" ORDER="148" O_E="0.0" SE="1.097104864063479" STUDY_ID="STD-Lucht-2003" TOTAL_1="34" TOTAL_2="59" VAR="1.203639082751745" WEIGHT="13.652158156165717"/>
<DICH_DATA CI_END="2.91019473252369" CI_START="0.6958805561571119" EFFECT_SIZE="1.4230769230769231" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="0.4639220503023765" LOG_CI_START="-0.15746529811002247" LOG_EFFECT_SIZE="0.15322837609617704" ORDER="145" O_E="0.0" SE="0.3650060043744256" STUDY_ID="STD-Golbert-1967" TOTAL_1="12" TOTAL_2="37" VAR="0.1332293832293832" WEIGHT="24.79881409299478"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.863221664771273" CI_END="8.37542479119274" CI_START="0.4301803620424613" DF="4" EFFECT_SIZE="1.8981420571007586" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" I2="41.71833294366857" ID="CMP-002.02.02" LOG_CI_END="0.9230068431467906" LOG_CI_START="-0.3663494192652944" LOG_EFFECT_SIZE="0.2783287119407481" MODIFIED="2009-12-29 14:33:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.14329544896882296" P_Z="0.3974519043504676" STUDIES="5" TAU2="1.1812985744985547" TOTAL_1="159" TOTAL_2="183" WEIGHT="99.99999999999999" Z="0.8461807914078917">
<NAME>Benzodiazepine vs. Anticonvulsant</NAME>
<DICH_DATA CI_END="162.8894181229835" CI_START="0.49726987138504036" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2118928719078457" LOG_CI_START="-0.30340785302919543" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2009-12-29 14:33:01 +0100" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="1.4775000967674123" STUDY_ID="STD-McGrath-1975" TOTAL_1="50" TOTAL_2="50" VAR="2.1830065359477127" WEIGHT="17.050051561376677"/>
<DICH_DATA CI_END="99.81638537428941" CI_START="0.25045988097300376" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9992018388177861" LOG_CI_START="-0.6012618301457486" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="153" O_E="0.0" SE="1.5275252316519468" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" VAR="2.3333333333333335" WEIGHT="16.320791794295523"/>
<DICH_DATA CI_END="3.9002267358793152" CI_START="0.00967813958821039" EFFECT_SIZE="0.19428571428571428" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5910898550467423" LOG_CI_START="-2.014208118334821" LOG_EFFECT_SIZE="-0.7115591316440393" ORDER="151" O_E="0.0" SE="1.5303649259972893" STUDY_ID="STD-Kalyoncu-1996" TOTAL_1="34" TOTAL_2="33" VAR="2.342016806722689" WEIGHT="16.280567986346245"/>
<DICH_DATA CI_END="3.725378952968956" CI_START="0.05051911685958585" EFFECT_SIZE="0.4338235294117647" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.5711704566312847" LOG_CI_START="-1.2965442500874316" LOG_EFFECT_SIZE="-0.3626868967280733" ORDER="152" O_E="0.0" SE="1.097104864063479" STUDY_ID="STD-Lucht-2003" TOTAL_1="34" TOTAL_2="59" VAR="1.203639082751745" WEIGHT="24.05160379221259"/>
<DICH_DATA CI_END="42.59442830538803" CI_START="0.8451809645593047" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6293527935984997" LOG_CI_START="-0.07305029283121235" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="150" O_E="0.0" SE="1.0" STUDY_ID="STD-Golbert-1967" TOTAL_1="12" TOTAL_2="12" VAR="1.0000000000000002" WEIGHT="26.29698486576896"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.9614647561645167" CI_END="0.07502902964769198" CI_START="-1.9975854258099797" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9612781980811439" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2009-12-30 13:31:17 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9619423804606654" P_Q="0.8086845135085976" P_Z="0.06905467832795462" Q="0.058623763216690605" RANDOM="YES" SCALE="10.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-01" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="319" TOTAL_2="296" UNITS="" WEIGHT="200.0" Z="1.8180618613378963">
<NAME>CIWA-Ar score (48 hrs)</NAME>
<GROUP_LABEL_1>Benzodiazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drugs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benzodiazepine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1335625136223069" CI_END="0.15098112881622794" CI_START="-2.2143335806439817" DF="4" EFFECT_SIZE="-1.031676225913877" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" MODIFIED="2009-12-03 10:30:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8889112448270526" P_Z="0.08731213842412262" STUDIES="5" TAU2="0.0" TOTAL_1="181" TOTAL_2="174" WEIGHT="100.0" Z="1.7097498598474963">
<NAME>Benzodiazepine vs. Other Drug</NAME>
<CONT_DATA CI_END="2.697291001080768" CI_START="-2.697291001080768" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="7.3" MEAN_2="7.3" ORDER="25" SD_1="8.2" SD_2="7.8" SE="1.376194165993179" STUDY_ID="STD-Malcolm-2002" TOTAL_1="75" TOTAL_2="61" WEIGHT="19.224819323013303"/>
<CONT_DATA CI_END="1.1130821272626905" CI_START="-5.1130821272626905" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="22.0" ORDER="24" SD_1="6.8" SD_2="6.1" SE="1.5883363938410526" STUDY_ID="STD-Malcolm-1989" TOTAL_1="34" TOTAL_2="32" WEIGHT="14.432338874888309"/>
<CONT_DATA CI_END="2.119944749870253" CI_START="-3.519944749870255" EFFECT_SIZE="-0.7000000000000011" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="9.3" ORDER="21" SD_1="5.4" SD_2="4.4" SE="1.4387737591678307" STUDY_ID="STD-Addolorato-1999" TOTAL_1="22" TOTAL_2="26" WEIGHT="17.588818806992748"/>
<CONT_DATA CI_END="0.5749417937783556" CI_START="-2.974941793778356" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.2" ORDER="23" SD_1="3.3" SD_2="2.8" SE="0.905599188443701" STUDY_ID="STD-Baumgartner-1987" TOTAL_1="21" TOTAL_2="26" WEIGHT="44.396592891868934"/>
<CONT_DATA CI_END="3.66557146714531" CI_START="-7.66557146714531" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="11.4" MEAN_2="13.4" ORDER="26" SD_1="11.4" SD_2="10.6" SE="2.8906508037058916" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" WEIGHT="4.357430103236714"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.7692784793255193" CI_END="1.4222074068801582" CI_START="-2.8791519059190804" DF="2" EFFECT_SIZE="-0.7284722495194611" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.02" NO="2" P_CHI2="0.6806963367662342" P_Z="0.5067712403495667" STUDIES="3" TAU2="0.0" TOTAL_1="138" TOTAL_2="122" WEIGHT="100.0" Z="0.6638735659894683">
<NAME>Benzodiazepine vs. Anticonvulsant</NAME>
<CONT_DATA CI_END="2.697291001080768" CI_START="-2.697291001080768" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="7.3" MEAN_2="7.3" ORDER="28" SD_1="8.2" SD_2="7.8" SE="1.376194165993179" STUDY_ID="STD-Malcolm-2002" TOTAL_1="75" TOTAL_2="61" WEIGHT="63.57638752402695"/>
<CONT_DATA CI_END="2.5838466279280397" CI_START="-6.58384662792804" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="22.0" ORDER="27" SD_1="9.8" SD_2="9.2" SE="2.3387402340475827" STUDY_ID="STD-Malcolm-1989" TOTAL_1="34" TOTAL_2="32" WEIGHT="22.013611518480758"/>
<CONT_DATA CI_END="3.66557146714531" CI_START="-7.66557146714531" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="11.4" MEAN_2="13.4" ORDER="29" SD_1="11.4" SD_2="10.6" SE="2.8906508037058916" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" WEIGHT="14.410000957492294"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.9964778416417692" CI_END="0.6921077765069602" CI_START="-1.3437875962853658" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.32583990988920275" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2009-12-30 13:34:42 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.981119640364235" P_Q="0.5241274904199069" P_Z="0.5304137392101724" Q="0.4057638507169261" RANDOM="YES" SCALE="10.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-01" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="362" TOTAL_2="333" UNITS="" WEIGHT="200.0" Z="0.6273745661425587">
<NAME>CIWA-Ar score (end of treatment)</NAME>
<GROUP_LABEL_1>Benzodiazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drugs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benzodiazepine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.3089644098573383" CI_END="0.9507755383645952" CI_START="-1.2946401604955353" DF="5" EFFECT_SIZE="-0.1719323110654701" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" MODIFIED="2009-12-03 10:34:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9340065586381675" P_Z="0.7640624865061593" STUDIES="6" TAU2="0.0" TOTAL_1="224" TOTAL_2="211" WEIGHT="100.0" Z="0.30015033531485946">
<NAME>Benzodiazepine vs. Other Drug</NAME>
<CONT_DATA CI_END="2.192496295001159" CI_START="-4.192496295001159" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="9.8" ORDER="34" SD_1="7.8" SD_2="10.6" SE="1.6288545708916908" STUDY_ID="STD-Malcolm-2002" TOTAL_1="75" TOTAL_2="61" WEIGHT="12.36723787523859"/>
<CONT_DATA CI_END="4.296972040553124" CI_START="-2.296972040553124" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="13.0" MODIFIED="2009-12-03 10:34:28 +0100" MODIFIED_BY="[Empty name]" ORDER="330" SD_1="4.6" SD_2="9.3" SE="1.6821595021945397" STUDY_ID="STD-Favre-2005" TOTAL_1="43" TOTAL_2="37" WEIGHT="11.595860702794106"/>
<CONT_DATA CI_END="3.1019388483623493" CI_START="-3.1019388483623493" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="33.0" MEAN_2="33.0" ORDER="33" SD_1="6.4" SD_2="6.45" SE="1.582650942991834" STUDY_ID="STD-Malcolm-1989" TOTAL_1="34" TOTAL_2="32" WEIGHT="13.099872065236529"/>
<CONT_DATA CI_END="1.565143810484865" CI_START="-1.9651438104848653" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="3.6" ORDER="32" SD_1="3.2" SD_2="2.9" SE="0.9006001255166391" STUDY_ID="STD-Baumgartner-1987" TOTAL_1="21" TOTAL_2="26" WEIGHT="40.45510472138694"/>
<CONT_DATA CI_END="3.0021138863929613" CI_START="-7.002113886392961" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="20.0" ORDER="35" SD_1="10.8" SD_2="8.5" SE="2.5521458179073684" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" WEIGHT="5.03763116826643"/>
<CONT_DATA CI_END="2.7880668614601944" CI_START="-2.588066861460195" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="11.2" MEAN_2="11.1" ORDER="30" SD_1="5.0" SD_2="4.4" SE="1.3714878858302106" STUDY_ID="STD-Addolorato-1999" TOTAL_1="22" TOTAL_2="26" WEIGHT="17.444293467077408"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2817495810675048" CI_END="1.3763513277410147" CI_START="-3.450353461996035" DF="2" EFFECT_SIZE="-1.03700106712751" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.02" NO="2" P_CHI2="0.8685980712115485" P_Z="0.39968544734222256" STUDIES="3" TAU2="0.0" TOTAL_1="138" TOTAL_2="122" WEIGHT="100.0" Z="0.8421831589208294">
<NAME>Benzodiazepine vs. Anticonvulsant</NAME>
<CONT_DATA CI_END="2.192496295001159" CI_START="-4.192496295001159" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="9.8" ORDER="37" SD_1="7.8" SD_2="10.6" SE="1.6288545708916908" STUDY_ID="STD-Malcolm-2002" TOTAL_1="75" TOTAL_2="61" WEIGHT="57.145321390329514"/>
<CONT_DATA CI_END="5.454368799282567" CI_START="-5.454368799282567" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="33.0" MEAN_2="33.0" ORDER="36" SD_1="12.9" SD_2="9.55" SE="2.782892360423932" STUDY_ID="STD-Malcolm-1989" TOTAL_1="34" TOTAL_2="32" WEIGHT="19.577285948459743"/>
<CONT_DATA CI_END="3.0021138863929613" CI_START="-7.002113886392961" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="20.0" ORDER="38" SD_1="10.8" SD_2="8.5" SE="2.5521458179073684" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" WEIGHT="23.277392661210744"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.6128858318986085" CI_START="-2.5871141681013907" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2009-12-03 13:05:52 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0014886907885453707" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="20" TOTAL_2="23" UNITS="" WEIGHT="0.0" Z="3.1768791053781924">
<NAME>HARS score (48 hrs)</NAME>
<GROUP_LABEL_1>Chlordiazepoxide</GROUP_LABEL_1>
<GROUP_LABEL_2>Clonidine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clonidine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chlordiazepoxide</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.6128858318986085" CI_START="-2.5871141681013907" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="10.2" MODIFIED="2009-12-03 12:06:40 +0100" MODIFIED_BY="[Empty name]" ORDER="342" SD_1="1.6" SD_2="1.7" SE="0.5036389320863147" STUDY_ID="STD-Baumgartner-1991" TOTAL_1="20" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.2571806383811537" CI_END="0.27006565104980673" CI_START="-4.371346396391423" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.050640372670808" ESTIMABLE="YES" I2="55.69694409937885" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2009-12-03 13:06:09 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.13299610151514862" P_Q="1.0" P_Z="0.08329516618334147" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="1.7405295031055865" TOTALS="YES" TOTAL_1="41" TOTAL_2="49" UNITS="" WEIGHT="100.00000000000003" Z="1.7318786759707399">
<NAME>HARS score (end of treatment)</NAME>
<GROUP_LABEL_1>Chlordiazepoxide</GROUP_LABEL_1>
<GROUP_LABEL_2>Clonidine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clonidine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chlordiazepoxide</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.6275394524418583" CI_START="-3.427539452441859" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="10.6" MODIFIED="2009-12-03 12:09:15 +0100" MODIFIED_BY="[Empty name]" ORDER="343" SD_1="6.15" SD_2="3.9" SE="1.5446913700061344" STUDY_ID="STD-Baumgartner-1987" TOTAL_1="21" TOTAL_2="26" WEIGHT="33.97438509316769"/>
<CONT_DATA CI_END="-1.6872437720301436" CI_START="-4.1127562279698555" EFFECT_SIZE="-2.8999999999999995" ESTIMABLE="YES" MEAN_1="7.3" MEAN_2="10.2" MODIFIED="2009-12-03 12:10:09 +0100" MODIFIED_BY="[Empty name]" ORDER="344" SD_1="2.2" SD_2="1.8" SE="0.6187645474794038" STUDY_ID="STD-Baumgartner-1991" TOTAL_1="20" TOTAL_2="23" WEIGHT="66.02561490683233"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="22.582304664885168" CI_START="-24.18230466488517" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2009-12-03 13:07:05 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.9465355092632134" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="75" TOTAL_2="61" UNITS="" WEIGHT="0.0" Z="0.06705802572091084">
<NAME>Zung Anxiety Scale (end of treatment)</NAME>
<GROUP_LABEL_1>Lorazepam</GROUP_LABEL_1>
<GROUP_LABEL_2>Carbamazepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours carbamazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lorazepam</GRAPH_LABEL_2>
<CONT_DATA CI_END="22.582304664885168" CI_START="-24.18230466488517" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="7.0" MODIFIED="2009-12-03 12:13:55 +0100" MODIFIED_BY="[Empty name]" ORDER="331" SD_1="79.6" SD_2="59.4" SE="11.929966493936522" STUDY_ID="STD-Malcolm-2002" TOTAL_1="75" TOTAL_2="61" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="37.04134387674393" CI_END="1.0962636153810694" CI_START="0.919451227725615" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0039725728689235" ESTIMABLE="YES" EVENTS_1="347" EVENTS_2="416" I2="56.80502291374624" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.03991500026066261" LOG_CI_START="-0.03647130295816283" LOG_EFFECT_SIZE="0.0017218486512499238" METHOD="MH" MODIFIED="2010-01-05 12:34:41 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0020691549311186996" P_Q="0.0" P_Z="0.9295902512303779" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-01" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.010939088309142298" TOTALS="SUB" TOTAL_1="435" TOTAL_2="522" WEIGHT="200.0" Z="0.08836037878704245">
<NAME>Global improvement</NAME>
<GROUP_LABEL_1>Benzodiazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drugs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benzodiazepine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="22.480875535277345" CI_END="1.1227921868260384" CI_START="0.8995828567680789" DF="10" EFFECT_SIZE="1.005009752679966" ESTIMABLE="YES" EVENTS_1="214" EVENTS_2="257" I2="55.51774669848672" ID="CMP-002.08.01" LOG_CI_END="0.05029938184791646" LOG_CI_START="-0.04595882945024053" LOG_EFFECT_SIZE="0.002170276198837985" MODIFIED="2010-01-05 12:34:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.012833753491113487" P_Z="0.9295744449277554" STUDIES="11" TAU2="0.01422122482615452" TOTAL_1="279" TOTAL_2="340" WEIGHT="99.99999999999999" Z="0.08838026655307925">
<NAME>Benzodiazepine vs. Other Drug</NAME>
<DICH_DATA CI_END="0.9877007695165219" CI_START="0.5592201731825366" EFFECT_SIZE="0.7431972789115646" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="-0.005374607872937313" LOG_CI_START="-0.2524171703384959" LOG_EFFECT_SIZE="-0.12889588910571664" ORDER="60" O_E="0.0" SE="0.1451140240726757" STUDY_ID="STD-Gillman-2004" TOTAL_1="28" TOTAL_2="23" VAR="0.021058079982565106" WEIGHT="9.062139845122688"/>
<DICH_DATA CI_END="2.1780781797345536" CI_START="1.003716712158692" EFFECT_SIZE="1.4785714285714286" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.3380734642250604" LOG_CI_START="0.001611155332299039" LOG_EFFECT_SIZE="0.16984230977867976" ORDER="58" O_E="0.0" SE="0.19763962575889812" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="10" TOTAL_2="23" VAR="0.03906142167011731" WEIGHT="6.000189833620526"/>
<DICH_DATA CI_END="1.1311976796697039" CI_START="0.9701052429337793" EFFECT_SIZE="1.0475594493116396" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" LOG_CI_END="0.053538505622133484" LOG_CI_START="-0.013181148263596282" LOG_EFFECT_SIZE="0.020178678679268612" MODIFIED="2009-12-03 12:19:04 +0100" MODIFIED_BY="[Empty name]" ORDER="687" O_E="0.0" SE="0.039191454960090875" STUDY_ID="STD-Tubridy-1988" TOTAL_1="46" TOTAL_2="44" VAR="0.0015359701418888316" WEIGHT="20.289524529188842"/>
<DICH_DATA CI_END="1.2942226238141417" CI_START="0.7966217698477059" EFFECT_SIZE="1.0153846153846153" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.11200898728943688" LOG_CI_START="-0.09874782949141069" LOG_EFFECT_SIZE="0.006630578899013076" MODIFIED="2009-12-03 12:17:29 +0100" MODIFIED_BY="[Empty name]" ORDER="686" O_E="0.0" SE="0.12379959744013844" STUDY_ID="STD-Lepola-1984" TOTAL_1="26" TOTAL_2="24" VAR="0.01532634032634033" WEIGHT="10.820045312205098"/>
<DICH_DATA CI_END="3.4171309869483775" CI_START="0.8457387238119528" EFFECT_SIZE="1.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.5336616266824505" LOG_CI_START="-0.07276378392590273" LOG_EFFECT_SIZE="0.2304489213782739" MODIFIED="2010-01-05 12:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.35621728804554254" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="10" TOTAL_2="17" VAR="0.126890756302521" WEIGHT="2.2656190584114677"/>
<DICH_DATA CI_END="1.0358307987050994" CI_START="0.37251277727484433" EFFECT_SIZE="0.6211764705882353" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.015288819897573497" LOG_CI_START="-0.4288588262585344" LOG_EFFECT_SIZE="-0.20678500318048046" ORDER="64" O_E="0.0" SE="0.2608945259184043" STUDY_ID="STD-Palestine-1976" TOTAL_1="25" TOTAL_2="24" VAR="0.06806595365418894" WEIGHT="3.8852467628562217"/>
<DICH_DATA CI_END="1.9420403261336583" CI_START="0.6006054479425492" EFFECT_SIZE="1.08" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.28825824371590547" LOG_CI_START="-0.22141073274200596" LOG_EFFECT_SIZE="0.03342375548694973" MODIFIED="2009-12-03 12:16:37 +0100" MODIFIED_BY="[Empty name]" ORDER="684" O_E="0.0" SE="0.2993820796734995" STUDY_ID="STD-Ansoms-1991" TOTAL_1="25" TOTAL_2="27" VAR="0.08962962962962961" WEIGHT="3.0785109616160704"/>
<DICH_DATA CI_END="1.1816943926871075" CI_START="0.7729934768584446" EFFECT_SIZE="0.9557416267942583" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="38" LOG_CI_END="0.07250517474279657" LOG_CI_START="-0.11182417099284662" LOG_EFFECT_SIZE="-0.019659498125025016" MODIFIED="2009-12-03 12:17:22 +0100" MODIFIED_BY="[Empty name]" ORDER="685" O_E="0.0" SE="0.10827597013009388" STUDY_ID="STD-Kramp-1978" TOTAL_1="44" TOTAL_2="47" VAR="0.011723685707612983" WEIGHT="12.32249359269236"/>
<DICH_DATA CI_END="1.1769170786863246" CI_START="0.7808564868749943" EFFECT_SIZE="0.9586466165413534" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.07074586510547494" LOG_CI_START="-0.10742877749969855" LOG_EFFECT_SIZE="-0.0183414561971118" ORDER="61" O_E="0.0" SE="0.10466066704498415" STUDY_ID="STD-Gillmer-1973" TOTAL_1="19" TOTAL_2="15" VAR="0.010953855226301032" WEIGHT="12.69930396047113"/>
<DICH_DATA CI_END="1.261922635870415" CI_START="0.9990816585541603" EFFECT_SIZE="1.1228373702422145" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="51" LOG_CI_END="0.10103273062565214" LOG_CI_START="-3.9901386597180304E-4" LOG_EFFECT_SIZE="0.05031685837984018" ORDER="63" O_E="0.0" SE="0.05958150880961283" STUDY_ID="STD-Lucht-2003" TOTAL_1="34" TOTAL_2="59" VAR="0.0035499561920299717" WEIGHT="17.99013771162339"/>
<DICH_DATA CI_END="1.3715290040644061" CI_START="0.2514880497786153" EFFECT_SIZE="0.5873015873015873" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="21" LOG_CI_END="0.13720499617090537" LOG_CI_START="-0.5994826469440788" LOG_EFFECT_SIZE="-0.2311388253865867" ORDER="62" O_E="0.0" SE="0.4327339682283877" STUDY_ID="STD-Golbert-1967" TOTAL_1="12" TOTAL_2="37" VAR="0.18725868725868727" WEIGHT="1.5867884321921912"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.719866965571132" CI_END="1.1580453643326825" CI_START="0.8673468489908299" DF="5" EFFECT_SIZE="1.0022110544902154" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="159" I2="66.03230170697402" ID="CMP-002.08.02" LOG_CI_END="0.06372557242550138" LOG_CI_START="-0.061807194934829605" LOG_EFFECT_SIZE="9.591887453358431E-4" MODIFIED="2009-12-03 12:19:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.011628836957531252" P_Z="0.9761053767217736" STUDIES="6" TAU2="0.016187920050842176" TOTAL_1="156" TOTAL_2="182" WEIGHT="100.0" Z="0.02995194696597702">
<NAME>Benzodiazepine vs. Anticonvulsant</NAME>
<DICH_DATA CI_END="1.1311976796697039" CI_START="0.9701052429337793" EFFECT_SIZE="1.0475594493116396" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" LOG_CI_END="0.053538505622133484" LOG_CI_START="-0.013181148263596282" LOG_EFFECT_SIZE="0.020178678679268612" MODIFIED="2009-12-03 12:19:36 +0100" MODIFIED_BY="[Empty name]" ORDER="689" O_E="0.0" SE="0.039191454960090875" STUDY_ID="STD-Tubridy-1988" TOTAL_1="46" TOTAL_2="44" VAR="0.0015359701418888316" WEIGHT="30.678234241369427"/>
<DICH_DATA CI_END="1.296666638290176" CI_START="0.4935732755829389" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.11282833710186523" LOG_CI_START="-0.3066483631179781" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="66" O_E="0.0" SE="0.24640269015229052" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="10" TOTAL_2="8" VAR="0.06071428571428569" WEIGHT="7.070507920950636"/>
<DICH_DATA CI_END="1.4972374427122874" CI_START="0.7790347520878411" EFFECT_SIZE="1.08" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.17529067935609235" LOG_CI_START="-0.10844316838219292" LOG_EFFECT_SIZE="0.03342375548694973" ORDER="65" O_E="0.0" SE="0.16666666666666666" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="10" TOTAL_2="12" VAR="0.027777777777777776" WEIGHT="12.367315472176134"/>
<DICH_DATA CI_END="1.1816943926871075" CI_START="0.7729934768584446" EFFECT_SIZE="0.9557416267942583" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="38" LOG_CI_END="0.07250517474279657" LOG_CI_START="-0.11182417099284662" LOG_EFFECT_SIZE="-0.019659498125025016" MODIFIED="2009-12-03 12:19:28 +0100" MODIFIED_BY="[Empty name]" ORDER="688" O_E="0.0" SE="0.10827597013009388" STUDY_ID="STD-Kramp-1978" TOTAL_1="44" TOTAL_2="47" VAR="0.011723685707612983" WEIGHT="19.48070131494315"/>
<DICH_DATA CI_END="1.261922635870415" CI_START="0.9990816585541603" EFFECT_SIZE="1.1228373702422145" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="51" LOG_CI_END="0.10103273062565214" LOG_CI_START="-3.9901386597180304E-4" LOG_EFFECT_SIZE="0.05031685837984018" ORDER="68" O_E="0.0" SE="0.05958150880961283" STUDY_ID="STD-Lucht-2003" TOTAL_1="34" TOTAL_2="59" VAR="0.0035499561920299717" WEIGHT="27.547931110231264"/>
<DICH_DATA CI_END="0.8240980382907817" CI_START="0.16045591521238406" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.08402111966696243" LOG_CI_START="-0.7946442679935628" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="67" O_E="0.0" SE="0.41742355496836103" STUDY_ID="STD-Golbert-1967" TOTAL_1="12" TOTAL_2="12" VAR="0.1742424242424243" WEIGHT="2.8553099403293913"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2698355348895087" CI_END="1.0972103207349873" CI_START="0.9747060563020057" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0341458043513294" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="172" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.0402898840739185" LOG_CI_START="-0.011126335453390666" LOG_EFFECT_SIZE="0.014581774310263897" METHOD="MH" MODIFIED="2009-12-03 16:49:43 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.6862662645486968" P_Q="0.0" P_Z="0.26626639376347827" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="205" TOTAL_2="209" WEIGHT="200.0" Z="1.1117018225592734">
<NAME>Global doctor's assessment of efficacy</NAME>
<GROUP_LABEL_1>Benzodiazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drugs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benzodiazepine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0054979753286093" CI_END="1.1142014375658933" CI_START="0.9653776564847742" DF="2" EFFECT_SIZE="1.0371235088692805" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="92" I2="0.0" ID="CMP-002.09.01" LOG_CI_END="0.04696371445956843" LOG_CI_START="-0.015302757079024464" LOG_EFFECT_SIZE="0.01583047869027198" MODIFIED="2009-12-03 12:22:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6048656688964363" P_Z="0.3189620675766922" STUDIES="3" TAU2="0.0" TOTAL_1="115" TOTAL_2="118" WEIGHT="100.0" Z="0.9965931045805653">
<NAME>Benzodiazepine vs. Other Drug</NAME>
<DICH_DATA CI_END="1.9420403261336583" CI_START="0.6006054479425492" EFFECT_SIZE="1.08" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.28825824371590547" LOG_CI_START="-0.22141073274200596" LOG_EFFECT_SIZE="0.03342375548694973" ORDER="69" O_E="0.0" SE="0.2993820796734995" STUDY_ID="STD-Ansoms-1991" TOTAL_1="25" TOTAL_2="27" VAR="0.08962962962962961" WEIGHT="1.4925610863191885"/>
<DICH_DATA CI_END="1.1816943926871075" CI_START="0.7729934768584446" EFFECT_SIZE="0.9557416267942583" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="38" LOG_CI_END="0.07250517474279657" LOG_CI_START="-0.11182417099284662" LOG_EFFECT_SIZE="-0.019659498125025016" ORDER="71" O_E="0.0" SE="0.10827597013009388" STUDY_ID="STD-Kramp-1978" TOTAL_1="44" TOTAL_2="47" VAR="0.011723685707612983" WEIGHT="11.410890798575023"/>
<DICH_DATA CI_END="1.1311976796697039" CI_START="0.9701052429337793" EFFECT_SIZE="1.0475594493116396" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" LOG_CI_END="0.053538505622133484" LOG_CI_START="-0.013181148263596282" LOG_EFFECT_SIZE="0.020178678679268612" ORDER="72" O_E="0.0" SE="0.039191454960090875" STUDY_ID="STD-Tubridy-1988" TOTAL_1="46" TOTAL_2="44" VAR="0.0015359701418888316" WEIGHT="87.09654811510579"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.314133473337115" CI_END="1.1415205795427934" CI_START="0.9253953538343059" DF="1" EFFECT_SIZE="1.02779270313383" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="80" I2="23.90422888623356" ID="CMP-002.09.02" LOG_CI_END="0.057483745437564265" LOG_CI_START="-0.03367268530855351" LOG_EFFECT_SIZE="0.011905530064505404" NO="2" P_CHI2="0.2516477604481341" P_Z="0.6086761350611561" STUDIES="2" TAU2="0.0020826508736293994" TOTAL_1="90" TOTAL_2="91" WEIGHT="99.99999999999999" Z="0.5119641028569599">
<NAME>Benzodiazepine vs. Anticonvulsant</NAME>
<DICH_DATA CI_END="1.1816943926871075" CI_START="0.7729934768584446" EFFECT_SIZE="0.9557416267942583" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="38" LOG_CI_END="0.07250517474279657" LOG_CI_START="-0.11182417099284662" LOG_EFFECT_SIZE="-0.019659498125025016" ORDER="73" O_E="0.0" SE="0.10827597013009388" STUDY_ID="STD-Kramp-1978" TOTAL_1="44" TOTAL_2="47" VAR="0.011723685707612983" WEIGHT="20.766885631853416"/>
<DICH_DATA CI_END="1.1311976796697039" CI_START="0.9701052429337793" EFFECT_SIZE="1.0475594493116396" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" LOG_CI_END="0.053538505622133484" LOG_CI_START="-0.013181148263596282" LOG_EFFECT_SIZE="0.020178678679268612" ORDER="74" O_E="0.0" SE="0.039191454960090875" STUDY_ID="STD-Tubridy-1988" TOTAL_1="46" TOTAL_2="44" VAR="0.0015359701418888316" WEIGHT="79.23311436814657"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.09438816233536701" CI_END="1.12395467190759" CI_START="0.9708237586525965" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0445869514485007" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="62" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.05074879687596242" LOG_CI_START="-0.012859603863113281" LOG_EFFECT_SIZE="0.018944596506424553" METHOD="MH" MODIFIED="2009-12-03 16:49:43 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.7586709464148766" P_Q="0.0" P_Z="0.2430171210356693" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="72" TOTAL_2="68" WEIGHT="100.0" Z="1.167478711076144">
<NAME>Global patient's assessment of efficacy</NAME>
<GROUP_LABEL_1>Benzodiazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drugs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benzodiazepine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.09438816233536701" CI_END="1.12395467190759" CI_START="0.9708237586525965" DF="1" EFFECT_SIZE="1.0445869514485007" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="62" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="0.05074879687596242" LOG_CI_START="-0.012859603863113281" LOG_EFFECT_SIZE="0.018944596506424553" NO="1" P_CHI2="0.7586709464148766" P_Z="0.2430171210356693" STUDIES="2" TAU2="0.0" TOTAL_1="72" TOTAL_2="68" WEIGHT="100.0" Z="1.167478711076144">
<NAME>Benzodiazepine vs. Other Drug</NAME>
<DICH_DATA CI_END="1.2942226238141417" CI_START="0.7966217698477059" EFFECT_SIZE="1.0153846153846153" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.11200898728943688" LOG_CI_START="-0.09874782949141069" LOG_EFFECT_SIZE="0.006630578899013076" ORDER="75" O_E="0.0" SE="0.12379959744013844" STUDY_ID="STD-Lepola-1984" TOTAL_1="26" TOTAL_2="24" VAR="0.01532634032634033" WEIGHT="9.108894921504405"/>
<DICH_DATA CI_END="1.1311976796697039" CI_START="0.9701052429337793" EFFECT_SIZE="1.0475594493116396" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" LOG_CI_END="0.053538505622133484" LOG_CI_START="-0.013181148263596282" LOG_EFFECT_SIZE="0.020178678679268612" ORDER="76" O_E="0.0" SE="0.039191454960090875" STUDY_ID="STD-Tubridy-1988" TOTAL_1="46" TOTAL_2="44" VAR="0.0015359701418888316" WEIGHT="90.8911050784956"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="24.849175134071412" CI_END="1.721274579076126" CI_START="1.042370512286635" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3394796992778737" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="105" I2="19.514430993818262" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.23585015485156968" LOG_CI_START="0.0180221170825629" LOG_EFFECT_SIZE="0.12693613596706624" METHOD="MH" MODIFIED="2010-01-05 10:10:38 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.20726242800401928" P_Q="0.0" P_Z="0.02235500515857437" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.06171818475948541" TOTALS="SUB" TOTAL_1="637" TOTAL_2="753" WEIGHT="199.99999999999997" Z="2.2842812833484376">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Benzodiazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.806793450163795" CI_END="1.7243998009656023" CI_START="0.9904479647231167" DF="12" EFFECT_SIZE="1.3068772984619972" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="69" I2="6.299730321280979" ID="CMP-002.11.01" LOG_CI_END="0.23663796405453338" LOG_CI_START="-0.004168336104472816" LOG_EFFECT_SIZE="0.11623481397503024" MODIFIED="2010-01-05 10:09:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.38323892673384474" P_Z="0.05847627661301022" STUDIES="18" TAU2="0.01671784835319259" TOTAL_1="426" TOTAL_2="493" WEIGHT="100.0" Z="1.8921103724474293">
<NAME>Benzodiazepine vs. Other Drug</NAME>
<DICH_DATA CI_END="3.2031892430550273" CI_START="0.8671912793789496" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.5055825973546417" LOG_CI_START="-0.061885098121928904" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="255" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Radouco_x002d_Thomas-1989" TOTAL_1="30" TOTAL_2="30" VAR="0.1111111111111111" WEIGHT="15.652425322146078"/>
<DICH_DATA CI_END="33.229668834707624" CI_START="0.15919508636434915" EFFECT_SIZE="2.3" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.5215260131422157" LOG_CI_START="-0.7980703411070298" LOG_EFFECT_SIZE="0.36172783601759284" ORDER="246" O_E="0.0" SE="1.3625423806731425" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="10" TOTAL_2="23" VAR="1.8565217391304347" WEIGHT="1.0681139003209006"/>
<DICH_DATA CI_END="24.290918562250997" CI_START="0.1189745045084943" EFFECT_SIZE="1.7" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.3854439379823262" LOG_CI_START="-0.9245460952257786" LOG_EFFECT_SIZE="0.2304489213782739" MODIFIED="2010-01-05 10:09:13 +0100" MODIFIED_BY="[Empty name]" ORDER="247" O_E="0.0" SE="1.3568995801415207" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="10" TOTAL_2="17" VAR="1.8411764705882352" WEIGHT="1.0769359815700745"/>
<DICH_DATA CI_END="576.7107256313936" CI_START="1.888295035275688" EFFECT_SIZE="33.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.760958028468663" LOG_CI_START="0.2760698512871118" LOG_EFFECT_SIZE="1.5185139398778875" MODIFIED="2009-12-03 12:28:21 +0100" MODIFIED_BY="[Empty name]" ORDER="692" O_E="0.0" SE="1.4596356156712984" STUDY_ID="STD-Krupitsky-2007" TOTAL_1="25" TOTAL_2="77" VAR="2.1305361305361306" WEIGHT="0.9318102384225605"/>
<DICH_DATA CI_END="2.113485882436621" CI_START="0.7257811057364871" EFFECT_SIZE="1.2385185185185186" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" LOG_CI_END="0.32499935119491663" LOG_CI_START="-0.13919434197893366" LOG_EFFECT_SIZE="0.09290250460799149" MODIFIED="2009-12-03 12:27:56 +0100" MODIFIED_BY="[Empty name]" ORDER="691" O_E="0.0" SE="0.2726696731661593" STUDY_ID="STD-Favre-2005" TOTAL_1="45" TOTAL_2="44" VAR="0.07434875066454014" WEIGHT="21.971098773909898"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="248" O_E="0.0" SE="0.0" STUDY_ID="STD-Gillmer-1973" TOTAL_1="19" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="245" O_E="0.0" SE="0.0" STUDY_ID="STD-Bailly-1992" TOTAL_1="13" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.27138099161219" CI_START="0.5707717682251504" EFFECT_SIZE="1.3664596273291925" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5147311258796133" LOG_CI_START="-0.24353751629890033" LOG_EFFECT_SIZE="0.13559680479035652" ORDER="257" O_E="0.0" SE="0.4454107539059733" STUDY_ID="STD-Tubridy-1988" TOTAL_1="46" TOTAL_2="44" VAR="0.1983907396950875" WEIGHT="9.301503302014025"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:29:53 +0100" MODIFIED_BY="[Empty name]" ORDER="693" O_E="0.0" SE="0.0" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.6440086831856218" CI_START="0.44114832429168443" EFFECT_SIZE="1.08" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.42226287708191146" LOG_CI_START="-0.355415366108012" LOG_EFFECT_SIZE="0.03342375548694973" ORDER="244" O_E="0.0" SE="0.4568120496191499" STUDY_ID="STD-Ansoms-1991" TOTAL_1="25" TOTAL_2="27" VAR="0.20867724867724866" WEIGHT="8.877004284402977"/>
<DICH_DATA CI_END="26.450125630660757" CI_START="0.3402630341221244" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4224277391527982" LOG_CI_START="-0.46818522971347337" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="249" O_E="0.0" SE="1.1105554165971787" STUDY_ID="STD-Lapierre-1983" TOTAL_1="20" TOTAL_2="20" VAR="1.2333333333333332" WEIGHT="1.6006010564489022"/>
<DICH_DATA CI_END="4.950090456644416" CI_START="0.7223175457901514" EFFECT_SIZE="1.8909090909090909" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6946131351886352" LOG_CI_START="-0.1412718355795622" LOG_EFFECT_SIZE="0.2766706498045365" ORDER="243" O_E="0.0" SE="0.49100296952657635" STUDY_ID="STD-Addolorato-1999" TOTAL_1="22" TOTAL_2="26" VAR="0.24108391608391608" WEIGHT="7.761130907662037"/>
<DICH_DATA CI_END="29.552910339652673" CI_START="0.5034208424625506" EFFECT_SIZE="3.857142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4706002561889702" LOG_CI_START="-0.2980688078995089" LOG_EFFECT_SIZE="0.5862657241447304" ORDER="251" O_E="0.0" SE="1.0389249632986395" STUDY_ID="STD-Longo-2002" TOTAL_1="7" TOTAL_2="9" VAR="1.0793650793650793" WEIGHT="1.8254396555448669"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:26:30 +0100" MODIFIED_BY="[Empty name]" ORDER="690" O_E="0.0" SE="0.0" STUDY_ID="STD-Addolorato-2006" TOTAL_1="19" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="19.81661614396266" CI_START="0.1860257055603865" EFFECT_SIZE="1.92" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2970294969973928" LOG_CI_START="-0.7304270395902938" LOG_EFFECT_SIZE="0.28330122870354957" ORDER="254" O_E="0.0" SE="1.190938005663323" STUDY_ID="STD-Palestine-1976" TOTAL_1="25" TOTAL_2="24" VAR="1.4183333333333332" WEIGHT="1.3942591508626176"/>
<DICH_DATA CI_END="3.5291253074271585" CI_START="0.47322184000747713" EFFECT_SIZE="1.2923076923076924" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5476670789771421" LOG_CI_START="-0.3249352201390899" LOG_EFFECT_SIZE="0.11136592941902611" ORDER="250" O_E="0.0" SE="0.5125709099519185" STUDY_ID="STD-Lepola-1984" TOTAL_1="26" TOTAL_2="24" VAR="0.26272893772893774" WEIGHT="7.159979436781214"/>
<DICH_DATA CI_END="1.2913895880132948" CI_START="0.43557730774751224" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.11105728053148967" LOG_CI_START="-0.3609347537480896" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="256" O_E="0.0" SE="0.2772504573340755" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" VAR="0.076867816091954" WEIGHT="21.37969798991384"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:29:01 +0100" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.0" STUDY_ID="STD-Lucht-2003" TOTAL_1="34" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.113699457974008" CI_END="2.6952522183732976" CI_START="0.8310670511353999" DF="7" EFFECT_SIZE="1.4966413442069684" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="36" I2="42.21418465692448" ID="CMP-002.11.02" LOG_CI_END="0.4305994121655876" LOG_CI_START="-0.08036393558608357" LOG_EFFECT_SIZE="0.17511773828975197" MODIFIED="2010-01-05 10:10:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.09688131358410634" P_Z="0.1791293391785732" STUDIES="9" TAU2="0.24102449198444784" TOTAL_1="211" TOTAL_2="260" WEIGHT="99.99999999999997" Z="1.3434406268562036">
<NAME>Benzodiazepine vs. Anticonvulsant</NAME>
<DICH_DATA CI_END="16.8446828987975" CI_START="0.08548691647396922" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2264628397992592" LOG_CI_START="-1.0681003477040096" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2010-01-05 10:10:38 +0100" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="1.347837774610382" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="10" TOTAL_2="12" VAR="1.8166666666666667" WEIGHT="4.37798742372826"/>
<DICH_DATA CI_END="3.2031892430550273" CI_START="0.8671912793789496" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.5055825973546417" LOG_CI_START="-0.061885098121928904" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="263" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Radouco_x002d_Thomas-1989" TOTAL_1="30" TOTAL_2="30" VAR="0.1111111111111111" WEIGHT="25.58260492633789"/>
<DICH_DATA CI_END="576.7107256313936" CI_START="1.888295035275688" EFFECT_SIZE="33.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.760958028468663" LOG_CI_START="0.2760698512871118" LOG_EFFECT_SIZE="1.5185139398778875" MODIFIED="2009-12-03 12:31:03 +0100" MODIFIED_BY="[Empty name]" ORDER="694" O_E="0.0" SE="1.4596356156712984" STUDY_ID="STD-Krupitsky-2007" TOTAL_1="25" TOTAL_2="77" VAR="2.1305361305361306" WEIGHT="3.7985729434640425"/>
<DICH_DATA CI_END="10.892770737658854" CI_START="0.05875456441834129" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.037138363045254" LOG_CI_START="-1.2309583890613667" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-01-05 10:09:26 +0100" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="1.3322912594474228" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="10" TOTAL_2="8" VAR="1.775" WEIGHT="4.468470522212735"/>
<DICH_DATA CI_END="1.2913895880132948" CI_START="0.43557730774751224" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.11105728053148967" LOG_CI_START="-0.3609347537480896" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="264" O_E="0.0" SE="0.2772504573340755" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" VAR="0.076867816091954" WEIGHT="28.338357945818267"/>
<DICH_DATA CI_END="26.450125630660757" CI_START="0.3402630341221244" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4224277391527982" LOG_CI_START="-0.46818522971347337" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="260" O_E="0.0" SE="1.1105554165971787" STUDY_ID="STD-Lapierre-1983" TOTAL_1="20" TOTAL_2="20" VAR="1.2333333333333332" WEIGHT="6.110149015249891"/>
<DICH_DATA CI_END="3.27138099161219" CI_START="0.5707717682251504" EFFECT_SIZE="1.3664596273291925" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5147311258796133" LOG_CI_START="-0.24353751629890033" LOG_EFFECT_SIZE="0.13559680479035652" ORDER="265" O_E="0.0" SE="0.4454107539059733" STUDY_ID="STD-Tubridy-1988" TOTAL_1="46" TOTAL_2="44" VAR="0.1983907396950875" WEIGHT="20.501214716792806"/>
<DICH_DATA CI_END="29.552910339652673" CI_START="0.5034208424625506" EFFECT_SIZE="3.857142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4706002561889702" LOG_CI_START="-0.2980688078995089" LOG_EFFECT_SIZE="0.5862657241447304" ORDER="261" O_E="0.0" SE="1.0389249632986395" STUDY_ID="STD-Longo-2002" TOTAL_1="7" TOTAL_2="9" VAR="1.0793650793650793" WEIGHT="6.8226425063961"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:31:46 +0100" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.0" STUDY_ID="STD-Lucht-2003" TOTAL_1="34" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8408892731723249" CI_END="7.180030487350717" CI_START="0.3944974602845793" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6830043945354713" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.8561262883175196" LOG_CI_START="-0.4039557883682319" LOG_EFFECT_SIZE="0.22608524997464383" METHOD="MH" MODIFIED="2009-12-03 16:49:43 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.8396639790552546" P_Q="0.0" P_Z="0.4818578534124014" Q="0.0" RANDOM="YES" SCALE="10000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="275" TOTAL_2="295" WEIGHT="200.0" Z="0.7033175942816706">
<NAME>Severe, life-treating adverse events</NAME>
<GROUP_LABEL_1>Benzodiazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5988449117210669" CI_END="15.284272408671502" CI_START="0.24994093474882378" DF="1" EFFECT_SIZE="1.9545243239159267" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.12.01" LOG_CI_END="1.184244769433054" LOG_CI_START="-0.602162610301503" LOG_EFFECT_SIZE="0.2910410795657755" MODIFIED="2009-12-03 12:35:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.43901924692417993" P_Z="0.5230612152434417" STUDIES="7" TAU2="0.0" TOTAL_1="159" TOTAL_2="181" WEIGHT="100.0" Z="0.6386337634312022">
<NAME>Benzodiazepine vs. Other Drug</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="266" O_E="0.0" SE="0.0" STUDY_ID="STD-Addolorato-1999" TOTAL_1="22" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="268" O_E="0.0" SE="0.0" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="10" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="110.22898165492303" CI_START="0.2186282880591475" EFFECT_SIZE="4.909090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.0422957952237453" LOG_CI_START="-0.6602936458942583" LOG_EFFECT_SIZE="0.6910010746647435" ORDER="269" O_E="0.0" SE="1.5875144157462069" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="10" TOTAL_2="17" VAR="2.5202020202020203" WEIGHT="43.691892554887765"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="270" O_E="0.0" SE="0.0" STUDY_ID="STD-Lapierre-1983" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:35:01 +0100" MODIFIED_BY="[Empty name]" ORDER="695" O_E="0.0" SE="0.0" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="272" O_E="0.0" SE="0.0" STUDY_ID="STD-Radouco_x002d_Thomas-1989" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="14.825810401113666" CI_START="0.06171223108049359" EFFECT_SIZE="0.9565217391304348" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1710184418752536" LOG_CI_START="-1.2096287522660267" LOG_EFFECT_SIZE="-0.01930515519538663" ORDER="273" O_E="0.0" SE="1.3984039462322553" STUDY_ID="STD-Tubridy-1988" TOTAL_1="46" TOTAL_2="44" VAR="1.9555335968379446" WEIGHT="56.308107445112235"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2012856553076599" CI_END="11.235707463164738" CI_START="0.1874672399426774" DF="1" EFFECT_SIZE="1.4513190782604752" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.12.02" LOG_CI_END="1.0506004232327075" LOG_CI_START="-0.7270746146305795" LOG_EFFECT_SIZE="0.16176290430106402" NO="2" P_CHI2="0.6536851077715481" P_Z="0.7213154598881539" STUDIES="5" TAU2="0.0" TOTAL_1="116" TOTAL_2="114" WEIGHT="100.0" Z="0.35670126396753493">
<NAME>Benzodiazepine vs. Anticonvulsant</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="274" O_E="0.0" SE="0.0" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="10" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="53.24621860927151" CI_START="0.11314969486641972" EFFECT_SIZE="2.4545454545454546" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.726288770881867" LOG_CI_START="-0.9463466128803427" LOG_EFFECT_SIZE="0.3899710790007623" ORDER="275" O_E="0.0" SE="1.5699192541804385" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="10" TOTAL_2="8" VAR="2.4646464646464645" WEIGHT="44.24103927072207"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="276" O_E="0.0" SE="0.0" STUDY_ID="STD-Lapierre-1983" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="277" O_E="0.0" SE="0.0" STUDY_ID="STD-Radouco_x002d_Thomas-1989" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="14.825810401113666" CI_START="0.06171223108049359" EFFECT_SIZE="0.9565217391304348" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1710184418752536" LOG_CI_START="-1.2096287522660267" LOG_EFFECT_SIZE="-0.01930515519538663" ORDER="278" O_E="0.0" SE="1.3984039462322553" STUDY_ID="STD-Tubridy-1988" TOTAL_1="46" TOTAL_2="44" VAR="1.9555335968379446" WEIGHT="55.75896072927792"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.287770474035374" CI_START="0.2538002751181573" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.158463465574917" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.7232725954898187" LOG_CI_START="-0.5955079114681351" LOG_EFFECT_SIZE="0.06388234201084186" METHOD="MH" MODIFIED="2010-01-05 12:44:58 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.8494007071828565" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="32" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="857" TOTAL_2="1231" WEIGHT="0.0" Z="0.1898831366231469">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Benzodiazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other drugs</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:39:13 +0100" MODIFIED_BY="[Empty name]" ORDER="345" O_E="0.0" SE="0.0" STUDY_ID="STD-Addolorato-1999" TOTAL_1="22" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:39:18 +0100" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="0.0" STUDY_ID="STD-Adinoff-1994" TOTAL_1="12" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:39:24 +0100" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="0.0" STUDY_ID="STD-Ansoms-1991" TOTAL_1="25" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:39:31 +0100" MODIFIED_BY="[Empty name]" ORDER="348" O_E="0.0" SE="0.0" STUDY_ID="STD-Bailly-1992" TOTAL_1="13" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:39:38 +0100" MODIFIED_BY="[Empty name]" ORDER="349" O_E="0.0" SE="0.0" STUDY_ID="STD-Baumgartner-1987" TOTAL_1="21" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:39:43 +0100" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="0.0" STUDY_ID="STD-Baumgartner-1991" TOTAL_1="20" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:39:48 +0100" MODIFIED_BY="[Empty name]" ORDER="351" O_E="0.0" SE="0.0" STUDY_ID="STD-Borg-1986" TOTAL_1="15" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:39:53 +0100" MODIFIED_BY="[Empty name]" ORDER="352" O_E="0.0" SE="0.0" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="10" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-05 12:44:58 +0100" MODIFIED_BY="[Empty name]" ORDER="353" O_E="0.0" SE="0.0" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="10" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:40:03 +0100" MODIFIED_BY="[Empty name]" ORDER="354" O_E="0.0" SE="0.0" STUDY_ID="STD-Dion-1968" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:40:08 +0100" MODIFIED_BY="[Empty name]" ORDER="355" O_E="0.0" SE="0.0" STUDY_ID="STD-Gillman-2004" TOTAL_1="28" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:40:20 +0100" MODIFIED_BY="[Empty name]" ORDER="356" O_E="0.0" SE="0.0" STUDY_ID="STD-Gillmer-1973" TOTAL_1="19" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="11.399138843814852" CI_START="0.02998254101575758" EFFECT_SIZE="0.5846153846153846" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="1.0568720434850878" LOG_CI_START="-1.5231315635371785" LOG_EFFECT_SIZE="-0.23312976002604538" MODIFIED="2009-12-03 12:41:01 +0100" MODIFIED_BY="[Empty name]" ORDER="357" O_E="0.0" SE="1.5155068899887056" STUDY_ID="STD-Golbert-1967" TOTAL_1="12" TOTAL_2="37" VAR="2.2967611336032387" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.117838849763759" CI_START="0.028390158602465004" EFFECT_SIZE="0.5865384615384616" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="1.0834251726923052" LOG_CI_START="-1.546832181268332" LOG_EFFECT_SIZE="-0.23170350428801328" MODIFIED="2009-12-03 12:41:08 +0100" MODIFIED_BY="[Empty name]" ORDER="358" O_E="0.0" SE="1.545026189700364" STUDY_ID="STD-Kaim-1969" TOTAL_1="103" TOTAL_2="304" VAR="2.387105926860025" WEIGHT="0.0"/>
<DICH_DATA CI_END="24.475737949006238" CI_START="0.042024064548823306" EFFECT_SIZE="1.0141843971631206" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.3887357947489203" LOG_CI_START="-1.3765019451295566" LOG_EFFECT_SIZE="0.006116924809681917" MODIFIED="2009-12-03 12:41:15 +0100" MODIFIED_BY="[Empty name]" ORDER="359" O_E="0.0" SE="1.6243143365521893" STUDY_ID="STD-Kaim-1972" TOTAL_1="46" TOTAL_2="142" VAR="2.6383970639289784" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:41:24 +0100" MODIFIED_BY="[Empty name]" ORDER="360" O_E="0.0" SE="0.0" STUDY_ID="STD-Kalyoncu-1996" TOTAL_1="34" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:41:31 +0100" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramp-1978" TOTAL_1="44" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:41:38 +0100" MODIFIED_BY="[Empty name]" ORDER="362" O_E="0.0" SE="0.0" STUDY_ID="STD-Lapierre-1983" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="98.2719903161007" CI_START="0.25439598729592483" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9924297519668148" LOG_CI_START="-0.5944897432947772" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2009-12-03 12:41:46 +0100" MODIFIED_BY="[Empty name]" ORDER="363" O_E="0.0" SE="1.5195693169746844" STUDY_ID="STD-Lenzenhuber-1999" TOTAL_1="21" TOTAL_2="21" VAR="2.309090909090909" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:42:03 +0100" MODIFIED_BY="[Empty name]" ORDER="364" O_E="0.0" SE="0.0" STUDY_ID="STD-Lepola-1984" TOTAL_1="26" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:42:09 +0100" MODIFIED_BY="[Empty name]" ORDER="365" O_E="0.0" SE="0.0" STUDY_ID="STD-Longo-2002" TOTAL_1="7" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:42:16 +0100" MODIFIED_BY="[Empty name]" ORDER="366" O_E="0.0" SE="0.0" STUDY_ID="STD-Lucht-2003" TOTAL_1="34" TOTAL_2="59" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:42:22 +0100" MODIFIED_BY="[Empty name]" ORDER="367" O_E="0.0" SE="0.0" STUDY_ID="STD-Malcolm-1989" TOTAL_1="34" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:42:33 +0100" MODIFIED_BY="[Empty name]" ORDER="368" O_E="0.0" SE="0.0" STUDY_ID="STD-Malcolm-2002" TOTAL_1="75" TOTAL_2="61" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:42:40 +0100" MODIFIED_BY="[Empty name]" ORDER="369" O_E="0.0" SE="0.0" STUDY_ID="STD-Palestine-1976" TOTAL_1="25" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:42:47 +0100" MODIFIED_BY="[Empty name]" ORDER="370" O_E="0.0" SE="0.0" STUDY_ID="STD-Pena_x002d_Ramos-1977" TOTAL_1="17" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:42:53 +0100" MODIFIED_BY="[Empty name]" ORDER="371" O_E="0.0" SE="0.0" STUDY_ID="STD-Radouco_x002d_Thomas-1989" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:43:00 +0100" MODIFIED_BY="[Empty name]" ORDER="372" O_E="0.0" SE="0.0" STUDY_ID="STD-Runion-1978" TOTAL_1="20" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:43:07 +0100" MODIFIED_BY="[Empty name]" ORDER="373" O_E="0.0" SE="0.0" STUDY_ID="STD-Sellers-1977" TOTAL_1="6" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:43:18 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.0" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:44:03 +0100" MODIFIED_BY="[Empty name]" ORDER="375" O_E="0.0" SE="0.0" STUDY_ID="STD-Tubridy-1988" TOTAL_1="46" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:44:09 +0100" MODIFIED_BY="[Empty name]" ORDER="376" O_E="0.0" SE="0.0" STUDY_ID="STD-Worner-1994" TOTAL_1="18" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="20.01147878988251" CI_END="1.2460903847688556" CI_START="0.7850227484468385" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9890446393689344" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="177" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.09554954487748768" LOG_CI_START="-0.10511775805501797" LOG_EFFECT_SIZE="-0.004784106588765151" METHOD="MH" MODIFIED="2010-01-05 10:15:45 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.7910122635002426" P_Q="0.0" P_Z="0.9255421358711442" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1095" TOTAL_2="1592" WEIGHT="200.0" Z="0.09345495230315931">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Benzodiazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="15.284852493747872" CI_END="1.2396952951392672" CI_START="0.697311093410496" DF="17" EFFECT_SIZE="0.9297597978776078" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="132" I2="0.0" ID="CMP-002.14.01" LOG_CI_END="0.09331495298384945" LOG_CI_START="-0.15657342561877186" LOG_EFFECT_SIZE="-0.031629236317461194" MODIFIED="2010-01-05 10:15:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5749723303455093" P_Z="0.6197823499859116" STUDIES="22" TAU2="0.0" TOTAL_1="716" TOTAL_2="1132" WEIGHT="99.99999999999999" Z="0.49615884009805605">
<NAME>Benzodiazepine vs. Other Drug</NAME>
<DICH_DATA CI_END="1.1375849863969651" CI_START="0.057466644629175924" EFFECT_SIZE="0.2556818181818182" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.055983851697946486" LOG_CI_START="-1.240584159775559" LOG_EFFECT_SIZE="-0.5923001540388062" MODIFIED="2009-12-03 12:48:31 +0100" MODIFIED_BY="[Empty name]" ORDER="697" O_E="0.0" SE="0.7616104680547038" STUDY_ID="STD-Favre-2005" TOTAL_1="44" TOTAL_2="45" VAR="0.580050505050505" WEIGHT="3.714509839011838"/>
<DICH_DATA CI_END="3.191305412946192" CI_START="0.18710444810272275" EFFECT_SIZE="0.7727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5039683688472687" LOG_CI_START="-0.7279158877351333" LOG_EFFECT_SIZE="-0.11197375944393231" ORDER="180" O_E="0.0" SE="0.723614910241919" STUDY_ID="STD-Radouco_x002d_Thomas-1989" TOTAL_1="33" TOTAL_2="34" VAR="0.5236185383244206" WEIGHT="4.114833892299951"/>
<DICH_DATA CI_END="4.532999855033855" CI_START="0.8824178530599416" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.6563857051698729" LOG_CI_START="-0.054325713841910456" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2009-12-29 14:34:15 +0100" MODIFIED_BY="[Empty name]" ORDER="276" O_E="0.0" SE="0.4174754056057845" STUDY_ID="STD-McGrath-1975" TOTAL_1="50" TOTAL_2="50" VAR="0.1742857142857143" WEIGHT="12.362477997489513"/>
<DICH_DATA CI_END="8.26138798110346" CI_START="0.022867951398689773" EFFECT_SIZE="0.43465045592705165" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.9170530184940302" LOG_CI_START="-1.6407727394638554" LOG_EFFECT_SIZE="-0.36185986048491253" MODIFIED="2009-12-03 12:49:26 +0100" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="1.502479511666165" STUDY_ID="STD-Kaim-1972" TOTAL_1="46" TOTAL_2="142" VAR="2.2574446829765975" WEIGHT="0.9544434574108336"/>
<DICH_DATA CI_END="110.22898165492303" CI_START="0.2186282880591475" EFFECT_SIZE="4.909090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.0422957952237453" LOG_CI_START="-0.6602936458942583" LOG_EFFECT_SIZE="0.6910010746647435" MODIFIED="2010-01-05 10:15:18 +0100" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.0" SE="1.5875144157462069" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="10" TOTAL_2="17" VAR="2.5202020202020203" WEIGHT="0.8549327755721633"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="171" O_E="0.0" SE="0.0" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="10" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.5109789715537785" CI_START="0.012329601758584751" EFFECT_SIZE="0.2833333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8136462927124466" LOG_CI_START="-1.9090509507231859" LOG_EFFECT_SIZE="-0.5477023290053697" ORDER="173" O_E="0.0" SE="1.599325838362809" STUDY_ID="STD-Gillmer-1973" TOTAL_1="19" TOTAL_2="16" VAR="2.557843137254902" WEIGHT="0.8423516191247851"/>
<DICH_DATA CI_END="67.90969947701805" CI_START="0.13252893282270775" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8319318085736291" LOG_CI_START="-0.8776892991343044" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="167" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-Bailly-1992" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="0.8505013058423239"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:50:24 +0100" MODIFIED_BY="[Empty name]" ORDER="698" O_E="0.0" SE="0.0" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.938588567514535" CI_START="0.6735607214618188" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.773683237880549" LOG_CI_START="-0.17162324655258673" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="165" O_E="0.0" SE="0.5552777082985894" STUDY_ID="STD-Addolorato-1999" TOTAL_1="30" TOTAL_2="30" VAR="0.30833333333333335" WEIGHT="6.987902620974767"/>
<DICH_DATA CI_END="18.51974486380783" CI_START="0.08132932490073998" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2676349993543585" LOG_CI_START="-1.0897528326807966" LOG_EFFECT_SIZE="0.08894108333678108" ORDER="168" O_E="0.0" SE="1.384741281795418" STUDY_ID="STD-Baumgartner-1987" TOTAL_1="22" TOTAL_2="27" VAR="1.9175084175084176" WEIGHT="1.1236473793077513"/>
<DICH_DATA CI_END="1.148745886353833" CI_START="0.3917201893116148" EFFECT_SIZE="0.6708106708106708" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="66" LOG_CI_END="0.06022396919327136" LOG_CI_START="-0.40702404427886596" LOG_EFFECT_SIZE="-0.1734000375427973" ORDER="174" O_E="0.0" SE="0.27446379602850235" STUDY_ID="STD-Kaim-1969" TOTAL_1="117" TOTAL_2="370" VAR="0.07533037533037533" WEIGHT="28.60205194364789"/>
<DICH_DATA CI_END="3.1141209472982534" CI_START="0.296426026195877" EFFECT_SIZE="0.9607843137254902" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4933354758378155" LOG_CI_START="-0.5280836679766608" LOG_EFFECT_SIZE="-0.017374096069422692" ORDER="182" O_E="0.0" SE="0.5999866611829291" STUDY_ID="STD-Tubridy-1988" TOTAL_1="51" TOTAL_2="49" VAR="0.359983993597439" WEIGHT="5.985275307944177"/>
<DICH_DATA CI_END="3.6663526459656133" CI_START="0.2727506316394255" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5642342349937015" LOG_CI_START="-0.5642342349937015" LOG_EFFECT_SIZE="0.0" ORDER="181" O_E="0.0" SE="0.6628679652796169" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="33" TOTAL_2="33" VAR="0.43939393939393945" WEIGHT="4.903579942649534"/>
<DICH_DATA CI_END="8.510841644427972" CI_START="0.015948372404628798" EFFECT_SIZE="0.3684210526315789" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.929972509962006" LOG_CI_START="-1.7972836318391503" LOG_EFFECT_SIZE="-0.43365556093857216" ORDER="183" O_E="0.0" SE="1.6020037578296284" STUDY_ID="STD-Worner-1994" TOTAL_1="18" TOTAL_2="20" VAR="2.5664160401002505" WEIGHT="0.8395378124467"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 12:47:17 +0100" MODIFIED_BY="[Empty name]" ORDER="696" O_E="0.0" SE="0.0" STUDY_ID="STD-Addolorato-2006" TOTAL_1="19" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.980198294830508" CI_START="0.543892065821494" EFFECT_SIZE="1.2731481481481481" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.47424516189020416" LOG_CI_START="-0.2644872765315407" LOG_EFFECT_SIZE="0.10487894267933175" ORDER="177" O_E="0.0" SE="0.433935091113479" STUDY_ID="STD-Kramp-1978" TOTAL_1="54" TOTAL_2="55" VAR="0.1882996632996633" WEIGHT="11.442417210831726"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="166" O_E="0.0" SE="0.0" STUDY_ID="STD-Adinoff-1994" TOTAL_1="12" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6119963268374247" CI_START="0.2580806128858863" EFFECT_SIZE="0.645" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.2073640478685414" LOG_CI_START="-0.5882446185980058" LOG_EFFECT_SIZE="-0.1904402853647322" ORDER="176" O_E="0.0" SE="0.46734446900886534" STUDY_ID="STD-Kalyoncu-1996" TOTAL_1="40" TOTAL_2="43" VAR="0.21841085271317828" WEIGHT="9.864909556318416"/>
<DICH_DATA CI_END="3.754457918288967" CI_START="0.012343864976933615" EFFECT_SIZE="0.2152777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.5745472409165846" LOG_CI_START="-1.9085488374385386" LOG_EFFECT_SIZE="-0.6670007982609769" ORDER="170" O_E="0.0" SE="1.4585829279496223" STUDY_ID="STD-Borg-1986" TOTAL_1="15" TOTAL_2="30" VAR="2.1274641577060933" WEIGHT="1.0127565723396514"/>
<DICH_DATA CI_END="3.307343350789749" CI_START="0.23328348277429198" EFFECT_SIZE="0.8783783783783784" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.5194792833965864" LOG_CI_START="-0.6321160095728278" LOG_EFFECT_SIZE="-0.056318363088120604" ORDER="178" O_E="0.0" SE="0.6764527755788704" STUDY_ID="STD-Lucht-2003" TOTAL_1="37" TOTAL_2="65" VAR="0.4575883575883576" WEIGHT="4.708606048216263"/>
<DICH_DATA CI_END="76.21167365123344" CI_START="0.14053941198914405" EFFECT_SIZE="3.272727272727273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8820214990825588" LOG_CI_START="-0.8522018678644345" LOG_EFFECT_SIZE="0.5149098156090622" ORDER="169" O_E="0.0" SE="1.606096340368614" STUDY_ID="STD-Baumgartner-1991" TOTAL_1="21" TOTAL_2="23" VAR="2.5795454545454546" WEIGHT="0.835264718571727"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.2333058397960315" CI_END="1.6305015255523159" CI_START="0.7509277055396488" DF="8" EFFECT_SIZE="1.1065210207953113" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="45" I2="0.0" ID="CMP-002.14.02" LOG_CI_END="0.21232120948275635" LOG_CI_START="-0.12440187204577607" LOG_EFFECT_SIZE="0.043959668718490164" MODIFIED="2010-01-05 10:15:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8354841539551207" P_Z="0.6088245389405254" STUDIES="11" TAU2="0.0" TOTAL_1="379" TOTAL_2="460" WEIGHT="100.0" Z="0.5117520727681508">
<NAME>Benzodiazepine vs. Anticonvulsant</NAME>
<DICH_DATA CI_END="16.569228727573215" CI_START="0.02856294279465138" EFFECT_SIZE="0.6879432624113475" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.2193022931414368" LOG_CI_START="-1.544197049919707" LOG_EFFECT_SIZE="-0.16244737838913503" MODIFIED="2009-12-03 12:52:32 +0100" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="1.623293193656485" STUDY_ID="STD-Kaim-1972" TOTAL_1="46" TOTAL_2="96" VAR="2.63508079257147" WEIGHT="1.4846601204378138"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-05 10:15:45 +0100" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="0.0" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="10" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.191305412946192" CI_START="0.18710444810272275" EFFECT_SIZE="0.7727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5039683688472687" LOG_CI_START="-0.7279158877351333" LOG_EFFECT_SIZE="-0.11197375944393231" ORDER="191" O_E="0.0" SE="0.723614910241919" STUDY_ID="STD-Radouco_x002d_Thomas-1989" TOTAL_1="33" TOTAL_2="34" VAR="0.5236185383244206" WEIGHT="7.471468407863418"/>
<DICH_DATA CI_END="53.24621860927151" CI_START="0.11314969486641972" EFFECT_SIZE="2.4545454545454546" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.726288770881867" LOG_CI_START="-0.9463466128803427" LOG_EFFECT_SIZE="0.3899710790007623" MODIFIED="2010-01-05 10:15:26 +0100" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="1.5699192541804385" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="10" TOTAL_2="8" VAR="2.4646464646464645" WEIGHT="1.5873267922925836"/>
<DICH_DATA CI_END="4.532999855033855" CI_START="0.8824178530599416" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.6563857051698729" LOG_CI_START="-0.054325713841910456" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2009-12-29 14:35:05 +0100" MODIFIED_BY="[Empty name]" ORDER="277" O_E="0.0" SE="0.4174754056057845" STUDY_ID="STD-McGrath-1975" TOTAL_1="50" TOTAL_2="50" VAR="0.1742857142857143" WEIGHT="22.447045547571886"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="184" O_E="0.0" SE="0.0" STUDY_ID="STD-Borg-1986" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6119963268374247" CI_START="0.2580806128858863" EFFECT_SIZE="0.645" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.2073640478685414" LOG_CI_START="-0.5882446185980058" LOG_EFFECT_SIZE="-0.1904402853647322" ORDER="188" O_E="0.0" SE="0.46734446900886534" STUDY_ID="STD-Kalyoncu-1996" TOTAL_1="40" TOTAL_2="43" VAR="0.21841085271317828" WEIGHT="17.912110677028085"/>
<DICH_DATA CI_END="3.1141209472982534" CI_START="0.296426026195877" EFFECT_SIZE="0.9607843137254902" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4933354758378155" LOG_CI_START="-0.5280836679766608" LOG_EFFECT_SIZE="-0.017374096069422692" ORDER="193" O_E="0.0" SE="0.5999866611829291" STUDY_ID="STD-Tubridy-1988" TOTAL_1="51" TOTAL_2="49" VAR="0.359983993597439" WEIGHT="10.867703665839771"/>
<DICH_DATA CI_END="2.980198294830508" CI_START="0.543892065821494" EFFECT_SIZE="1.2731481481481481" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.47424516189020416" LOG_CI_START="-0.2644872765315407" LOG_EFFECT_SIZE="0.10487894267933175" ORDER="189" O_E="0.0" SE="0.433935091113479" STUDY_ID="STD-Kramp-1978" TOTAL_1="54" TOTAL_2="55" VAR="0.1882996632996633" WEIGHT="20.776454393530106"/>
<DICH_DATA CI_END="3.6663526459656133" CI_START="0.2727506316394255" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5642342349937015" LOG_CI_START="-0.5642342349937015" LOG_EFFECT_SIZE="0.0" ORDER="192" O_E="0.0" SE="0.6628679652796169" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="33" TOTAL_2="33" VAR="0.43939393939393945" WEIGHT="8.903626145273341"/>
<DICH_DATA CI_END="3.307343350789749" CI_START="0.23328348277429198" EFFECT_SIZE="0.8783783783783784" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.5194792833965864" LOG_CI_START="-0.6321160095728278" LOG_EFFECT_SIZE="-0.056318363088120604" ORDER="190" O_E="0.0" SE="0.6764527755788704" STUDY_ID="STD-Lucht-2003" TOTAL_1="37" TOTAL_2="65" VAR="0.4575883575883576" WEIGHT="8.549604250163"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.710268771914477" CI_END="1.7243744092773472" CI_START="0.26835394075350905" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6802519151491455" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.23663156904609076" LOG_CI_START="-0.5712920227546717" LOG_EFFECT_SIZE="-0.16733022685429055" METHOD="MH" MODIFIED="2010-01-05 10:16:43 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.6796491679449691" P_Q="0.0" P_Z="0.4168708477360942" Q="0.0" RANDOM="YES" SCALE="10000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="369" TOTAL_2="534" WEIGHT="200.0" Z="0.8118619668682806">
<NAME>Dropouts due to adverse events</NAME>
<GROUP_LABEL_1>Benzodiazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.6259026157792853" CI_END="2.879244764222851" CI_START="0.23337639066138857" DF="4" EFFECT_SIZE="0.8197241919725377" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-002.15.01" LOG_CI_END="0.45927858576483416" LOG_CI_START="-0.6319430811274167" LOG_EFFECT_SIZE="-0.08633224768129127" MODIFIED="2010-01-05 10:16:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4589945518886802" P_Z="0.756465154426642" STUDIES="8" TAU2="0.0" TOTAL_1="208" TOTAL_2="325" WEIGHT="100.0" Z="0.3101259831865681">
<NAME>Benzodiazepine vs. Other Drug</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="279" O_E="0.0" SE="0.0" STUDY_ID="STD-Addolorato-1999" TOTAL_1="22" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="281" O_E="0.0" SE="0.0" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="10" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="110.22898165492303" CI_START="0.2186282880591475" EFFECT_SIZE="4.909090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.0422957952237453" LOG_CI_START="-0.6602936458942583" LOG_EFFECT_SIZE="0.6910010746647435" MODIFIED="2010-01-05 10:16:43 +0100" MODIFIED_BY="[Empty name]" ORDER="282" O_E="0.0" SE="1.5875144157462069" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="10" TOTAL_2="17" VAR="2.5202020202020203" WEIGHT="16.30293548161693"/>
<DICH_DATA CI_END="6.731669671526588" CI_START="0.08847452630710712" EFFECT_SIZE="0.7717391304347826" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.8281227966452887" LOG_CI_START="-1.0531817538982486" LOG_EFFECT_SIZE="-0.11252947862647998" ORDER="283" O_E="0.0" SE="1.105087605596991" STUDY_ID="STD-Kaim-1972" TOTAL_1="46" TOTAL_2="142" VAR="1.2212186160440905" WEIGHT="33.64400967706081"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="284" O_E="0.0" SE="0.0" STUDY_ID="STD-Lapierre-1983" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="67.5293252326011" CI_START="0.12322062879346876" EFFECT_SIZE="2.8846153846153846" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8294924101789118" LOG_CI_START="-0.9093165793371476" LOG_EFFECT_SIZE="0.4600879154208821" ORDER="286" O_E="0.0" SE="1.6087899577648812" STUDY_ID="STD-Palestine-1976" TOTAL_1="25" TOTAL_2="24" VAR="2.588205128205128" WEIGHT="15.874588334691632"/>
<DICH_DATA CI_END="2.6478392990454207" CI_START="0.007707478045462773" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4228916236469527" LOG_CI_START="-2.1130877036754665" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="287" O_E="0.0" SE="1.4896468101693163" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" VAR="2.219047619047619" WEIGHT="18.51546158059824"/>
<DICH_DATA CI_END="7.631609792779905" CI_START="0.013346600025979092" EFFECT_SIZE="0.3191489361702128" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8826161566154813" LOG_CI_START="-1.8746293543755537" LOG_EFFECT_SIZE="-0.4960065988800362" ORDER="288" O_E="0.0" SE="1.6196196617415348" STUDY_ID="STD-Tubridy-1988" TOTAL_1="46" TOTAL_2="44" VAR="2.6231678486997634" WEIGHT="15.663004926032395"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9021114358175177" CI_END="2.1645668340502207" CI_START="0.13596657778466667" DF="3" EFFECT_SIZE="0.5425022993610248" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-002.15.02" LOG_CI_END="0.3353709998101158" LOG_CI_START="-0.8665678333028479" LOG_EFFECT_SIZE="-0.26559841674636614" NO="2" P_CHI2="0.592970483220765" P_Z="0.386377197363427" STUDIES="6" TAU2="0.0" TOTAL_1="161" TOTAL_2="209" WEIGHT="100.0" Z="0.8662060278483616">
<NAME>Benzodiazepine vs. Anticonvulsant</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="289" O_E="0.0" SE="0.0" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="10" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="53.24621860927151" CI_START="0.11314969486641972" EFFECT_SIZE="2.4545454545454546" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.726288770881867" LOG_CI_START="-0.9463466128803427" LOG_EFFECT_SIZE="0.3899710790007623" ORDER="290" O_E="0.0" SE="1.5699192541804385" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="10" TOTAL_2="8" VAR="2.4646464646464645" WEIGHT="20.22484985082598"/>
<DICH_DATA CI_END="6.506548557470257" CI_START="0.07437613702495685" EFFECT_SIZE="0.6956521739130435" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.8133506752138054" LOG_CI_START="-1.1285663819371416" LOG_EFFECT_SIZE="-0.1576078533616681" ORDER="291" O_E="0.0" SE="1.14069169201493" STUDY_ID="STD-Kaim-1972" TOTAL_1="46" TOTAL_2="96" VAR="1.3011775362318838" WEIGHT="38.3092262929757"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="292" O_E="0.0" SE="0.0" STUDY_ID="STD-Lapierre-1983" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.6478392990454207" CI_START="0.007707478045462773" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4228916236469527" LOG_CI_START="-2.1130877036754665" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="293" O_E="0.0" SE="1.4896468101693163" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" VAR="2.219047619047619" WEIGHT="22.46328751801975"/>
<DICH_DATA CI_END="7.631609792779905" CI_START="0.013346600025979092" EFFECT_SIZE="0.3191489361702128" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8826161566154813" LOG_CI_START="-1.8746293543755537" LOG_EFFECT_SIZE="-0.4960065988800362" ORDER="294" O_E="0.0" SE="1.6196196617415348" STUDY_ID="STD-Tubridy-1988" TOTAL_1="46" TOTAL_2="44" VAR="2.6231678486997634" WEIGHT="19.002636338178572"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-01-01 11:28:19 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Benzodiazepine 1 versus Benzodiazepine 2</NAME>
<DICH_OUTCOME CHI2="1.7076565276389948" CI_END="1.2170874697497194" CI_START="0.18507195263189485" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4746037869111379" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.08532179126585358" LOG_CI_START="-0.7326593929172491" LOG_EFFECT_SIZE="-0.32366880082569777" METHOD="MH" MODIFIED="2009-12-29 14:40:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6352330090380609" P_Q="0.0" P_Z="0.12088130365720179" Q="0.0" RANDOM="YES" SCALE="100000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="107" TOTAL_2="107" WEIGHT="400.0" Z="1.551085048908978">
<NAME>Alcohol withdrawal seizures</NAME>
<GROUP_LABEL_1>Benzodiazepine 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benzodiazepine2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3494755583658373" CI_START="0.14637602213168877" DF="0" EFFECT_SIZE="0.4444444444444445" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.13016502304372257" LOG_CI_START="-0.8345300592664475" LOG_EFFECT_SIZE="-0.3521825181113625" MODIFIED="2009-12-04 11:45:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1524149334844679" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="1.4310533227346978">
<NAME>Chlordiazepoxide vs Alprazolam .</NAME>
<DICH_DATA CI_END="1.349475558365837" CI_START="0.14637602213168877" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.13016502304372252" LOG_CI_START="-0.8345300592664475" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2009-12-03 16:01:36 +0100" MODIFIED_BY="[Empty name]" ORDER="314" O_E="0.0" SE="0.5666666666666667" STUDY_ID="STD-Wilson-1985" TOTAL_1="50" TOTAL_2="50" VAR="0.32111111111111107" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.450631558527997" CI_START="0.014912978884848133" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.8721930876152056" LOG_CI_START="-1.8264355970545303" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2009-12-04 11:45:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4882790296766242" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.6930486441661347">
<NAME>Chlordiazepoxide vs Diazepam</NAME>
<DICH_DATA CI_END="7.450631558527997" CI_START="0.014912978884848133" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8721930876152056" LOG_CI_START="-1.8264355970545303" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2009-12-03 16:02:32 +0100" MODIFIED_BY="[Empty name]" ORDER="377" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Day-2004" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9664412916709404" CI_START="0.010084606592815406" DF="0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.5984010305641998" LOG_CI_START="-1.9963410392362373" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2009-12-04 11:45:39 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2909920990722461" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="1.055947757364389">
<NAME>Chlordiazepoxide vs Lorazepam.</NAME>
<DICH_DATA CI_END="3.9664412916709404" CI_START="0.010084606592815406" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5984010305641998" LOG_CI_START="-1.9963410392362373" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2009-12-04 11:45:03 +0100" MODIFIED_BY="[Empty name]" ORDER="312" O_E="0.0" SE="1.5241643359811707" STUDY_ID="STD-Solomon-1983" TOTAL_1="25" TOTAL_2="25" VAR="2.3230769230769233" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.5152908317231" CI_START="0.12946791838627933" DF="0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.01.04" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.4771212547196624" MODIFIED="2009-12-04 11:45:34 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.49327758741034355" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6851051308492763">
<NAME>Lorazepam vs. Diazepam</NAME>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="313" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Ritson-1986" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.249592719770881" CI_END="1.8557331542409523" CI_START="0.17770835522270007" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5742641261409186" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.2685155268545734" LOG_CI_START="-0.7502921527134958" LOG_EFFECT_SIZE="-0.2408883129294611" METHOD="MH" MODIFIED="2009-12-29 14:42:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7411362143214857" P_Q="0.0" P_Z="0.35401312806947227" Q="0.0" RANDOM="YES" SCALE="100000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="152" TOTAL_2="151" WEIGHT="400.0" Z="0.9268332524515758">
<NAME>Alcohol withdrawal delirium</NAME>
<GROUP_LABEL_1>Benzodiazepine 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benzodiazepine 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.718788952018382" CI_START="0.21191878046850707" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.6738305539431859" LOG_CI_START="-0.6738305539431859" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 16:02:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.0">
<NAME>Alprazolam vs. Chlordiazepoxide</NAME>
<DICH_DATA CI_END="4.718788952018382" CI_START="0.21191878046850707" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6738305539431859" LOG_CI_START="-0.6738305539431859" LOG_EFFECT_SIZE="0.0" ORDER="316" O_E="0.0" SE="0.7916228058025278" STUDY_ID="STD-Wilson-1985" TOTAL_1="50" TOTAL_2="50" VAR="0.6266666666666666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.796078149940863" CI_START="0.01425218025962887" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.891876183949684" LOG_CI_START="-1.8461186933890088" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2009-12-03 16:02:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.494553663934557" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="99.99999999999999" Z="0.6830841673583029">
<NAME>Diazepam vs Abecamil</NAME>
<DICH_DATA CI_END="7.796078149940863" CI_START="0.01425218025962887" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.891876183949684" LOG_CI_START="-1.8461186933890088" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2009-12-03 15:04:00 +0100" MODIFIED_BY="[Empty name]" ORDER="378" O_E="0.0" SE="1.6083117442419756" STUDY_ID="STD-Anton-1997" TOTAL_1="24" TOTAL_2="24" VAR="2.5866666666666664" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8462530487945656" CI_START="0.00969487479450035" DF="0" EFFECT_SIZE="0.19310344827586207" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.5850378535061828" LOG_CI_START="-2.0134577952916937" LOG_EFFECT_SIZE="-0.7142099708927557" MODIFIED="2009-12-03 16:04:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.28129604761999716" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="1.0774124797913691">
<NAME>Diazepam vs Lorazepam .</NAME>
<DICH_DATA CI_END="3.8462530487945656" CI_START="0.00969487479450035" EFFECT_SIZE="0.19310344827586207" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5850378535061828" LOG_CI_START="-2.0134577952916937" LOG_EFFECT_SIZE="-0.7142099708927557" MODIFIED="2009-12-03 16:04:03 +0100" MODIFIED_BY="[Empty name]" ORDER="315" O_E="0.0" SE="1.5263692068647823" STUDY_ID="STD-Miller-1984" TOTAL_1="28" TOTAL_2="27" VAR="2.329802955665025" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.99146782835324" CI_START="0.013903717501920699" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.02.04" LOG_CI_END="0.9026265554350377" LOG_CI_START="-1.8568690648743624" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2009-12-29 14:42:34 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.497922686342418" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.6777618841839292">
<NAME>Lorazepam vs Chlordiazepoxide</NAME>
<DICH_DATA CI_END="7.99146782835324" CI_START="0.013903717501920699" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9026265554350377" LOG_CI_START="-1.8568690648743624" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2009-12-29 14:42:34 +0100" MODIFIED_BY="[Empty name]" ORDER="279" O_E="0.0" SE="1.6209413870933633" STUDY_ID="STD-Kumar-2009" TOTAL_1="50" TOTAL_2="50" VAR="2.627450980392157" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.5426000782375056" CI_END="0.6039928814835197" CI_START="-0.5751786297488121" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.014407125867353843" ESTIMABLE="YES" I2="21.340362681559746" I2_Q="21.340362681559746" ID="CMP-003.03" MODIFIED="2009-12-29 14:44:13 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.28046687696001105" P_Q="0.28046687696001105" P_Z="0.9618009541944658" Q="2.5426000782375056" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.7596808270323075" TOTALS="SUB" TOTAL_1="85" TOTAL_2="83" UNITS="" WEIGHT="300.0" Z="0.047893707661302735">
<NAME>CIWA-Ar score (48 hrs)</NAME>
<GROUP_LABEL_1>Benzodiazepine 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benzodiazepine 1</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.45473288232148" CI_START="-1.8547328823214784" DF="0" EFFECT_SIZE="1.8000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.01" MODIFIED="2009-12-03 16:09:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3343916354514592" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.9653058884925022">
<NAME>Diazepam vs Abecamil</NAME>
<CONT_DATA CI_END="5.45473288232148" CI_START="-1.8547328823214784" EFFECT_SIZE="1.8000000000000007" ESTIMABLE="YES" MEAN_1="12.3" MEAN_2="10.5" MODIFIED="2009-12-03 15:13:04 +0100" MODIFIED_BY="[Empty name]" ORDER="379" SD_1="6.8" SD_2="6.1" SE="1.8646938980254462" STUDY_ID="STD-Anton-1997" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.4443701759682597" CI_START="-11.44437017596826" DF="0" EFFECT_SIZE="-4.5" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.02" MODIFIED="2009-12-03 16:10:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2040596347683029" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="9" WEIGHT="99.99999999999999" Z="1.2700702449521257">
<NAME>Diazepam vs Chlordiazepoxide .</NAME>
<CONT_DATA CI_END="2.4443701759682597" CI_START="-11.44437017596826" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="8.5" MEAN_2="13.0" MODIFIED="2009-12-03 16:10:11 +0100" MODIFIED_BY="[Empty name]" ORDER="295" SD_1="9.7" SD_2="6.0" SE="3.543111113645233" STUDY_ID="STD-Jauhar-2000" TOTAL_1="11" TOTAL_2="9" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5996336761865283" CI_START="-0.5996336761865283" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.03" MODIFIED="2009-12-29 14:44:13 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.00000000000001" Z="0.0">
<NAME>Lorazepam vs Chlorziazepoxide</NAME>
<CONT_DATA CI_END="0.5996336761865283" CI_START="-0.5996336761865283" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.5" MODIFIED="2009-12-29 14:44:13 +0100" MODIFIED_BY="[Empty name]" ORDER="280" SD_1="1.2" SD_2="1.8" SE="0.3059411708155671" STUDY_ID="STD-Kumar-2009" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.545131284170832" CI_END="0.5357585158823319" CI_START="-0.4698180447701626" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.03297023555608466" ESTIMABLE="YES" I2="21.418591943025366" I2_Q="21.418591943025366" ID="CMP-003.04" MODIFIED="2009-12-29 14:45:20 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.2801121429953761" P_Q="0.2801121429953761" P_Z="0.8977341281604259" Q="2.545131284170832" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.7745344730284738" TOTALS="SUB" TOTAL_1="85" TOTAL_2="83" UNITS="" WEIGHT="300.0" Z="0.12852422536539077">
<NAME>CIWA-Ar score (end of treatment)</NAME>
<GROUP_LABEL_1>Benzodiazepine 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benzodiazepine 1</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.135246689723861" CI_START="-1.1352466897238602" DF="0" EFFECT_SIZE="2.5" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" MODIFIED="2009-12-03 16:10:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.17769400374955732" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="1.3478892574749421">
<NAME>Diazepam vs Abecamil</NAME>
<CONT_DATA CI_END="6.135246689723861" CI_START="-1.1352466897238602" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="14.5" MEAN_2="12.0" MODIFIED="2009-12-03 15:11:25 +0100" MODIFIED_BY="[Empty name]" ORDER="380" SD_1="6.4" SD_2="6.45" SE="1.8547517803379154" STUDY_ID="STD-Anton-1997" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.1942690163394625" CI_START="-10.79426901633946" DF="0" EFFECT_SIZE="-3.299999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.02" MODIFIED="2009-12-03 16:11:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.38811348700854054" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="9" WEIGHT="100.0" Z="0.8630436317245229">
<NAME>Diazepam vs Chlordiazepoxide .</NAME>
<CONT_DATA CI_END="4.194269016339463" CI_START="-10.794269016339461" EFFECT_SIZE="-3.299999999999999" ESTIMABLE="YES" MEAN_1="14.1" MEAN_2="17.4" MODIFIED="2009-12-03 16:11:21 +0100" MODIFIED_BY="[Empty name]" ORDER="296" SD_1="9.4" SD_2="7.7" SE="3.8236769019498826" STUDY_ID="STD-Jauhar-2000" TOTAL_1="11" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.508836245284064" CI_START="-0.508836245284064" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.03" MODIFIED="2009-12-29 14:45:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.0">
<NAME>Lorazepam vs Chlordiazepoxide</NAME>
<CONT_DATA CI_END="0.508836245284064" CI_START="-0.508836245284064" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.3" MODIFIED="2009-12-29 14:45:20 +0100" MODIFIED_BY="[Empty name]" ORDER="281" SD_1="0.9" SD_2="1.6" SE="0.2596150997149434" STUDY_ID="STD-Kumar-2009" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.2031114267852407" CI_END="0.7586589623852606" CI_START="-1.103567135035734" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.17245408632523668" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2009-12-03 15:25:21 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9034309274666212" P_Q="0.9034309274666212" P_Z="0.7165970536429963" Q="0.2031114267852407" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="61" TOTAL_2="51" UNITS="" WEIGHT="300.0" Z="0.3630104836918872">
<NAME>HARS score (48 hrs)</NAME>
<GROUP_LABEL_1>Benzodiazepine 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benzodiazepine 1</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.1358131850326285E-33" CI_END="1.1181815742579924" CI_START="-1.9181815742579922" DF="0" EFFECT_SIZE="-0.39999999999999986" ESTIMABLE="YES" I2="100.0" ID="CMP-003.05.01" MODIFIED="2009-12-03 15:17:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.6055766183834688" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0" Z="0.5163977794943221">
<NAME>Clobazam vs. Diazepam</NAME>
<CONT_DATA CI_END="1.1181815742579924" CI_START="-1.9181815742579922" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="2.9" ORDER="300" SD_1="2.0" SD_2="2.0" SE="0.7745966692414834" STUDY_ID="STD-Martin-1975" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.552740044932318" CI_START="-5.952740044932317" DF="0" EFFECT_SIZE="-0.6999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.02" MODIFIED="2009-12-03 15:19:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7939442842448117" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.2611922115775891">
<NAME>Clobazam vs Chlordiazepoxide</NAME>
<CONT_DATA CI_END="4.552740044932318" CI_START="-5.952740044932317" EFFECT_SIZE="-0.6999999999999993" ESTIMABLE="YES" MEAN_1="5.9" MEAN_2="6.6" MODIFIED="2009-12-03 15:18:41 +0100" MODIFIED_BY="[Empty name]" ORDER="381" SD_1="9.1" SD_2="7.8" SE="2.6800186566514794" STUDY_ID="STD-Mukherjee-1983" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2097160344783204" CI_START="-1.2097160344783204" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.03" MODIFIED="2009-12-03 15:19:02 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="0.0">
<NAME>Lopirazepam vs. Prazepam</NAME>
<CONT_DATA CI_END="1.2097160344783204" CI_START="-1.2097160344783204" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="4.8" ORDER="299" SD_1="2.0" SD_2="2.0" SE="0.6172133998483676" STUDY_ID="STD-Saletu-1983" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="32.40685366351583" CI_END="0.38059284179597874" CI_START="-0.8673269088247526" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2433670335143869" ESTIMABLE="YES" I2="87.65693195170235" I2_Q="87.65693195170235" ID="CMP-003.06" MODIFIED="2009-12-03 15:25:51 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.579645977356492E-6" P_Q="1.579645977356492E-6" P_Z="0.44459483786741405" Q="32.40685366351583" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="3.8437271266835977" TOTALS="SUB" TOTAL_1="104" TOTAL_2="95" UNITS="" WEIGHT="500.0" Z="0.7644572024367583">
<NAME>HARS score (end of treatment)</NAME>
<GROUP_LABEL_1>Benzodiazepine 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benzodiazepine 1</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.9831256217918265" CI_START="-0.3831256217918322" DF="0" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.01" MODIFIED="2009-12-03 15:20:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1850787304853923" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="1.3252787013921352">
<NAME>Alprazolam vs. Diazepam</NAME>
<CONT_DATA CI_END="1.9831256217918265" CI_START="-0.3831256217918322" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" MEAN_1="17.4" MEAN_2="16.6" ORDER="302" SD_1="2.0" SD_2="2.0" SE="0.6036466134705398" STUDY_ID="STD-Kolin-1981" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.7041097456936116" CI_START="-4.095890254306389" DF="0" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.02" MODIFIED="2009-12-03 15:21:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="2.0056204759370803E-6" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="100.0" Z="4.752857157835769">
<NAME>Alprazolam vs. Chlordiazepoxide</NAME>
<CONT_DATA CI_END="-1.7041097456936116" CI_START="-4.095890254306389" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="14.6" MEAN_2="17.5" ORDER="301" SD_1="2.0" SD_2="2.0" SE="0.6101593007521661" STUDY_ID="STD-McLendon-1980" TOTAL_1="22" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2181815742579916" CI_START="-1.818181574257993" DF="0" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.03" MODIFIED="2009-12-03 15:21:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6985353591861583" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0" Z="0.3872983346207426">
<NAME>Clobazam vs. Diazepam</NAME>
<CONT_DATA CI_END="1.2181815742579916" CI_START="-1.818181574257993" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="12.3" ORDER="304" SD_1="2.0" SD_2="2.0" SE="0.7745966692414834" STUDY_ID="STD-Martin-1975" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6485907384642466" CI_START="-8.648590738464247" DF="0" EFFECT_SIZE="-3.5" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.04" MODIFIED="2009-12-03 15:23:20 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.1827356941249612" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001" Z="1.3323789546217448">
<NAME>Clobazam vs Chlordiazepoxide</NAME>
<CONT_DATA CI_END="1.6485907384642466" CI_START="-8.648590738464247" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="16.3" MEAN_2="19.8" MODIFIED="2009-12-03 15:23:20 +0100" MODIFIED_BY="[Empty name]" ORDER="382" SD_1="10.1" SD_2="6.0" SE="2.6268802789621" STUDY_ID="STD-Mukherjee-1983" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.809716034478322" CI_START="0.390283965521681" DF="0" EFFECT_SIZE="1.6000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.05" MODIFIED="2009-12-03 15:22:24 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.009533762703234099" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="2.5922962793631465">
<NAME>Lopirazepam vs. Prazepam</NAME>
<CONT_DATA CI_END="2.809716034478322" CI_START="0.390283965521681" EFFECT_SIZE="1.6000000000000014" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="18.4" ORDER="303" SD_1="2.0" SD_2="2.0" SE="0.6172133998483676" STUDY_ID="STD-Saletu-1983" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.5918111823195904" CI_END="1.0585370530560536" CI_START="0.8971720032040182" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9745202965336216" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="90" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.024706064675824903" LOG_CI_START="-0.04712428730007754" LOG_EFFECT_SIZE="-0.011209111312126313" METHOD="MH" MODIFIED="2009-12-03 16:51:49 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7438576818823806" P_Q="0.0" P_Z="0.5407336614263369" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="95" TOTAL_2="97" WEIGHT="300.0" Z="0.6117039347889698">
<NAME>Global doctor's assessment of efficacy</NAME>
<GROUP_LABEL_1>Benzodiazepine 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benzodiazepine 1</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1331910453025955" CI_START="0.8748398919405062" DF="0" EFFECT_SIZE="0.9956709956709957" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="0.05430313398197215" LOG_CI_START="-0.05807142173107502" LOG_EFFECT_SIZE="-0.0018841438745514142" NO="1" P_CHI2="1.0" P_Z="0.9475975434280467" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="0.06572402644674072">
<NAME>Alprazolam vs. Diazepam</NAME>
<DICH_DATA CI_END="1.1331910453025955" CI_START="0.8748398919405062" EFFECT_SIZE="0.9956709956709957" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.05430313398197215" LOG_CI_START="-0.05807142173107502" LOG_EFFECT_SIZE="-0.0018841438745514142" ORDER="309" O_E="0.0" SE="0.066009370288866" STUDY_ID="STD-Kolin-1981" TOTAL_1="21" TOTAL_2="23" VAR="0.004357236965932626" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0736660614644755" CI_START="0.8138643446808447" DF="0" EFFECT_SIZE="0.9347826086956522" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="46" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="0.030869225297750658" LOG_CI_START="-0.08944797750172571" LOG_EFFECT_SIZE="-0.02928937610198753" NO="2" P_CHI2="1.0" P_Z="0.33995899927267026" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.9542462915335261">
<NAME>Alprazolam vs. Chlordiazepoxide</NAME>
<DICH_DATA CI_END="1.0736660614644755" CI_START="0.8138643446808447" EFFECT_SIZE="0.9347826086956522" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="46" LOG_CI_END="0.030869225297750658" LOG_CI_START="-0.08944797750172571" LOG_EFFECT_SIZE="-0.02928937610198753" ORDER="310" O_E="0.0" SE="0.07067492050417162" STUDY_ID="STD-Wilson-1985" TOTAL_1="50" TOTAL_2="50" VAR="0.004994944388270979" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1860079077022685" CI_START="0.8431646985704894" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" I2="0.0" ID="CMP-003.07.03" LOG_CI_END="0.07408758469435739" LOG_CI_START="-0.07408758469435739" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 15:28:46 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.0">
<NAME>Diazepam vs Abecamil</NAME>
<DICH_DATA CI_END="1.1860079077022685" CI_START="0.8431646985704894" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" LOG_CI_END="0.07408758469435739" LOG_CI_START="-0.07408758469435739" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 15:28:46 +0100" MODIFIED_BY="[Empty name]" ORDER="383" O_E="0.0" SE="0.08703882797784895" STUDY_ID="STD-Anton-1997" TOTAL_1="24" TOTAL_2="24" VAR="0.007575757575757583" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1769451425175133" CI_START="0.9232786320604456" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0424242424242425" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.07075622082376387" LOG_CI_START="-0.034667215436478584" LOG_EFFECT_SIZE="0.018044502693642654" METHOD="MH" MODIFIED="2009-12-03 16:51:49 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.5022566395833163" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="0.6709433244268688">
<NAME>Global patient's assessment of efficacy</NAME>
<GROUP_LABEL_1>Alprazolam</GROUP_LABEL_1>
<GROUP_LABEL_2>Diazepam</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diazepam</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours alprazolam</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1769451425175133" CI_START="0.9232786320604456" DF="0" EFFECT_SIZE="1.0424242424242425" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="0.07075622082376387" LOG_CI_START="-0.034667215436478584" LOG_EFFECT_SIZE="0.018044502693642654" NO="1" P_CHI2="1.0" P_Z="0.5022566395833163" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="0.6709433244268688">
<NAME>Alprazolam vs. Diazepam</NAME>
<DICH_DATA CI_END="1.1769451425175133" CI_START="0.9232786320604456" EFFECT_SIZE="1.0424242424242425" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.07075622082376387" LOG_CI_START="-0.034667215436478584" LOG_EFFECT_SIZE="0.018044502693642654" ORDER="311" O_E="0.0" SE="0.061926248313692284" STUDY_ID="STD-Kolin-1981" TOTAL_1="21" TOTAL_2="23" VAR="0.0038348602302090765" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.038014536982143" CI_END="2.619998964984102" CI_START="0.5015901437608926" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1463706457772571" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.4183011197541798" LOG_CI_START="-0.299651005973816" LOG_EFFECT_SIZE="0.05932505689018191" METHOD="MH" MODIFIED="2010-01-01 11:28:19 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.694125002610857" P_Q="0.0" P_Z="0.7460082015845906" Q="0.0" RANDOM="YES" SCALE="100000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="172" TOTAL_2="178" WEIGHT="500.0" Z="0.3239073211675353">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Benzodiazepine 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benzodiazepine 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.550748330704528" CI_START="0.25090676030089926" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-003.09.01" LOG_CI_END="0.40666761110760385" LOG_CI_START="-0.6004876371237167" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2009-12-03 16:14:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.706038770313687" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.37718144361687084">
<NAME>Chlordiazepoxide vs Clobazam</NAME>
<DICH_DATA CI_END="2.550748330704528" CI_START="0.25090676030089926" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.40666761110760385" LOG_CI_START="-0.6004876371237167" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2009-12-03 16:14:23 +0100" MODIFIED_BY="[Empty name]" ORDER="384" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Mukherjee-1983" TOTAL_1="20" TOTAL_2="20" VAR="0.35000000000000003" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="63.149196457537265" CI_START="0.1425196281959308" DF="0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.09.02" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.4771212547196624" MODIFIED="2009-12-03 16:14:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4797519380309755" STUDIES="2" TAU2="0.0" TOTAL_1="16" TOTAL_2="18" WEIGHT="100.0" Z="0.706701603364751">
<NAME>Chlordiazepoxide vs. Diazepam</NAME>
<DICH_DATA CI_END="63.149196457537265" CI_START="0.1425196281959308" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="340" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Brown-1972" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="341" O_E="0.0" SE="0.0" STUDY_ID="STD-Jauhar-2000" TOTAL_1="9" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.567504680592264" CI_START="0.049626987975438436" DF="0" EFFECT_SIZE="0.5256410256410257" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.09.03" LOG_CI_END="0.7456605908169043" LOG_CI_START="-1.3042820827583939" LOG_EFFECT_SIZE="-0.27931074597074484" MODIFIED="2009-12-03 16:14:36 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5932711292278757" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="41" WEIGHT="100.0" Z="0.5341017674829799">
<NAME>Chlordiazepoxide vs. Halazepam</NAME>
<DICH_DATA CI_END="5.567504680592264" CI_START="0.049626987975438436" EFFECT_SIZE="0.5256410256410257" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7456605908169043" LOG_CI_START="-1.3042820827583939" LOG_EFFECT_SIZE="-0.27931074597074484" ORDER="342" O_E="0.0" SE="1.2041464738380192" STUDY_ID="STD-Mendels-1985" TOTAL_1="39" TOTAL_2="41" VAR="1.4499687304565354" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9451045880315967" CI_END="18.6213962165845" CI_START="0.3529424468379807" DF="1" EFFECT_SIZE="2.5636460645379366" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-003.09.04" LOG_CI_END="1.2700122409001626" LOG_CI_START="-0.45229610780905605" LOG_EFFECT_SIZE="0.4088580665455533" MODIFIED="2009-12-03 16:14:31 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3309686906146033" P_Z="0.35208635869418103" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="49" WEIGHT="100.0" Z="0.9305500792799776">
<NAME>Lorazepam vs. Diazepam</NAME>
<DICH_DATA CI_END="134.06598991475204" CI_START="0.39206438585522474" EFFECT_SIZE="7.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1273186192708176" LOG_CI_START="-0.4066426061288299" LOG_EFFECT_SIZE="0.8603380065709937" ORDER="338" O_E="0.0" SE="1.4884613671101143" STUDY_ID="STD-Miller-1984" TOTAL_1="27" TOTAL_2="28" VAR="2.2155172413793105" WEIGHT="46.19786266847436"/>
<DICH_DATA CI_END="15.67561456624075" CI_START="0.0703321707318807" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1952245764561868" LOG_CI_START="-1.1528459783163107" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="339" O_E="0.0" SE="1.3792682670100667" STUDY_ID="STD-O_x0027_Brien-1983" TOTAL_1="20" TOTAL_2="21" VAR="1.9023809523809523" WEIGHT="53.80213733152564"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.357023897403046" CI_START="0.1872920131201609" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-003.09.05" LOG_CI_END="1.3295407336099565" LOG_CI_START="-0.7274807422819939" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2010-01-01 11:28:19 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.5662028528062903" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.5736526882995394">
<NAME>Lorazepam vs chlordiazepoxide</NAME>
<DICH_DATA CI_END="21.357023897403046" CI_START="0.1872920131201609" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3295407336099565" LOG_CI_START="-0.7274807422819939" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2009-12-29 14:46:59 +0100" MODIFIED_BY="[Empty name]" ORDER="282" O_E="0.0" SE="1.2083045973594573" STUDY_ID="STD-Kumar-2009" TOTAL_1="50" TOTAL_2="50" VAR="1.46" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.248513186035065" CI_END="4.110557387812737" CI_START="0.11145715422328298" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.67686854611298" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="19.904730587930317" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="0.6139007158026736" LOG_CI_START="-0.9528920497501456" LOG_EFFECT_SIZE="-0.16949566697373608" METHOD="MH" MODIFIED="2009-12-03 16:51:49 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.2638367283191996" P_Q="0.0" P_Z="0.6715236094943352" Q="0.0" RANDOM="YES" SCALE="100000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4817988484160204" TOTALS="SUB" TOTAL_1="165" TOTAL_2="167" WEIGHT="200.0" Z="0.42405787173379517">
<NAME>Severe, life-treating adverse events</NAME>
<GROUP_LABEL_1>Benzodiazepine 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benzodiazepine 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="71.92321045517915" CI_START="0.12513345751728625" DF="0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.10.01" LOG_CI_END="1.8568690648743624" LOG_CI_START="-0.9026265554350377" LOG_EFFECT_SIZE="0.4771212547196624" MODIFIED="2009-12-03 16:24:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.497922686342418" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.6777618841839291">
<NAME>Chlordiazepoxide vs Alprazolam .</NAME>
<DICH_DATA CI_END="71.92321045517915" CI_START="0.12513345751728625" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8568690648743624" LOG_CI_START="-0.9026265554350377" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2009-12-03 16:15:31 +0100" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="1.6209413870933633" STUDY_ID="STD-Wilson-1985" TOTAL_1="50" TOTAL_2="50" VAR="2.627450980392157" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-12-03 16:24:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Chlordiazepoxide vs Clobazam</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 15:37:39 +0100" MODIFIED_BY="[Empty name]" ORDER="385" O_E="0.0" SE="0.0" STUDY_ID="STD-Mukherjee-1983" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.10.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-12-03 16:24:10 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Chlordiazepoxide vs. Diazepam</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="343" O_E="0.0" SE="0.0" STUDY_ID="STD-Jauhar-2000" TOTAL_1="9" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.10.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-12-03 16:24:13 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Chlordiazepoxide vs. Halazepam</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="344" O_E="0.0" SE="0.0" STUDY_ID="STD-Mendels-1985" TOTAL_1="39" TOTAL_2="41" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9822977569213727" CI_START="0.037256880488624015" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-003.10.05" LOG_CI_END="0.4745510018709087" LOG_CI_START="-1.4287935113102337" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2009-12-03 16:24:16 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.32579022497989607" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.9826287033514063">
<NAME>Diazepam vs Abecamil</NAME>
<DICH_DATA CI_END="2.9822977569213727" CI_START="0.037256880488624015" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4745510018709087" LOG_CI_START="-1.4287935113102337" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2009-12-03 15:38:17 +0100" MODIFIED_BY="[Empty name]" ORDER="386" O_E="0.0" SE="1.1180339887498947" STUDY_ID="STD-Anton-1997" TOTAL_1="24" TOTAL_2="24" VAR="1.2499999999999998" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.10.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-12-03 16:25:40 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Diazepam vs Alprazolam</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 16:24:50 +0100" MODIFIED_BY="[Empty name]" ORDER="345" O_E="0.0" SE="0.0" STUDY_ID="STD-Kolin-1981" TOTAL_1="23" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.2089345292728755" CI_END="1.8196530625291887" CI_START="0.7041421235923448" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1319427422138528" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="0.2599885927147528" LOG_CI_START="-0.1523396742920219" LOG_EFFECT_SIZE="0.053824459211365465" METHOD="MH" MODIFIED="2009-12-29 14:50:09 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.5142673631754391" P_Q="0.0" P_Z="0.6088616181824117" Q="0.0" RANDOM="YES" SCALE="100000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="279" TOTAL_2="282" WEIGHT="600.0" Z="0.5116990998819304">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Benzodiazepine 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benzodiazepine 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.034429616768603" CI_START="0.012870055470422949" DF="0" EFFECT_SIZE="0.2545454545454545" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-003.11.01" LOG_CI_END="0.7019502736340228" LOG_CI_START="-1.8904195812660345" LOG_EFFECT_SIZE="-0.5942346538160059" MODIFIED="2009-12-03 15:43:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.368895883828693" STUDIES="2" TAU2="0.0" TOTAL_1="27" TOTAL_2="33" WEIGHT="100.0" Z="0.8985434834026799">
<NAME>Alprazolam vs. Diazepam</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="323" O_E="0.0" SE="0.0" STUDY_ID="STD-Adinoff-1994" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.034429616768603" CI_START="0.012870055470422949" EFFECT_SIZE="0.2545454545454545" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.7019502736340228" LOG_CI_START="-1.8904195812660345" LOG_EFFECT_SIZE="-0.5942346538160059" ORDER="324" O_E="0.0" SE="1.5227708852060342" STUDY_ID="STD-Kolin-1981" TOTAL_1="21" TOTAL_2="27" VAR="2.318831168831169" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="96.8511049722614" CI_START="0.37170458726630495" DF="0" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-003.11.02" LOG_CI_END="1.986104579940192" LOG_CI_START="-0.42980207917290464" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2009-12-03 15:44:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.20673699597662687" STUDIES="2" TAU2="0.0" TOTAL_1="23" TOTAL_2="18" WEIGHT="100.0" Z="1.2625888666051766">
<NAME>Chlordiazepoxide vs. Diazepam</NAME>
<DICH_DATA CI_END="96.8511049722614" CI_START="0.37170458726630495" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.986104579940192" LOG_CI_START="-0.42980207917290464" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="321" O_E="0.0" SE="1.4191155304938667" STUDY_ID="STD-Brown-1972" TOTAL_1="11" TOTAL_2="7" VAR="2.013888888888889" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 15:44:10 +0100" MODIFIED_BY="[Empty name]" ORDER="387" O_E="0.0" SE="0.0" STUDY_ID="STD-Day-2004" TOTAL_1="12" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.512052866172402" CI_START="0.79504394123948" DF="0" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" ID="CMP-003.11.03" LOG_CI_END="0.9782742553430943" LOG_CI_START="-0.09960886768256909" LOG_EFFECT_SIZE="0.43933269383026263" MODIFIED="2009-12-03 15:44:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.11010590656694198" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="44" WEIGHT="100.0" Z="1.5977173011507961">
<NAME>Chlordiazepoxide vs. Halazepam</NAME>
<DICH_DATA CI_END="9.512052866172402" CI_START="0.79504394123948" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9782742553430943" LOG_CI_START="-0.09960886768256909" LOG_EFFECT_SIZE="0.43933269383026263" ORDER="322" O_E="0.0" SE="0.6331538820727852" STUDY_ID="STD-Mendels-1985" TOTAL_1="48" TOTAL_2="44" VAR="0.4008838383838384" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.014705452950342" CI_START="0.3238026000028923" DF="0" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" ID="CMP-003.11.04" LOG_CI_END="0.304211561887181" LOG_CI_START="-0.4897196683609784" LOG_EFFECT_SIZE="-0.09275405323689868" MODIFIED="2009-12-03 16:17:45 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6469807631002576" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="0.45796058106344717">
<NAME>Chlordiazepoxide vs Clobazam</NAME>
<DICH_DATA CI_END="2.014705452950342" CI_START="0.3238026000028923" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.304211561887181" LOG_CI_START="-0.4897196683609784" LOG_EFFECT_SIZE="-0.09275405323689868" MODIFIED="2009-12-03 16:17:45 +0100" MODIFIED_BY="[Empty name]" ORDER="388" O_E="0.0" SE="0.4663591346707412" STUDY_ID="STD-Mukherjee-1983" TOTAL_1="26" TOTAL_2="28" VAR="0.2174908424908425" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3960958408411845" CI_END="2.3678871134905966" CI_START="0.23654285851997514" DF="1" EFFECT_SIZE="0.7484028236703002" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" I2="28.371679741021673" ID="CMP-003.11.05" LOG_CI_END="0.3743609940151019" LOG_CI_START="-0.6260901592289683" LOG_EFFECT_SIZE="-0.1258645826069332" MODIFIED="2009-12-29 14:50:09 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2373785612934456" P_Z="0.6219012304487004" STUDIES="2" TAU2="0.1995078435615661" TOTAL_1="77" TOTAL_2="81" WEIGHT="100.0" Z="0.4931576080228139">
<NAME>Chlordiazepoxide vs Lorazepam .</NAME>
<DICH_DATA CI_END="4.384751004320472" CI_START="0.35634862697115655" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6419449362379852" LOG_CI_START="-0.44812491022187245" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-12-29 14:50:09 +0100" MODIFIED_BY="[Empty name]" ORDER="283" O_E="0.0" SE="0.6403124237432849" STUDY_ID="STD-Kumar-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.41" WEIGHT="56.6614499248168"/>
<DICH_DATA CI_END="1.7408797803717206" CI_START="0.08413652459323656" EFFECT_SIZE="0.38271604938271603" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.24076878115530365" LOG_CI_START="-1.0750154312440579" LOG_EFFECT_SIZE="-0.4171233250443771" MODIFIED="2009-12-04 12:36:49 +0100" MODIFIED_BY="[Empty name]" ORDER="320" O_E="0.0" SE="0.7728981596002804" STUDY_ID="STD-Solomon-1983" TOTAL_1="27" TOTAL_2="31" VAR="0.5973715651135005" WEIGHT="43.3385500751832"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.34783134431186946" CI_END="2.6451943837479073" CI_START="0.5431414415589417" DF="2" EFFECT_SIZE="1.1986303395094147" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" ID="CMP-003.11.06" LOG_CI_END="0.4224575919429216" LOG_CI_START="-0.2650870593805689" LOG_EFFECT_SIZE="0.0786852662811763" MODIFIED="2009-12-04 12:36:29 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8403677941897678" P_Z="0.6537117922815903" STUDIES="3" TAU2="0.0" TOTAL_1="78" TOTAL_2="78" WEIGHT="100.0" Z="0.4486117017365573">
<NAME>Lorazepam vs. Diazepam</NAME>
<DICH_DATA CI_END="3.7683928678751806" CI_START="0.28276157744651553" EFFECT_SIZE="1.032258064516129" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.576156173169704" LOG_CI_START="-0.5485796041984375" LOG_EFFECT_SIZE="0.013788284485633283" ORDER="317" O_E="0.0" SE="0.6606753631579363" STUDY_ID="STD-Miller-1984" TOTAL_1="31" TOTAL_2="32" VAR="0.436491935483871" WEIGHT="37.368080992509874"/>
<DICH_DATA CI_END="3.4463915302281247" CI_START="0.4178283248928142" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5373646143071551" LOG_CI_START="-0.37900212221190543" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="318" O_E="0.0" SE="0.538278357119799" STUDY_ID="STD-O_x0027_Brien-1983" TOTAL_1="26" TOTAL_2="26" VAR="0.2897435897435898" WEIGHT="56.29413928423086"/>
<DICH_DATA CI_END="66.4433184667098" CI_START="0.12341968180365896" EFFECT_SIZE="2.8636363636363638" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8224513148659036" LOG_CI_START="-0.9086155776031525" LOG_EFFECT_SIZE="0.4569178686313755" ORDER="319" O_E="0.0" SE="1.6042422116354729" STUDY_ID="STD-Ritson-1986" TOTAL_1="21" TOTAL_2="20" VAR="2.5735930735930737" WEIGHT="6.337779723259271"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0890972765236406" CI_END="2.406716034309463" CI_START="0.3188871073914825" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8760540591160141" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="0.3814248513852766" LOG_CI_START="-0.4963630389317745" LOG_EFFECT_SIZE="-0.05746909377324896" METHOD="MH" MODIFIED="2009-12-03 16:51:49 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.6862518050043391" P_Q="0.0" P_Z="0.7974573762649644" Q="0.0" RANDOM="YES" SCALE="100000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="267" TOTAL_2="268" WEIGHT="500.0" Z="0.2566391158097185">
<NAME>Dropouts due to adverse events</NAME>
<GROUP_LABEL_1>Benzodiazepine 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepine 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benzodiazepine 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.718788952018382" CI_START="0.21191878046850707" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-003.12.01" LOG_CI_END="0.6738305539431859" LOG_CI_START="-0.6738305539431859" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 16:20:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="2" TAU2="0.0" TOTAL_1="71" TOTAL_2="72" WEIGHT="100.0" Z="0.0">
<NAME>Chlordiazepoxide vs Alprazolam .</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 16:20:45 +0100" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="0.0" STUDY_ID="STD-McLendon-1980" TOTAL_1="21" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.718788952018382" CI_START="0.21191878046850707" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6738305539431859" LOG_CI_START="-0.6738305539431859" LOG_EFFECT_SIZE="0.0" ORDER="348" O_E="0.0" SE="0.7916228058025278" STUDY_ID="STD-Wilson-1985" TOTAL_1="50" TOTAL_2="50" VAR="0.6266666666666666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.12.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-12-03 16:22:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Chlordiazepoxide vs Clobazam</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-03 15:57:36 +0100" MODIFIED_BY="[Empty name]" ORDER="389" O_E="0.0" SE="0.0" STUDY_ID="STD-Mukherjee-1983" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="63.149196457537265" CI_START="0.1425196281959308" DF="0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.12.03" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.4771212547196624" MODIFIED="2009-12-03 16:22:09 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4797519380309755" STUDIES="2" TAU2="0.0" TOTAL_1="16" TOTAL_2="18" WEIGHT="100.0" Z="0.706701603364751">
<NAME>Chlordiazepoxide vs. Diazepam</NAME>
<DICH_DATA CI_END="63.149196457537265" CI_START="0.1425196281959308" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="351" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Brown-1972" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="352" O_E="0.0" SE="0.0" STUDY_ID="STD-Jauhar-2000" TOTAL_1="9" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.12.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-12-03 16:22:12 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Chlordiazepoxide vs. Halazepam</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="354" O_E="0.0" SE="0.0" STUDY_ID="STD-Mendels-1985" TOTAL_1="39" TOTAL_2="41" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.12.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-12-03 16:22:16 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Chlordiazepoxide vs Lorazepam .</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="353" O_E="0.0" SE="0.0" STUDY_ID="STD-Solomon-1983" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6246806717009323" CI_START="0.007775484265703283" DF="0" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.12.06" LOG_CI_END="0.4190764730927677" LOG_CI_START="-2.1092725531212815" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2009-12-03 16:22:23 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.19011741126161746" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="1.3102318585449177">
<NAME>Diazepam vs Abecamil</NAME>
<DICH_DATA CI_END="2.6246806717009323" CI_START="0.007775484265703283" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4190764730927677" LOG_CI_START="-2.1092725531212815" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2009-12-03 15:59:51 +0100" MODIFIED_BY="[Empty name]" ORDER="390" O_E="0.0" SE="1.48516473352766" STUDY_ID="STD-Anton-1997" TOTAL_1="24" TOTAL_2="24" VAR="2.2057142857142855" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="64.03897577638367" CI_START="0.11809214479643353" DF="0" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.12.07" LOG_CI_END="1.8064443773037593" LOG_CI_START="-0.9277789896432341" LOG_EFFECT_SIZE="0.43933269383026263" MODIFIED="2009-12-03 16:23:02 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.5287922713453946" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="21" WEIGHT="100.0" Z="0.6298507046260426">
<NAME>Diazepam vs Alprazolam .</NAME>
<DICH_DATA CI_END="64.03897577638367" CI_START="0.11809214479643353" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8064443773037593" LOG_CI_START="-0.9277789896432341" LOG_EFFECT_SIZE="0.43933269383026263" MODIFIED="2009-12-03 16:23:02 +0100" MODIFIED_BY="[Empty name]" ORDER="355" O_E="0.0" SE="1.606096340368614" STUDY_ID="STD-Kolin-1981" TOTAL_1="23" TOTAL_2="21" VAR="2.5795454545454546" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.263533275245723" CI_END="4.6933529112758965" CI_START="0.07720746635093617" DF="1" EFFECT_SIZE="0.6019650213844673" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.12.08" LOG_CI_END="0.6714832117145606" LOG_CI_START="-1.112340699169201" LOG_EFFECT_SIZE="-0.22042874372732027" MODIFIED="2009-12-03 16:23:44 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6077031172568889" P_Z="0.6281097786061725" STUDIES="2" TAU2="0.0" TOTAL_1="49" TOTAL_2="47" WEIGHT="100.0" Z="0.48438906578947566">
<NAME>Diazepam vs Lorazepam .</NAME>
<DICH_DATA CI_END="7.572301178989834" CI_START="0.013678852869532623" EFFECT_SIZE="0.3218390804597701" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8792278791655181" LOG_CI_START="-1.8639503217183169" LOG_EFFECT_SIZE="-0.4923612212763993" MODIFIED="2009-12-03 16:23:37 +0100" MODIFIED_BY="[Empty name]" ORDER="349" O_E="0.0" SE="1.6113564541502576" STUDY_ID="STD-Miller-1984" TOTAL_1="28" TOTAL_2="27" VAR="2.5964696223316914" WEIGHT="42.28593327980144"/>
<DICH_DATA CI_END="14.218244504526753" CI_START="0.06379335213776025" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1528459783163107" LOG_CI_START="-1.1952245764561868" LOG_EFFECT_SIZE="-0.021189299069938095" MODIFIED="2009-12-03 16:23:44 +0100" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="1.3792682670100667" STUDY_ID="STD-O_x0027_Brien-1983" TOTAL_1="21" TOTAL_2="20" VAR="1.9023809523809523" WEIGHT="57.71406672019855"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-12-03 16:31:28 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Benzodiazepine alone vs benzodiazepine + other drugs</NAME>
<DICH_OUTCOME CHI2="7.585557895198283E-32" CI_END="1.8952522393957274" CI_START="0.3903215578406588" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8600917431192661" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" I2="100.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.2776670184664137" LOG_CI_START="-0.40857746154814806" LOG_EFFECT_SIZE="-0.06545522154086718" METHOD="MH" MODIFIED="2009-12-03 16:29:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.7084863688323904" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="130" TOTAL_2="77" WEIGHT="99.99999999999999" Z="0.3738897158559812">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Benzodiazepine alone</GROUP_LABEL_1>
<GROUP_LABEL_2>benzodiazepine + other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.585557895198283E-32" CI_END="1.8952522393957274" CI_START="0.3903215578406588" DF="0" EFFECT_SIZE="0.8600917431192661" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" I2="100.0" ID="CMP-004.01.01" LOG_CI_END="0.2776670184664137" LOG_CI_START="-0.40857746154814806" LOG_EFFECT_SIZE="-0.06545522154086718" NO="1" P_CHI2="0.0" P_Z="0.7084863688323904" STUDIES="3" TAU2="0.0" TOTAL_1="130" TOTAL_2="77" WEIGHT="99.99999999999999" Z="0.3738897158559812">
<NAME>Benzodiazepine+Other Drug vs. Other Drug</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="357" O_E="0.0" SE="0.0" STUDY_ID="STD-Dion-1968" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="358" O_E="0.0" SE="0.0" STUDY_ID="STD-Sellers-1977" TOTAL_1="6" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.8952522393957274" CI_START="0.3903215578406588" EFFECT_SIZE="0.8600917431192661" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.2776670184664137" LOG_CI_START="-0.40857746154814806" LOG_EFFECT_SIZE="-0.06545522154086718" ORDER="359" O_E="0.0" SE="0.4031034045255152" STUDY_ID="STD-Spies-1996" TOTAL_1="109" TOTAL_2="50" VAR="0.16249235474006116" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="29.906442568016658" CI_START="0.5059371856163575" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.889830508474576" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="1.4757647558943972" LOG_CI_START="-0.29590339943212546" LOG_EFFECT_SIZE="0.5899306782311358" METHOD="MH" MODIFIED="2009-12-03 16:30:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.19180467755040295" Q="0.0" RANDOM="YES" SCALE="10000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="118" TOTAL_2="51" WEIGHT="100.0" Z="1.3052589777967931">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="29.906442568016658" CI_START="0.5059371856163575" DF="0" EFFECT_SIZE="3.889830508474576" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="1.4757647558943972" LOG_CI_START="-0.29590339943212546" LOG_EFFECT_SIZE="0.5899306782311358" NO="1" P_CHI2="1.0" P_Z="0.19180467755040295" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="51" WEIGHT="100.0" Z="1.3052589777967931">
<NAME>Benzodiazepine+Other Drug vs. Other Drug</NAME>
<DICH_DATA CI_END="29.906442568016658" CI_START="0.5059371856163575" EFFECT_SIZE="3.889830508474576" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.4757647558943972" LOG_CI_START="-0.29590339943212546" LOG_EFFECT_SIZE="0.5899306782311358" ORDER="356" O_E="0.0" SE="1.0406866443376075" STUDY_ID="STD-Spies-1996" TOTAL_1="118" TOTAL_2="51" VAR="1.08302869170267" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="19.122892262932254" CI_START="0.27508913848314326" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.293577981651376" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="1.2815535782558372" LOG_CI_START="-0.5605265567930093" LOG_EFFECT_SIZE="0.36051351073141397" METHOD="MH" MODIFIED="2009-12-03 16:31:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.4429809774090492" Q="0.0" RANDOM="YES" SCALE="10000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="109" TOTAL_2="50" WEIGHT="100.0" Z="0.7671691187907295">
<NAME>Dropouts due to adverse events</NAME>
<GROUP_LABEL_1>Benzodiazepine alone</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine + other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.122892262932254" CI_START="0.27508913848314326" DF="0" EFFECT_SIZE="2.293577981651376" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="1.2815535782558372" LOG_CI_START="-0.5605265567930093" LOG_EFFECT_SIZE="0.36051351073141397" NO="1" P_CHI2="1.0" P_Z="0.4429809774090492" STUDIES="1" TAU2="0.0" TOTAL_1="109" TOTAL_2="50" WEIGHT="100.0" Z="0.7671691187907295">
<NAME>Benzodiazepine+Other Drug vs. Other Drug</NAME>
<DICH_DATA CI_END="19.122892262932254" CI_START="0.27508913848314326" EFFECT_SIZE="2.293577981651376" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.2815535782558372" LOG_CI_START="-0.5605265567930093" LOG_EFFECT_SIZE="0.36051351073141397" ORDER="360" O_E="0.0" SE="1.0820469897714213" STUDY_ID="STD-Spies-1996" TOTAL_1="109" TOTAL_2="50" VAR="1.1708256880733945" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2009-12-04 13:49:58 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Benzodiazepine (fixed schedule) versus Benzodiazepine (symptom-triggered)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.371642969023155" CI_START="0.012739709647581223" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.30645161290322587" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.8675642928603865" LOG_CI_START="-1.8948404699512362" LOG_EFFECT_SIZE="-0.5136380885454248" METHOD="MH" MODIFIED="2009-12-03 16:37:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.46608333002728086" Q="0.0" RANDOM="YES" SCALE="1.0E7" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="61" TOTAL_2="56" WEIGHT="100.0" Z="0.7288665065957817">
<NAME>Alcohol withdrawal seizures</NAME>
<GROUP_LABEL_1>Benzodiazepine fixed</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine triggered</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fixed</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours triggered</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.371642969023155" CI_START="0.012739709647581223" DF="0" EFFECT_SIZE="0.30645161290322587" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.8675642928603865" LOG_CI_START="-1.8948404699512362" LOG_EFFECT_SIZE="-0.5136380885454248" NO="1" P_CHI2="1.0" P_Z="0.46608333002728086" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="56" WEIGHT="100.0" Z="0.7288665065957817">
<NAME>Oxazepam (fixed schedule) vs. Oxazepam (symptom-triggered)</NAME>
<DICH_DATA CI_END="7.371642969023155" CI_START="0.012739709647581223" EFFECT_SIZE="0.3064516129032258" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8675642928603865" LOG_CI_START="-1.8948404699512362" LOG_EFFECT_SIZE="-0.5136380885454249" ORDER="366" O_E="0.0" SE="1.6226502317996565" STUDY_ID="STD-Daeppen-2002" TOTAL_1="61" TOTAL_2="56" VAR="2.632993774759479" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="28.43777065708306" CI_START="0.3292663167204981" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0599999999999996" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="1.453895547427765" LOG_CI_START="-0.482452694464605" LOG_EFFECT_SIZE="0.48572142648157995" METHOD="MH" MODIFIED="2009-12-03 16:37:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.32546445297385973" Q="0.0" RANDOM="YES" SCALE="1000000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="111" TOTAL_2="107" WEIGHT="100.00000000000001" Z="0.9832905898093431">
<NAME>Alcohol withdrawal delirium</NAME>
<GROUP_LABEL_1>Benzodiazepine fixed</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine triggered</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fixed</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours triggered</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="56" WEIGHT="0.0" Z="0.0">
<NAME>Oxazepam (fixed schedule) vs. Oxazepam (symptom-triggered)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="367" O_E="0.0" SE="0.0" STUDY_ID="STD-Daeppen-2002" TOTAL_1="61" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="28.43777065708306" CI_START="0.3292663167204981" DF="0" EFFECT_SIZE="3.0599999999999996" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="1.453895547427765" LOG_CI_START="-0.482452694464605" LOG_EFFECT_SIZE="0.48572142648157995" NO="2" P_CHI2="1.0" P_Z="0.32546445297385973" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="51" WEIGHT="100.00000000000001" Z="0.9832905898093431">
<NAME>Chlordiazepoxide (fixed schedule) vs. Chlordiazepoxide (symptom-triggered)</NAME>
<DICH_DATA CI_END="28.43777065708306" CI_START="0.3292663167204981" EFFECT_SIZE="3.06" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.453895547427765" LOG_CI_START="-0.482452694464605" LOG_EFFECT_SIZE="0.48572142648158" ORDER="368" O_E="0.0" SE="1.1374205423659616" STUDY_ID="STD-Saitz-1994" TOTAL_1="50" TOTAL_2="51" VAR="1.2937254901960784" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.37999951334680304" CI_START="-11.020000486653197" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.7" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2009-12-03 16:36:52 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.03573225264101974" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="21" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="2.0999612199108024">
<NAME>CIWA-Ar score (48 hrs)</NAME>
<GROUP_LABEL_1>Benzodiazepine fixed</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine triggered</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours triggered</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fixed</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.37999951334680304" CI_START="-11.020000486653197" DF="0" EFFECT_SIZE="-5.7" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.01" NO="1" P_CHI2="1.0" P_Z="0.03573225264101974" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="2.0999612199108024">
<NAME>Flunitrazepam (fixed schedule) vs. Flunitrazepam (symptom-triggered)</NAME>
<CONT_DATA CI_END="-0.37999951334680393" CI_START="-11.020000486653196" EFFECT_SIZE="-5.7" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="11.5" ORDER="361" SD_1="8.8" SD_2="9.2" SE="2.7143358391361683" STUDY_ID="STD-Spies-2003" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0114820237155837" CI_END="1.3265638545935399" CI_START="-2.349501986714679" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5114690660605696" ESTIMABLE="YES" I2="1.1351683417373628" I2_Q="1.1351683417373628" ID="CMP-005.04" MODIFIED="2009-12-03 16:38:54 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.31454832848005476" P_Q="0.31454832848005476" P_Z="0.5854792682099446" Q="1.0114820237155837" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.025030461935308845" TOTALS="SUB" TOTAL_1="82" TOTAL_2="79" UNITS="" WEIGHT="200.0" Z="0.5453987996734595">
<NAME>CIWA-Ar score (end of treatment)</NAME>
<GROUP_LABEL_1>Benzodiazepine fixed</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine triggered</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours triggered</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fixed</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0665229875874531" CI_START="-3.2665229875874533" DF="0" EFFECT_SIZE="-1.1" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.01" NO="1" P_CHI2="1.0" P_Z="0.3196756669087425" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="56" WEIGHT="100.0" Z="0.9951246284235575">
<NAME>Oxazepam (fixed schedule) vs. Oxazepam (symptom-triggered)</NAME>
<CONT_DATA CI_END="1.0665229875874531" CI_START="-3.2665229875874533" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="3.9" ORDER="362" SD_1="4.6" SD_2="7.0" SE="1.1053891830037235" STUDY_ID="STD-Daeppen-2002" TOTAL_1="61" TOTAL_2="56" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.471988560744599" CI_START="-2.4719885607445993" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.02" NO="2" P_CHI2="1.0" P_Z="0.5724087212637414" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="0.5645076158084238">
<NAME>Flunitrazepam (fixed schedule) vs. Flunitrazepam (symptom-triggered)</NAME>
<CONT_DATA CI_END="4.471988560744599" CI_START="-2.4719885607445993" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="19.8" MEAN_2="18.8" ORDER="363" SD_1="4.6" SD_2="7.0" SE="1.7714552859803556" STUDY_ID="STD-Spies-2003" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="22.433187871377637" CI_START="0.21388783299787095" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1904761904761907" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="1.3508909934480218" LOG_CI_START="-0.6698139195527121" LOG_EFFECT_SIZE="0.34053853694765485" METHOD="MH" MODIFIED="2009-12-04 13:49:58 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.5088660574238513" Q="0.0" RANDOM="YES" SCALE="10000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0" Z="0.6606043895585102">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Benzodiazepine fixed</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine triggered</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fixed</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours triggered</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="56" WEIGHT="0.0" Z="0.0">
<NAME>Oxazepam (fixed schedule) vs. Oxazepam (symptom-triggered)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="371" O_E="0.0" SE="0.0" STUDY_ID="STD-Daeppen-2002" TOTAL_1="61" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>Chlordiazepoxide (fixed schedule) vs. Chlordiazepoxide (symptom-triggered)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="372" O_E="0.0" SE="0.0" STUDY_ID="STD-Saitz-1994" TOTAL_1="50" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.433187871377637" CI_START="0.21388783299787095" DF="0" EFFECT_SIZE="2.1904761904761907" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-005.05.03" LOG_CI_END="1.3508909934480218" LOG_CI_START="-0.6698139195527121" LOG_EFFECT_SIZE="0.34053853694765485" NO="3" P_CHI2="1.0" P_Z="0.5088660574238513" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="0.6606043895585102">
<NAME>Flunitrazepam (fixed schedule) vs. Flunitrazepam (symptom-triggered)</NAME>
<DICH_DATA CI_END="22.433187871377637" CI_START="0.21388783299787095" EFFECT_SIZE="2.1904761904761907" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3508909934480218" LOG_CI_START="-0.6698139195527121" LOG_EFFECT_SIZE="0.34053853694765485" ORDER="373" O_E="0.0" SE="1.1869720685472709" STUDY_ID="STD-Spies-2003" TOTAL_1="21" TOTAL_2="23" VAR="1.4089026915113871" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.23554523896286528" CI_END="7.703282733609225" CI_START="0.500802894605331" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.964134998149253" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.8866758380654003" LOG_CI_START="-0.3003331695989655" LOG_EFFECT_SIZE="0.29317133423321734" METHOD="MH" MODIFIED="2009-12-04 13:49:58 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.627442280680212" P_Q="0.0" P_Z="0.3329662171711334" Q="0.0" RANDOM="YES" SCALE="100000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="77" TOTAL_2="77" WEIGHT="200.0" Z="0.9681565222951265">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Benzodiazepine fixed</GROUP_LABEL_1>
<GROUP_LABEL_2>Benzodiazepine triggered</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fixed</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours trigggered</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.616508052823855" CI_START="0.2611266636329106" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="0.9353312982324606" LOG_CI_START="-0.5831487801210982" LOG_EFFECT_SIZE="0.17609125905568124" NO="1" P_CHI2="1.0" P_Z="0.649414091705931" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.00000000000001" Z="0.4545762972612252">
<NAME>Chlordiazepoxide (fixed schedule) vs. Chlordiazepoxide (symptom-triggered)</NAME>
<DICH_DATA CI_END="8.616508052823855" CI_START="0.2611266636329106" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9353312982324606" LOG_CI_START="-0.5831487801210982" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="369" O_E="0.0" SE="0.8919627146224944" STUDY_ID="STD-Saitz-1994" TOTAL_1="53" TOTAL_2="53" VAR="0.7955974842767295" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="26.840679812292354" CI_START="0.3353119243976162" DF="0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-005.06.02" LOG_CI_END="1.4287935113102335" LOG_CI_START="-0.4745510018709088" LOG_EFFECT_SIZE="0.4771212547196624" NO="2" P_CHI2="1.0" P_Z="0.32579022497989607" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.9826287033514061">
<NAME>Flunitrazepam (fixed schedule) vs. Flunitrazepam (symptom-triggered)</NAME>
<DICH_DATA CI_END="26.840679812292354" CI_START="0.3353119243976162" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4287935113102335" LOG_CI_START="-0.4745510018709088" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="370" O_E="0.0" SE="1.1180339887498947" STUDY_ID="STD-Spies-2003" TOTAL_1="24" TOTAL_2="24" VAR="1.2499999999999998" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-02-15 12:14:27 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flow chart of studies.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2010-01-07 10:58:28 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow chart of identified studies</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-02-15 12:14:27 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADOCAMAAAAdQhu+AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-02-15 12:14:27 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATIAAAiICAIAAADYbb5SAABtWElEQVR42u3dvW4kxfv+/5FICBw4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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2009-12-30 11:07:57 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Benzodiazepine versus Placebo, outcome: 1.1 Alcohol withdrawal seizures.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA48AAACwCAMAAACYc6vYAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2009-12-30 12:44:17 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Benzodiazepine versus Placebo, outcome: 1.2 Adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA48AAACgCAMAAACbpalDAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2010-01-05 10:03:34 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Benzodiazepine versus Placebo, outcome: 1.3 Dropouts.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA48AAACwCAMAAACYc6vYAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2009-12-30 12:49:08 +0100" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-002.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Benzodiazepine versus Other Drug, outcome: 2.1 Alcohol withdrawal seizures.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8IAAAJACAMAAABxOi/4AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2009-12-30 13:30:17 +0100" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-002.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Benzodiazepine versus Other Drug, outcome: 2.2 Alcohol withdrawal delirium.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA6gAAAHgCAMAAACfC7AyAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAvOUlEQVR42u1dTc8luVV2v/0OZ/jQTEjPJAMkIQgFKSKCBWLPhp0l
FuyQkNiwY8Ge34BgwYING/YtEPKC/4CCBIoUFARSCBHJNK0wISQ5TItw760Pf7tsV7nKdd/n0dt9
695yuVwuPz7HLj91npEAAKB3PKAKAABEBQAARAWAp4HHTsohb/+r5WRKJlPJ5Tzm811TSpU4JDez
xnWii2Fu2fWVvA7g/FX82E2dXapASpWVrnqvRUF5q/muMdSJWq4vmX/pwCmr+LG3ipNTD3fj0tTf
DZU22MD5B2vvfISarG6iZm/7lZRDPzl+l+a59NnEnLFZKrVrlZjndHr1sYCX6ziiaPdjWXuv4of+
amyoi8HRUEr/dqPJ6IQob+94hHZS5t/T3any0is1O9li/mr8lJNxs2rxGtGtKpTuXLr3Ejrmas9V
/NhRRVk9lQoNE5UeU/h7Van/u5ReychPMVepZZ1IpfwhlBLg5ROp4n4sqpoMo1yezpGmd2ofYaYq
rODM9Ko85/o68c8p7X2YQnoaVfzQYc0t2iun5mJHZORUlV4psVsnO3XnKjDoHh12kO0pVHGPz1G1
vXLrSEb4OkwL5dvI270J3AA7vfS3R5OvDqgSZTcr4GlV8UNHFSWHAYHFg+HXaZeuSenuFe4TVpVi
1LTTuCdOen22eVt/7EjVeVY7cM5bgaQ9BQ4Te59V/OxeFuXvUHtSYUgIHIRHVEF+z4unlMBReAaZ
GwD0DyzKBwAQFQAAEBUAQFQAAHqBOes7PicS0tEOxCc6pyOWU+YhpUrNkcA5x8tw0erOkpn3sLzF
fJDjax2tk0ypjVWRxqGxki7dlWnxlJLWI+FZaSQCJYhLfVdLMZNHS9VORHZ87W5PVDnq72RZ9WeJ
SLOxwJPFo81akpueJTfv5ZPJsvooreBJazue2byfeldx/9nusZSsL9gGre342i23qFNznIV3yuiC
DHmmfeOU0CnnpHJ66Kg7GUMpmsV/ncOYm8zXAmoFYfyQ2rMs5D11dDJw8WI6oXM3lztHS3OrNQm2
EDdqFaRp2wP9hpKmfyAMMW9IimncRSuxowO2P4RVTq/OW1L02NptMkYdl0oJV4FpFs/UbHqLaaWl
Gx1Fo6YFKXmpgiU0HZf75WkBh3TDIWrhkNKz5OStdY16S87XX3E75zOZFWyVPFSxskLko7W/t4+w
FFPaF2j/HspB33zpHaAsof4R2K92t7GoKrhQXQ0dbrAavSOUsaPM57TtlVRmF2ENAQvvZphJ25yl
aPG2ktHrv410ZNgxdiSRwQpWkYx1C5M1Xb2KXqFa2lbBOvLLqTJHsavc2z5rd43rO7q9pTRoN0aV
fp0X308Z1H9vcxYpFrwqWVcDMmScZX7LNPuE2+RgycRD2RUuXnw4h8PkKV3Vbv0YtVzg01QSFNIy
FPYLGZSrPksobzUIfSZBT2GbDrstUpV1T2VyWSnive0qM5dyaFW5r7Vutuqo2m0xRpUy1OmlppyN
I6TVUcpEbRVN3joC0U39o13OImW+DTF167LGVA8HyVm0ZU92TA6QTJ1XiNwipFLNKsT845qP+I6q
3e2JqrQk1FFgWknsAYitFFW2blR4UtLF3kvqMbp9srFUWSTSZzWrdJuzLOYdqi27Hj0vRCUvSksi
zR/iysjxGYG1WwbvX/Ly5o+4FNNOnMohVjHNnbK+ancF8tQzReePyzafrJizQslaNfKXEOHda+0+
ZtG0zImHbHN9lYCn4GmFRQUAAACA/vDbXZXmERYVAILoihqQuQHACQCiAsAJ4OpRlbNliQn2DGC6
HMFUZhUIAO7MolpiDyWcOBw6OMwS0ivaVX4E0/F99sm88Np44KlZ1GA0NBmxdFsGMLWVoYbhXYhg
Kqalmn4IUwB4YmNUFbF02wcwDepAExFMQ1Z6jdoDAM5CVP/1Pl4YGJfBMqRI1MFhcgKYziGzZNQx
LrCRMKfAfbu+IZ46DJDSFfnEA5hK4UxEiaAXbeS/rAOFtQRA1AWelpgsN4BpXk7LOlBYSwCur47f
vRDJe/MAppa4TP+0HME09GJAWF3g/l3f0INUe+9tJtaeFlbjb2p+16gygqyr+Qg3gKmTk/19+ma8
Ic89wJT1jOdWUmI2CbhD7Kee2eWpCUKYAlu2pU4t6vkBLSzwBFzfthy6o7MAwM7AonwAAFEBAABR
AQBEBQAARAUAAEQFgHuC+XiGr/8lF0DwsN/72O09UFx6Kibzo/ConFTJq9fFneuKygvjZqKv6vLV
32tmb9TX8POtuNzBe7uYKu4LiDqAMir38s/+2PNtbVzazNn6KDwqLxXlFFdXGVNFp2FlYpSPAns5
XF9s3GPi4xseMfXF0zd9r/55jHXhQz3emtXcLVO99TkTuKAhF1z96nqiFYUff+7wZtnu2bYoWfb9
117yhcBChxPV6upMy7mVO7o75bjMhFBR3rkEmj1UatqRUPrnfm7WYAQ892xTqDXJO17rO9xFMuuR
li0IPemhRurqyRhA3tridXTIon6IWHokebzs6GZ5YwDqhwnnGKNy0ZCtY47WzSQV5U2ZQ2rSlTXa
j7peoexgz051eLM40qUAWa5vhIonM508X832Ba/MlNfP5PBduTAEvywHD9Fejpxp/hhPueM2QHTz
5YePJnnvefVsnXlNFh32p6BisUUdBlKhgQ4Po9jxB/tjp2FNbw5SskTjTiadbByolp/BzCRj79Cl
6r29VyBc3wUgPuqJkfAVmSoPBCb0NeuLJYSnZuo9OcBAoesLnAVUtQs+5hkBiwoAICoAACAqAICo
AAD0AkuP6koE/Wdbzgq2WeNIWs3aWJ5arHKj8pXoWelz8jaeQE+pc1bgBGSsIqJA9Ytg3pNITtCj
npuo7uLBRUUDm8lI5EjPV9/fsuSUdR2BNpSRfjlvvXOsnDw9akjGqtcMm2cMFMG6J5GcoEddjTdi
5ycmjxE6zKLwqW2NXTGT1nB4y1Z7q3umjvJusNo4tKCTDFX5KZ7DtNSjrrIEL1PJnhcYDdqcqDdp
G9sOrqH3uHbFZOwNS+Ca1njhkvaWZSnMm2l7woaWFFp9bc/YQ49aU6x5K7ky6Y3YuWN5TJd3VqhS
soNg+8hurGrLsuTlzU7jzNSj8toizL3p5DLbw+VOmNrA8jyJMWqoKfBi07EX8bcdoVIpl3boeUVm
zTj+Sclh5UWg8Lg3N+vdfc2zLcp/7PWEnJB0bfaOkay7eqYJCAp5vrxnB9O/1YIeNQsPEW+Ex3fV
2Q9rMty0pv11oRST23YZrc7P26Vz2z70qHfl+o6KSdMdmXym0DuTLK+lJx+mUuuYlT4nb08OmqdH
9TSm1klie+1XrkzPtqc3SnYr+4QeNQ/Qo54K1QrUVWP9pwnoUYG2HvehQwJgR9cX6BW1CtTqpAAs
KgAAICoAgKgAAICoAABYCMZH5UTYtmCI1N1QrCzVQUE3P0syb1egsGV81Lg61bsl4diqOy/YD0tP
8YiomqgzSSnSXkQ0ROqOt5wrliZRg7Mk82Ynoy3jo0bUqaFbEomtSk/4+cybkz7p8ApN080el7tE
xacnmORvGRQ0mbdXWVuX4JzWaGpNHHQCiruwSM+ZxvOTPkZ+XOjH4+LTEzSWlkFBk3nToiO4cgBA
K/uXw5iq/3wnYGXN5B395qS93GP51bOu8pOs0CxsBEVXlZs3jytaV8VHNZt7I4uzS89pVwCd2k3o
hKiBRkx6/uQc772peWlK7lUVEHoa/a+Ij1rfoMf71tnN4v27kMcnQlR0e9uMbY/qrfoiq9Hdo2Wk
8VA4hDpjhfLxeXMnddAkVGzOUMJpV+xsgadFFtV4Jhgbpx0XG7V49Fh9VEn6A+KjFqhT07FVj7pt
cwXoIhOYugDoUU/tRtfsElhskAXoUYGDnXqYr5O7vsC5gPioTwewqAAAogIAAKICAIgKAEAvSMRH
DczhHy9JzX2wEIkSmn3YctBTU+AZLycfq0e1XqA+B7GFHvXcRHXqj0JNRhwrSS17iXxxEXP0q26m
nMqIvYN21aNa0W6nC8PyAhNvgizon6hs6gNHAWE/ktTchbJ2OirMnlc/2wiWc3VlUXGiUDkOtGRt
9ah1Hfzz6O6XhzTxTKIyWX349N6OXiSptHG6yGFcTu5IRnon7xlLK1APU1EO9Tib6lHrGsSb6O6+
ViY9BnpbJxZqWpIqzrDQpbBLWWg0NR3UrN9dp0fNacsdS/qhR92GqJPzkWaeLUk9xYrqMgUoFeTG
mS9z0MEF1+tRay62z6mbA/Soi5M0ZyAqCR2tPbshP/F+MCnw5NBk54pmuYJu3KPMH3rUbDz45nKp
j9sxHmrrmYSa9E4I8ZTAc2v1Z57ju0tRiugIPWoDy3+xqQve7LGS1NIWsnl81PJMt9KjjtFOy6Ol
Hm1GoUddD+hRz+x2Q4/aENCjAkc59ecZrgBLri9wHkCP+nQAiwoAICoAACAqAICoAAD0gjI9ahB7
ilS5MtBp2fOIrLPkXOnG8VHdqKtBPaqVfVitCj3quYlaV397ilQL801rRtedJedKN46P6kVdDelR
rWuNqFWxvMDASQKmJvSo+u5aoVJnozC1gNiiteMvjhoeRkWnoG26KS5M1JnR2lOPmt0XRQOmvuyq
US/oUa2u2hYTpoveldaKezIh9a2RdusSGl77XnrU7LyiAVNPpEclq5OjRW7qj9ZSrvx+lZqxacw7
fQq2stwmPmqJK2+cC/FR8wZ/J3B98/So4VswLKy2tao9tIx2XcaYcSJ/f7X5FnrUojXspMNFdTgy
5W66kHMRNVOPusGYbff2UDjtS1tx2ctyAzecdjtoHwsLPWoG0nrU8PA+JCHssm+sDQpaoPvkTA91
Q6vONUmPvDHQo7bw0H09qq0mHCbuPE9qH5FqYb6VxeCcB6k5V+pJSdfpUUNXFYuAGomPeox6GHrU
9VjQo+KpdM+AHrUlzqRHxQ3tnKm7Hgb05Pr2PwMBZNwe6FHvDFiUDwAgKgAAICoAgKgAAPQCewmh
EKV6SXYf3bXVpdbpUUtL0YkeVa/FzA2Mai3sJQE96n0SdZbO1HJItNal1ulRuaLz6UKPStFzhYSo
7oJFJuhRN8dh6tXHEOOY2IyPaugI7Q+yCN4iJOi6/NqGYmpdEi7TumYlP9aKHRcfNc/K2AjpUePq
1da17S8htBb4WsbRs5amTwNHZmP+1b93putrPyY+ag2lgiuT3vSgxgsI1CxNDAUvjyncO3GboUjF
i0xEo7U4OXnbgYzL9Kj5bXfyfJ3XJRkfVPn6qEZ8OG181McuTrw0Rg0pRpxm6uhSu0DLwiTzNncO
hqNEj7rGz/duQ38hF2MNCsibTFqaP/G7Q6aoDe7EoLZpoBl5U3ictoM3HZUHd8VW6FGz8ZDu7dhz
4MxPXuwju+ApN+Rpph61pgi8oiRRU3UET6FHbTVG1ZLUcZrOEqEaKsLxMFtraEbp3HiGozC/UEDR
zIZFW+QdEIsW6FHTYtJY2FRLiOplwYdMOUGPuh7PcnSLeDbd29iuVojao//bKxAfFdhqFuaQo4Gj
XV+RPyUBdDAJU7qrKA3QF2BRAQBEBQAARAUAEBUAgF6wtDLJfkATFJvu+mSuMtBp6fMIztKjDk8m
g1fvRTKdUq+Kj2oH28uXpZoF2F+PuljPeFpURtSsag2paPar6cpAp9ziNLYYNJSB3jkWYmV81DkA
V6Es1SpAX3rUrjj6RvQbM+ox3jKMaGXsNQGnve52W4uaGB3VwsZyUpMmWfDKdK8A3ZkuYvL9hqN6
+udWgpfHtvVsi2raTOqk46Nd+J0ZMTi1djBBoBVVuapc3Hvk1F1KSEsWVSfoOT5q4Koy3nTD/T5B
b1g0ylmXzyH12epC8cKKB1P5793Azm4WYYC6/Rg12jS6reyq+KglatGFBeUhEWB1fFSmjAqnhXvT
3c3qiKk9xzR+aNCG+7OrXDadVJKeqKzi1tRg6XWc/84BaaLG5Ixhx7dfgk5cKouPmpW+MD7qJrZn
KBfnz5bwGW4WJG7F1n6YqjRe4+FQ1FY+HhpyM7sJUNu8M/WoZj22jY8akqVGju3qNjG0Akk8Q+2c
F4iP2hLQowIb+/Y7HQb04voC5wLioz4dwKICAIgKAACICgAgKgAAvcCeTGJXJOXP47MVPMwOx3X9
pe1ERXGkUyo7qiB98po9IWxNfFS3ykVSj2opTv36YlOXBz1qFt4EKNIFUQskDKFoqDXKz/L7WhTp
tPCogvTJa/aEsHXxUc1C6c2IHtVSnHr1pbWLoqu1QHiiW0HUQXPKdq/MdgTLaDTU3V7VXRSRuMzI
l6SnVFujTZsy52bulYQWMzsae+tRC7rGlzd9qu4oqRuizuUxemUrMqp2hv1Qizv5MEVeG7XrA/Js
QogXXB+lbYFmGTn3q0fsKdrcUA6p3nRUZ48Lg0Baus8cHc02up/cMnp3SXeQTsSuELU8Puoml8MU
cKF7NKlAEVEpfD85Vsuh6Md9+L3rTpNlnXLiVNoGYxs9ahUfelWpgKmVrm8RQegcMwMNCxbJep4+
ZtpulKhnCLJLwmcK531ScuyCB8c/c293OsTnSVZ3l7+fc22icSRfKIRd6i3H7Goc347vFPSoxZ3G
JAo0xIFzZNRgDPG9Jal1JyoNCpp1lmQidl/GWxMfNT7WNDKPKU4ni86ji96z3hN61AxAj3piQI/a
EtCjApsxddfDABAVqBu0xndVHvfk8cOf+8Of/tkfwvUFgI7xlV9/69WL1+K9n3z9cWeu73O84gEA
Bnz0F3/+ne+LHwjx/Y/eeef9T3+tV4sqr/8p/U25Y2oZ2imHg4aD5XV7TjbsuqTdu3MyyqTM4m6V
9+1Cx4sTbt7SOLXePdWFWT/5VzJuKuMmSfv04WuV9l6jEICLz/zPx6/N7y/e/WafY9TLTVXDrffa
pbepf7keNbaey4bVAvSuwKFteXo78Xz+jc9+vVB1u1rzEq1ackswb6mqKxn6RLOep27Czd8ujAxW
CFgaGJr+zLv/8q3XLyaOXv97/a/v/Oxb3RTQ9XzV0AvLsdO+Wo7JakrTgOrkdtdt2N3bT8O22peo
yi6c3LgTMLZU2OCmc1B1551vTuKSwzwFFvDz/N5rcRmbvr78Mz5fvfri977zcXcW9XJjpduipNId
97BpWl27VUi55DDuaFOtBq02zltm9BItrkmWnh62MwdffvG1r1+IefV73X9f/cb33nvWG1GVS1UV
bAexdjIQWC43pV1sqvYIN2+us4+pRGD8q5YNY2X9jOcNDE88DyZSFuV0YMANv/UbiZ0vftSfRR1H
Xbmun8Xccdx0sbdS9dMWGjRLpdacYnX9KFVzreNNknGWP2X8+8uf+sv3buNS75/87Cdf/6g7oqaa
Qbw5KNVtH93SfMjt55MbXmvHN6kHfPz7P/z8sxejx6s/3/+pP/nw3zop4kNwhFowVSul7RDrqZLB
FT6iA5eyHU+lLO8KzGOqppJ0BsH6lNIpiJXquldiwLpA1f949e4Hw+b8jOYXP/zWl7opYOg56m2y
d/ybJoGFuTnuGVqdnB/rDZ/GU4j5Oereqzzm54VToTZ+jjpPv8rAWNB/jmpUoVU/BVeiws+G9ZNq
61qlMGbepX50ujB1/NTx97/JM0t/5+9+patKWreEMPeOo2Xs7OumO0bcjhjeenz8z8vH+3/8u2/f
lXpGbZ4QKLPtdTwFYh7wD159/oNP/8KHv/92byXDonwAqOjtzmVRAQAAUQEAAFEBAEQFAABEBQAQ
FQCAbonKA+avwt8KY5eX2vE+J+OxJtAygK5gCMep5/e97spTwptvgRO4vjeDcnvJumVaxp+F3nFJ
E0zZgEB78gYcBXq2qCYpmIgpFr1a2PFSvZQNudM4EC8jDgpwHouaMi3X8J4UTnBHhojh+QLdW9TA
yND7wj5/9yBqY/4YMQrBVOA8RL05tEGLSQHju0fb5ranYcwiASd0fT3TyUaAaBYJC9tqqLptwNFI
9hinAmewqJMbe50mMqLMkh+VU1veuwpviVidQOdEJed/mv4Md5dCSdo37J1C3JMQYClwPtcXAAAQ
FQAAEBUAQFQAAEBUAABAVAA4E8zHM8NSBr00p3iRDjtL78ZnsHY2LPznH+45nce003PdMUUqBycn
94nosNaK3PKI+WgWgcyNbOYt+1qDhRp/moovoJ4DNiHqapD/nYOLDX0eWFu2FsdR5lAqByenkKjH
/U76MCarSxB+CeatGwnNdKEVTeYhtz/wFNjU9XUVqabklHkQpRqKVDOZTu/mp7WslLanPmvHBVK8
nEPS4IeKVuU6hDqZWKHATaCVRfUVqXrz+iccRao2NDQpOilskcS88N1IFpHNeSqAyduM56D1pAFl
6VByYm1CKeY2CzeJn9dkUuOX5fndcHyBbYjKeU6tyQG/6ZHv4YVkq6k2G1lsS/k5RDKaS05JC1mz
jpCCnYt2mId10wwDC6wn6jSRk/NiMxZ5FM/ZHbboFW6o60NXZERlJ8rPiYQ/2wYAqyaTaLndUkHz
5uj0D5VzMJWD1pMuKEstD5UWk4R2hg8LHcUUdccBYA1RRfIpDYenfrQGjqI2lcss15wdU47tI3MG
J1GKPLc5vS9CbwrxE80MaEJUS5E6j76GzVGjao/+jG8cMFP6mJRN0YeM2U2kK5WHRjJaOH2kh7Gz
scuS9qyno4znwIQxKlCHqvioTGt2b3Wa7TMqPSFeAHzP6Cs+avGCB84akZ4ThQsSwFGgX6LSBik2
O9XWGVVMEIOswB7AonwAAFEBAABRAQBEBQCgFxiTSUH1qF7pUzJr4i2VY+8RorlIX4SknKT3krXA
fVk0aj7NxdQscGdETT0UXNncU4RJC0BNtYxeSpE+xloHBQ0ocK+uLxsa01F86khTRSRaqh8ndcrE
UbQO0tW8boDz1TIAcP8W1TFNWpQ6mCVDgSoS0VJt2lnKVlO/ako5Uz6w53vniEZH51iLRgHg/ojq
uKWp32ztKWVbvaC6ZMmsmq8oElhuADx5oo5mKn8tPAc3/e9cP/4tVdUJrPAD7p2oekyY2dYdPUmU
UpRBdyqiceSYuSAgK3DXrm/ucw0KvKYzaTHdV5JaYb7LQZEfx6lh8BS4X6Jq4an1GCSqQBW2aNXS
fFoHGYrWW77ja8YCT0VtQaqVT4ZotMKzBoC+8ex0zbhGNAoAxehLj3q+JYSFLx4CT4F7wAnX+lLD
1AAAogIAAKICAIgKAACICgAAiAoAICoAACAqAAAgKgCAqAAAgKgAAKICAACiAgAAogIAiAoAAIgK
AACICgAgKgAAICoAPE2YbyGUl38qtiVvXxff9ySFkslUUmS+M0paZ5Mq78hoor5eVQUA1Rb10sbV
wMfQ1oU2ejMJper3JlhbeaSRAQDcg0VVyS3H7o6WU4rx2y3pYM7k/IO1dz5CTVZ3stbjFyXNE16/
S538YhGleSIRykpq4+8lgkkFntQYdbaxA4uU0r+NXLvtU97e8QjtyJrW2rXets965ZgS1oncHP0S
SmUkUkKAp8DdEFWP8AJbUloDQBUaFKrpQ0p/b8xQj9wbKeb5ygnfWZlHO1SdywCGAndG1CRP5zGq
lMuTN7MTOnxERoj27yqesAhTPhIUBe5xjLrA09S4NcLTpSOU8C3rbKhF9bhyyAc8Be7Tomrz521F
LaG7X8Y8aSmCM69ynm+6earKyFxFZnk9q2tNIg0JQFHgji1q+kHquKWk84DzSqnht+s07TgsnNhk
7BXuE1Y3J/e7sNMqnSSU0jm50mUwMwCAc2K/aG6wc8CpgGhuAACscX2bAvYUAGBRAQBEBQAARAUA
AEQFABAVAAAQFQAAYT+eYdL/Dz8I4ayHuOw09k9H3JLxdXP8bLiKgkvy5rlIRSXKSp/O+1bMqUrM
qqKMS9B5jlvzD9fjrb1+Ecx7EsmJBR3e8LzGdi68EXs+2nRPxhPfjK+00FbnZG7LbHR/y5JT1nUE
2lBG+lTePKdgp6qYlnlKZjse+8bxKOtLqAjWPYnkRHx8S6fSuwKLGqTDVIs0ta2xKx64PHbv7g3v
re75KMuua4YjVdWqCMaJSIgz8MCz/YcXZ8TLVLLnBUaDNicqXSnJtoNLwuqKydhLYW+mZY0XNviW
ZUnlTS6XqEnvESgCWX1tzyCejartNBxcrHkrudb3jdi5Y3lMl5enjpmSHQTbR3ZjVVuWpSbvSzdz
+cvgEK8twtybTi6zMczth6kNLM/Tcn2NuuPFpjO0vl1qu5AZ1LYPqDzKmZBbqtC6IlB43Jub9e6+
JvG5iPrY6wmdeaag9aVd7uqZJiBC00wZRKF2Jeiv8qg/R6xHPES8ER46OedhTYab1rS/JqKSpsZt
u4yjs+ZynnKXjZB7LVjvJpyGUZTpjkw+U6DXs72WnnyYsSylRcpKX5C38+SZlsaoY55DUu8ksb3W
nZl+GyfrqbYqur1HTw7PUDtnQsI7LH1SDCwAb3gADva44WfeiesL9Aqq2rUiKQCLCgAAiAoAICoA
ACAqAAAWbJmbKF4hYi6ICAght346VphfZSly9aiJvF2Bwpy6oH61sndRlkrCEQL3pEcNS09P+Yjo
jceZI4jKtKb+QkLIrTURhflVliIrfTpvdjLSqTP0qDMoeq6A1NST6PStRwVWWNSpkbGWs40mgANm
kq1FvsE1rFt3mtQ0+XZ526rQypLkErpkqfWxVky3o9ALLEq6sM1LFvgtpEd9HkvcvLYf/czJdmdN
YxD4QUTEqU8aKVVofmus8/N7xtxsgi+wONAZDp05tDLpzWFN3SQq+a87oqRZCL/2hu0P2vxeVyTn
Rs1uIW9D0cbjitY8PepUvZlXO3m+1qpi68PQox7IZgoSg7ow92dyfZfGqBzwE5xmOi7e70r32LIw
6bwtuT1Tph51Az/fuw19vqGIRbtudK+R4lGTSUvzJ353yBS1wZ0Y1DYNtC7vFm9PCkmaYmTviq1k
tSsggYd0b+d2efb7Hnixj+yCp9yQp5l51xSBV5QkaqqO4GlAH8nOFnhaNUa9TeAP32ZlKpn+1PRt
PIzsPMjVQ27oKhXlNyZvokfNyduTjubpUWNHR2SpdklGO+9KVRvdkKoKNVqOMNoVkMIzypkuwTC/
s7HdSlkqbmgGoEcFtpqFOeRo4GjXV+RPSQAdTMKU7ipKA/QFWFQAAFEBAABRAQBEBQCgFyTio2bL
JnfQoc7nqlynzmfUo/qlcXINylLdBb/QoyZxnMK0nqh19beHDtUsXLketfR5RDd6VLc03rLdkCyV
g8dCj3pHFnXmKdshcme5oG0UphYQuesddJjU8LDkk6tN9KipXDMTdfYcZk89am5fFFeYvuyqUT+G
eEreK1YsDaodPCFWT9RXAzmmh1ilR13TgfSJHfWouXnFFaZ9rUx6DDQiYz2p2cnRIjf1R66Uq3nL
qGy4OYUf806dYp0edb25sErXgb8LPeo2RJ14WXFLHQFkP5GM23UZNOm1eTnyeI0edaGqiwrZ6cL3
DvSoj2ck6vgalip9YM+rDYujqjb0BjZww2m3g/axsNCjZuDB766NPi48vA9JCLvU6k9XURZVNdfx
Lblg3v6qypIeeWOgR21h+UmLUY16tuKfhiSEtgCyVbTLwnwri5El2sy50nV6VC+T0FUFTmHONiQl
rbsyFXrUdViIjwrhYs+olqXitmbgTHpU3NDOmbrrYUBPrm//MxBAxu0h3Nb7AhblAwCICgAAiAoA
ICoAAL1g6U359gtDg6LTXR/NVQpLS6evOUuPOrwpN3T1/olZLwyu16Pa4qb8MKnjRC8do0ddrOee
pKm9ril8LK3WUFS3/Wq6UljKLU5jByddOPEsJV2jR50FD4VhUsVM4e70qHgAWE9UvdyXdLftNgGn
ve52W4uaGB3VwmhlwVdcVVyDOIkCugIx+X7DQT39czvFy2PberZFNW0mddLx0S78zlRo58S9mDKi
TWzIqnJx70rVXUpIi67vnKJnPWrgqjLedMP9PkFvWDRKx4kKtrqN9Ki8sNTBVP17N7Czm0VwfrOw
xaxvx+/guRWtwUySlvVx0YJbWjNGnLOjvJCswaTd3Sysx19vUe9l7F9K1pL0lKooDr18j3e7jvPf
uZ650INFjYktw45vzwQdjEiZHjUrfVqPOk61lgphs8rF+bMlfIabBZNa3Ivw5BtNb1VxWp4difNQ
iWN2E6C2eYdPwf7DT73dVo8aCpMaObar28TQCiTxDLVzXkCP2hKIjwps7NvvdBiAATRQ5TNW7YKP
eUbAogIAiAoAAIgKACAqAAC9wIk94y4f52iMo0BU1Enz2BClT9vcMKVFh63I25Pq1sRHDQc3FSJH
iOpKVy35LPSo9ThKtProVltmpYWiotYoP8vva8ld5aqj8i4ilbcn1a2JjxoJbiqG7jAtRPWlq6Z8
FnrUc1vU4W6z/doCtiNYzpEZ3XtNe9V7CU+pysiXxCGlpTKui49K65o8dU+IvfWoBX31y+CO5wtd
Oe1A1PlMZpBrciJYOpEZLTrv0ByKvLYdAhmXF7ckYroo9AMo3tl0vkRv1/eE5N3e8MqkN03pmE9U
jsSujLbOfcOh1p6oZek4rtNeFx8182KnZbLhpm54vtUxNXcxqUARUSl8IznaRvYNh3qym7ouPmrZ
WJaSnQfZNwxMPTtRC9sMnWNm4CCDWj0A3mSMNdn0M/d0pyXM5nhwfCj3zqYjbJ5kdffxPOVdqGnc
ylEJq99W2u8Ngx61uIOYRzts+Uq2WpDJO2A3MWHdibjhTEo4b1u4WxkfNR3cNC1EtctxdHzUnAuF
HjUN6FHPiGohau9jlJ4APSqwrZ+789EAiApkOotxi0jrDgccfPmDd9/91Jfh+gJAv67v5/6XvyVe
vBbi/bd//OvHluY5XvEAACF8++EP/uaj7wnxg8v297/7+pN/9o8fdWJR5fU/pb8pd0wtQzvlcNBw
sLxuz8mGXZe0+4/LpS7TVMLt89Yfy7unujDrJ/9sws9RupcmvfK4ZzcLASTx8/zDb3s/fvG///aX
3z5+jHq50Wq49XY7CW3qX65HjYy4bFgtQO8KHNqapwOGKwpc1tq8x0wDeYd3T1uq9koCJ7QvTTpV
Lvyzjx9g6QLe+uCdr339ytMX4w/j51d/8KVPvX/QeNX1fNXQMw93U95M5GQ1pWlAdXK73zfs7u2n
YVvJI3japklKp7pSu2Njn8qzLUMV/QwE8Lnf+9NX37sy8zI2fX0dn1qfr8SXPv1jR4xXrVlfKd0W
JZXuuIdNZXXZ1sFyuwa3FiqnTOvy1nWmWpIiN7u5ewx3TxKGNIulH7z7z3/0SogLL6P/vv2Nr73z
qc8dSFTlUlUF202s7Q8Elq3oUdW6t/V5zbzV1PTdU6hlC1lSP8XsMsqjDHqOPi/4msZf/d/P5CX8
xpEWVakM0+cbkFuzU2oaE1669k7aglILfcu6CaWaTqC+fhauIuRPe2WUTXque8KvffhPX/jsp25j
0ui/9z77le9++KNDXd+paRfwdJxD6hr9l3CDq5BSgINb4N8+/OgLP/GrFy/3xejtWp/vfebdVx/+
2gHFegiOUAumaqW0u3vdtQ+u8IGNZzy33PrxTHxUn5Gq6knVJYPUVUg5Tbmbl+weDORz9Z9+6S/f
fz1+05/yM1959eqbxzygCT1HvU32jn/TJLAwN8c9Q6sbnzlM7UgaTyHm56j7L3B2HmaqhnkvP0c1
qtCqn+yzSf3003iOauUf+ME/u3EfgSW8+2Mv/sH4+t7b//mjA0uzbglh7h1Hy2jUFZUMWXE7CitY
ibc+8fFt2cOLZz/+1r+8fWhp1i3KV5snBEqoWstTIA8fv/qvL3zm0+9/4jIu/eaxPMWifACo6e3O
ZVEBAABRAQAAUQEARAUAAEQFABAVAIC+YOhRx3fT+e/vXXq55C4vn6yMdFp1KrMaAKAzolLP73ut
jHRahfZxXgFgA9eXmceXrN+2nJ+F3nFJE0zZyp7uZ+bwhmqgW4tqNtJrVGqyDZj5xYqX6qVsZOT2
tN/gKdC/RU3R4xrek8IJ9gmQCg4BsKjhkWHgC/v83SlMFKwdAKKGnOCgxaSA8b0fBqEvAE7l+nqm
k40A0SwSFrYVg3DDAFhUx429ThMZUWZN79bxdG8p93B9EUUTAFFnj1b/T9Of4e5SKInY5eHmXixF
XwCczfUFAABEBQAARAUAEBUAABAVAAAQFQDOBPPxzCj5zNahemBngZ+jcNU/kn+gXQb7Me30XHdM
EchBH8CzTI3cM3D8vEOm/nMZ9vW59kUGSzMmnotCWOwEbEjU1SD/OwcXG/p0sLZsLY6jzKFADjrJ
rOnxT80hGupdJMKHTP2D2c+Y6QLXM/ygi8IEngItXF9XkWpKTpkHUaqhSDWT6fRuflrLSml76rN2
XCDFsRyC1tAwe6EyFTsLUZZHWAhuAo0tqq9I1ZvXP+EoUrXlodGHDPidpBu4XuxPdlqKtnQynE4/
h4Bba/wwFJlYv7nBdKIj/QOFWTe6ukwifj064+pBBAAkiMp5Tq3ZDP0WSL6jF5KtpppuZEkvxXOY
B456obLFjrnI8dOy32+U+PsU6/GGBdMMAwtsRtRpIscbNEbadQ7Fc3aHLXrV6Hg6lPLOUuqpZpUq
kDFDRws0mEyi5eZb0so5OoFEJdxdl4N/EIeJl8yXY2QNZawniqHPA1oQVSSf0nB46kdr4KKtPyJD
TxvLmH2lYn7aB8XMNqUt9/LUETk8BYA2RLUUqfMgbNgcNar2MNL4Nj/ttPMbj0mZFn3ImN306sFl
Eao+QJdS57Bw3kjX4hek0Ddn4wEwYYwKrEJVfFSmNbu3Os2GOZSeibGE4f7RV3zU4gUPnDUiPRkK
FySAo0D3RKUNUmx2qs1yoPJsQVZgR2BRPgCAqAAAgKgAAKICANAL4vFRp1+nxTZF6wvIW+juPkk0
F+mLLH2psNf5pLSjhh4UM7TAnRE19WxwZXNPLXVN60C1Lsfct6AdNfWgkIIC9+r6sqExHcWnjjRV
RKKl+nFSp0wcResgXc3vBsA2ABZVBE2TaZAcaapIREu1SWUpW039qqnoTPnAnl+boR21F8HDpAL3
SVTHLU39ZmtPKXsVAIXMZfDYaaGv3QHUakcB4I6IyhZFcoagwU3/O5e7taMVpuUOBH4y8MSIqt9Z
kNnkyeZVlFKUQfcykkVcX5AVeBqub+4bCYjJtWKcNHDuK0lNHWuFkaTIj+ApcPdEtSWdc5uPKlCF
LVq1pJ/WQYai9Zbv+LAz8FQ0pi8VJdrRmJgUAM6HZ6drxjXaUQAoRl961PMtISx8/xB4CtwDTrjW
lxqmBgAQFQAAEBUAQFQAAEBUAABAVAAAUQEAAFEBAABRAQBEBQAARAUAEBUAABAVAAAQFQBAVAAA
QFQAAEBUAABRAQAAUQHgaeIZXlUCnBDrX4W1mMNSgh2KAIsKAHB9AQAAUQEAY1QA6GIMiiq4gkBU
4NxExmQSAAAYowIAAKICwF0CY1QAOAEeUQXAOaBD7U6Re8cfigNx6tnU1KG8HFmbK4KQWUc6VwKi
AufnKZnx6i//ph+4OqPkoSwWdzJV9RLeJeTkgzEqcH4CNzg0w57uWloQFTg3qM2h1Oac1UeCqABw
AoCoAACiAgAAogLAEwEezwDnAA0PG5mmLeK6uRmd0UZFqj+y4EqwMgkA4PoCAACiAgCICgAAiAoA
AIgKnBTyioLkmYlkZSaFxck4oayqFjyeATqD2j9XtXtxYFGB+7Gsg/WR4/b8Rf8yJpyTX/fJ2QrK
ac9kx6S3c0g/5mrkU1+cMZ30C2YWdkox/CIT54VFBfrmqRr+udvDV+OX4dv0w21TmWmuf2Y21s5p
08untjjjOYxzK2HvllMyfbSfJywqcA5TOnqcSgaarwp9pBxVFd+nFl3cwuLEiqKsDRXapWBRgfON
UZOe4IUxTruWngGMTuPcdsrcqZ664iQyLM4BRAU6d32TbJYqar8iPB2ylCplvtQ2xVnMsCAHuL5A
31y9WRoVMk8yZLEyHohI92eZbwPzirNoVP2iyxy7C4sK9OkAy5s7aPqFxk+Gp3j91XEdb/Ooyjtq
2LJ2jkcvu6C5xZm2ZkLbGdrH3PbNH2nbC/UM8MQd7HOUAhYVAI727zPSwaICwAmAySQAAFEBAABR
AQBEBQAARAUAAEQFABAVAAAQFQAAG/8P+0g8AiL0sYsAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2010-01-15 11:04:24 +0100" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-002.11" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Benzodiazepine versus Other Drug, outcome: 2.11 Adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8IAAALACAMAAABvijsgAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2009-12-04 11:33:54 +0100" MODIFIED_BY="[Empty name]" NO="10" REF_ID="CMP-002.12" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Benzodiazepine versus Other Drug, outcome: 2.12 Severe, life-treating adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAywAAAHQCAMAAAB0nx7kAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2010-01-15 11:04:23 +0100" MODIFIED_BY="[Empty name]" NO="11" REF_ID="CMP-002.14" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Benzodiazepine versus Other Drug, outcome: 2.14 Dropouts.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8IAAAMgCAMAAADfuSsWAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2009-12-29 14:39:07 +0100" MODIFIED_BY="[Empty name]" NO="12" REF_ID="CMP-003.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Benzodiazepine 1 versus Benzodiazepine 2, outcome: 3.1 Alcohol withdrawal seizures.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA10AAAIQCAMAAABNFPRrAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-13" MODIFIED="2009-12-29 14:42:35 +0100" MODIFIED_BY="[Empty name]" NO="13" REF_ID="CMP-003.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Benzodiazepine 1 versus Benzodiazepine 2, outcome: 3.2 Alcohol withdrawal delirium.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA2MAAAIQCAMAAAA7LkbgAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-14" MODIFIED="2010-01-01 11:28:20 +0100" MODIFIED_BY="[Empty name]" NO="14" REF_ID="CMP-003.09" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Benzodiazepine 1 versus Benzodiazepine 2, outcome: 3.9 Adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA2MAAAKgCAMAAAAh5FWVAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-15" MODIFIED="2009-12-29 14:50:10 +0100" MODIFIED_BY="[Empty name]" NO="15" REF_ID="CMP-003.11" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Benzodiazepine 1 versus Benzodiazepine 2, outcome: 3.11 Dropouts.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA2MAAANACAMAAACR10WjAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-01-07 13:01:18 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-11-27 11:47:06 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-03-25 09:10:10 +0100" MODIFIED_BY="[Empty name]">CENTRAL - The Cochrane Library 4, 2004) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-27 11:47:06 +0100" MODIFIED_BY="[Empty name]">
<P>Free text: (((alcohol*) AND (withdraw* or detox* or abstinen* or abstain*)) AND (benzodiazepine)))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-11-27 11:48:48 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-11-27 11:48:48 +0100" MODIFIED_BY="[Empty name]">PubMed search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-27 11:47:44 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Alcohol-related disorders [mesh]</LI>
<LI>Alcohol-Induced Disorders, Nervous System<B> </B>[mesh]</LI>
<LI>((alcohol*) and (disorder* or withdr* or abstinen* or abstain* or detox* or neuropathy)) [tiab]</LI>
<LI>1 or 2 or 3</LI>
<LI>BENZODIAZEPINES [mesh]</LI>
<LI>benzodiazepine or alprazolam or bromazepan or Brotizolam or Chlordiazepoxide or Clobazam or Clotiazepam or Adinazolam or Bentazepam or  camazepam or  Diazepam or Cloxazolam or Etizolam or Flutoprazepam or flunitrazepam or flurazepam or halazepam or Ketazolam or Loflazepate or lorazepam or Lormetazepam or loprazolam or Metaclazepam or midazolam or nitrazepam or oxzepam or prazepam or temazepan or triazolam or Propazepam or Ripazepam or Serazepine or Tofisopam).tw</LI>
<LI>exp ANTI-ANXIETY AGENTS [mesh]</LI>
<LI>5 or 6 or 7</LI>
<LI>randomized controlled trial[pt]</LI>
<LI>controlled clinical trial[pt]</LI>
<LI>random*[tiab]</LI>
<LI>placebo[tiab]</LI>
<LI>drug therapy[mesh]</LI>
<LI>trial[tiab]</LI>
<LI>groups[tiab]</LI>
<LI>9 or 10 or 11 or 12 or 13 or 14 or 15</LI>
<LI>animals [mesh]</LI>
<LI>humans [mesh]</LI>
<LI>animals NOT (17 and 18)</LI>
<LI>16 NOT 19</LI>
<LI>4 and 8 and 20</LI>
<LI>Benzodiazepine/adverse effects [mesh] or Benzodiazepine /poisoning [mesh] or Benzodiazepine /toxicity [mesh]</LI>
<LI>Benzodiazepine/contraindications [mesh]</LI>
<LI>adverse effects [subheadings]</LI>
<LI>Drug toxicity [mesh]</LI>
<LI>&#8220;adverse effect*&#8221;[tiab]</LI>
<LI>&#8220;side effect* [tiab]</LI>
<LI>serious or safety or surveillance or adverse or toxicity or complication or tolerability [tiab]</LI>
<LI>22 or 23 or 24 or 25 or 26 or 27 or 28</LI>
<LI>4 AND 8 AND 29</LI>
<LI>30 NOT 19</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-11-27 11:49:11 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-11-27 11:48:48 +0100" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-27 11:49:11 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Exp Alcohol Withdrawal/</LI>
<LI>Exp Withdrawal Syndrome/</LI>
<LI>((alcohol*) and (disorder* or withdr* or abstinen* or abstain* or detox* or neuropathy)) [tiab]</LI>
<LI>1 or 2 or 3</LI>
<LI>Exp benzodiazepine derivative/</LI>
<LI>(benzodiazepine or alprazolam or bromazepan or Brotizolam or Chlordiazepoxide or Clobazam or Clotiazepam or Adinazolam or Bentazepam or  camazepam or  Diazepam or Cloxazolam or Etizolam or Flutoprazepam or flunitrazepam or flurazepam or halazepam or Ketazolam or Loflazepate or lorazepam or Lormetazepam or loprazolam or Metaclazepam or midazolam or nitrazepam or oxzepam or prazepam or temazepan or triazolam or Propazepam or Ripazepam or Serazepine or Tofisopam).ti,ab</LI>
<LI>5 or 6</LI>
<LI>random*.ti,ab</LI>
<LI>placebo.ti,ab</LI>
<LI>(singl* or doubl* or trebl* or tripl*) and (blind* or mask*)).ti,ab</LI>
<LI>crossover*.ti,ab</LI>
<LI>exp randomized controlled trial/</LI>
<LI>exp double blind procedure/</LI>
<LI>exp single blind procedure/</LI>
<LI>exp triple blind procedure/</LI>
<LI>exp latin square design</LI>
<LI>exp crossover procedure/</LI>
<LI>exp Latin square design/</LI>
<LI>exp placebos/</LI>
<LI>exp multicenter study/</LI>
<LI>8/20 OR</LI>
<LI>4 and 7 and 21</LI>
<LI>limit 22 to human</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2009-12-14 11:32:39 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2009-11-27 11:49:35 +0100" MODIFIED_BY="[Empty name]">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-12-14 11:32:39 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>MESH alcohol related disorders</LI>
<LI>MESH alcohol withdrawal delirium</LI>
<LI>TX ((alcohol*) and (disorder* or withdr* or abstinen* or abstain* or detox* or neuropathy))</LI>
<LI>1 or 2 or 3</LI>
<LI>MH Antianxiety agents, Benzodiazepine</LI>
<LI>TW benzodiazepine or alprazolam or bromazepan or Brotizolam or Chlordiazepoxide or Clobazam or Clotiazepam or Adinazolam or Bentazepam or  camazepam or  Diazepam or Cloxazolam or Etizolam or Flutoprazepam or flunitrazepam or flurazepam or halazepam or Ketazolam or Loflazepate or lorazepam or Lormetazepam or loprazolam or Metaclazepam or midazolam or nitrazepam or oxzepam or prazepam or temazepan or triazolam or Propazepam or Ripazepam or Serazepine or Tofisopam</LI>
<LI>5 or 6</LI>
<LI>MH Random Assignment/</LI>
<LI>MH Clinical Trials/</LI>
<LI>TW random*</LI>
<LI>TW placebo*</LI>
<LI>TW group*</LI>
<LI>TW (singl* or doubl* or tripl* or trebl*) and (mask* or blind*)</LI>
<LI>MH crossover design</LI>
<LI>TW crossover*</LI>
<LI>TW allocate*</LI>
<LI>TW assign*</LI>
<LI>9/17 OR</LI>
<LI>4 and 8 and 18</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2010-01-07 13:01:18 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2009-11-27 12:07:10 +0100" MODIFIED_BY="[Empty name]">Criteria for Risk of bias in RCTs and CCTs</TITLE>
<APPENDIX_BODY MODIFIED="2010-01-07 13:01:18 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="4" ROWS="13">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Item</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Judgment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Description</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>
<B>Was the method of randomisation adequate?</B>
</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>The investigators describe a random component in the sequence generation process such as: random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimization</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>The investigators describe a non-random component in the sequence generation process such as: odd or even date of birth; date (or day) of admission; hospital or clinic record number; alternation; judgement of the clinician; results of a laboratory test or a series of tests;  availability of the intervention</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information about the sequence generation process to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>
<B>Was the treatment allocation concealed?</B>
</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web-based, and pharmacy-controlled, randomization); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Investigators enrolling participants could possibly foresee assignments because one of the following method was used: open random allocation schedule (e.g. a list of random numbers); assignment envelopes without appropriate safeguards (e.g. if envelopes were unsealed or non ­opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3/4</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>
<B>Was knowledge of the allocated interventions adequately prevented during the study? (blinding of patients, provider, outcome assessor)</B>
</I>
</P>
<P>
<I>
<B>Objective outcomes</B>
</I>
</P>
<P>
<I>
<B>Subjective outcomes</B>
</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Blinding of participants, providers and outcome assessor and unlikely that the blinding could have been broken;</P>
<P>Either participants or providers were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.</P>
<P>No blinding, but the objective  outcome measurement are not likely to be influenced by lack of blinding</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding;</P>
<P>Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken;</P>
<P>Either participants or outcome assessor were not blinded, and the non-blinding of others likely to introduce bias</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>
<B>Were incomplete outcome data adequately addressed? </B>
</I>
</P>
<P>
<I>
<B>For all outcomes except retention in treatment or drop out</B>
</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No missing outcome data;</P>
<P>Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias);</P>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;</P>
<P>For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;</P>
<P>For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;</P>
<P>Missing data have been imputed using appropriate methods</P>
<P>All randomised patients are reported/analysed in the group they were allocated to by randomisation irrespective of non-compliance and co-interventions (intention to treat)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;</P>
<P>For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;</P>
<P>For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size;</P>
<P>&#8216;As-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient reporting of attrition/exclusions to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217; (e.g. number randomised not stated, no reasons for missing data provided; number of drop out not reported for each group);</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>